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Abstract
This thesis describes work designed to identify genomic prognostic and predictive
markers for melanoma using nucleic acids extracted from formalin-fixed (FFPE) tumour
samples and emerging technologies for gene expression profiling.
I report use of the cDNA-mediated annealing, selection, extension and ligation (DASL)
assay using a 502-gene Human Cancer panel to identify prognostic markers. The
study identified over-expression of SPP1 and DNA repair genes in primary tumours as
associated with reduced relapse-free survival time. These genes remained associated
with survival in analyses adjusted for current prognostic markers. I also report use of
the DASL assay to study gene expression of tiny metastatic specimens, allowing
assessment of gene expression in matched primary and metastatic tumours.
I report studies of driver mutations in BRAF and NRAS as prognostic markers in which
V600K BRAF mutations, were independently associated with survival in multivariate
analysis. Gene expression profiling using the DASL assay identified a number of genes
differentially expressed in BRAF and NRAS mutated tumours, for example ETV1 and
TYRO3, providing biological insight into these tumours.
Ulceration of a primary tumour is a poor prognostic sign, but paradoxically also predicts
response to interferon- adjuvant therapy. I report greater numbers of macrophages in
ulcerated tumours and both over-expression of interleukin-6 and deranged expression
of genes in the interferon Jak-STAT signalling pathway. These factors may contribute
to mechanisms of responsiveness to interferon- in ulcerated tumours.
I report an investigation of predictive markers for dacarbazine therapy. The Fluidigm
quantitative Real-time PCR system was used to identify over-expression of MGMT as
independently associated with chemotherapy resistance and shorter survival after
starting chemotherapy.
Following validation of these findings, prognostic and predictive markers were identified
which could potentially be used clinically to provide additional information to patients
with melanoma, allowing a more personalised approach to melanoma treatment.
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1 Introduction
Histological prognostic markers are used in malignant melanoma to provide information
regarding risk of relapse following diagnosis, the American Joint Committee on Cancer
(AJCC) staging system being most widely used. Current prognostic markers however
explain only a proportion of the variance in survival between patients and are therefore
inadequate for subsets of patients. This thesis describes work carried out to identify
new genetic predictors of outcome which I postulated would also increase knowledge
of the biology of melanoma.
There are some predictive biomarkers associated with treatment benefit currently used
in melanoma, for example codon 600 BRAF mutations predict benefit from BRAF
inhibitors (BRAFi). However, much better markers are required; as yet we have no
marker which predicts resistance to BRAFi and we have no markers predicting
response to older therapies such as dacarbazine (DTIC). In this thesis I also report
results of work to evaluate putative predictive biomarkers for benefit from DTIC.
Identification of prognostic and predictive markers provides more information for
patients and clinicians allowing a more personalised approach to treatment for
melanoma.
1.1 Major thesis aims
The major aims of this thesis are:
 To develop methods for use of formalin-fixed paraffin-embedded (FFPE) melanoma
tumour tissue for genomic analyses.
 To assess use of technologies for gene expression profiling in FFPE tissue.
 To identify novel prognostic factors in melanoma tumour tissue which provide
additional prognostic information to that provided by current staging algorithms.
 To identify tumour factors predictive of responses to treatment in melanoma.
 To gain biological insight into mechanisms of melanoma progression.
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1.2 Aims of this chapter
The aims of this chapter are:
 To describe what is known about malignant melanoma and common genetic
alterations in melanoma tumours.
 To provide an overview of current prognostic factors and their limitations.
 To review prognostic markers identified in melanoma tumour tissue.
 To review current options for therapies in more advanced melanoma and their
mechanism of action.
 To provide an overview of current predictive markers of treatment benefit and their
limitations.
 To introduce further chapters of this thesis.
1.3 Cutaneous malignant melanoma
The skin is the largest organ of the body arranged into three layers: the superficial
epidermis, dermis and hypodermis [1]. The epidermis is mostly made up of
keratinocytes, with five to ten percent of cells being of different cell types, mainly
melanocytes, Merkel cells and Langerhans cells [1]. Melanocytes migrate from the
neural crest to epidermis where they produce pigment called melanin [1]. Melanoma
arises from melanocytes in response to environmental and genetic factors [2].
1.3.1 Incidence
Malignant melanoma is the sixth most common cancer in the UK with an age-
standardised incidence rate of 16 new cases per 100,000 population in 2009 [3].
Incidence is rising faster than any other common cancer in the UK [3].
1.4 Melanoma development
1.4.1 Risk factors for melanoma development
There is clearly a genetic contribution to melanoma susceptibility with a strong risk
factor being family history [4-6]. Other risk factors associated with genetic
predisposition are having a sun-sensitive skin phenotype and presence of multiple
melanocytic naevi (moles) [4, 5, 7-9]. The importance of having sun-sensitive skin is
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highlighted by genome-wide association studies which have identified polymorphisms
in a number of genes associated with pigmentation, for example the gene encoding
melanocortin-1 receptor (MC1R), as being associated with increased melanoma risk [5,
10, 11]. Emergence of naevi is also genetically determined with sun-exposure having a
small effect on naevus number [12, 13]. Additional risk factors for melanoma
development are having a previous melanoma, exposure to ultraviolet radiation and
immunosuppression [4, 5, 7-9, 14, 15].The contribution of genetic factors to melanoma
development has been estimated to be 18-55% [16, 17]
1.4.2 Process of melanoma development
During melanoma development from a normal melanocyte, a series of genetic
alterations occur (Figure 1-1). This model is a useful for the purposes of discussion but
relates to only one developmental route where melanoma commonly develops from
naevi. Melanoma can also develop from otherwise phenotypically normal melanocytes
[18].
It is known that as tumours progress an increasing number of genetic changes develop
within the cells. However, genetic (mutations, amplifications, deletions or
translocations) and epigenetic changes (such as promoter hypermethylation) either
drive the development of a melanoma, so-called driver events, or are passenger events
that occur but have no effect on the cell [4, 18-22]. Some of the genetic changes
involved in these processes can be inherited through families and predispose an
individual to melanoma [2, 23, 24]. I will briefly describe some of the pathways
commonly altered in melanoma tumours during their development.
1.4.2.1 Mitogen-activated protein kinase (MAPK) pathway
Activation of the mitogen-activated protein kinase (MAPK) pathway appears to occur
early in melanoma development with oncogenic mutations driving this pathway
commonly found in benign and dysplastic naevi [2, 18, 25]. A dysplastic naevus is
clinically diagnosed and larger in diameter with irregular or variable shape and
pigmentation. Such naevi are associated with melanoma risk and are more common in
families with multiple melanoma cases [26, 27]. The MAPK pathway (Figure 1-2)
regulates a number of processes within a cell including cell survival, growth and cell
migration [28, 29]. BRAF is mutated in around 40% of melanoma tumours, with the
majority of mutations due to a single base substitution (V600E) [30-32]. In tumours
without BRAF mutations, there are usually mutations elsewhere in the MAPK pathway,
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such in NRAS in cutaneous melanomas (18%) [30, 31], KIT in acral or mucosal
melanomas [33] and GNAQ in uveal melanomas [34]. Identification of mutations in this
pathway are the subject of Chapter 6 and will be discussed in further detail in this
chapter.
Figure 1-1: Melanoma development – a hypothetical model.
Genetic changes drive melanoma progression. Cells can only progress to the
next step following changes in specific genes. See text for further details.
Adapted from [18, 22]. Abbreviations used: MAPK, mitogen-activated protein
kinase; G1, gap 1 phase of the cell cycle; PI3K, phosphatidylinositol-3-kinase.
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Figure 1-2: Deregulated pathways during melanoma progression.
A. The CDKN2A locus encodes p16INK4A and p14ARF, p16INK4A inhibits the cyclin-D-
dependent kinases CDK4 and CDK6. Loss of p16INK4A leads to CDK-mediated
phosphorylation of retinoblastoma protein (RB), leading to release of E2F
transcription factors which stimulate entry into the cell cycle. HDM2 is inactivated
by p14ARF which activates the tumour suppressor p53. Inactivation of p14ARF
leads to HDM2-mediated inactivation of p53 via activation of HDM2, which targets
p53 for degradation [18]. (Continued on following page)
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(Figure 1-2 cont.) B. The mitogen-activated protein kinase (MAPK) pathway and
phosphatidylinositol-3-kinase (PI3K) pathway. NRAS mutations activate both
pathways. The MAPK pathway can also be activated by mutations in BRAF. ERK
can also be constitutively active in absence of NRAS and BRAF mutations. The
PI3K pathway may be activated by loss of the inhibitory function of PTEN, or by
gene amplification of AKT3 [35]. Figure adapted from reference [18].
1.4.2.2 p16INK4a, cyclin dependent kinases 4/6 and retinoblastoma (RB)
protein
Melanocytes that develop BRAF mutations usually do not evolve into a tumour as the
cells enter senescence after a period of time as a result of induction of tumour
suppressor proteins such as p16INK4A or p15INK4b [19, 36, 37]. When the p16INK4a - cyclin
dependent kinases 4/6 - RB senescence barrier is inactivated, continued development
into a melanoma may occur [18, 19]. p16INK4A is encoded by the CDKN2A locus [18, 19]
and inhibits the cyclin-dependent kinases, CDK4 and CDK6, which maintains RB
protein in an inactivated, hypophosphorylated state so preventing entry into the S-
phase of the cell cycle (Figure 1-2) [18, 19]. p16INK4A is usually inactivated in
melanomas secondary to mutations, deletions or promoter hypermethylation of
CDKN2A [19, 21]. Less frequently, genetic changes can affect other parts of this
pathway, for example mutations in CDK4 are found in up to 10% of melanomas [19,
21]. CDK4 mutant proteins cannot bind p16INK4A and consequently RB protein remains
phosphorylated and active [38]. Inactivating mutations in the gene that encodes RB
protein (RB1) have been identified in melanoma cell lines, but have not been assessed
further in melanoma tumours [38].
1.4.2.3 p14ARF and p53
Melanocytic cells that lack p16INK4A eventually undergo growth arrest in many cases
[22] and up-regulate p53 [39] which is likely to be an alternative senescence barrier to
that of the p16INK4A - CDK4/6 - RB pathway. p14ARF is a positive regulator of p53,
therefore the p14ARF-p53 senescence barrier may also need to be inactivated to allow
melanoma development [18]. TP53 mutations are found in 5-25% of melanoma
tumours [19, 21]. However, p14ARF is also encoded by the CDKN2A locus using an
alternative reading frame to p16INK4a and so is also lost when CDKN2A is mutated with
p14ARF loss having the same effect as p53 loss [18] (Figure 1-2). There is also evidence
that inactivation of p14ARF is common in melanomas and occurs independently of
p16INK4A inactivation [40].
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1.4.2.4 PTEN and the phosphatidylinositol-3-kinase (PI3K) pathway
PTEN is a tumour suppressor which negatively regulates the PI3K signalling pathway;
inactivation of PTEN by deletion or mutation activates this pathway, which stimulates
cell growth and survival [18, 41] (Figure 1-2). The P13K pathway is usually hyperactive
in melanoma metastases, but PTEN inactivation accounts for less than 50% of cases,
in the remaining cases mutations in other genes can activate the pathway, such as
NRAS [30], KIT [33] and PIK3CA [42]. Inactivation of PTEN is usually associated with
BRAF mutations, so BRAF mutated tumours have up-regulation of both MAPK and
PI3K pathways [43, 44].
1.5 Melanoma tumour progression
1.5.1 Melanoma metastasis
A primary tumour is a heterogeneous mix of cells with a minority harbouring genetic
alterations that allow them to spread and colonize distant organs [45-47]. Metastasis is
the spread of primary tumour cells to distant organs that then grow and is the usual
cause of death from cancer [46, 47]. It is dependent on characteristics of tumour cells
as well as the response of the host [45-47]. Characteristics of primary tumour cells that
predispose to metastasis formation are loss of cellular adhesion, greater motility and
invasiveness, being able to enter and then survive in the circulation, leaving vessels
into a new tissue and then colonization of a new site [46-48].
To expand further on the model presented in Figure 1-1, there are a number of
histological changes that occur as normal melanocytes progress to a metastatic
melanoma, which were originally described by Clark [49]. The Clark model describes
five phases of progression from a melanocyte to melanoma, these being proliferation of
melanocytes to form benign naevi where nested melanocytes lie along the basement
membrane of the epidermis. Benign naevi transform into dysplastic naevi or dysplastic
naevi can develop independently in a new location, the cells of these lesions are
commonly more atypical. Melanoma cells then develop which progress through a radial
growth phase where cells grow horizontally within the epidermis or the upper papillary
dermis which then progress to a vertical growth phase where cells penetrate the
basement membrane and invade the dermis. This primary melanoma then makes the
transition into a metastatic melanoma, having sustained sufficient genetic aberrations
to allow tumour cell growth throughout the body [4, 49]. In order for an established
melanoma to progress through to the invasive vertical growth phases and then become
metastatic, it develops some of the important characteristics of a metastatic tumour
- 8 -
described above. An example of this is that there is loss of adhesion between
keratinocytes and melanoma cells in the epidermis, by down-regulation of E-cadherin
expression, with up-regulation of N-cadherin allowing adhesion with dermal fibroblasts
and vascular endothelium [50-52]. Metastases develop when cells leave the primary
tumour, migrate into stroma and invade lymphatics and blood vessels to form tumour at
a distant site [4, 53]. Typically, the first site for melanoma metastasis is the regional
nodal basin, specifically a “sentinel-node”, which is the first tumour-draining node in the
lymphatic chain [54, 55]. Following this, the tumour disseminates systemically [55]. This
is the predominant pattern of metastasis in melanoma, but a minority develop systemic
disease early, sometimes to a single organ, such as the lungs or the brain, but in some
cases more widely to a number of visceral sites [56, 57]. The presence of nodal
metastases is an important clinical predictor of outcome, which will be discussed
further in section 1.7.1.2 [58, 59].
1.5.2 Melanoma interactions with host immunity
As discussed, melanoma spread is dependent on characteristics of tumour cells but it
is clear that the response of the host to those cells is also critical [45-47]. Host/tumour
interaction involves the immune system and the tumour microenvironment; these
interactions are active and complicated. The reported efficacy of immunotherapies in
melanoma in recent times however shows the potential for immunotherapies in the
future [60, 61].
Immune responses to the tumour are usually categorised as either innate or adaptive,
although both are intimately connected. Innate immune mechanisms are rapid
compared to adaptive responses and are usually associated with inflammation [62].
Cells associated with innate responses are plasmacytoid dendritic cells and phagocytic
neutrophils which are activated by pattern recognition receptors [62]. Natural killer cells
recognise major histocompatibility complex (MHC) class 1 antigens on cells, and are
regulated by balance in the function of activating and inhibitory receptors [63]. Myeloid
dendritic cells, monocytes and macrophages are phagocytic and can present antigen to
components of the adaptive immune response, such as T and B cells [62].
The immune system of the skin and lymphatics is essential for identifying and targeting
destruction of melanoma cells by adaptive immune systems. Langerhans cells are
dendritic cells present in the epidermis of skin, which migrate via dermal lymphatics to
draining lymph nodes and present antigen to T cells [64]. Activated tumour antigen-
specific T cells expressing the skin homing receptor cutaneous leucocyte antigen
(CLA), migrate out of dermal blood vessels into the skin and mediate cellular immunity
- 9 -
[64]. Presence of cytokines either support or inhibit this process. Melanoma is a tumour
that interacts with the immune system and expresses antigens that T cells recognise. T
cells can destroy melanoma cells and regression of melanoma tumours indicating
immune destruction of melanoma cells is well described [64]. The presence of a brisk T
cell infiltrate in melanoma tumours is associated with longer survival [65, 66] as is the
development of vitiligo due to autoimmune destruction of melanocytes [67-69]
highlighting the prognostic importance of the immune response to tumour.
Although active immune responses to melanoma cells can be demonstrated, it is
usually not effective in destroying the tumour and there are data to suggest that tumour
cells inhibit these responses. Melanoma cells can inhibit antigen processing cell
maturation preventing expression of co-stimulatory molecules required for T cell
activation [70], tumour cells can also down-regulate MHC class 1 expression [71, 72]
so becoming invisible to class 1 restricted cytotoxic T cells [70]. Factors secreted by
the tumour microenvironment, such as immunosuppressive cytokines (IL10 and TGFβ), 
can also render cytotoxic T cells inactive or enhance function of regulatory T cells
which promote tolerance [73-75].
In summary, melanoma is an immunogenic tumour which interacts with the host
immune system and adapts to evade detection and destruction. These interactions are
relevant to both the prognosis of a patient with melanoma and to the response of the
tumour to therapy, but much more needs to be understood about these interactions in
order to optimise immunotherapies.
1.6 Patient assessment and melanoma tissue processing
I will briefly describe the assessment of a patient who presents with a suspicious skin
lesion and focus on processing of melanoma tumour tissue following surgical removal
because of the impact this has on tumour research. This process if summarized in
Figure 1-3.
If a melanoma is suspected, it is excised completely ideally with a margin of 2mm of
normal skin and a cuff of fat [76]. The specimen is then placed in 10% neutral buffered
formalin which fixes the tissue by generating cross-links between proteins and nucleic
acids [77]. The specimen is embedded in paraffin and sectioned. Sections are stained
with haematoxylin and eosin (H+E) and reviewed by a pathologist. The Royal College
of Pathologists has advised that a minimum dataset should be reported for all
specimens which are tumour thickness, mitotic rate, histological subtype, margins of
excision, growth phase, presence of ulceration, regression, tumour-infiltrating
Figure 1-3: Summary of surgical treatments and investigation
diagnosis and staging of melanoma.
Further detail is provided in the text. This flow
[76]. Abbreviations used: CT, computed tomography; LDH, lactate
dehydrogenase.
lymphocytes, lymphatic or v
pathological staging [
patients usually undergo a wide local excision to the depth of the muscle fascia
ensure complete removal of the melanoma along with any micrometastases that may
be present [76]. This specimen will also be formalin
to determine the margin of melanoma free tissue
in thickness or less than 1mm with ulceration or a mitotic rate equal to or greater than
1/mm2, a sentinel lymph node biopsy is usually offered to identify presence of
metastatic deposits [79
wide local excision procedure
tracer into the skin where the melanoma is located and identifying the first draining
node which is then removed
likely to contain micrometastatic tumour cells. Assessment of the FFPE sentinel node
involves bivalving the node and a minimum of six serial secti
=<1mm thickness,
not ulcerated and
mitotic rate <1/mm
Wide local excision
only
Negative sentinel
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-chart presents guidelines in the UK
ascular invasion, perineural invasion, microsatellites and
76, 78]. Once the diagnosis of melanoma has been confirmed,
-fixed and examined pathologically
[76]. If a tumour is greater than 1mm
]. This procedure normally takes place simultaneously with the
[76, 80]. It involves injecting blue dye and radioactive
[54, 80]. This “sentinel node” represents the node most
ons are taken
Primary tumour
excised
2
>1mm or =<1mm
and ulcerated or
mitotic rate
=>1/mm2
Wide local excision
and sentinel node
biopsy
node
Positive sentinel
node biopsy
Completion
lymphadenectomy
Clinically evident
nodal disease
Completion
lymphadenectomy
Systemic disease
suspected
CT scan and LDH
s used in the
to
[76, 81].
level
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These sections are stained with H+E and immunohistochemical stains specific for
melanoma cells, such as S100 or Melan A [76]. The depth of metastases from the node
capsule is measured, as is the size of the largest deposit, and the site is categorized as
either subcapsular or parenchymal [82, 83]. If a patient has a positive sentinel lymph
node or palpable nodal disease at diagnosis, they will usually undergo a completion
lymphadenectomy to remove regional nodes. The pathologist will examine sections
stained with H+E and immunohistochemical stains from all the nodes from at least one
level and count the number with metastatic deposits [76]. If there is any extracapsular
spread or involvement of fat around the node this is also recorded [76]. If further
systemic spread of disease is suspected, computed tomography (CT) scanning of the
body is usually performed to identify sites of disease and lactate dehydrogenase (LDH)
level measured [76]. The factors assessed are of importance prognostically and will be
discussed further in section 1.7.1 below.
1.7 Prognosis in melanoma
Survival from melanoma has improved over the last 25 years in England and Wales
[84, 85]. Prognosis for those with thin tumours (≤1mm) following surgery is excellent, 
however for those with thicker primary tumours (≥2mm) or with nodal or more extensive 
metastatic spread, survival rates at 5 and 10 years are much lower (Table 1-1)[58, 86].
Outcome from melanoma can be influenced by factors specific to the patient and to the
tumour. Many of these factors have been identified by studying outcome in large
cohorts of patients and are currently used to provide general prognostic estimates for
patients with melanoma in the form of the American Joint Committee on Cancer
(AJCC) Staging Guidelines (Table 1-1) [58]. I will review the current factors used for
staging of melanoma tumours and then describe additional factors which influence
prognosis, but are not currently included in staging criteria.
1.7.1 Prognostic factors currently used in melanoma staging
1.7.1.1 Primary tumour features
1.7.1.1.1 Breslow thickness
Tumour thickness was identified as an important prognostic factor in melanoma in 1953
[87] and was further developed by Breslow in 1970, who suggested that measurement
of maximal tumour thickness can be used to calculate maximal cross-sectional area of
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tumour which is proportional to tumour volume [88], which further correlates with
prognosis [89, 90]. This was incorporated into the AJCC staging system and remains
the most important single prognostic factor in localised melanoma today [58, 91]. It is
now accepted that Breslow thickness is a more powerful prognostic factor than level of
invasion as described by Clark et al. [92, 93]. Breslow thickness is also predictive of
survival in patients with nodal metastases (stage III) disease [58, 59].
1.7.1.1.2 Tumour ulceration
Ulceration of a primary melanoma is defined as absence of intact epidermis, including
stratum corneum and basement membrane [94]. Primary tumour ulceration is a
powerful prognostic factor in both localised melanoma and stage III melanoma [58, 59].
Breslow thickness remains the strongest predictor of survival in localised disease,
however presence of ulceration influences survival from tumours strongly, modifying
survival to that of a non-ulcerated melanoma in the next thickness category [58].
Further discussion of the pathogenesis and prognostic influence of ulceration is
presented in Chapter 7.
1.7.1.1.3 Mitotic rate
The mitotic rate (number of mitoses seen per mm2 in the most mitotically active
component of viable tumour sample) reflects proliferation and is a strong independent
predictor of survival [58] A number of studies have demonstrated that the presence and
number of mitoses within a stage I or II tumour strongly correlates with prognosis
second only to tumour thickness [95-98]. The 7th edition of AJCC staging criteria has
replaced Clark level with mitotic rate ≥1 mitoses/mm2 as a primary criteria (with
ulceration) for defining a subcategory T1b [58].
1.7.1.2 Nodal metastatic disease (stage III)
Development of metastases is associated with poorer prognosis and is influenced by
interaction between tumour characteristics, such as high proliferative rate and host
factors, for example the immune system and physical barriers such as walls of
lymphatic vessels. Development of metastases represents the tumour breaching host
defences and biological features of the tumour indicating cellular ability to grow in
disparate tissues.
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The number of tumour bearing nodes and whether tumour deposits in involved nodes
are microscopic, being diagnosed after a sentinel lymph node biopsy, or macroscopic,
which are clinically detected, all determine prognosis with smaller burden associated
with better outcome [58, 59]. Location of deposits in sentinel nodes is also of
prognostic importance as deposits confined to the subcapsular sinus are less
frequently associated with more extensive nodal spread, than deposits within the
parenchyma of the node [99]. The size of sentinel node deposits also influences
outcome, with small (<0.1mm) deposits associated with similar prognosis to patients
with a negative sentinel node biopsy [100]. Location and size of sentinel nodal deposits
are not currently integrated into staging criteria, however with more sentinel node
biopsy procedures taking place and improved pathological reporting, this may change
[58]. Primary tumour thickness and ulceration remain prognostic in stage III disease
[58, 59]. In transit or satellite metastases are considered as intralymphatic metastases
and consequently associated with poorer prognosis equivalent to that of stage III
disease [101, 102].
1.7.1.3 Systemic metastatic disease (stage IV)
In stage IV disease, non-visceral metastases to skin, subcutaneous tissues and lymph
nodes are associated with better survival than metastases at visceral sites [58, 91].
Furthermore, lung metastases are associated with better prognosis than other visceral
sites [58, 103, 104]. These survival differences are likely related to biological
differences between tumours able to grow in different tissues, but the determinants are
as yet poorly understood.
Elevated serum levels of lactate dehydrogenase (LDH) correlate with poor prognosis in
stage IV disease [58, 105-108]. This enzyme is widely distributed in cells of many
lineages and levels are increased in the blood in the presence of cellular break down
[108]. Levels of LDH in some cancer patients reflect tumour burden and rate of
proliferation of cells [107, 108]. In the current AJCC guidelines, elevated LDH indicates
a poorer prognosis in stage IV disease irrespective of the metastatic site [58].
Stage TNM Thickness(mm)
Ulceration
and mitotic
rate (per mm2)
No. positive nodes Nodalsize
Distant
metastasis
5-year
survival
%
10-year
survival
%
5 year UK
survival %
10 year UK
survival %
IA T1a ≤1 No andmitosis <1 0 - - 95.3 87.9 95 87-89
IB T1b ≤1 
Yes or
mitosis ≥1 
0 - - 90.9 83.1 88-92 78-85
T2a 1.01-2.0 No 0 - - 89.0 79.2
IIA T2b 1.01-2.0 Yes 0 - - 77.4 64.4 77-79 62-66T3a 2.01-4.0 No 0 - - 78.7 63.8
IIB T3b 2.01-4.0 Yes 0 - - 63.0 50.8 61-70 49-57T4a >4.0 No 0 - - 67.4 53.9
IIC T4b >4.0 Yes 0 - - 45.1 32.3 43-47 31-34
IIIA N1a Any No 1 Micro - 69.5 63.0 57-73 50-67N2a Any No 2-3 Micro - 63.3 56.9
IIIB
N1a Any Yes 1 Micro - 52.8 37.8
41-57 29-53
N2a Any Yes 2-3 Micro - 49.6 35.9
N1b Any No 1 Macro - 59.0 47.7
N2b Any No 2-3 Macro - 46.3 39.2
N2c Any No
In transit
metastases/satellites
with no metastatic
nodes
- -
IIIC
N1b Any Yes 1 Macro - 29.0 24.4
20-34 11-29
N2b Any Yes 2-3 Macro - 24.0 15.0
N2c Any Yes
In transit
metastases/satellites
with no metastatic
nodes
- -
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Stage TNM Thickness(mm)
Ulceration
and mitotic
rate (per mm2)
No. positive nodes Nodalsize
Distant
metastasis
5-year
survival
%
10-year
survival
%
5 year UK
survival %
10 year UK
survival %
IIIC
cont. N3 Any Any
4 or more nodes, or
matted nodes, or in
transit
metastases/satellites
with metastatic
nodes
Micro or
macro - 26.7 18.4
IV
M1a Any Any Any Any
Distant skin,
subcutaneous or
nodal
18.8 15.7
5-22
M1b Any Any Any Any Lung 6.7 2.5
M1c Any Any Any Any
Other visceral
metastases or any
distant metastasis
with elevated LDH
level
9.5 6.0
Table 1-1: Survival rates for melanoma based on the American Joint Committee on Cancer staging system for cutaneous melanoma (7th
edition).
Adapted from [58, 102]. Survival rates for pathological stage are for the UK taken from [109], with survival rates for individual TNM staging
taken from [102] which used Clark (invasion) level to determine T1a and T1b stages and has now been replaced with mitotic rate.
Abbreviations used: TNM, tumour, node, metastasis; SEM, standard error mean; SC, subcutaneous; LDH, lactate dehydrogenase.
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1.7.2 Prognostic factors not part of current staging guidelines
1.7.2.1 Tumour factors
1.7.2.1.1 Vascular and lymphatic invasion
As metastasis occurs via lymphatic and blood vessels, it is unsurprising that high
tumour vascularity and presence of lymphovascular invasion in primary tumours has
been associated with poorer prognosis in a number of studies [110-112]. Lymphatic
invasion appears to predominate over vascular invasion in primary tumours [110, 113],
however identification of lymphatic invasion using slides routinely stained using H+E
alone can be difficult as invasion can be focal and it is difficult to distinguish vessel
walls from other stromal tissues without special stains [114]. It has been shown that
use of specific immunohistochemical staining for vessels can increase detection [110,
113]. These factors are not routinely reported on many primary melanoma histology
reports and so have not been assessed in large sample sets, such as the AJCC
staging database. Consequently, these factors do not form part of AJCC staging, but
may represent a primary tumour factor which reflects propensity to metastasis. Use of
immunohistochemical staining for these factors is discussed further in Chapter 7.
1.7.2.1.2 Perineural infiltration
Perineural invasion occurs when melanoma cells invade the nerve sheath and spread
along the protective layer, the perineurium, that surrounds fascicles of nerve fibres
[115]. This feature has been associated with increased incidence of local recurrences
in desmoplastic melanomas which have a tendency to neurotropism [116]. Again, this
feature is often not recorded on histology reports and so associations with prognosis in
large cohorts of melanoma have not been assessed.
1.7.2.1.3 Tumour regression
Regression represents the result of interaction between tumour cells and the host
immune system leading to replacement of tumour cells with non-malignant tissue [64,
117]. Regression can be focal or complete where no tumour cells are present [64].
Regression may lead to underestimation of Breslow thickness which may be related to
greater metastatic potential in thin tumours where regression is seen [118]. It would be
anticipated that an immune response leading to destruction of tumour cells would be
beneficial, but if this process is limited, it has been postulated that cells that survive
and escape immune recognition would be selected and progress [119]. The presence
of regression and influence on prognosis is controversial with some studies suggesting
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that presence of regression is a poor prognostic factor, especially in thin melanoma
tumours [118, 120, 121] and others suggesting it does not influence survival [65, 122,
123]. This may be a consequence of lack of consensus on exact definition and
measurement of regression [117, 118]. As the significance of the presence of
regression on prognosis is unclear, it is not part of current AJCC staging guidelines
[58].
1.7.2.1.4 Tumour infiltrating lymphocytes (TILs)
Tumour-infiltrating lymphocytes (TILs) are an important feature of the immune
response to melanoma [124]. The infiltrate can be brisk (diffuse or involves the entire
base of the tumour), non-brisk (focal infiltration) or absent (no lymphocytes mixed with
melanoma cells) [125], however the reporting of this is highly subjective [65, 114, 117].
Presence of TILs indicates that the host immune system is responsive and that the
melanoma cells can be recognised [126]. Generally presence of TILs has been
reported to be associated with better prognosis [65, 66, 124, 127, 128], however the
exact cellular composition of the infiltrate may have more prognostic and perhaps
predictive value and needs to be assessed in large studies [129]. Currently, TILs are
not part of AJCC staging [58], however presence of a brisk infiltrate appears to
influence prognosis.
1.7.2.1.5 Histological subtype
Melanomas can be grouped by the histopathologist into superficial spreading (70%),
nodular, lentigo maligna and acral lentiginous types, with various other rarer subtypes
[92, 114, 130]. Nodular melanomas quickly spread downwards in the vertical growth
phase, with superficial spreading tumours remaining in the radial growth phase for
variable amounts of time before invading vertically [114]. Lentigo maligna tumours
arise from a pigmented macule which may have been present for years prior to
invasion developing [114]. The biological characteristics of these tumours are therefore
very different and this is reflected in the poorer prognosis associated with nodular
tumours compared to superficial spreading tumours, which in turn have a poorer
prognosis than lentigo maligna tumours [114]. Acral tumours present on the palms,
soles or nail matrix (subungual) are also associated with poorer prognosis which has
been related to late diagnosis and the inherent aggressiveness of acral lentiginous
tumours. This may be related to differing mutational profiles in acral tumours, with
lower incidence of BRAF or NRAS mutations and higher incidence of KIT mutations
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[33, 131, 132]. Again, histological subtype is not included in current AJCC staging
guidelines [58], but is regularly reported on histology reports.
1.7.2.2 Host factors
In 2001, the American Joint Committee on Cancer (AJCC) staging guidelines were
updated for the 6th edition and the committee reported the analysis of 17,600
melanoma patients from 13 cancer centres to identify prognostic factors in melanoma
[91]. This assessment, amongst others, found that increasing age, male sex and
tumours on the trunk, head, neck, palms, soles and under nails were associated with
poorer prognosis [91, 132-134]. In the AJCC study, site of tumour and the age of the
patient continued to influence survival for those with stage III disease [91]. This has
been confirmed more recently in analysis of 2313 patients with stage III disease in the
AJCC melanoma staging database, with age at diagnosis and site of tumour
independently predicting survival in patients with micrometastases, and patient age
remaining independently predictive when macrometastases are present [59].
The poorer prognosis associated with increasing age is especially evident for those
over 60 years of age [135-138]. Older patients are more likely to have thicker or
ulcerated tumours, both of which are important prognostic factors in melanoma,
however the association between age and outcome remains significant when adjusted
for these factors [135-138]. Delayed diagnosis or under-treatment of older patients may
contribute, but melanoma presentation, outcome and pathology appear to be
dependent on the age of the patient and it is unclear whether this is related to the
tumour or the host response [139]. For example, older patients are less likely to
develop regional metastases, but still have poorer survival [140, 141]. Immunological
responses of elderly patients are lower and age-related changes to the lymphatic
system, such as involution of lymph nodes or slower lymphatic flow, may also be
contributing factors [139, 142, 143], however there is likely to be a biological
explanation for this effect.
A recent pooled analysis of European Organisation for Research and Treatment of
Cancer (EORTC) trials in patients with stage I or II disease has confirmed the superior
prognosis for women with a relative survival advantage of 30% [144]. Tumours on the
leg are more commonly found in women, with truncal tumours in men, however women
have a survival advantage for tumours at both of these sites, indicating that primary
location does not explain the difference [144]. Differences in behaviour between the
sexes related to tumour detection and seeking treatment may contribute [145, 146], but
gender is associated with survival independently of factors which may be related to
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tumour detection, such as thickness or stage at diagnosis [146]. The more likely
explanation is biological differences between men and women, perhaps related to sex
hormones, immunological responses, oxidative stress or vitamin D metabolism [144,
147-150]. Understanding this gender effect may tell us something of fundamental
importance about the biology of host/tumour interaction.
As discussed above, the site of a tumour has prognostic significance and is also
related to the gender of the patient. The exception are tumours from the head and neck
which have poorer prognosis, but are not related to gender [144]. These tumours more
associated with chronic sun exposure and have lower rates of BRAF and NRAS
mutations, with greater incidence of KIT mutations [33, 151, 152]. This is a similar
genetic profile to that seen in the poorly prognostic tumours found on the palms, soles
and subungual sites, suggesting that these tumours are inherently more aggressive
[151]. It has been suggested that the poorer prognosis of truncal tumours may be
related to drainage to multiple lymphatic basins [153, 154], but the far more likely
explanation for differing prognosis in tumours according to site is related to biological
differences in the tumours. These factors are not currently integrated into AJCC
staging of melanoma [58], but remain as independent prognostic factors that need to
be taken into account when making assessments of new prognostic indicators.
1.7.3 Limitations of current melanoma staging
Despite the intensive efforts that have been placed into identifying prognostic factors
for patients with melanoma, within every stage of the disease there are still variations
in survival which cannot be explained using current prognostic models [134] and there
are a significant proportion of patients with ‘low-risk’ melanoma who go onto relapse
[121]. There is increasing interest in identification of new prognostic biomarkers to
further individualise risk of progression for patients with melanoma and enable early
therapeutic intervention for those classified at high risk of relapse.
1.7.4 New prognostic biomarkers for melanoma
1.7.4.1 Biomarkers
A biomarker is measurable factor that can be used to indicate a biological process
such as the presence of a disease [155, 156]. Prognostic biomarkers offer information
about outcome from a disease, irrespective of treatment [157], and a number of
prognostic biomarkers already exist for melanoma such as tumour Breslow thickness,
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ulceration or nodal involvement. Additional biomarkers may provide further information
to help further refine prognostic information.
This thesis focuses on identification of biomarkers in melanoma tumour tissue. A
number of biomarkers have been identified in serum, for example LDH as previously
discussed. There has also been interest in germline genetic variation that predicts
outcome in melanoma, for example improved survival in patients with melanocortin 1
receptor gene (MC1R) variants [158], so far investigated predominantly of interest as a
means of understanding host/tumour interaction better. The following section will
review current progress in identification of biomarkers in tumour tissue.
1.7.4.2 Prognostic tumour biomarkers
A number of studies have sought to identify tumour markers that indicate disease
progression or increased chance of recurrence. As discussed above, prognosis in
melanoma is strongly linked to the histological features of the tumour, such as Breslow
thickness, and the ability of the tumour to metastasise and spread. Consequently,
many studies have assessed the relationship between biomarkers and poor prognostic
histological features of the tumour.
1.7.4.2.1 Candidate biomarker studies
Techniques such as gene expression profiling, immunohistochemistry, mutation
screening and comparative genomic hybridization have been used to identify tumour
biomarkers that provide additional prognostic information to that already provided with
histological staging [159]. For this review I have concentrated on studies which have
sought to identify altered gene or protein expression. A number of studies have aimed
to do this using melanoma cell lines, but the vast majority have used tissue samples
and immunohistochemistry [155, 160, 161]. Many studies compared expression in
benign tissues with that in primary or metastatic melanoma samples, or compared
expression in primary melanomas with similar histological features from patients who
do not relapse versus those that go onto relapse. Many reports are of relatively poor
quality often because they were performed using small numbers of samples and were
not validated in other sample/data sets. This was largely a function of the small size of
melanomas and the consequent lack of cryopreserved tumour samples. The studies
also often lacked multivariate analyses which provide vital information as to whether
the biomarker identified adds anything additional to current staging [155, 160, 162].
Some of these markers however have been identified in more than one study, for
example osteopontin [163, 164], E-cadherin [165] [166] and MMP2 [167-169], with
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deranged expression of proteins involved in many biological processes, such as tissue
invasion, cell adhesion, DNA repair and apoptosis. To be considered as a useful
biomarker, these candidates require validation in large, prospective studies [155].
It has been suggested that the lack of consistency across studies is related to
methodological differences, therefore the “REporting Recommendations for Tumour
MARKer prognostic studies” (REMARK) guidelines were published, which recommend
standardised reporting of study design, hypotheses, patients, specimens, assays and
statistical analysis used in prognostic biomarker studies [162]. A recent systematic
review and meta-analysis identified biomarker studies in melanoma which conformed
to REMARK guidelines [161]. The authors specifically assessed reports which used
primary cutaneous melanoma samples, reported clear methodological information
regarding immunohistochemistry techniques used and statistical analysis using
multivariate proportional hazards modelling adjusted for known prognostic factors in
melanoma. They identified 51 eligible studies evaluating 80 proteins [160, 161]. Three
studies assessed the combined effect of three or more proteins in multivariate analysis
[170-172]. In meta-analysis, the use of multiple proteins most strongly predicted
survival, these combinations being p16INK4a, survivin and p53 [170], p16INK4a and
p21WAF1 [171] and RGS1, osteopontin (SPP1) and NCOA3 [172]. Individual proteins
associated with survival were RGS1, nucleolin, HER3, ING4 and β-catenin [161]. 
Overall, proteins involved in the cell cycle (regulation of G1-S transition) were most
associated with progression [161]. Other pathways identified were those involved in
immune responses, transcription, cell adhesion, cytoskeleton modelling, signal
transduction, DNA damage, development, apoptosis and DNA damage [161].
The authors of this study extended their analyses to gene expression data from
microarrays. Across the microarray studies assessed there was evidence at both the
protein and expression level that PCNA and survivin were associated with outcome
and so the authors highlighted these candidates for further assessment [161].
In view of the strength of multiple markers in predicting outcome, there have been high
hopes that the development of gene expression arrays, allowing assessment of
thousands of genes in a single sample, would identify single genes or profiles of genes
associated with outcome and I will review the results of these studies now.
1.7.4.2.2 Identification of gene expression signatures
A number of studies have now been published using gene expression microarray
technology to identify genes which are differentially expressed in melanoma tumours
associated with prognosis, tumour progression or differing histological features. The
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advantages of this technique are that novel genes can be identified which may serve to
provide essential biological insight into the disease. Profiling of thousands of genes
allows biological pathways to be assessed as a whole, again providing critical
information about gene expression derangement. Some of the studies have used cell
lines to identify genes differentially expressed in lines with differing characteristics
[173-175]. Other studies have used frozen melanoma samples to identify gene
signatures associated with relapse or progression and are summarised in Table 1-2.
The main deficiencies of these studies to date are the small number of samples
assessed and the limited number of studies using primary melanoma tissue. This is
because frozen tissue is required to extract enough high quality RNA from tissues for
use with traditional gene expression microarrays, and as melanoma tumours are small
and require extensive pathological assessment to accurate stage a tumour, availability
of frozen tissue is limited. I will discuss this further in Chapter 3 and section 1.9 as the
microarray assay used to produce results for this thesis is designed for use with
degraded RNA samples from well-annotated FFPE archival tissue with mature follow-
up data.
Microarray studies have demonstrated that up-regulation of DNA repair and genes
involved in the cell cycle or cell division are associated with progression of tumours and
poorer outcome [175-180]. They have also shown that genes involved in cell adhesion
and invasion are associated with progression [175, 176, 181-184], with over-
expression of genes associated with the immune system associated with a better
prognosis [179, 180, 183, 185]. A unpublished study of 79 frozen metastatic specimens
has also found an association between immune response gene expression profiles and
survival in stage III disease [186].
The meta-analysis of Schramm et al. (2011) identified only two microarray gene
expression studies assessing gene expression in primary tumours reported to
REMARK standards [161]. One of these studies is based on the data presented in
Chapter 3 [187], the other by Winnepenninckx and colleagues [178]. Bioinformatic
analysis of the Winnepenninckx microarray gene expression data in primary tumours
revealed that expression of genes involved in the cell-cycle metaphase checkpoint was
most deranged along with other cell cycle pathways [161]. Other pathways involved
were apoptosis, immune responses and DNA damage [161]. When this analysis was
extended to studies of metastatic tumour reported to REMARK standards, six studies
were assessed [188]. Genes associated with immune response processes and the
NRAS-regulation pathway were over-represented in these datasets [188]. Cross-
validation of signatures between datasets predicted outcomes with low levels of
Samples Number of samples Methods Outcomemeasure Results Reference
Frozen naevi
and MM 6 naevi, 6 tumours
298 gene custom array, 9 genes
validated with qRT-PCR Progression
THBD, FABP7, H2AFJ, RRAGD, MYADM,
HR, CKS2, NCK2 and GDF15 associated
with progression
[189]
Frozen naevi,
primary and
MM
9 naevi, 6 primary
tumours, 19 MM.
Independent 25 primary
melanoma validation
group
19,740 gene array, 2 genes
validated with IHC in validation
group
Progression
2602 gene signature that correlated with
sample class including MMP10 and
cadherin-3
[182]
Frozen skin,
benign and
atypical naevi,
early and MM
2 skin samples, 4 naevi,
6 early melanomas, 3
MM. Separate validation
set of 2-4 tumours per
stage of melanoma
progression
14,500 array, 2 genes validated in
separate samples. 1 gene validated
with immunoblot in cell lines
representing vertical growth phase
and MM
Progression
Gene were found to be over-expressed
(e.g. osteopontin) and under-expressed
(e.g. dermcidin) in MM
[190]
Frozen skin,
benign naevi
and primary
melanomas
7 skin samples, 18 naevi,
45 melanomas
14,500 array, 3 genes validated
with qRT-PCR in 14 melanoma
samples, 7 naevi and 5 skin
samples (from same sample set as
array data)
Progression
Genes differentially expressed between
benign and melanoma samples, including
L1CAM and PLAB
[184]
Frozen MM
and normal
melanocytes
10 tumours
1.2K human cancer array and
human apoptosis array, 1 gene
validated with qRT-PCR, 2 genes
validated with Western blots
Progression
Hepatocyte growth factor receptor, c-met,
growth-factor receptor bound protein 10,
BRAF and several mitogen activated
protein kinase genes were up-regulated
[191]
Frozen benign
naevi and MM 4 naevi, 4 tumours
14,000 array, 1 gene validated with
qRT-PCR in cell lines, 11 naevi and
4 MM tumours and with IHC in 35
naevi and 103 tumours
Progression
190 genes significantly over-expressed in
tumours compared to naevi including
osteopontin, which was validated using
qRT-PCR and IHC
[192]
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Samples Number of samples Methods Outcomemeasure Results Reference
Frozen primary
melanomas
83 primary melanomas,
58 patients with 4 years
follow-up.17 sample
independent validation
set. Further IHC
validation independent
set of 176 primary
tumours
Whole human genome 41,000
microarray, 23 proteins confirmed
with IHC. Gene signature validated
in independent sample set. Five
genes associated with survival in
larger validation set with IHC
DMFS (OS in
IHC validation
set)
254 gene signature associated with DMFS:
genes involved in activating DNA
replication, e.g. minichromsome
maintenance genes, geminin
[178]
Frozen MM 43 tumours samples from38 patients
17,500 gene array, 2 genes
validated with IHC. Survival
prediction model cross-validated in
dataset
OS
70 genes associated with survival. Immune
cell genes in survival group, cell
proliferation and invasion genes in poor
survival group
[183]
Frozen primary
and MM
19 primary melanomas,
22 MM. Independent
validation set of 20
primary and 20 MM
14,500 gene array, 9 genes
validated with immunoblots in a cell
line. 4 genes validated in an
independent set using IHC.
Progression
308 genes differentially expressed
between primaries and MM. Associated
with cell cycle, mitosis, cell communication
and cell adhesion.
[176]
Frozen primary
melanomas
34 tumours, independent
validation set of 127
primary tumours
2,489 cancer gene cDNA array, 5
genes validated with IHC in
separate cohort
Metastatic
disease
(DMFS in
validation
group)
243 genes with differential expression in
tumour types. N-cadherin, SPP1 and
SPARC/osteonectin were associated with
metastasis development in validation group
[164]
Frozen primary
melanomas
Sample set as
Winnepenninckx et al.
(2006), 60 patients with 4
years follow-up
As above, then dataset analysed
using “Searching for a biological
interpretation of microarray
experiments (SBIME)” with Gene
Ontology annotations
DMFS
DNA repair and DNA replication pathways
most significantly associated with
metastasis
[177]
Frozen MM
29 patients, 2
independent validation
sets of 10 and 14 MM
30,888 probe array, 21 genes
validated with qRT-PCR. 2
predictive scores validated in
independent sample sets
Progression
to stage IV
2140 genes differentially expressed,
including immunological signalling [185]
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Samples Number of samples Methods Outcomemeasure Results Reference
Frozen primary
cutaneous
cancers (and
primary
melanomas)
and MM
40 MM, 42 primary
cutaneous cancers (16
melanomas)
14,500 gene array, 6 genes
validated with qRT-PCR, 4 genes
validated with Western blots
Progression
Gene signature identified when transition in
expression from intermediate thickness
tumour to thick tumour. Several oncogenes
(Osteopontin, MITF etc.) and suppressor
genes (PITX-1, CST-6 etc.) change
expression
[193]
Frozen MM 44 tumours from 38patients
>47,000 transcript array, gene
signature associated with survival
validated in data from [185]
OS
266 genes identified as associated with
survival. Good prognosis genes were
associated with immune responses and
poor prognosis with cell proliferation
[179]
Frozen MM
Tumours from 57
patients, independent
validation sample set of
20 tumours
>47,000 transcript array, signatures
validated in separate cohort and
gene expression data from [179]
OS
Four distinct subtypes of tumour based on
gene expression, with tumours of a
proliferative subtype associated with poor
prognosis and immune gene expression
associated with better prognosis
[180]
Frozen MM
32 tumours validated in
independent set of 89
MM
>47,000 transcript array, qRT-PCR
and IHC used to assess expression
of TYRP1 in validation cohort
DMFS and
OS
278 probes associated with survival with
TYRP1 most associated [194]
Table 1-2: Studies using microarray technology to identify genes associated with prognosis or progression in melanoma tissue samples.
Abbreviations used: MM, metastatic melanoma; qRT-PCR, quantitative Real-time PCR; IHC, immunohistochemistry; DMFS, distant metastasis
free survival; OS, overall survival.
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misclassification, highlighting the importance of these pathways [188]. The authors of
this review suggested that all new gene signatures should be assessed in a
multivariate analysis with current prognostic clinico-pathological factors to identify
whether gene expression adds to current prognostic algorithms [188]. Discussion of
approaches for analysis of groups of genes using bioinformatics techniques is
discussed further in Chapter 4.
As technology develops, it is likely that RNA-sequencing (RNA-seq), where cDNA
synthesised from RNA is sequenced using next generation sequencing, will be
increasingly used to identify genes with altered expression levels associated with
melanoma prognosis [195, 196]. This method directly sequences the transcript which is
mapped back to a reference genome, reads are then counted to assess the level of
gene expression [197]. As the transcript is sequenced directly, this technology has
many advantages, including detection of alternative splice variants and detection of
transcripts from gene fusion events [198].
1.8 Treatment of melanoma
For patients with thin primary melanomas with no metastatic spread, treatment is
surgical removal of the primary lesion and prognosis is excellent [58]. However for
those with thick tumours or nodal spread (stages IIB-III) survival at 5 years is much less
at 20-70% (Table 1-1) [109]. This group of patients are classified as having disease at
high-risk of relapse and adjuvant treatments have been investigated in clinical trials to
try to prevent recurrences in this high-risk group. For patients with stage IV disease, 5-
year survival rates are 5-22% [109] and until relatively recently, chemotherapy and
radiotherapy regimens were used only as palliation with very few long term survivors.
More effective treatment options for stage IV disease are now found in the form of
BRAFi [199] and immunotherapies [60, 61].
I will briefly review adjuvant therapies for melanoma and treatment options for stage IV
disease and then concentrate on interferon- (IFN) and chemotherapy with
dacarbazine or temozolomide which are discussed further in this thesis. These are
older approaches to treatment. They are of relevance here as these were the only
options when I started my work and because they are likely to retain some value for the
foreseeable future in patients without targetable oncogenic mutations. Furthermore
both DTIC and IFN have a demonstrable therapeutic effect albeit in a small proportion
of patients with melanoma and understanding the biological determinants of those
effects is important.
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1.8.1 Adjuvant therapies
Adjuvant treatments are used after tumour has been surgically removed to help reduce
risk of recurrence. A range of adjuvant regimens have been tested in melanoma
including chemotherapy, immunotherapy, radiotherapy, anti-angiogenic therapies and
combination chemo-immunotherapy [200, 201]. Overall, studies assessing these
agents have not demonstrated any survival benefit. The only promising results have
come from use of IFN [200, 202-205] and ipilimumab [206].
Ipilimumab, is a monoclonal antibody that blocks the cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4). Expression of the CTLA4 protein causes inhibition of T
cell activation and proliferation [207, 208]. In the adjuvant setting, a phase II trial of
patients with high-risk resected stage IIIC or IV melanoma, was associated with
improved survival outcome [209] and a phase III EORTC trial is on-going to assess this
further in patients with stage III (with metastases >1mm) disease [206].
Part of this thesis focuses on identification of factors associated with benefit from IFN
therapy, therefore I will discuss the evidence for use of IFN in further detail.
1.8.1.1 Interferon- (IFN)
1.8.1.1.1 Action of endogenous type 1 interferons
Interferons are cytokines which have direct antiviral and anti-proliferative effects, but
also enhance immune recognition of viruses and tumour cells [210]. IFN- is a type 1
interferon as is IFN- [211]. The major producers of type 1 interferons are plasmocytoid
dendritic cells, which present antigen from tumour cells or viruses to T lymphocytes
[212]. Type 1 interferons are also produced by T cells, monocytes, macrophages and
natural killer cells [213]. Effects of type 1 interferons are predominantly mediated
through the IFN receptor [214] which activates the JAK-STAT pathway (Figure 1-4).
This signalling cascade induces expression of hundreds of IFN stimulated genes
(ISGs) associated with a number of biological processes [211, 213, 214] (Figure 1-5).
IFN can have direct anti-proliferative effects on tumour cells by decreasing activity of
cyclin dependent kinases (CDK) in the cell cycle via influences on function and
expression of CDK2, cyclins, the transcription factor, E2F, retinoblastoma protein and
CDK inhibitors, such as p15INK4b [215-217]. The effects of IFN on host immunity have
been reported to play a more central role in tumour response than direct
antiproliferative effects [218]. These include increased anti-tumour responses by
cytotoxic T cells and natural killer cells and reduction of regulatory T cells [219-221]. In
view of the numerous actions of interferon, additional exogenous interferon therapy
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would be expected to have a direct anti-proliferative effect on the tumour and aid the
immune system in halting progression of any residual tumour that may be present
following surgery or in-transit melanoma cells. However, clinical trials which have
aimed to identify clear overall survival benefit with IFN therapy have yielded conflicting
results. This may reflect tumour-induced immune suppression, for example defects in
IFN signalling in lymphocytes, and tumour evasion of anti-tumour immune responses
[70, 222-224].
1.8.1.1.2 Clinical trials of interferon- in melanoma
There have been 14 randomised controlled trials to date comparing use of adjuvant
IFN versus observation in patients with high risk melanoma with dosing regimens
varying between trials [205, 225]. Results from these studies are conflicting. Some
showed benefit in terms of prolonging relapse free survival (RFS) with little influence on
overall survival (OS) [226-228] whereas others showed no benefit [229, 230]. However,
in meta-analysis, it was clear that IFN does provide benefit in terms of RFS (hazard
ratio from most recent analysis 0.82 (95% CI 0.77-0.87), p<0.001), with a less clear
benefit in terms of OS time (HR 0.89 (95% CI 0.83-0.96), p=0.002) [203-205]. Dose
and duration of IFN therapy did not appear to influence these effects [203-205]. In the
most recent trial comparing pegylated IFN therapy (pegylation prolongs action of IFN
so less injections are required) with observation, particular benefit was seen in RFS
and OS for patients with microscopic nodal involvement compared with palpable nodal
involvement and ulcerated primary tumours were more sensitive to IFN than non-
ulcerated tumours [227]. The association between primary tumour ulceration and IFN
benefit has been confirmed in recent meta-analysis of IFN trials [204, 227, 231]. This
association will be explored in further detail in Chapter 7.
IFN therapy is associated with significant side effects, including most commonly
fatigue, but also myalgia, arthralgia, anorexia, depression and liver toxicity [69, 229,
230]. The frequency of side effects is related to the dose of IFN received, with 15% of
patients terminating treatment due to toxicity in lower dose regimens [230], increasing
to 31% of patients in higher dose regimens [227]. For those patients who persevere
with IFN therapy, treatment has been demonstrated to have a detrimental effect on
their quality of life [232]. IFN causes release of a cascade of cytokines including tumour
necrosis factor- (TNF-), interleukin-1 (IL1), IL2, IL6, IFN- and IFN inducible protein
10. These cytokines initiate cellular processes that produce many of the observed
toxicities associated with IFN therapy [233]. The mechanism of hepatotoxicity
associated with IFN is poorly understood [234, 235].
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Figure 1-4: Activation of the classical JAK-STAT pathway by type 1 IFN.
The IFN receptor subunit, IFNAR1 is associated with TYK2 and IFNAR2 is
associated with JAK1. Phosphorylation and activation of TYK2 and JAK1 result in
tyrosine phosphorylation of STAT2 and STAT1, which leads to formation of
STAT1-STAT2-IRF9 complexes, also known as ISGF3 complexes [236]. These
complexes move to the nucleus and bind to ISREs in DNA and initiate
transcription of ISGs. Figure adapted from [211, 214]. Abbreviations used:
IFNAR1 and IFNAR2, IFN receptor subunits; TYK2, tyrosine kinase 2; JAK1,
Janus activated kinase 1; STAT, signal transducer and activator of transcription;
IRF9, IFN-regulatory factor 9; ISGF3, IFN-stimulated gene (ISG) factor 3; ISRE,
IFN-stimulated response element; ISG, IFN stimulated genes.
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Figure 1-5: Production and action of endogenous type 1 interferons.
Reviewed by [211, 214, 220]. Abbreviations used: MHC, major histocompatibility
complex.
IFN appears to provide benefit in terms of prolonging RFS time for patients with
melanoma, but this benefit is limited by the toxicity associated with use of the drug.
Currently clinicians cannot identify those patients who will obtain an overall benefit from
IFN therapy so there is no standard systematic adjuvant therapy recommended in
Europe for those with resected high risk melanoma [76, 200, 237].
1.8.2 Treatment of stage IV disease
Metastatic melanoma has a dismal prognosis and until recently, treatment was limited
to chemotherapy with dacarbazine (DTIC) or temozolomide (TMZ). Recent advances
have seen the development of immunotherapies and targeted therapies which are
effective in stage IV disease. In phase III trials, the anti-CTLA4 antibody, ipilimumab,
improves survival in unresectable stage III and stage IV disease compared to peptide
vaccine or DTIC [60, 61]. As with IFN therapy, the use of ipilimumab is limited by the
significant incidence of immune related side effects [60, 61, 206]. Investigation into new
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immunoregulatory monoclonal antibodies with less toxicity continues. For example,
antibodies against another molecules that regulate T-cell activation, such as the
programmed death-1 protein (PD-1) and its ligand PD-L1 have shown promising
results [238-241].
The BRAFi, vemurafenib, has been shown to prolong survival in a phase III trial with a
relative reduction of 74% in risk of either death or disease progression and a 48%
response rate in patients with metastatic melanoma with a BRAF V600E mutation
compared to DTIC [199]. Despite the initial responses seen with vemurafenib,
treatment is associated with side effects, such as development of cutaneous squamous
cell carcinomas and keratoacanthomas [199, 206]. Of greater concern, is that
resistance to vemurafenib invariably develops and understanding the mechanism by
which a BRAF mutation modifies gene expression will greatly assist the intensive
efforts underway investigating mechanisms of resistance [199, 206, 242].
Despite these significant advances in treatment of advanced disease, use of
ipilimumab is limited by side-effects [60, 61, 206] and use of vemurafenib is limited to
the approximately 40% of patients with tumours with mutated BRAF and resistance is
an issue [31, 199, 206, 242]. Therefore, chemotherapy with DTIC and TMZ still has a
role in treatment and is discussed in further detail.
1.8.2.1 Chemotherapy for stage IV disease
First line chemotherapy for advanced melanoma is DTIC, which achieves response
rates of 7-13%, with a further 15-28% having stable disease, but few of these
responses are long-lasting [243, 244]. Despite numerous trials to assess combination
chemotherapies and chemotherapy in combination with IFN or interleukin-2 (IL2), none
of these regimens prolong survival and any survival benefit is negated by toxicity and
expense of the agents [245, 246]. Therefore, DTIC monotherapy is regularly used for
patients with stage IV disease. DTIC is an alkylating agent which methylates DNA at
the O6-position of guanine. During cell replication this causes mutations and following
mismatch repair, double-stranded breaks in DNA which eventually lead to cell death by
apoptosis [247]. Temozolomide (TMZ) is also an alkylating agent used in melanoma
which undergoes spontaneous conversion to the active alkylating agent 5-(3-
methyltriazen-1-yl)imidazole-4-carboximide (MTIC) which has similar actions to DTIC
[248]. TMZ has the advantage that it is can be administered orally and it crosses the
blood-brain barrier making it suitable for treatment of brain metastases. TMZ has
similar efficacy to DTIC [243, 249], and so is frequently used in melanoma.
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In common with adjuvant IFN therapy, response to DTIC treatment cannot currently be
predicted and predictive biomarkers of response would assist clinicians and patients in
being able to decide whether DTIC treatment is worthwhile.
1.8.3 Personalized therapies for melanoma
Predictive biomarkers provide information about likely responses to treatment [157].
Host and tumour factors may influence how a patient and a tumour respond to
treatments such as IFN or chemotherapy. Patient characteristics may influence toxicity
derived from a therapy or efficacy by modifying metabolism of a drug. Tumour
characteristics such as the presence of mutations or altered gene expression may
influence how effective a treatment is if the therapy targets the pathway affected by the
genetic alteration, for example BRAF mutations predict response to BRAFi [199].
As the focus of this thesis is on identification of biomarkers in tumour tissue, in the next
section, I will review the tumour factors that have been associated with treatment
benefit from IFN and DTIC chemotherapy.
1.8.4 Tumour factors that predict benefit from IFN therapy
As mentioned previously, patients with ulcerated tumours or those with microscopic
nodal involvement appear to receive greater survival benefit with IFN therapy [204,
227, 231]. An EORTC trial is underway comparing adjuvant therapy with pegylated IFN
or observation in patients with ulcerated melanoma and/or low lymph node burden to
investigate this further. The biological significance of melanoma ulceration is
furthermore unclear; because it is such a strong prognostic indicator and predictive
factor, there is a need for better understanding of the biological processes in an
ulcerated tumour and I will report an investigation of this in Chapter 7.
In melanoma cell lines, expression of a number of genes and proteins have been
associated with IFN resistance or sensitivity. These genes have been identified using
techniques such as gene expression microarrays and proteomic approaches. Many are
associated with the classical IFN signalling pathway such as IFN-regulated
transcription factors and genes with IFN responsive promoter regions [250-254]. Other
markers identified include HLA antigens along with novel genes not previously known
to be regulated by IFN [255]. Functional studies in cell lines have demonstrated that
epigenetic mechanisms may also influence responses to IFN therapy [256-258]. These
findings provide insight into the mechanisms of IFN resistance in cell lines, but require
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confirmation in tumour samples before being considered as potential predictive
biomarkers.
In a small study using 26 primary melanoma tumours which were methylthioadenosine
phosphorylase (MTAP) positive using immunohistochemistry, patients who received
IFN received significant benefit in terms of OS than those who did not receive IFN
therapy. This observation was not seen in MTAP negative tumours [259]. MTAP
catalyses phosphorylation of methylthioadenosine (MTA). MTA inhibits
methyltransferase which reduces the level of methylated STAT1 in cells, methylated
STAT1 is required for growth inhibition of cells by IFN so when MTAP is present in cells
there are higher levels of methylated STAT1 which would correlate with the
observation of better IFN response in MTAP positive tumours [260-262]. The
association between STAT1 and STAT3, which down-regulates response to IFN, was
further investigated in a small study of nodal tumour tissue from 21 patients.
Phosphorylated STAT1 and STAT3 were identified using IHC and higher
pSTAT1/pSTAT3 ratios before treatment were associated with longer OS after IFN
therapy [263].
Again, studies using tumours to identify predictive markers of IFN benefit have been
few and small. A well powered study to identify gene expression in tumours which
correlates with IFN benefit would be likely to identify candidates which would provide
insight into mechanisms of IFN resistance in melanoma cells and perhaps identify
predictive markers of survival benefit or toxicity which could be used clinically.
Currently tumour ulceration represents a predictive marker and further investigation
into the biological processes of ulceration may provide insight into mechanisms of IFN
responsiveness and is the subject of Chapter 7.
1.8.5 Tumour factors that predict response from chemotherapy
In view of the DNA damage caused by DTIC/TMZ therapy, over-expression of genes
related to DNA repair in melanoma tumours has been postulated to be linked to the
chemoresistance of melanoma [264]. The association between expression of candidate
DNA repair genes and chemotherapy responses has been explored by a number of
previous authors. Examples of genes and pathways investigated are O6-
methylguanine-DNA-methyltransferase (MGMT), which removes alkyl groups from
DNA [265-273], the mismatch repair pathway [248, 265, 274, 275] and the base
excision repair pathway [265, 276-278]. The association between DNA repair gene
expression and chemotherapy response is this subject of Chapter 8 and will explored
further in this chapter.
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Bcl-2 is a antagonist of apoptosis and over-expression is common in melanoma,
particularly in melanoma metastases that do not respond to chemotherapy [279, 280].
Studies have shown that use of BCL2 antisense therapy and small-interfering RNAs
sensitizes melanoma to apoptosis inducing therapies such as DTIC [279, 281],
highlighting the importance of this protein in chemoresistance.
Isolated limb perfusion of chemotherapeutic drugs is occasionally used for treatment of
metastatic melanoma. Melphalan is the chemotherapy typically used for these
procedures and is also classified as an alkylating agent [282]. In a study of 30 patients
treated with isolated limb perfusion with melphalan, high expression of the tumour
suppressor p16INK4a and absence of an activating BRAF mutation independently predict
response to therapy [283].
Large-scale screens of cell lines from cancers which are either sensitive or resistant to
chemotherapeutic regimens, other than DTIC or TMZ, have used genomic and gene
expression analysis to identify biomarkers which predict chemotherapy sensitivity in
validation datasets [284-287]. In vitro drug sensitivity assays of melanoma cells have
been assessed as a means of identifying those patients with melanoma who will
respond to non-standard chemotherapeutic regimens with some success [288]. These
assays have also been used in other cancers [289]. Results from these approaches
are promising and could be extended to DTIC or TMZ in melanoma treatment in the
future.
In summary, there are a number of tumour biomarkers which have been linked with
chemotherapy response. To assess these further, a well-powered study is required
with robust response data, ideally to Response Evaluation Criteria in Solid Tumours
(RECIST) standards [290]. I have developed such a study during my PhD, which is
described in further detail in Chapter 8.
1.9 Formalin-fixed paraffin embedded tissue (FFPE) for
identification of prognostic and predictive biomarkers
Identification of prognostic and predictive biomarkers in melanoma would be greatly
enhanced by being able to use stocks of FFPE tissue from patients with long-term
follow-up and information about current prognostic markers. Use of FFPE tissue has
been limited in the past because of the severely degraded nature of RNA and DNA
extracted from such tumour blocks, which has been unusable in many assays [291].
This thesis describes the analysis of FFPE melanoma tissue with new technologies,
specifically designed for use with degraded nucleic acids, and more established
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techniques, to identify prognostic and predictive biomarkers. I will briefly discuss some
of the methodological issues faced when working with small melanoma tumours to
identify genetic markers of prognosis and responses to therapy.
As previously discussed, histological examination of melanoma tumours is essential to
accurately assess features that have prognostic value such as Breslow thickness or
mitotic rate. Histological specimens are routinely fixed for histological diagnosis using
formalin and then embedded in paraffin to allow sections to be taken for staining and
histological review. Formalin is a cross-linking fixative which preserves tissue and
cellular structure by cross-linking proteins and nucleic acids [77]. When nucleic acids
are extracted, cross-links cause degradation. Furthermore addition of monomethylol
groups to bases can interfere with down-stream reverse transcription and amplification
reactions [292]. Despite modifications to RNA extraction protocols, RNA can be
severely degraded being less than 300 base pairs in length, limiting the ability to
examine variation in RNA [291]. Therefore, use of microarray technology has been
limited with RNA extracted from FFPE tissue, restricting the use of this valuable tissue
resource. This thesis describes use of the cDNA-mediated annealing, selection,
extension and ligation (DASL) assay (Illumina, San Diego, CA) to assess gene
expression in FFPE melanoma samples. DASL was specifically designed for use with
degraded RNA, such as that extracted from FFPE tissue [293] and produces
reproducible gene expression results from degraded RNA [293-297].
1.10Outline of thesis chapters
To address the major aims of the thesis outlined in section 1.1, I will briefly outline the
contents of the chapters of this thesis.
Chapter 2 describes the patients, samples and methods used throughout the thesis. It
also presents methodological work assessing use of new technologies and discusses
techniques for tumour sampling.
Chapter 3 presents results using the DASL assay to identify prognostic markers in
FFPE primary melanoma tumours. It includes an assessment of quality control
measures to predict assay performance and validates findings in an independent
sample set.
Chapter 4 describes use of the DASL assay to identify a group of genes with
prognostic significance in primary melanoma tumours. This chapter includes an
assessment of gene ontology and pathway analyses with gene expression microarray
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data. Development of methods for validation of DASL results using quantitative Real-
time PCR with FFPE melanoma tissue are also presented.
Chapter 5 describes a pilot study to assess the performance of the DASL assay using
very small sentinel node biopsy samples. Results from nodal specimens are compared
with matched primary tumours to identify genes associated with metastatic
progression. This chapter also includes an assessment of quality control methods for
the DASL assay in different tissue types.
Chapter 6 reports identification of BRAF and NRAS mutations in primary melanoma
tumours and identifies associations between mutation status, clinico-pathological
factors and outcome. This chapter also presents gene expression profiles associated
with mutation status.
Chapter 7 describes analyses to identify factors associated with primary tumour
ulceration to gain insight into the prognostic and predictive significance of this tumour
factor. Clinico-pathological factors independently associated with ulceration are
identified in a large cohort of patients, with tumour gene expression profiles and
immunohistochemical features assessed for a subset of patients.
Chapter 8 presents results of analyses using medium-throughput gene expression
platforms assessing associations between DNA repair gene expression and response
to DTIC or TMZ chemotherapy. This chapter includes a methodological assessment of
the Fluidigm gene expression profiling system with FFPE melanoma tissue. It also
describes the study design for the “Predicting Response to Chemotherapy” study,
which I started during my PhD.
Finally, Chapter 9 will summarise the main findings of my thesis, discuss limitations
and describe future work that will be required.
- 37 -
2 Methods
2.1 Aims
The aims of this chapter are:
 To describe the studies from which patient samples and clinical data have been
derived for work presented in this thesis.
 To describe methodology used throughout the thesis.
 To justify use of tissue microarray needles to sample melanoma tumour tissue.
 To describe an assessment of the Illumina Whole-Genome cDNA-mediated
annealing, selection, extension and ligation (DASL) HT assay with RNA
extracted from formalin-fixed paraffin-embedded (FFPE) melanoma tissue.
2.2 Patients and samples
2.2.1 Samples from patients recruited to studies
Samples from patients recruited to the following studies have been used repeatedly in
the work I will present in my thesis. Studies have received ethical approval for use of
tissue samples. The Leeds Melanoma Cohort Study and Retrospective Sentinel Node
Biopsy Study were underway when I started my PhD.
2.2.1.1 Leeds Melanoma Cohort Study
Patients diagnosed with melanoma in the Yorkshire and Northern region of the UK
have been recruited to a population-based case-control/ cohort study since 2000. The
aims of this study are to identify histological and molecular predictors of survival in
primary melanomas, to investigate how hereditary variation in melanoma patients
influences how a patient interacts with their tumour, how somatic changes in tumour
may influence hereditary effects and to assess how environmental factors influence
survival. A total of 2135 patients have been recruited and recruitment of patients
ceased on 31st December 2011, except for those with melanomas of rare (sun-
protected) sites. For each case, lifestyle indicators and lifetime environmental exposure
data have been collected using questionnaires, and blood samples have been taken for
DNA, lymphocytes, serum and plasma extraction. Patients have been followed-up
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using annual questionnaires to identify melanoma relapses, and their general
practitioners have been asked to complete updated surveys on their health/relapse
status every two years. Further information relating to tumour relapse and overall
survival has been obtained from hospital notes and the Office for National Statistics.
Primary melanoma tumour samples are being been traced for each case.
Between September 2000 and December 2001 and from July 2003 until December,
patients with tumours of Breslow thickness less than 0.75mm were not recruited in
order to increase the power of the study to identify predictors of relapse as tumours
thinner than 0.75mm are usually cured by excision. Between January 2002 and June
2003 all patients diagnosed with invasive melanoma were recruited to the study for the
purpose of the case-control component of the study. For this thesis, I will present data
derived from the first 254 FFPE primary melanoma tissue blocks identified from
patients with tumours greater that 0.75mm with the longest follow-up period. Approvals
for the study have been granted by the Multicentre Research Ethics Committee
(MREC) (1/3/057) and the Patient Information Advisory Group (PIAG) (3-09(d)/2003).
2.2.1.2 Retrospective Sentinel Node Biopsy Study
This study was carried out in order to identify the clinico-pathological predictors of
positive sentinel node biopsy (micrometastases). Patients with tumours equal to, or
greater than 0.75mm in thickness who underwent sentinel node biopsy to identify nodal
metastatic spread of tumour between 1994 and 2006, were recruited from five centres
to this retrospective study. Cases were patients who had had a positive sentinel node
and controls were those with a negative sentinel node biopsy. Controls were randomly
selected to be frequency matched with cases by year of sentinel node biopsy and
centre where the biopsy was performed. Clinical and survival data relating to patients
was obtained from hospital notes and the Office for National Statistics. The first 218
FFPE primary tumour blocks from participants with longest follow-up were used for
work I will present. Ethical approval for the study was granted by Leeds (East)
Research Ethics Committee (06/Q1206/149) and PIAG (3-06(b)/2006).
2.2.1.3 Predicting Benefit from Interferon Treatment: Personalised
Therapy for Melanoma
Melanoma tumour samples are currently being collected for this study, which I
developed and started during my PhD, and aims to identify genetic factors predictive of
benefit from interferon-. Although I set up the study the recruitment to it will continue
beyond my PhD period, and in fact the direction of work that I pursued meant that I did
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not need to use samples from this study as a major component of my work. A number
of samples have been used for methodological work described in this chapter but I will
not report any results from the study in this thesis. Ethical approval for this study has
been granted by the North West Research Ethics Committee (08/H1010/61) and PIAG
(3-06(d)/2008).
2.2.1.4 Predicting Response to Chemotherapy in Malignant Melanoma:
The role of DNA repair genes
This is the second study I developed and ran, with management help from Mr Christy
Walker, a Research Nurse within the research group, during my PhD and the study
design and aims are described in detail in Chapter 8. Melanoma tumour samples are
still being collected for this study to increase the statistical power to determine whether
expression of DNA repair genes is associated with response to chemotherapy in
advanced melanoma, but I have analysed sufficient to report in Chapter 8. A number of
samples have been used for methodological work described in this current chapter.
Ethical approval for this study has been granted by the Yorkshire and Humber Central
Research Ethics Committee (10/H1313/72) and the National Information Governance
Board for Health and Social Care (formerly PIAG) (ECC 8-02 (FT2)/2010).
2.2.2 Central review of tumour histology
For specimens from the Leeds Melanoma Cohort Study and the Retrospective Sentinel
Node Biopsy Study used in gene expression work detailed in Chapters 3, 4, 6, 7 and 8
and immunohistochemical staining described in Chapter 7, diagnostic haematoxylin
and eosin (H+E) slides of tumours were centrally reviewed by Dr Andrew Boon (Leeds
Melanoma Cohort Study) or Professor Martin Cook (Retrospective Sentinel Node
Biopsy Study). Both pathologists were blinded to the contents of the original histology
report. There can be much variability in reporting of melanomas between pathologists
[298, 299], therefore central review of the specimens was undertaken to ensure
consistent reporting of histological features across tumours within each study. This
process also allowed us to obtain a more complete dataset, for example by providing
mitotic rate data which has only recently been added to the American Joint Committee
on Cancer (AJCC) staging guidelines and has not been reported on histology reports
for many of the older specimens used in this study [58]. For tumours from patients
recruited to the Leeds Melanoma Cohort Study, the pathology review was limited to
Breslow thickness, presence of ulceration, mitotic rate and histological subtype of
tumour, whereas review of tumours from patients recruited to the Retrospective
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Sentinel Node Biopsy Study was more detailed including assessment of vascular or
perineural infiltration, presence of tumour infiltrating lymphocytes, regression,
microsatellites and sentinel node biopsy status. For analyses described in Chapter 7,
centrally reviewed data was used where available, if this was not available details from
histology reports were used.
2.2.3 Patient samples used in pilot work
In view of the small size of melanoma primary tumours, pilot work has been undertaken
using metastatic melanoma FFPE nodal samples which are much larger than primary
tumours allowing multiple sampling without exhausting tissue blocks of tumour
material. A total of 14 tissue blocks, from 10 patients were traced from the Pathology
Department from Leeds Teaching Hospitals Trust which were archived between 2000-
2005. Informed consent for use of these tissue samples has been obtained from all
patients and tissue collection was approved by the Leeds Ethics Committee.
2.3 Sampling of FFPE primary melanoma tumour blocks
2.3.1 Justification for sampling using a tissue microarray (TMA)
needle
In this work, sampling of tumour was carried out using a TMA needle inserted
horizontally through the deepest part of the primary tumour containing the lowest
proportion of stromal or inflammatory cells. The projects described here were intended
to allow analysis of unselected, “population-ascertained” primary tumours thicker than
0.75mm. Therefore, this sample set is less biased than are normally available,
especially when frozen samples were used. However most primaries are small and
when selecting sampling procedure the priorities were to sample representative areas
of the tumour without destroying the tissue block.
Loss of the block must be avoided in case it is needed by the patient again either for
review of the histology if the diagnosis is contested, or if the tumour tissue is required
for clinical genetic testing. Thus the need was to balance the clinical needs of the
patient, which are paramount, with the scientific needs of the study. When the Leeds
Melanoma Cohort study was instigated, the clinical need for mutation testing was a
theoretical issue for the future, but became a clinical reality surprisingly quickly during
the study.
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The sampling options were using a TMA needle or taking tissue sections and using
laser capture microdissection (LCM). The decision to use a TMA needle was made by
the group after considering the following:
 Use of a TMA needle leaves the block physically intact so that the site of
sampling can be reviewed subsequently. A section taken after sampling,
compared with a clinical slide leaves a permanent image of the histological
appearances of the tumour sampled.
 The shape of the melanocytic tumour and its relationship with the stroma is not
then prejudiced if clinical re-review of the block is required.
 Sectioning wastes tissue as sections are discarded.
 LCM is too time consuming for large-scale studies.
 LCM is more likely to avoid stromal and inflammatory cells. However, work
done by Dr Caroline Conway, as a previous PhD student, showed that when
cores were horizontally sectioned, a minimum of tumour cells were present
which is widely accepted as being required for accurate results when LCM
cannot be performed [187] with percentages as low at 50% used for
identification of prognostic gene expression profiles in breast cancer [300].
 Much of the work done by the group is directed towards the identification of
biomarkers. Work done in breast cancer research has shown that signatures of
good prognosis are often a result of the presence of inflammatory cells within
the tumour [301, 302]. We judged that clinical tests are more likely to be
feasible using TMA needles than using LCM, although evolving technology may
prove this assumption to be wrong. The group therefore argues that TMA
samples would be appropriate for biomarker work. Incidentally we have been
consistent in sampling to chose the least inflamed component of the tumour but
have not sampled tumours where the inflammatory component appeared to be
dominant. For biomarker work there is an argument that all tumours should
have been sampled but where sampling would have resulted in less than 70%
of tumour cells this was avoided. There is some recognisable bias therefore in
this approach.
To accurately sample an area of confluent tumour from a tissue block a section of
tissue was taken for staining with H+E. Sectioning and staining of tissue was
undertaken by Dr Filomena Esteves and Dr Jon Laye.
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2.3.2 Sectioning of tumour blocks
Blocks were mounted onto a microtome and trimmed until a clean face was achieved.
One five micron tissue section was taken from each primary tumour block and floated
onto the surface of a microtome water bath at 45oC and then mounted onto a
Superfrost glass slide (Solmedia, Romford, UK) labelled with study number. Sections
were dried overnight in an oven at 36oC and then fixed to the slide by placing the slide
tissue side up on a heating block at 60oC for 20 minutes.
2.3.3 Haematoxylin and eosin (H+E) staining
Slides were placed into a plastic slide rack with up to 24 slides being processed at
once. Sections were dewaxed by immersing the slide in xylene for 5 minutes which
was repeated 3 times using fresh xylene each time. The slides were drained on tissue
paper and rehydrated by immersing in 100% ethanol for 2 minutes repeating 3 times
using fresh ethanol each time followed by 90% ethanol for 2 minutes and 75% ethanol
for 2 minutes. Slides were then placed under a fast flowing tap for 1 minute. Slides
were stained in Mayer’s haematoxylin for 2 minutes and then placed under a fast
flowing tap for 1 minute before being immersed in Scott’s Tap Water for 1 minute and
then rinsed again in water for 1 minute. Slides were then placed in eosin stain for 3
minutes followed by rinsing in water for 1 minute. The slides were drained and then
dehydrated by being immersed in 100% ethanol for 1 minute repeated twice using
fresh ethanol each time. Slides were dried in air and immersed in xylene for 1 minute
and then fresh xylene for another minute. Cover slips were mounted to the slides using
one drop of Depex mounting medium (Solmedia, Romford, UK) and dried in a fume
hood overnight.
2.3.4 Slide review
The stained slides were reviewed by Professor Newton Bishop to identify an area of
tumour suitable for sampling. The optimum area was not necrotic and the deepest part
of the tumour with the highest percentage of tumour cells and minimal stromal or
lymphocyte contamination. This area was marked on the H+E slide using a fine-tipped
permanent marker (Figure 2-1). If the tumour was large, and it was judged that more
TMA cores could be taken without prejudicing the clinical sample, a maximum of two
areas were marked for sampling on primary samples and a maximum of four areas on
metastatic specimens. The number of cores which could be taken was stipulated in the
protocol for each study.
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As melanin interferes with polymerases [303], the function of which is essential for
many of the molecular techniques described in this thesis, the least pigmented
component of the dermal tumour was selected for sampling. Pigmentation of tumours
reflects the biological nature of the cells [304, 305] and therefore avoiding these areas
may limit our analyses. Furthermore, there are tumours which show marked
heterogeneity having pigmented and non-pigmented areas. The group has planned
studies to compare these areas in the future. For the studies described in this thesis,
consistency of sampling was judged to be the priority.
Figure 2-1: A haematoxylin and eosin slide marked for tumour sampling.
2.3.5 Sampling using a tissue microarray (TMA) needle
The marked slide was used to guide sampling from the tumour block. Tumour sampling
was undertaken by a number of members of the Section of Epidemiology and
Biostatistics, including myself. The tissue block was placed under the TMA needle, the
H+E was placed on top of the block and the needle lined up above the mark on the
slide. The slide was removed and the needle manually guided into the tissue block
(Figure 2-2).
Figure 2-2: Using a tissue microarray needle to take a tissue core from a tumour
block.
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A 0.6mm x 2mm tissue core was taken from the block and placed into a labelled 1.5ml
micro-centrifuge tube. The core was stored at 4oC prior to nucleic acid extraction. As
the TMA needle is not disposable and cannot be cleaned using standard techniques,
the TMA needle was effectively cleared of any residual tumour cells by two cores being
taken from a blank, paraffin-only block.
Dr Caroline Conway has previously assessed the tumour content of tissue cores
sampled using this technique. To do this, Dr Conway embedded representative cores
horizontally in wax blocks and blocks were sectioned to obtain 5 micron sections
throughout the tissue core. H+E sections were prepared from these sections and
reviewed visually using light microscopy to determine the percentage tumour content of
each core. The tumour content was estimated to be at least 70% tumour cells [187].
2.4 Melanin score
Melanin in melanoma tumours can lead to unreliable spectrophotometric quantification
of nucleic acids [306] and can inhibit DNA polymerases [303]. To assess the
association between dark, and therefore tumours with high melanin concentrations and
performance in the cDNA-mediated annealing, selection, extension and ligation (DASL)
assay, each tumour that was given a melanin score based on the visual melanin
content of the TMA cores (0, no melanin to 3, black tumour).
2.5 Tumour sampling from small sentinel node biopsy samples
2.5.1 Laser capture microdissection (LCM)
In Chapter 5, tissue for RNA extraction was sampled from small sentinel node biopsy
samples using LCM. There are two general types of microdissection; infrared laser
capture systems and ultraviolet (UV) laser-cutting systems such as that used in this
work [307, 308]. Laser-cutting systems use a narrow-beam UV-A laser to draw around
and sample cells of interest. These cells are then catapulted using the laser into a
collection tube or through contact with the collection cap [307]. Tissue sections for
dissection using the PALM MicroBeam LCM microscope (Carl Zeiss, Jena, Germany)
used in this work can be mounted onto polyethylene naphthalate (PEN) or polyethylene
terephthalate (PET) coated slides which act to stabilise larger pieces of tissue so an
entire piece of tissue can be drawn around and catapulted into the collection tube
[309]. From normal glass slides sample material can be captured directly using the
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“AutoLPC” function where pieces of tissue are catapulted into the collection tube using
multiple laser pulses [309]. There are concerns that the UV laser can damage cells
directly hit by the laser [310], however using the PALM MicroBeam system, dissection
and catapulting of single live cells and subsequent culture appears to have no effect on
proliferation rate suggests that any laser damage to cells is minimal [311].
In the study described in Chapter 5, tissue was sampled using LCM from either new
tissue sections, unstained archival sections or diagnostic H+E slides with the coverslip
removed. Coverslips were removed by soaking the slide in xylene until the coverslip
floated off the specimen. Following coverslip removal, sections were dried and stored
at -80oC prior to LCM. New and archival unstained sections were stained with H+E
using diethylpyrocarbonate (DEPC) treated water as described in section 2.3.3 and
dehydrated in ethanol before being stored at -80oC prior to sampling. LCM was
performed using the PALM MicroBeam LCM microscope. As archival sections were
stored on Superfrost slides, new sections were mounted onto Superfrost slides to allow
a comparison between archival and new sections. Tissue was microdissected in
“AutoLPC” mode under the supervision of a Consultant Histopathologist with expertise
in melanoma (Dr Andrew Boon). Number of cells or area of tissue dissected, as
calculated by microscope software, was recorded. Sample pieces were catapulted into
20μl 10% sodium dodecyl sulphate solution aliquoted into the cap of a 0.5μl micro-
centrifuge tube. Tubes were immediately placed on dry ice prior to RNA extraction.
2.6 Extraction of nucleic acids from FFPE tissue cores
2.6.1 Extraction of RNA using the Roche High Pure RNA Paraffin Kit
RNA was extracted from cores of tissue using the High Pure RNA Paraffin Kit (Roche
Diagnostics, Burgess Hill, UK) for the studies described in Chapters 3, 4, 6, 7 and 8.
This kit uses a column containing two layers of glass fibre fleece in a filter. Nucleic
acids are structurally altered and denatured when diluted in guanidine thiocyanate and
in the presence of this high salt solution, they bind to glass fibres [312]. A series of
washing steps removes cellular components. The column is optimized for RNA
extraction, however a DNase I digestion step removes any contaminating DNA.
Purified RNA is eluted from the filter in the presence of very low salt concentrations
[313].
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2.6.1.1 De-paraffinisation of the tissue core and tissue homogenisation
A single tissue core was de-paraffinised in a 1.5ml micro-centrifuge tube by adding
500μl xylene and mixing. Samples were heated to 45oC for 15 minutes on a heating
block and then pulse vortexed for 10 seconds. The xylene was removed carefully using
a pipette. Residual xylene was removed by adding 400μl of 100% ethanol to the tube, 
vortexing and careful removal using a pipette. This ethanol wash step was repeated
and excess ethanol was evaporated by placing the open micro-centrifuge tube on a
heating block at 55oC for 5 minutes.
The tissue was homogenised by adding 100μl tissue lysis buffer, 16μl 10% sodium 
dodecyl sulphate (SDS) solution and 40μl Proteinase K to the dried tissue pellet. This 
mixture was vortexed and incubated at 55oC until the tissue was fully digested (48-84
hours) with regular vortexing throughout the incubation period.
2.6.1.2 Nucleic acid binding and washing
Following complete tissue digestion, 325μl binding buffer, containing guanidine 
thiocyanate, and 325μl absolute ethanol was added to the lysate and mixed by gentle 
pipetting. This mixture was added to the upper reservoir of a High Filter tube inserted
into a collection tube. The filter and collection tube were centrifuged at 8000g for 30
seconds. The flow-through liquid was discarded and the filter tube centrifuged again at
12,000g for 30 seconds to ensure the filter was dry.
The filter containing the bound nucleic acids was then washed. 500μl wash buffer 1 
was added to the upper reservoir of the filter tube and centrifuged at 8000g for 15
seconds. The flow-through liquid was discarded and 500μl wash buffer 2 was added to 
the upper reservoir of the filter tube and centrifuged through the filter at 8000g for 15
seconds. The flow-through liquid was again discarded and a further 300μl wash buffer 
2 was added to the upper reservoir and centrifuged through the filter at 8000g for 15
seconds. Following disposal of the flow-through liquid the filter was centrifuged at
12,000g for 2 minutes to ensure all residual wash buffer was removed.
2.6.1.3 Elution of RNA
The filter column was transferred into a sterile 1.5ml micro-centrifuge tube and 90μl 
elution buffer was added to the upper reservoir of the column. The column was
centrifuged at 8000g for 1 minute and the filter column was discarded. Contaminating
DNA was removed from the eluate by the addition of 10μl DNase incubation buffer and 
1μl DNase I. The tube was mixed gently by inversion and incubated for 45 minutes at 
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37oC. A second incubation step with Proteinase K increases the purity of eluted RNA,
so 20μl tissue lysis buffer, 18μl 10% SDS and 40μl Proteinase K was added to the 
eluate and the solution was incubated at 55oC for 1 hour. The binding and washing
steps were then repeated as described in section 2.6.1.2. Following the final wash, the
filter column was placed into a sterile 1.5ml microcentrifuge tube. The RNA was eluted
by adding 26μl RNase-free deionized water to the upper reservoir of the filter column 
which was centrifuged through the filter at 8000g for 1 minute. The column was then
discarded. In order to remove any contaminating residual glass fibres from the eluate, it
was centrifuged at 12,000g for 2 minutes to pellet the fibres and the supernatant was
carefully removed into a 0.2ml PCR tube. Extracted RNA was stored at -80oC.
2.6.2 Extraction of DNA using the Qiagen QIAamp DNA FFPE kit
DNA was extracted from tissue cores using the Qiagen QIAamp DNA FFPE kit
(Qiagen, Crawley, UK) for the work described in Chapter 6. This kit uses a column
containing a silica-gel membrane. Samples are de-paraffinised and lysed, DNA then
binds to the membrane in a high salt, chaotropic environment, bound DNA is washed
and finally eluted from the membrane in a low salt solution [314]. Following sample
lysis, there is an incubation period at 90oC to partially remove formalin crosslinks [315,
316], which improves yield and performance of DNA in downstream reactions.
2.6.2.1 De-paraffinisation and tissue digestion
One tissue core was de-paraffinised in a 1.5ml micro-centrifuge tube by incubation at
37oC for 30 minutes in 1ml xylene with regular vortexing during the incubation period.
The xylene was then carefully removed using a pipette and 1ml of absolute ethanol
was added to the sample to remove residual xylene. The tube was then pulse vortexed
and the ethanol carefully removed using a pipette, before 1ml of 70% ethanol was
added. Again the tube was vortexed and ethanol removed using a pipette. The tubes
were left open on a heat block at 37oC to allow any residual ethanol to evaporate.
The dry tissue core was resuspended in 180μl buffer ATL and 20μl Proteinase K was 
added. The tube was vortexed and incubated at 56oC, with agitation and regular
vortexing, until the tissue pellet was fully digested (48-84 hours). The lysed sample was
incubated at 90oC for 1 hour to partially reverse formalin cross-links then briefly
centrifuged and incubated for 2 minutes at room temperature with 2μl RNase A 
(100mg/ml) to remove RNA.
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2.6.2.2 DNA binding, washing and elution
Following this, 200μl buffer AL, which contains guanidine hydrochloride, was added to 
the sample. The tube was vortexed and 200μl of absolute ethanol was added followed 
by further mixing. The tube was briefly centrifuged and the entire lysate transferred to a
QIAamp MinElute column, placed into a 2ml collection tube. The lid was closed and the
column centrifuged at 6000g for 1 minute. The column was placed into a clean
collection tube and the tube containing the flow-through liquid was discarded. Bound
DNA was then washed by adding 500μl of wash buffer AW1 to the column and 
centrifuging at 6000g for 1 minute. The column was placed into a clean collection tube
and a second wash was performed by adding 500μl of wash buffer AW2 to the column 
followed by centrifugation at 6000g for 1 minute. Again the column was transferred to a
clean collection tube and centrifuged at 20,000g for 3 minutes to dry the silica-gel
membrane. Finally, the column was placed into a labelled 1.5ml micro-centrifuge tube
and 30μl of elution buffer ATE was applied to the centre of the membrane and 
incubated at room temperature for 5 minutes to maximise DNA yield. The column and
micro-centrifuge tube were centrifuged at 16,000g for 1 minute to elute the DNA. Eluted
DNA was stored at -20oC.
2.6.3 Extraction of RNA and DNA using the Qiagen AllPrep®
RNA/DNA FFPE kit
Extraction of both RNA and DNA from one tissue core was achieved using the Qiagen
AllPrep® RNA/DNA FFPE kit (Qiagen, Crawley, UK) for studies described in Chapters
6 and 8. This kit became available during my PhD. Methodological work, not presented
here, has demonstrated that the yield and quality of DNA extracted using this kit is
comparable to that from the Qiagen QIAamp DNA FFPE kit. However, the yield and
quality of RNA is significantly better using the Qiagen AllPrep® RNA/DNA FFPE kit
than when using the Roche High Pure RNA Paraffin Kit making it suitable for use in our
studies, with the advantage that RNA and DNA can be derived from the same core,
maximising the use of these precious tissue resources. The AllPrep® kit is designed to
sequentially release RNA and DNA from the same sample. It integrates the QIAamp
technology described in section 2.6.2 with well-established technology for RNA
extraction. Optimized lysis conditions using different buffers allow differential release of
DNA and RNA. Following de-paraffinisation, FFPE tissue is initially incubated in lysis
buffer and Proteinase K optimised to allow RNA release into solution, while genomic
DNA and other insoluble material is precipitated. The sample is then centrifuged to give
a supernatant containing RNA and a DNA containing pellet. The supernatant is
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incubated at 80oC to partially reverse formalin cross-links. Following mixing with
ethanol and buffer containing guanidine thiocyanate, the sample is applied to an
RNeasy MinElute spin column where RNA binds to the silica membrane. Bound RNA is
treated with DNase to remove any residual DNA and washed to remove any further
contaminants. Finally RNA is eluted into RNase-free water. The DNA containing pellet
is lysed further using Proteinase K and incubated at 90oC to reverse formalin
crosslinking. The sample is then mixed with buffer containing guanidine hydrochloride
and ethanol to provide optimal DNA binding conditions and applied to a QIAamp
MinElute spin column. Bound DNA is washed and finally eluted into a low salt buffer
[317].
2.6.3.1 Tissue de-paraffinisation and digestion
Tissue cores were initially de-paraffinised using the methods described in section 2.6.2.
The resulting pellet was resuspended in 150μl tissue lysis buffer PKD and 10μl 
Proteinase K was added, the mixture was then vortexed and incubated on a shaking
heat block at 56oC overnight. Following this, the tube was placed on ice for 3 minutes
and centrifuged for 15 minutes at 20,000g. The supernatant was carefully removed into
a new 1.5ml micro-centrifuge tube, taking care not to disturb the DNA-containing pellet.
2.6.3.2 Extraction of RNA
The supernatant was incubated at 80oC for 15 minutes and following a brief
centrifugation step, 320μl of buffer RLT, containing guanidine thiocyanate, was added. 
Following vortexing, 720μl absolute ethanol was added, the sample was thoroughly 
mixed and transferred to the RNeasy MinElute spin column in aliquots of up to 700μl. 
Following addition of each aliquot the lid of the spin column was closed gently and the
column centrifuged at 8000g for 15 seconds. After each centrifugation step, the flow-
through liquid was discarded and the bound RNA washed using 350μl buffer FRN, 
followed by centrifugation at 8000g for 15 seconds. To remove any contaminating
DNA, 10μl of DNase I stock solution (1500 Kunitz units in 550μl RNase-free water) was 
mixed gently with 70μl buffer RDD, applied directly to the spin column membrane, and 
incubated at room temperature for 15 minutes. Once DNA digestion was complete,
500μl buffer FRN was added to the column which was centrifuged at 8000g for 15
seconds. As the flow-through contains RNA following the DNase I treatment, the
column was placed into a new 2ml collection tube and the flow-through was applied to
the column, followed by a further centrifugation step for 15 seconds at 8000g. The RNA
on the column was washed twice using 500μl of buffer RPE, followed by centrifugation 
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for 15 seconds at 8000g. The flow-through liquid was discarded following each wash.
The spin column was then placed into a new 2ml collection tube, the lid was opened
and the column centrifuged at full speed (16,000g) for 5 minutes. This process dried
the column membrane, as residual ethanol may interfere with downstream reactions.
The column was finally placed into a 1.5ml micro-centrifuge tube and 26μl RNase-free 
water was applied to the membrane. Following incubation at room temperature for 1
minute, the column as centrifuged at 16,000g for 1 minute to elute RNA. The resulting
RNA was stored at -80oC.
2.6.3.3 Extraction of DNA
The DNA containing pellet was resuspended in 180μl tissue lysis buffer ATL and 40μl 
Proteinase K was added. The mixture was vortexed and incubated on a shaking heat
block at 56oC overnight. The lysate was then incubated at 90oC for two hours without
agitation, briefly centrifuged and allowed to cool before 2μl of RNase A (100mg/ml) was 
added and incubated at room temperature for 2 minutes to remove any contaminating
RNA. The tube was briefly centrifuged and 200μl buffer AL, which contains guanidine 
hydrochloride, was added and the sample vortexed. Once mixed, 200μl absolute 
ethanol was added and again the sample was thoroughly vortexed. The entire sample
was transferred to a QIAamp MinElute spin column, the lid was closed gently and the
column centrifuged for 1 minute at 8000g. The collection tube containing the flow-
through liquid was discarded and the column was placed into a new 2ml collection
tube. The bound DNA was then washed by addition of 700μl buffer AW1, followed by 
centrifugation at 8000g for 15 seconds, and 700μl buffer AW2, followed by further 
centrifugation for 15 seconds at 8000g. Following each centrifugation step, the flow-
through liquid was discarded from the collection tube. As a final wash step, 700μl 
absolute ethanol was added to the column, which was centrifuged for 15 seconds at
8000g. To remove any residual ethanol, the column was then placed into a new
collection tube, the lid of the column was opened and the column centrifuged at
16,000g for 5 minutes. Finally the column was placed into a 1.5ml micro-centrifuge
tube, 30μl of elution buffer ATE was applied directly to the spin column, the lid was 
closed and the column was incubated at room temperature for 5 minutes to maximise
DNA yield. The tube was centrifuged at 16,000g for 1 minute to elute DNA. DNA was
stored at -20oC prior to use.
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2.7 Extraction of RNA from microdissected sentinel node
biopsy samples
For the gene expression study described in Chapter 5, RNA was extracted from small
sentinel node biopsy samples sampled using LCM. Following tumour sampling, the
micro-centrifuge tube cap contained tumour specimens in 10% sodium dodecyl
sulphate solution. Tubes were briefly centrifuged and 100μl tissue lysis buffer and 40μl 
Proteinase K were added and then the contents digested at 55oC overnight. RNA was
extracted using the High Pure Paraffin RNA kit (Roche Diagnostics Ltd, Burgess Hill,
UK) as described in section 2.6.1 and eluted in 26μl nuclease free water. Extracted 
RNA was stored at -80oC prior to analysis.
2.8 cDNA synthesis from extracted RNA
2.8.1 cDNA generation using the Invitrogen Superscript™ First-
strand synthesis system
The Invitrogen Superscript™ First-strand Synthesis System (Invitrogen, Paisley, UK)
was used to generate cDNA from extracted tumour RNA from patients recruited to the
Leeds Melanoma Cohort Study as described in Chapters 3 and 4. The standard
protocol uses a mixture of oligo(dT)’s, to bind to mRNA 3`poly(A) tails, and random
hexamers for priming to maximise the amount of cDNA generated from degraded RNA.
First-strand cDNA synthesis is catalysed by Superscript™ II reverse transcriptase which
has been engineered to reduce RNase H activity, which can degrade mRNA, and is not
inhibited by ribosomal or transfer RNA so increasing the yield of cDNA from total RNA.
RNase H is added at the end of the reaction to remove the RNA template and increase
sensitivity of the following PCR reactions [318].
2.8.1.1 cDNA synthesis for osteopontin qRT-PCR
For work described in Chapter 3, 5μl of RNA of variable concentrations was used to 
generate cDNA using the manufacturers protocol.
An RNA and primer mix was prepared by combining 5μl RNA with 1μl of 10mM 
deoxyribonucleotide triphosphate (dNTP) mix (containing 10mM of deoxyadenosine
triphosphate (dATP), deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate
(cGTP) and deoxythymidine triphosphate (dTTP)), 100ng of random hexamers, 500ng
of oligodeoxythymidylic acid residues (oligo(dT)12-18) and diethylpyrocarbonate (DEPC)
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treated water to a final volume of 10μl. The mixture was incubated at 65oC for 5
minutes and then placed on ice. In a separate micro-centrifuge tube a mix was
prepared containing 2μl of 10x reverse transcriptase (RT) buffer (200mM Tris-HCl (pH 
8.4), 500mM KCl), 4μl of 25mM magnesium chloride, 2μl 0.1M dithiothreitol (DTT) and 
40 units of RNase OUT recombinant ribonuclease inhibitor in a final volume of 9μl. This 
mixture was added to the RNA and primer mix on ice, vortexed briefly and then
incubated at 25oC for 10 minutes. 50 units of Superscript™ II reverse transcriptase
were added to the mix and incubated at 25oC for 10 minutes, followed by 42oC for 50
minutes and finally 70oC for 15 minutes. Following first strand synthesis, the tube was
placed on ice and 2 units of E. Coli RNase H were added. The mixture was incubated
at 37oC for 20 minutes and cDNA was stored at 4oC until required.
2.8.1.2 cDNA synthesis for DNA repair gene qRT-PCR
For work described in Chapter 4, 200ng of input RNA measured using spectro-
photometry was used in each reaction. This RNA quantity was selected as it did not
exhaust stock of eluted RNA from precious samples and in qRT-PCR experiments,
cDNA samples with 200ng of input RNA had lower cycle threshold (Ct) values with
greater reproducibility between replicate samples, than cDNA samples generated using
smaller amounts of RNA. In order to maximise the amount of cDNA generated in each
reaction, the volume of reagents was increased from those stated in the manufacturers
protocol. Methodological work, not presented here, has demonstrated that these
modifications do not significantly alter gene expression results derived from samples.
In detail, reagents were used as described above. The RNA and primer mix was
prepared in a 20μl final volume by combining 200ng of RNA with 3μl of 10mM 
deoxyribonucleotide triphosphate (dNTP) mix, 300ng random hexamers, 1.5μg of 
oligo(dT)12-18 and DEPC treated water to a total volume of 20μl. The mixture was 
incubated at 65oC for 5 minutes and then placed on ice. In a separate micro-centrifuge
tube, 6μl of 10x RT buffer, 12μl of 25mM magnesium chloride, 6μl 0.1M DTT and 120 
units of RNase OUT recombinant ribonuclease inhibitor were mixed in a final volume of
27μl. This mixture was added to the RNA and primer mix on ice, vortexed briefly and 
then incubated at 25oC for 10 minutes. 150 units of Superscript™ II reverse
transcriptase were added to the mix and incubated at 25oC for 10 minutes, followed by
42oC for 50 minutes and finally 70oC for 15 minutes. Following first strand synthesis,
the tube was placed on ice and 6 units of E. Coli RNase H were added. The mixture
was incubated at 37oC for 20 minutes and cDNA was stored at 4oC until required.
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2.8.2 cDNA generation using Applied Biosystems High Capacity
cDNA Reverse Transcription kit
For the Chemotherapy study (Chapter 8), cDNA was generated using the Applied
Biosystems High Capacity cDNA Reverse Transcription kit (Warrington, UK) [319]. This
kit became available during my PhD and uses a simplified protocol compared to the
Invitrogen system. The kit uses random priming and MultiScribe™ reverse
transcriptase to catalyse first strand synthesis [319]. Two further cDNA kits are
marketed by Applied Biosystems, the High Capacity RNA-to-cDNA kit and the High
Capacity RNA-to-cDNA master mix. These offer even simpler work-flows using a blend
of random primers and oligo(dT)’s for priming [320]. When tested, the results of which
are not presented here, the High Capacity cDNA Reverse Transcription kit using
random priming produced superior cDNA from degraded melanoma RNA samples and
so was used for cDNA generation for the Chemotherapy Study (Chapter 8).
For each sample a 2x RT master mix was prepared by mixing 2μl of 10x RT buffer with 
0.8μl 25x dNTP mix (100mM), 2μl of 10x RT random primers, 50 units of MultiScribe™ 
reverse transcriptase, 1μl of RNase inhibitor and 3.2μl of nuclease-free water in a final 
volume of 10μl. This solution was mixed gently and pipetted into a well of a 96-well 
plate. 10μl of RNA (up to 1 microgram) was then added to the mixture, and pipetted 
gently to mix. The plate was sealed, briefly centrifuged and loaded into a thermal cycler
for incubation at 25oC for 10 minutes, followed by 37oC for 2 hours, then 85oC for 5
minutes and finally cooled to 4oC. cDNA was stored at -20oC prior to use.
In all cDNA synthesis reactions, a positive control using supplied control RNA (50
ng/μl) and a reverse transcriptase negative control was included in each experiment. 
cDNA concentrations were measured using spectrophotometry as described in section
2.10.
2.9 Cell line samples
2.9.1 Culture conditions
To optimise assays used in this thesis described in Chapters 6 and 8, RNA and DNA
were extracted from melanoma cell line samples to provide high quality RNA and DNA.
MeWo, SkMel28, Mel Juso, Mel 624 and SkMel5 cell lines were routinely grown in
Dulbecco’s Modification of Eagles high glucose Medium (DMEM, Sigma-Aldrich, UK)
supplemented with 10% foetal calf serum (FCS) and 2mM L-glutamine at 37oC in 5%
carbon dioxide. Cells were harvested at 80-90% confluency, excess serum was
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removed by rinsing cells in 10ml of phosphate-buffered saline (PBS) and then trypsin
was added and incubated at 37oC to detach cells from the culture flask. Supplemented
DMEM was added to the flask to neutralize the trypsin, the suspension was centrifuged
at 400g for 5 minutes to pellet the cells and the pellet resuspended in fresh DMEM.
Cells were counted using trypan blue exclusion and a haemocytometer. For MeWo and
SkMel28 cells, the solution was split into two and centrifuged at 400g for 5 minutes to
pellet the cells. One cell pellet was frozen at -80oC for RNA extraction, the other used
immediately for DNA extraction. For other cells, the entire cell pellet was used for RNA
extraction.
2.9.2 RNA extraction from cell line samples using the Qiagen
RNeasy® Mini kit
The RNeasy® Mini kit (Qiagen, Crawley, UK) was used for RNA extraction from cell
line samples according to the manufacturer’s protocol for ‘Purification of total RNA from
animal cells using spin technology’. This kit uses technology similar to that described in
section 2.6.3. Cells are homogenized and suspended in buffers containing guanidine
thiocyanate, therefore when the lysate is centrifuged through the spin column, RNA
binds to the membrane. Following DNase I treatment and wash steps, RNA is eluted
into RNase-free water [321]. Depending on the cell line, varying numbers of cells were
used for extraction but the number did not exceed 1x107 cells as recommended by the
manufacturer.
Cell pellets were thawed and dislodged from the microcentrifuge tube. Cells were
disrupted and homogenized by adding 600μl Buffer RLT, vortexing the suspension and 
transferring to a QIAshredder spin column. The column was centrifuged for 2 minutes
at 16,000g and then 600μl 70% ethanol was added to the homogenized lysate. The 
sample was transferred in 700μl aliquots into an RNeasy spin column. Each aliquot 
was centrifuged for 15 seconds at 8000g and the flow through liquid was discarded.
Once all the homogenized lysate had passed through the RNeasy column, 350μl of 
Buffer RW1 was added and centrifuged for 15 seconds at 8000g to wash the column
membrane. Flow-through liquid was discarded and 10μl of DNase I stock solution 
(1500 Kunitz units dissolved in 550μl RNase-free water) was gently mixed with 70μl 
buffer RDD. The DNase I solution was applied directly to the spin column membrane
and incubated at room temperature for 15 minutes to remove any DNA. A further 350μl 
Buffer RW1 was added to the column and centrifuged for 15 seconds at 8000g. Flow-
through liquid was discarded and 500μl Buffer RPE was added to the column and 
centrifuged for 15 seconds at 8000g. Flow-through liquid was again discarded and a
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further 500μl Buffer RPE was added followed by centrifugation for 2 minutes at 8000g
to wash the spin membrane. The column was then placed into a new 2ml collection
tube and centrifuged at 16,000g for 1 minute. Finally, the spin column was placed into
a 1.5ml microcentrifuge tube, 30μl of RNase-free water was applied directly to the 
membrane and the column centrifuged at 8000g for 1 minute to elute RNA. RNA was
stored at -80oC prior to use.
2.9.3 DNA extraction from cell line samples using the Qiagen
QIAamp DNA Mini kit
DNA was extracted from cultured cells using the QIAamp DNA Mini kit (Qiagen,
Crawley, UK) according to the manufacturer’s ‘Protocol for cultured cells’. Different
numbers of cells were used for extraction depending on the cell line, but this did not
exceed 5x106 as recommended in the protocol. The kit uses Proteinase K to digest
cells, followed by use of a spin column to bind DNA in optimal conditions. The protocol
also contains an RNase A treatment step to remove any contaminating RNA [322].
Cell pellets were resuspended in 200μl PBS in a microcentrifuge tube and 20μl of 
Proteinase K was added. 4μl of RNase A (100mg/ml) (Qiagen) was then added and the 
mixture incubated for 2 minutes at room temperature. After removal of RNA 200μl 
Buffer AL was added, the sample was mixed and then incubated at 56oC for 10
minutes. Following digestion and brief centrifugation, 200μl 100% ethanol was added 
and the sample was vortexed again. The tube was briefly centrifuged and the mixture
applied to the QIAamp Mini spin column. The column was centrifuged at 6000g for 1
minute and placed into a clean collection tube. To wash bound DNA, 500μl of Buffer 
AW1 was added, the column was centrifuged at 6000g for 1 minute and then placed
into a new collection tube. The bound DNA was washed again by the application of
500μl Buffer AW2 followed by centrifugation at 16,000g for 3 minutes. The column was
transferred into a fresh collection tube and centrifuged again at 16,000g to eliminate
any wash buffer carryover. The column was then placed into a 1.5ml microcentrifuge
tube and 200μl distilled water applied to the membrane. The column was incubated at 
room temperature for 5 minutes and centrifuged at 6000g for 1 minute to elute DNA.
DNA samples were was stored at -20oC prior to use.
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2.9.4 cDNA generation from RNA extracted from cell line samples
cDNA was generated from extracted RNA using the standard method described in
section 2.8.1 with the Invitrogen Superscript™ First-strand synthesis system. One
microgram of RNA was used in each reaction and cDNA was stored at 4oC prior to use.
2.10Quantification of nucleic acid concentrations using
spectrophotometry
Concentration and quality of RNA and DNA extracted from FFPE melanomas was
determined using the ND-8000 spectrophotometer (Nanodrop, Wilmington, DE, USA).
Prior to nucleic acid quantification, the spectrophotometer pedestals were cleaned and
the instrument was blanked using 1.5μl of molecular grade water. The sample (1.5μl) 
was placed on the pedestal for measurement. Between samples the pedestals were
wiped dry using a clean tissue. Using UV spectrophotometry, nucleic acid
concentration is measured. RNA, single stranded DNA and double stranded DNA
absorb UV light at 260nm and the spectrophotometer also provides A260/A280 and
A260/A230nm ratios which give an indication of any contaminants in the sample that
absorb UV light at 230nm (organic compounds) or 280nm (protein). An A260/A280 ratio of
around 1.8 is accepted to indicate pure DNA and 2.0 for pure RNA [312].
This method was also used to measure concentrations of cDNA generated from RNA
samples.
2.11cDNA-mediated annealing, selection, extension and
ligation (DASL) assay
The DASL assay is a gene expression profiling platform which uses highly multiplexed
Real-time PCR to allow analysis of thousands of genes at once [293]. This assay has
been used to derive gene expression data from primary FFPE melanoma tumours
described in Chapter 3 with gene expression data being used in Chapters 3 to 8. The
assay is reported to have a dynamic range of 2.5-3 logs and can detect 1x104
molecules [323, 324]. It is specifically designed for use with degraded RNA typically
extracted from FFPE tissue as it uses random priming in cDNA synthesis and a target
sequence of only 50 nucleotides is required for probe groups to anneal [293]. Probe
groups are composed of two oligonucleotides; the first oligonucleotide consists of a
gene specific sequence and a universal PCR sequence at the 5’ end, the second
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consists of the gene specific sequence, a universal PCR sequence at the 3’ end and,
for the Human Cancer panel described in section 2.11.3, a short (approximately 22
nucleotides) unique address sequence and for the WG-DASL HT assay described in
2.11.4, 50 nucleotide sequences which allow hybridization to a universal array [293,
323, 324] (Figure 2-3).
For the work described in this thesis, the DASL assay was performed by Floor de Kort
at the service provider, ServiceXS (Leiden, Netherlands). To start the assay, 200ng
total RNA was converted into cDNA using biotinylated random nonamers, biotinylated
oligo d(T)18 and Illumina-supplied reagents. Pooled probe groups were annealed to
sequence-specific targets [325]. Biotinylated cDNA was immobilized on streptavidin-
conjugated paramagnetic beads and washed to remove unhybridized oligonucleotides
[293]. Correctly annealed oligos were extended and ligated using Illumina supplied
reagents and conditions to generate templates which were amplified using PCR.
During PCR, templates were labelled with Cy3 or Cy5 fluorescent primers for the
Human Cancer panel or Cy3-labelled primers only for the WG-DASL HT assay
described in section 2.11.4 [326]. PCR products were denatured and then hybridized to
a universal array [325] which was scanned using an automated BeadArray™ reader
(Illumina Inc., San Diego, CA, USA) to generate fluorescence intensity data.
2.11.1 The Sentrix Array Matrix (SAM) universal array
There are two formats of universal array used with the DASL assay, the Sentrix Array
Matrix (SAM) and the Beadchip platform. The SAM was used with the 502-gene
Human Cancer panel described in 2.11.3 and uses nearly 50,000 individual light
conducting fibre strands that are chemically etched to create a 3μm well at the end of 
each strand. Glass beads derivatised with one of 1536 address sequences are loaded
into the bundles. These array bundles are approximately 1.4mm in diameter and are
grouped together into a 96-array configuration allowing assessment of 96 samples at
once [325]. For both SAM and the Beadchip platforms, each probe is represented by
an average of 30 beads for each sample [324, 327]. Beads are positioned randomly, so
require decoding to determine the position and identity of each bead on the array [293,
328, 329]. Isolated PCR products are hybridised at 45oC for 18 hours to the SAM array.
After hybridization and scanning, fluorescence intensity data is analysed using
BeadStudio software (Illumina, USA). BeadStudio summarizes the pixel intensities for
each bead across the array and then averages across beads for each probe to
generate intensity data which is used in downstream analysis [327].
Figure 2-3: The DASL assay.
RNA is converted to cDNA using biotinylated primers. Pooled probe groups
anneal to target sequences and biotinylated cDNA is immobilized on streptavidin
conjugated paramagnetic b
and amplified using PCR. During PCR, templates are labelled with Cy3 or Cy5
fluorescent primers. PCR products are then hybridized to a universal array and
scanned to produce fluorescence intensity data.
(blue sections on probes) are used to hybridize PCR products to the Sentrix Array
Matrix (SAM) used with the Human Cancer panel. Longer, 50 nucleotide
sequences, are used for hybridization to the HumanHT
Beadchip used with the WG
2.11.2 The HumanHT
The HumanHT-12 v4 Expression Beadchip uses similar bead technology to SAM and
is the array used with the whole
section 2.11.4. Resultant PCR products from the WG
using 50 nucleotide sequences to the HumanHT
hours at 58oC [324]. This array format allows processing of up to twelve samples and
features content covering over 47,000 transcripts derived from the National Center for
Biotechnology Information Reference Sequence
November 2009) [330
probes. After hybridization, HumanHT
HiScan™SQ, iScan or BeadArray™ readers and data are analysed using Illumina’s
GenomeStudio® software in a similar way to the SAM array form
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eads. Correctly annealed oligos are extended, ligated
Short unique address sequences
-12 v4 Expression
-DASL HT assay. Figure adapted from
-12 v4 Expression Beadchip
-genome DASL HT (WG-DASL HT) assay described in
-DASL HT assay are hybridized
-12 v4 Expression Beadchip for 16
(RefSeq) database (Release 38,
, 331]. The WG-DASL HT assay targets over 29,000 of those
-12 v4 Beadchips are scanned using
at
-
[330].
[330].
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2.11.3 The Illumina Human Cancer panel
Gene expression profiling results presented in Chapters 3 to 8 were performed using
the Illumina Human Cancer panel gene set (Illumina Inc.). The Cancer Panel includes
1536 unique sequence-specific probes which target 502 genes. Each gene is targeted
in different locations by three probe pairs designed using a proprietary algorithm [293].
The genes on the Cancer Panel were derived from 10 publically available cancer gene
lists and include oncogenes, tumour suppressor genes, cell cycle control genes and
DNA repair genes among others (see Appendix I for full list).
2.11.4 The Illumina Whole-Genome DASL HT (WG-DASL HT)
assay
The WG-DASL HT assay targets over 29,000 annotated transcripts and has been
developed from the Human WG-DASL assay which previously targeted more than
24,000 transcripts and used the HumanRef-8 v3 Beadchip for hybridization. Targeted
regions on the WG-DASL HT assay are 3’ biased in common with HumanHT-12 v4
Expression Beadchip sequences unlike the Human Cancer panel where targeted
regions are not restricted in position [323, 326]. In contrast to the Human Cancer panel,
the WG-DASL HT assay has between one and eight probes representing each gene
[324]. The original WG-DASL assay was found to provide reproducible results and has
been used in a number of studies [332-335]. Illumina report that the WG-DASL HT
assay provides highly reproducible gene expression profiles for replicate samples and
that relative gene expression relationships are maintained in samples analysed using
both the WG-DASL assay and the newer WG-DASL HT platform [326, 330]. An
assessment of the performance of the WG-DASL HT assay with FFPE melanoma
tissue is included below in section 2.13.
2.11.5 Quality control measures before the DASL assay
RNA sent for analysis using the DASL assay went through a number of quality control
measures as recommended by Illumina and previous authors. A commonly used
quality control measure is quantitative Real-time PCR (qRT-PCR) of the housekeeping
gene, RPL13a. Cycle threshold (Ct) values of 29 cycles [296, 297] or 28 cycles [293,
294, 296] have been used to indicate adequate quality of RNA samples in previous
studies. Others have used spectrophotometry to measure RNA concentration and
A260/A280 ratios. RNA concentrations of <20ng/L, <25ng/L or total RNA input <50ng
and A260/A280 ratios <1.5 or <1.8 have been reported to indicate an inadequate sample
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[293, 294, 296]. The Agilent 2100 Bioanalyzer has also been used to assess sample
quality and generates an RNA integrity number (RIN) for each RNA sample derived
from the electropherogram [336]. To generate a RIN, a number of features are
assessed including total RNA ratio, measured as the fraction of the area in the region
of the 18S and 28S peaks compared to the total area under the electropherogram
curve, and the height of the 28S peak [336]. A score of 1 indicates totally degraded
RNA and a score of 10 represents intact RNA [336]. It has been suggested that
samples with an RIN number >2.0 or 2.0 with a RNA fragment size >200 nucleotides
are suitable for use in the assay [294], however others have reported that RIN values
do not correlate with performance of RNA samples in the DASL assay [296].
For samples sent for DASL analysis for my analyses, concentrations of extracted RNA
were determined using the ND-1000 spectrophotometer (NanoDrop, Wilmington, DE,
USA) as described in section 2.10. A selection of samples, detailed in Chapter 3, were
analysed on the Agilent 2100 Bioanalyser using an RNA 6000 nano-chip and standard
manufacturer’s protocols to determine the average fragment length of the RNA. The
RNA fragment length traces were visually evaluated by Dr Caroline Conway and a
fragment analysis trace score of 1-3 was created where 1 = peak visible and labelled
with fragment size marker, 2 = peak visible but not labelled with fragment size marker
and 3 = little or no peak visible.
The final quality control measure performed on extracted RNA samples was a
quantitative Real-time PCR (qRT-PCR) experiment to assess amplification of a 90bp
fragment of the control gene RPL13a. The service provider, ServiceXS, performed
these experiments. Samples were assessed in duplicate using SYBR Green and the
ABI 7500 Real-time PCR System (Applied Biosystems) with standard protocols and
PCR conditions. Primer sequences were, forward: GTACGCTGTGAAGGCATCAA and
reverse: GTTGGTGTTCATCCGCTTG. Mean cycle threshold values were determined
for all samples and those samples with a Ct values 29 cycles were used in the assay.
An assessment of the usefulness of these quality control measures in FFPE melanoma
samples is included in Chapter 3.
2.11.6 Control and replicate samples
To monitor intra-assay variation, each DASL assay experiment plate included 6-12
technical replicates (RNA samples from the same extraction) and biological replicates
(RNA samples from different tissue cores removed from the same tumour) within and
across plates. An assessment of equality and correlation across these replicate
samples is included in Chapter 3.
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To further monitor variation across plates and runs of the DASL assay, replicate
Stratagene Universal Human Reference RNAs (Agilent Technologies, Edinburgh, UK)
were assessed across DASL plates. Analysis of results from these reference RNAs is
described in detail in Chapter 5.
2.12Normalisation of gene expression data
The fluorescence intensity file generated following scanning of the array was sent to us
by our service provider. This data was uploaded into Illumina BeadStudio software
(Illumina Inc., CA, USA) for analysis of the 502-gene Human Cancer panel data and
GenomeStudio (Illumina Inc.) for the WG-DASL HT data. The number of genes
detected in each sample represents the genes for which target sequence signal is
distinguishable from negative controls on the array with p<0.05. Data were normalized
within BeadStudio Gene Expression Module v3.4 (Illumina Inc.) for the Human Cancer
Panel data and GenomeStudio v2010.3 Gene Expression Module 1.8.0 for the WG-
DASL HT data. Normalization of gene expression data is required to remove any non-
biological variation that may be present. This may be due to red-green bias due to
differences in labelling efficiencies of the Cy5 and Cy3 dyes, differences in dye
scanning properties with position on the array, artefacts on the array, variations in
scanning across the array or because of non-uniform hybridization [337].
Fluorescence intensities from Cy3 and Cy5 dyes were averaged for each probe and
the expression level for each gene was calculated as the mean of the average
intensities from the three probes on the Human Cancer panel. PCR products from the
WG-DASL HT assay were labelled with Cy3 only, the mean fluorescent intensities for
the available probes for each gene were calculated as the gene expression level [326].
Background correction and cubic B-spline smoothing methods were used to normalise
data. For samples assessed using SAM, sample scaling across plates removed
variation between arrays assessing 96 samples from a 96-well plate.
Background correction removes gene expression from non-specific hybridization, the
level of which is identified by the average expression for negative control genes, which
is present on the array. The cubic spline method is a non-linear method of
normalization in which a reference sample is generated using the average gene
expression of all samples. This is then split into 15 quantiles which are used to fit
smoothing B-splines. The splines are then used to normalize the signals of the sample
in a given quantile by scaling signals to match intensities in the reference sample [338].
This method assumes that all transcripts have the same abundance and it is well suited
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to remove the effects that might cause non-linear transformation such as saturation
[337, 338]. Sample scaling is based on the presence of technical replicates across
plates which are used to calculate a scaling factor that is applied to other samples to
create equal average intensity for each probe across all plates. The quality of the
normalisation was assessed by testing the equality and the correlation between gene
expression levels across sample replicates.
2.13Assessment of the WG-DASL HT assay with FFPE
melanoma samples
2.13.1 Background and methods
The ability to perform unbiased whole-genome expression profiling using FFPE tissue
would greatly enhance our ability to detect alterations in gene expression associated
with prognosis and responses to treatment in malignant melanoma.
To assess the WG-DASL HT assay, 5 FFPE melanoma samples from patients
recruited to the “Predicting Response to Chemotherapy in Malignant Melanoma” study,
were sampled as described in section 2.3.5 and RNA was extracted using the Qiagen
AllPrep® RNA/DNA FFPE kit as described in section 2.6.3. RNA samples were sent in
duplicate for analysis using the WG-DASL HT assay at ServiceXS (Leiden,
Netherlands) by Floor de Kort. All samples passed quality control procedures as
described in section 2.11.5.
2.13.2 Results and discussion
Previous authors have used the number of genes detected in each sample using the
DASL assay, defined as a probe signal significantly greater than average signal from
negative controls with p<0.05, as a measure of the quality of results [294]. An
argument for not using this measure to determine result quality is presented in Chapter
5, however for the purposes of this assessment, number of detected genes was
assessed. Generally the samples performed well with the mean number of genes
detected (p<0.01) being 11943 (range 6346-14287). One of the five samples
performed less well with the number of detected genes being 6346 and 8050 in the
replicate samples. For the samples with a high number of detected genes,
reproducibility between replicate samples was good with probe signal intensity
Pearson’s correlation coefficients ranging from 0.96-1.00 (Figure 2-4). For the sample
with lower numbers of detected genes, the Pearson’s correlation coefficient was 0.89.
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The assay appears to generate reproducible gene expression results in FFPE
melanoma samples, therefore further assessment of the WG-DASL HT assay is
underway using larger sample sets. In this pilot study, I was unable to identify the
poorly performing sample using quality control measures described in section 2.11.5.,
therefore efforts will be directed to identifying further quality control measures to
determine sample performance.
Figure 2-4: Scatter plot demonstrating correlation between probe signal
intensities for replicate FFPE melanoma samples on the WG-DASL HT
assay.
The Pearson’s correlation coefficient is reported.
These results are the final in a number of test experiments using the WG-DASL HT
assay. Previous assessments showed poor reproducibility between sample replicates
and an analysis problem where a grid, which is superimposed onto the array to identify
the position of beads, could not be placed by the scanning software. On enquiry, issues
with sample reproducibility were also noted by other groups world-wide, however the
grid registration problem was identified by our group and brought to the attention of
Illumina. These issues were discussed in detail with Illumina and following investigation
were attributed to the short shelf-life of the reagent used for cDNA synthesis. This led
to withdrawal of the assay from the market and development of a new reagent. The
new product was released in May 2012 and the results presented above indicate that
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the assay now produces reproducible results, although some problems with grid
placement remain and further investigation into this issue is on-going. Once these
issues are resolved, a further test set of samples will be analysed and then a larger set
of RNA samples extracted from primary melanoma tumours which will be published but
which will not be available in sufficient time for this thesis.
2.14Quantitative Real-time PCR (qRT-PCR) using Taqman®
Gene Expression Assays
qRT-PCR experiments using Taqman® Gene Expression Assays have been used in
Chapters 3 and 4 to validate gene expression findings from the DASL array. Taqman®
Gene Expression Assays consist of a target specific oligonucleotide which has a
reporter dye, such as 6-fluorescein amidite (FAM™), linked to the 5’ end of the probe
and a non-fluorescent quencher at the 3’ end of the probe which suppresses the
reporter fluorescence. During PCR the probe specifically anneals to the target of
interest and the 5’ nuclease activity of DNA polymerase then cleaves the probe. This
separates the reporter and quencher dyes, resulting in fluorescence of the reporter.
Polymerization of the strand continues and increasing amounts of PCR products are
detected by directly monitoring the increase in fluorescence of reporter dye (Figure 2-5)
[339].
Fluorescent intensity of the reporter dye is normalised to the fluorescence of a passive
ROX dye which corrects for differences in fluorescent intensity due to different
concentrations or volumes in the sample mix. The threshold of a PCR reaction is set
when there is a significant increase in fluorescence for the reporter dye which occurs
during the exponential phase of the PCR reaction. From this threshold, for each sample
a cycle threshold (Ct) value is derived which is the number of PCR cycles at which the
fluorescence of a sample crosses the threshold [339].
For qRT-PCR experiments reported in this thesis, the following section describes the
standard protocol. Any deviation from this is described in the relevant chapter.
Figure 2-5: Action of Taqman® Gene Exp
During PCR, the Taqman® probe is cleaved by the 5’ nuclease activity of
AmpliTaq Gold® DNA Polymerase Ultra Pure. Diagram adapted from reference
[339].
2.14.1 Standard TaqMan® gene expression protocol
Assays were performed in triplicate using 1 microgram of cDNA in each reaction. PCRs
were performed using Gene Expression Master Mix (Applied Biosystems, Warrington,
UK) which contains AmpliTaq Gold® DNA Polymerase Ultra Pure, Uracil
Glycosylase (UDG), deoxyribonucleotide triphosphates (dNTPs), ROX
Reference and buffer components
volume made up using 5μl Master Mix, 0.5μl Taqman® Assay, 3.5μl DNase
and 1μl cDNA sample. PCRs were performed using the ABI 7500 Fast Real
System (Applied Biosystems
50oC for 2 minutes, AmpliTaq Gold® DNA Polymerase activation at 95
minutes, then 50 cycles of 95
cycles was increased to 50 to ensure
Automatic settings were used for baseline and threshold determination, Ct values were
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ression Assays.
[339]. Reactions were performed in a 10μl final 
) using the following cycling conditions: UDG activation at
oC for 15 seconds and 60oC for 1 minute. The number of
that amplification of every sample was identified.
-DNA
™ Passive
-free water
-time PCR
oC for 10
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exported to Excel for further analysis. Mean Ct values for each probe for each sample
were generated from replicate samples.
2.14.2 Analysis of qRT-PCR data
qRT-PCR can be used for absolute quantitation of gene products, or relative
quantitation [340]. In this thesis, relative quantitation has been used to assess
differences in gene expression between samples, reported as a fold-change, or relative
quantity, in expression relative to a calibrator or reference sample [341]. Two methods
for relative quantitation exist, the relative standard curve method and the comparative
Ct method [342]. A detailed assessment of methods for relative quantitation using
Taqman® Gene Expression Assays and methods for qRT-PCR is included in Chapter
4 and will not be discussed in further detail here.
I will briefly describe a method commonly used for analysis of comparative Ct studies,
which has been used in Chapters 3 and 4. The comparative Ct method quantifies gene
transcript levels relative to those of a single control gene [342]. To use this method, it is
essential that the PCR efficiencies of probes for test genes and control genes are
similar [340, 342]. If this is the case, ΔΔCt values can be calculated where ΔCt = Ct 
value for gene of interest – Ct value for endogenous control and ΔΔCt = ΔCt sample – 
ΔCt calibrator sample. Relative quantity (RQ) levels are then calculated using 
(1+efficiency of target amplification)–ΔΔCt . Therefore when amplification efficiency is
100%, with doubling of PCR product during every PCR cycle, RQ = 2-ΔΔCt [340, 342].
This method will be described as the 2-ΔΔCt method in this thesis.
To improve accuracy of qRT-PCR normalisation, multiple control genes have been
used for data normalisation in this thesis (discussed further in Chapter 4) according to
the methods described by Vandesompele et al. [343]. For this method, ΔCt values are 
calculated, where ΔCt = mean Ct gene of interest in sample – mean Ct gene of interest 
in calibrator sample [340]. ΔCt values are converted to 2-ΔCt to provide a non-
normalized value for each gene of interest for each sample. For each sample, the
geometric mean of the 2-ΔCt value for the normalisation genes is calculated as a
normalisation factor. The 2-ΔCt value for the unknown genes is divided by the
normalisation factor to provide a normalised quantity [343].
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2.15Chemo-sensitivity Gene Expression Assay (CGEA-1)
Chapter 8 describes use of a customized Taqman® Array microfluidic qRT-PCR card
(Chemo-sensitivity Gene Expression Assay, CGEA-1, CanTech Ltd, Portsmouth, UK)
for validation of DASL gene expression results. For this study, I collaborated with the
Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth
where the experimental work was performed by Dr Katharine Parker. The CGEA-1
assay contained 92 genes known or hypothesized to be involved in cytotoxic resistance
or sensitivity based on the current literature [289] which are listed in Chapter 8.
Taqman® array cards (Applied Biosystems, Warrington, UK) are 384-well microfluidic
cards which allow 384 simultaneous PCR reactions using Taqman® gene expression
assays which are described in more detail in section 2.14.1 [344]. The gene expression
assays are preloaded into each well, so samples and master mix are simply added to
the card, the array is centrifuged and then sealed prior to PCR [344].
Each sample was made up with Taqman Gene Expression Master Mix and mixed with
an equal volume of cDNA to give a final concentration ranging from 240-300ng/μl 
suitable for the small volume dry PCR Taqman array wells. Samples were then each
pipetted into two ports (100μl per port) of the 384 well card, for the 96 genes assessed. 
The loaded array was then placed into a balanced centrifuge and spun at 380g to fill
the card and then re-spun to remove any air bubbles. The card was sealed using a
Taqman array slide sealer and loading ports cut from the card before loading into an
ABI 7900HT thermal cycler (Applied Biosystems). PCR was performed using the
following conditions: 50oC for 2 minutes, 94.5oC for 10 minutes, then 40 cycles of 30
seconds at 97oC and 1 minute at 59.7oC. Automatic settings were used for baseline
and threshold determination and Cycle threshold (Ct) values for each target were
exported to Excel and sent to myself further analysis. Details of data analysis are
included in Chapter 8.
2.16Fluidigm Biomark HD qRT-PCR system
To identify differential gene expression of DNA repair genes in samples from patients
recruited to the “Predicting Response to Chemotherapy in Malignant Melanoma” study
described in Chapter 8, the Fluidigm Biomark HD qRT-PCR system (Fluidigm, San
Francisco, CA) was used. The Fluidigm Biomark HD quantitative PCR chip uses
microfluidic technology to allow assessment of up to 96 genes in 96 samples in a total
of 9216 PCR reactions in a single experiment. Fluidigm microfluidic technology uses
integrated fluidic circuits (IFC) containing valves and channels which allows assembly
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of individual PCR reactions in a volume of 10nl [345-347]. The ability to use small
amounts of RNA to assess expression in up to 96 genes simultaneously is clearly
useful for validation of microarray results or assessment of a group of biologically
related genes. A detailed assessment of the performance of this system with FFPE
melanoma tissue is included in Chapter 8.
2.16.1 Integrated fluidic circuits (IFC)
The IFC is a network of fluid lines, NanoFlex™ valves, which flex under pressure, and
chambers [347] (Figure 2-6). Valves are used to regulate flow of liquid in the IFC.
Before samples are loaded into the IFC, the chip is primed by pressurizing control lines
which close interface valves. Gene expression assays are pipetted into the detector
inlets and samples into sample inlets. The IFC is then loaded by pressure being
applied to sample and detector inlets, samples are pushed into individual wells, but as
the interface valves are shut assays cannot enter the wells. Containment valves are
then closed, interface valves are opened which allows assays to enter the wells and
mixing of sample and assay. Once mixed, the interface valves are shut and the IFC is
ready for cycling [347]. In common with other qRT-PCR platforms, the chip is imaged
following each PCR cycle to generate amplification curves for each gene for each
sample [347]. Specific target amplification (STA) of cDNA samples for genes of interest
increases the sensitivity of the technique [348].
2.16.2 DELTAgene™ assays
The Fluidigm systems can be used with Taqman® assays, but for the purposes of this
study, we have used gene specific primers (DELTAgene™ assays, Fluidigm) in
conjunction with the DNA-binding dye, EvaGreen. EvaGreen is a flurophore, which
when bound to double-stranded DNA emits a strong fluorescent signal, the intensity of
which is directly proportional to the increase in the amount of double-stranded DNA
during a PCR reaction [349, 350]. Use of EvaGreen significantly reduces the cost of the
experiment, however the specificity of the reaction is reduced as only a primer pair are
used for PCR, the additional probe present in Taqman® based assays being absent
[349]. Primers were designed to target DNA repair genes in the study detailed in
Chapter 8. A detailed assessment of the performance of DELTAgene™ assays in RNA
extracted from FFPE melanoma tissues is included in Chapter 8.
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Figure 2-6: The Fluidigm 96:96 Dynamic Array™ integrated fluidic circuit (IFC).
(A) A photograph of the array showing assay and sample inlets. The IFC in the
centre of the chip and is a network of fluid lines, Nanoflex™ valves and reaction
chambers. (B) shows a close-up of the IFC with one of the reaction chambers
(RC) and associated containment valves (CV) and interface valve (IV). Samples
(S) and assays (A) are directed through the IFC using pressure and valves.
Initially samples enter the RC as CVs are open. Assay is prevented from mixing
with the sample by a closed IV. CVs are then closed and the IV opened to allow
mixing of sample and assay prior to PCR. Figure adapted from [347, 351].
2.16.3 Standard Fluidigm qRT-PCR protocol
For experiments using the Fluidigm qRT-PCR system reported in Chapter 8, the
following section describes the standard protocol. Any deviation from this is described
in the relevant section in Chapter 8.
2.16.3.1 Specific target amplification (STA) of samples
Amplification of specific target assays is performed using pooled primers to increase
the number of specific cDNA targets without introducing bias [348]. Each DELTAgene
primer pair (100μM) was combined in equal volume and diluted in 1x DNA suspension 
buffer (10nM Tris, pH 8.0, 0.1mM EDTA) (TEKnova, Hollister, CA) so each primer is at
a final concentration of 500nM. The primer mixture was vortexed and 0.5μl was 
combined with 2.5μl Taqman® Preamplification master mix (Applied Biosystems, 
Warrington, UK), 0.75μl of DNA suspension buffer and 1.25μl of cDNA in a 96-well 
plate. The plate was sealed and placed on a thermal cycler, cycling conditions were
95oC for 10 minutes, followed by 22 cycles of 95oC for 15 seconds and 60oC for 4
A.
B.
S
CV CV
RC
AIV
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minutes, then finally the mixture was cooled to 4oC. Exonuclease I (New England
Biolabs, Hitchen, UK ) was used to remove unincorporated primers, 8 units were added
to each STA reaction and heated to 37oC for 30 minutes, followed by 80oC for 15
minutes before being cooled to 4oC. The products were diluted 1:5 using DNA
suspension buffer and stored at -20oC for use in the qRT-PCR reaction.
2.16.3.2 qRT-PCR reaction
To prepare the sample pre-mix solution for each sample, 3μl of 2x Taqman® gene 
expression master mix (Applied Biosystems) was mixed with 0.3μl 20x DNA binding 
dye sample loading reagent (Fluidigm, Amsterdam, Netherlands), 0.3μl EvaGreen DNA 
binding dye (Biotium, Cambridge, UK) and 2.4μl of the STA sample. The pre-mix 
solution was thoroughly vortexed and centrifuged. The assay mix was prepared by
combining 3μl of 2x assay loading reagent (Fluidigm), with 2.46μl DNA suspension 
buffer and 0.54μl of each 100μM primer pair. This mix was thoroughly vortexed and 
centrifuged.
Control line fluid (Fluidigm) was injected into the two accumulators on the 96:96
Dynamic Array IFC (Fluidigm) (Figure 2-6). The chip was placed into the IFC Controller
HX (Fluidigm) and primed with control line fluid. Five microliters of the samples and
assays were loaded into the respective inlets on the chip (Figure 2-6), the chip was
again placed into the IFC Controller HX and the chip was loaded with samples and
assays. The chip was removed from the Controller and dust particles were removed
from the chip surface using Scotch tape. The chip was placed into the Biomark HD
Reader (Fluidigm) for the qRT-PCR reaction. Cycling conditions consisted of a thermal
mix stage, consisting of 50oC for 2 minutes, followed by 70oC for 30 minutes and then
25oC for 10 minutes, uracil-N-glycosylase (UNG) was then activated at 50oC for 2
minutes followed by activation of polymerase at 95oC for 10 minutes and then 40 cycles
of 95oC for 15 seconds, followed by 60oC for 1 minute. Finally a melt curve was
generated by increasing the temperature from 60-90oC. Data from the Biomark Reader
was imported into Fluidigm Real-time PCR Analysis software, the image view was
assessed to confirm presence of ROX passive reference dye in each well of the IFC, if
this was not present these wells were excluded from further analysis. The auto(global)
method was used to determine thresholds for calculation of cycle threshold (Ct) values,
linear baseline correction was used for baseline determination. Ct values were
exported to Stata version 10 (StataCorp 2007, College Station, TX) for further analysis.
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2.17Identification of mutations in FFPE primary melanoma
tumours
2.17.1 BRAF and NRAS mutation screening using
pyrosequencing
Pyrosequencing was used to identify mutations in codon 600 of BRAF and codons 12,
13 and 61 of NRAS in FFPE melanoma tumour sample sets described in Chapter 6.
Pyrosequencing is a DNA sequencing technique which uses primers to direct a
polymerase extension reaction and then nucleotides are added sequentially to the
reaction [352]. When a base is incorporated, pyrophosphate is released which is
converted to ATP by ATP sulfurylase, which provides energy to luciferase to oxidise
luciferin and generate light. The amount of light that is released is proportional to the
number of nucleotides incorporated so allowing the DNA sequence to be determined.
In liquid-phase pyrosequencing, the enzyme apyrase degrades the unbound
nucleotides before the next nucleotide is added [352-355]. Previous authors have
compared mutation detection results from codons 600 and 601 of BRAF in cell lines,
fresh tissue and FFPE tissue using pyrosequencing and traditional sequencing. There
was good concordance in mutation results between the methods and a mutant peak
can be detected using pyrosequencing when 15-20% of mutated BRAF (V600E)
melanoma cell line derived DNA is present [356]. Using traditional Sanger sequencing,
at least 40% of DNA needs to be mutant to detect the mutation, suggesting that
pyrosequencing is more sensitive than Sanger sequencing for detecting this mutation
[356]. This study also compared pyrograms generated from paired frozen and FFPE
tumours with V600E and V600K mutations; these pyrograms showed similar patterns
and the authors concluded that pyrosequencing generated accurate results with FFPE
tissue [356]. Another study compared mutation results generated using
pyrosequencing, single-strand conformation polymorphism (SSCP) analysis and
sequencing for NRAS codons 12, 13 and 61 in frozen melanoma tissue [353]. All
mutation results were concordant across assays and the sensitivity of pyrosequencing
was reported to be comparable to that of sequencing (15-30%), but less than SSCP
analysis (10%) [353]. Therefore pyrosequencing produces accurate results for BRAF
and NRAS mutation screening from FFPE tissue, it also requires small amounts of
DNA and using automated systems, large numbers of samples can be processed
quickly making it particularly suitable for mutation screening in my samples.
Pyrosequencing of cDNA and DNA samples was undertaken by Dr Philip Chambers in
the Genomics Facility, Cancer Research UK Centre, Leeds Institute of Molecular
Medicine with mutation detection based on NCBI RefSeq accession number
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NM_004333 for BRAF and NM_002524 for NRAS [331]. Primers for amplification and
pyrosequencing analysis of NRAS codons 12 and 13, NRAS codon 61 and BRAF
codon 600 were designed using proprietary Pyrosequencing assay design software
version 2.0.1.15 (Qiagen, Crawley, UK). NRAS codons 12 and 13 were amplified in
one PCR reaction; NRAS codon 61 and BRAF codon 600 were amplified in separate
PCR reactions (Table 2-1).
Region of
interest PCR primers (5’ → 3’) 
Pyrosequencing
primer (5’ → 3’) 
Amplicon
length
(bp)
NRAS
codons
12 and 13
Fwd: CTTGCTGGTGTGAAATGACTGAG
Rev: biotin-TGGATTGTCAGTGCGCTTTTC
CTGGTGGTGGTTG
GA 79
NRAS
codon 61
Fwd: biotin-
GAAACCTGTTTGTTGGACATACTG
Rev: TCGCCTGTCCTCATGTATTG
CTCTCATGGCACT
GTACT 83
BRAF
codon 600
Fwd: TGAAGACCTCACAGTAAAAATAGG
Rev: biotin-
TCCAGACAACTGTTCAAACTGAT
TGATTTTGGTCTAG
CTACA 91
Table 2-1: PCR and pyrosequencing primer sequences for amplification and
analysis of NRAS codons 12 and 13, NRAS codon 61 and BRAF codon 600.
PCR reactions contained 12.5µl of Qiagen HotStarTaq Master Mix (Qiagen, Crawley,
UK), additional magnesium chloride to a final concentration of 2mM, 200nM each of
forward and reverse primers, 20ng of genomic DNA or 2μl of undiluted cDNA and 
sufficient water to make a final volume of 25l. Thermal cycling conditions were 94°C
for 12 minutes followed by 40 cycles of 94°C for 10 seconds, 55°C for 20 seconds and
72°C for 20 seconds. Streptavidin-coated magnetic beads were used to capture
biotinylated PCR product which were sequenced on a PyroMark ID system (Qiagen,
Crawley, UK) following the manufacturer’s protocols. Data were analysed by visual
inspection of pyrograms and by analysis of peak height data. Examples of pyrograms
from BRAF codon 600 are shown in Figure 2-7. Percentage mutation levels were
calculated using peak height data. For example, for V600E A allele percentage levels,
the calculation is (peak height of the A allele x 0.85)/(peak height of the A allele x 0.85)
+ peak height of the T allele [357]. Based on previous experience with the BRAF assay
using other tumour types and other experimental data, Dr Phil Chambers has advised
that the assay sensitivity is 5% with good quality data, where a peak can be
A.
B.
Figure 2-7: Pyrograms for BRAF codon 600.
A shows a pyrogram from a wild-type sample, B shows a pyrogram from a specimen with a V600E (c.1799T>A) mutation.
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distinguished from background, and therefore samples with >5% A allele percentage
were classified as having mutations. With poorer quality data, the sensitivity is less and
for these runs, samples with >10% mutation levels for the BRAF assay were classified
as mutated. As discussed further in Chapter 6, the term “mutation percentage” reflects
the number of mutated alleles in cells assessed, but as tumours are heterogeneous it
will also reflect the number of non-mutated tumour cells along with contaminating
normal stromal cells. Pyrosequencing can detect low levels of mutation in FFPE
melanoma samples and is more sensitive than Sanger sequencing based on the
published literature described above. In some cases mutation results were confirmed
using traditional sequencing using methods described in 2.17.3 by Dr Phil Chambers.
2.17.2 BRAF and NRAS mutation screening using Applied
Biosystems PRISM® SNaPshotTM Multiplex system
The Applied Biosystems PRISM® SNaPshotTM Multiplex system (Applied Biosystems,
Warrington, UK) was used to confirm mutations in BRAF and NRAS in FFPE tumour
DNA or cDNA identified using pyrosequencing as described in Chapter 6. As discussed
in Chapter 6, a limited spectrum of mutations has been found at specific hot-spots in
BRAF and NRAS in melanoma tissues [30]. Most of these mutations involve either a
single (e.g. V600E) or dinucleotide change (e.g. V600K), therefore the SNaPshot
assay can be used to identify these mutations. The primer extension (SNaPshot) assay
uses a reaction mix of four fluorescently labelled dideoxynucleoside triphosphates
(ddNTPs) [358, 359]. Template DNA is amplified using PCR and a primer anneals to
the sequence adjacent to the site of the altered base. Single-base extension occurs by
the addition of the complementary dye-labelled ddNTP to the primer. The result is
marker fragments for mutant and wild-type alleles that are the same length, but vary in
colour. After electrophoresis and fluorescence detection, the alleles appear as different
coloured peaks of roughly the same size in the electropherogram plot. The size of the
different allele peaks will vary slightly due to differences in molecular weight of the
fluorescent dyes [359]. Peaks are colour-coded by Genemapper® software (Applied
Biosystems) according to the dye labelling of the incorporated ddNTP. The
identification of a genotype is based on the peak colour and position of the peak
relative to a size standard [358]. SNaPshot can be used to investigate up to ten sites
simultaneously by using primers of different length [359].
In a previous study using the SNaPshot assay to detect BRAF V600E and various
NRAS mutations in DNA extracted from FFPE tissues, assay sensitivity was
determined using serially diluted positive control samples. Sensitivity to detect BRAF
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mutations was 4.9% and for NRAS mutations 3.2-7.2% depending on the mutation
[360]. These sensitivity levels were comparable to that of Sanger sequencing in this
study [360] suggesting that this method is sensitive, but pyrosequencing is more
sensitive for the V600E BRAF mutation as previously discussed [356].
To assess the mutation status of BRAF and NRAS, methods were optimised using
cDNA and DNA from melanoma cell line material and metastases samples. PCR
primers were selected as described in Table 2-2 to generate small exonic PCR
fragments (70-80bp) suitable for use with DNA extracted from FFPE material and
cDNA synthesized from degraded RNA. SNaPshot probes for detection of mutations in
NRAS and BRAF as described in Table 2-3 were designed to anneal adjacent to the
mutation site. Each probe was synthesised with a different length poly(dT) tail to allow
separation of SNaPshot products during electrophoresis on the basis of size.
Gene
Exon
(codons
covered)
Forward sequence
(5’3’)
Reverse sequence
(5’3’)
Conc. in
primer mix –
cDNA (μM) 
Conc. in
primer mix –
DNA (μM) 
NRAS 2 (12/13) GGTGTGAAATGACTGAGTAC
GATTGTCAGTGCG
CTTTTCC 0.4 0.4
NRAS 3 (61) TGGTGAAACCTGTTTGTTGG
TTGGTCTCTCATGG
CACTGT 0.5 0.5
BRAF 15(600/601)
TCTTCATGAAGAC
CTCACAGT
CCAGACAACTGTT
CAAACTGA 0.7 0.7
Table 2-2: Primers used for PCR amplification of template cDNA and DNA prior to
the SNaPshot assay.
Primer concentrations in the final PCR mix for use with cDNA and DNA are also
presented.
Two assays were performed separately on PCR products to assess the mutation status
of the BRAF gene. The first assay used the V600E probe on the sense strand and
K601E probe on the anti-sense strand, the second assay used the V600E/K probe on
the anti-sense strand and the V600K probe on the sense strand to identify V600K
mutations. This design was chosen because the V600K mutation is a dinucleotide
change at c.1798_1799delinsAA , whereas the V600E mutation is a single base
change at c.1799T>A [361]. Therefore, the V600E probe used in the first assay would
not anneal in the presence of a V600K mutation, however the combination of the
V600E/K probe on the antisense strand and V600K probe on the sense strand in the
- 76 -
second assay would allow identification of both V600E and V600K mutations (Figure
2-8). The K601E mutation is a single nucleotide change at c.1801A>G [361].
Probe
(gene) Sequence (5’3’) Strand
Product
Length
(bp)
Conc. in
SNaPshot
probe mix
(μM) 
Position 182
(NRAS exon 3) T33GACATACTGGATACAGCTGGAC Sense 55 0.6
Position 181
(NRAS exon 3) T18CTCATGGCACTGTACTCTTCTT Anti-sense 40 0.1
Position 37
(NRAS exon 2) T26GGTGGTGGTTGGAGCAGGT Sense 45 0.1
Position 35
(NRAS exon 2) T71CTGGTGGTGGTTGGAGCAG Sense 90 0.3
V600E (BRAF) T14GGTGATTTTGGTCTAGCTACAG Sense 36 0.2
V600E/K (BRAF) T50ACCCACTCCATCGAGATTTC Anti-sense 70 0.2
V600K (BRAF) T40GGTGATTTTGGTCTAGCTACA Sense 62 0.1
K601E (BRAF) T30GGACCCACTCCATCGAGATT Anti-sense 50 0.2
Table 2-3: Probes used in the SNaPshot assay.
The final working concentration of these probes in the SNaPshot reaction is also
presented.
5’ATATATTTCTTCATGAAGACCTCACAGTAAAAATAGGTGATTTTGGTCTAGC
TACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGTTGTCTGGATC
CATTTTGTGGATG 3’
Figure 2-8: A section of exon 15 of the BRAF gene to demonstrate the position of
SNaPshot probes in relation to common BRAF mutations.
The site of the V600K mutation is underlined and highlighted in bold. The position
of the PCR primers are shown in blue, the site of the V600K probe is shown in
yellow and the V600E/K probe on the anti-sense strand is shown in green.
Separate PCR mixes for BRAF, NRAS exon 3 and NRAS exon 2 contained 0.9x
GeneAmp PCR Gold Buffer (Applied Biosystems), 0.5 units AmpliTaq Gold DNA
polymerase (Applied Biosystems), 1.25 mM magnesium chloride solution, 0.2mM
dNTPs (Applied Biosystems), 0.4-0.7 μM of each primer mix (listed in Table 2-2), 5% 
glycerol, 2 micrograms of cDNA or 20ng of DNA and nuclease-free water to a final
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volume of 10μl. Thermal cycler conditions were 95oC for 5 minutes, 35 cycles of 95oC
for 45 seconds, 55oC for 45 seconds and 72oC for 45 seconds followed by 72oC for 10
minutes. PCR products were treated with 2 units of shrimp alkaline phosphatase (USB,
Affymetrix, High Wycombe, UK ) and 1.3 units of exonuclease I (New England Biolabs,
Hitchen, UK) and incubated at 37oC for 1 hour, followed by 72oC for 15 minutes, to
remove excess dNTPs and primers, respectively.
SNaPshot analysis was performed using the Applied Biosystems PRISM® SNaPshotTM
Multiplex kit. Two reaction mixes were prepared for analysis of BRAF as described
above, and two reaction mixes were prepared for NRAS analysis, one containing the
NRAS probes on exon 2, the other with probes for exon 3. Reactions contained 2.5μl 
SNaPshot Ready Multiplex Ready Reaction Mix, 1x BigDye sequencing buffer (Applied
Biosystems), 0.1-0.6 μM probe mix (Table 2-3), 1μl of the relevant PCR product and 
nuclease-free water to a final volume of 9μl. A control reaction without template was 
performed for each assay using the same reaction mix and 1μl nuclease-free water. 
Extension reactions were performed by incubating the mixture for 35 cycles at 96oC for
10 seconds to denature followed by 58.5oC for 40 seconds to anneal and extend.
Products were treated with 1 unit of shrimp alkaline phosphatase, followed by
incubation at 37oC for 60 minutes and then 72oC for 15 minutes. Products were diluted
1 in 5 using nuclease-free water. 1μl of the diluted extension product was mixed with 
9.8μl HiDi™ formamide (Applied Biosystems) and 0.2μl of Genescan-120LIZ size 
standard (Applied Biosystems). Products were denatured at 100oC for 5 minutes and
then separated using an Applied Biosystems PRISM 3130xl Genetic Analyzer with a
36cm length capillary and POP-7™ polymer. Analysis was performed using
GeneMapper® 3.7 software. Some examples of the results obtained are presented in
Figure 2-9. Significant peaks were not identified in traces from no template control
reactions. Percentage mutation results were calculated based on peak heights using
similar methods as for pyrosequencing data.
Figure 2-9: Examples of mutations detected using SNaPshot in cDNA and DNA.
Graph A demonstrates a V600K mutation in BRAF, the A>T change alone using the probe on the anti-sense strand would represent a V600E
mutation. Graph B shows a c.181C>A mutation in exon 3 of NRAS. Graph C shows a c.182A>G mutation in exon 3 of NRAS. Orange peaks
represent the internal Genescan-120LIZ size standards. Bases are represented by the following colours: A=green, C=black, G=blue and T=red.
Small non-specific peaks are noted in graph A, which were seen in all BRAF assays.
A B C
A>T (anti-sense) G>T (anti-sense)
A (sense)
G (anti-sense)
G>A (sense)
A>G
(sense)
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2.17.3 Sequencing methods
To confirm mutations identified in BRAF and NRAS using pyrosequencing, traditional
Sanger sequencing was performed on a selection of samples by Dr Phil Chambers.
Pyrosequencing primers as described in Table 2-1 were used as sequencing primers in
this analysis. Sequencing of both forward and reverse strands was performed.
To remove any unincorporated dNTPs and primers, 1μl of ExoSAP-IT (USB, 
Affymetrix, High Wycombe, UK) was added to 2.5μl of the PCR product, mixed and 
incubated at 37oC for 15 minutes, followed by 80oC for 15 minutes and finally cooled to
15oC. The sequencing reaction comprised of 1μl of 1.6μM primer, 1μl of purified PCR 
product, 4.25μl of distilled water, 3.5μl of ABI 5x Sequencing Buffer (Applied 
Biosystems, Warrington, UK) and 0.25μl of Ready Reaction Mix v1.1 (from Applied 
Biosystems BigDye® Terminator Cycle Sequencing kit v1.1). The mixture was
incubated at 96oC for 1 minute, followed by 25 cycles of 96oC for 10 seconds, 50oC for
5 seconds and 60oC for 4 minutes, finally the mixture was cooled to 15oC.
Products were concentrated and purified using ethanol precipitation. To the
sequencing product, 1μl of 3M sodium acetate and 25μl of 95% ethanol were added 
and the mixture incubated at room temperature for 15-30 minutes to precipitate the
sequencing product. The samples were centrifuged at 2250g for 30 minutes to pellet
the product, the 96-well plate was then inverted onto absorbent paper and centrifuged
again at 180g for 1 minute. To the pelleted product, 70μl of 70% ethanol was added to 
wash away residual sodium acetate and the mixture centrifuged at 1650g at 4oC for 15
minutes. Again, the 96-well plate was inverted onto absorbent paper and centrifuged at
180g for 1 minute. The pellet of sequencing product was dried by heating to 95oC for 1
minute. Sequencing products were suspended in 20μl of Hi-Di™ formamide (Applied 
Biosystems) and heated to 95oC for 1 minute before being snap cooled on ice water
immediately prior to electrophoresis. Products were separated using the Applied
Biosystems PRISM 3130xl Genetic Analyzer with a 36cm length 16-capillary array and
POP-7™ polymer. Sequence analysis was carried out using Sequencing Analysis 5.2
(Applied Biosystems) and Mutation Surveyor 3.2 (Soft Genetics, State College, PA).
2.18Gene ontology and pathway analysis
Gene ontology and pathway analysis have been used in this thesis to further
investigate lists of genes identified as differentially expressed in groups of interest. The
function of these systems and an assessment of their usefulness is included in Chapter
4. I will briefly described the algorithms used by these analysis methods below.
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2.18.1 Gene ontology analysis
Gene ontology analysis described in Chapter 4 was performed by Dr Binbin Liu and Dr
Lee Hazelwood of the Bioinformatics Group in the Leeds Institute of Molecular
Medicine. Cytoscape v2.8.1 [362, 363] and its plug-in, BiNGO v2.44 [364, 365] were
used to search a custom built GO database with gene lists. Cytoscape provides a
graphic interface for visualizing GO networks. BiNGO assesses the enrichment of a
GO term in the test gene set using a hypergeometric approach and controls the false-
positive rate by performing a multiple testing correction with either a Bonferroni [366] or
Benjamini and Hochberg correction. The latter technique controls for the false
discovery rate (FDR) which is the expected proportion of false positives among the
positively identified tests [367]. For the analysis described in Chapter 4 a customized
gene reference and annotation databank were built, as gene expression data were
based on the 502-gene Human Cancer panel rather than a genome-wide platform.
Therefore, the databank used contained GO terms associated with the 502 genes only.
2.18.2 DAVID (the database for annotation, visualisation and
integrated discovery)
DAVID [368], maps a gene list to the associated biological annotation (e.g. GO terms)
and then highlights the most overrepresented annotation [369-371]. This publically
available software was used in Chapters 4 and 7, by myself, to identify pathways
containing genes identified as differentially expressed in my analyses. The DAVID
functional annotation tool uses a list of genes inputted by the user and iteratively tests
the enrichment of each annotation term [369, 371, 372]. The individual annotation
terms passing the enrichment P-value threshold are reported. In DAVID, these tests
are performed using a Fisher’s exact test (modified as EASE score using Expression
Analysis Systematic Explorer (EASE) software) [371, 373]. Annotation terms can be
combined into clusters which have an overall enrichment score which is the geometric
mean of all the enrichment EASE scores [369]. EASE can calculate a number of
probability corrections, including Bonferroni corrections and methods which correct for
the FDR [373]. DAVID incorporates further network discovery algorithms by assessing
relationships between enriched terms using a wide range of resources including
pathway databases (KEGG (Kyoto Encylopedia of Genes and Genomes), Biological
Biochemical Image Database (BBID), Reactome Pathway, EC number, Biocarter and
Panther Pathway) [371].
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For the purposes of enrichment analysis described in this thesis, a background
population of genes from the Human Cancer panel has been used for comparison with
the annotation composition of the inputted gene lists [368].
2.18.3 Ingenuity Pathway Analysis
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Redwood City, California,
www.ingenuity.com) was used in Chapter 4 by Dr Jeremie Nsengimana and transforms
gene lists into networks using the Ingenuity Pathways Knowledge Base (IPKB) [374,
375]. The IPKB contains annotations based on biological interactions and function
created by modelling relationships based on literature between proteins, genes,
isoforms, complexes, cells, tissues, drugs and diseases [376]. IPA users can specify
cut-offs based on gene expression data, which select a subset of important focus
genes. The IPA application maps each gene identifier to its corresponding gene object
in the IPKB. Focus genes are then overlaid onto a global molecular network developed
from information in the IPKB. Focus genes are sorted in order of interconnectedness.
Genes connected with the largest number of other genes are ranked highest and this
gene is labelled the seed gene. The next focus gene most connected to the seed gene
is added to the growing network. This gene is identified by calculating the ‘specific
connectivity’ metric which is a measure of how much a new gene’s neighbourhood
(new gene plus all genes related to the new gene) overlaps the current network.
Connected genes are added until the maximum network size of 35 genes is reached.
Smaller gene networks are combined to make larger networks where possible and for
networks which still have less than 35 genes, additional genes are added to the
periphery of the network to provide additional biological context to the focus genes.
Each IPA network is assigned a significance score (p-score) derived from p-values
representing the likelihood that the focus genes in the network are found by random
chance. The p-value is the probability of finding one or more focus genes in a set of
genes randomly selected from the global molecular network calculated using Fisher’s
exact test. The p-score is equal to the negative exponent of the respective significance
value (p-score = -log10(p-value)) [375-378].
2.19Immunohistochemistry
Immunohistochemical staining of tissue sections was performed by Sarah Storr and
Sabreena Safuan at the Department of Academic Oncology at the University of
Nottingham on a subset of tumours described in Chapter 7. This collaboration was
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designed to study associations between ulceration and tumour vascularity, blood and
lymphatic vascular invasion, vessel density and presence of tumour-associated
macrophages [113].
Sections of tumour were stained with the lymphatic-specific antibody D2-40, the
endothelial marker, CD34, and a CD68 antibody to detect macrophages [113].
Immunohistochemistry (IHC) allows direct visualisation of specific antigens within a
tissue using monoclonal antibodies [379, 380]. Following specific binding of an
unlabelled primary antibody, the indirect method use a biotinylated IgG antibody
against the species that the primary antibody was generated from and binds to the
constant fragment (Fc) of the primary antibody. Streptavidin conjugated enzymes then
bind to biotin on the secondary antibody which generate an insoluble substrate product
which can be visualised [379-381].
Use of specific antibodies for lymphatic vessels increases detection rates versus H+E
slides alone [382-385]. D2-40 is a monoclonal antibody against the 40-kD
sialoglycoprotein, M2A, and is a specific marker for lymphatic endothelial cells [386-
389]. CD34 is an endothelial marker in both lymphatic and blood vessels, but is more
weakly expressed in lymphatic vessels [110, 389, 390]. It is not specific to endothelium
in skin however, as CD34 is also expressed on dermal dendritic cells and perifollicular
cells as well as endothelial cells in normal skin [391]. CD68 is widely used to stain for
macrophages, but does have cross-reactivity with organelles in other cell types, so is
not entirely macrophage specific [392-394]. Despite this, it has been used either alone
or in combination with other antibodies to identify macrophages in melanoma tumours
[393, 395-397].
2.19.1 Immunohistochemistry (IHC) methods
Samples used for IHC staining are described in Chapter 7. IHC staining and
measurement of vessels and macrophages in consecutive tissue sections was
performed at the University of Nottingham. To visualise vessels and macrophages,
three consecutive tumour slides were stained with antibodies as described in Table
2-4.
Staining methods have been previously described [113, 398, 399]. Briefly, sections
were deparaffinised in histolene and then rehydrated in a series of ethanol baths
(100%, 90%, 70%, 50% and 30%) and finally immersed in water. For CD34 and CD68
antibodies, antigen retrieval was performed by immersing slides in 0.01mol/l sodium
citrate buffer (pH6) which was heated in a microwave at 750W for 10 minutes, followed
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by 400W for 10 minutes. Endogenous peroxidase activity was blocked by incubating
tissue with 0.01% hydrogen peroxide in methanol for 10 minutes.
Antibody target Target location Manufacturer Dilution
CD34 Endothelial cells (predominantlyblood vessels)
AbD Serotec,
Kidlington, UK 1:500
D2-40 Endothelial cells (lymphaticvessels)
Covance SIGNET,
NJ, USA 1:100
CD68 Macrophages Abcam, Cambridge,UK 1:100
Table 2-4: Primary antibodies used for IHC staining.
Antibody targets are presented with manufacturers details and dilutions used for
IHC staining. All antibodies were diluted in blocking buffer.
To reduce non-specific binding, potential reactive sites were blocked by incubating
sections with normal swine serum (Dako, Glostrup, Denmark) diluted 1:5 using Tris-
buffered saline (TBS) for 10 minutes. Diluted primary antibodies (Table 2-4) were
incubated with tissue for 1 hour and then a biotinylated secondary antibody (1:100
dilution in blocking buffer) was added for 30 minutes, followed by streptavidin-coupled
horseradish peroxidase (1:100 dilution in blocking buffer) for 1 hour according to the
manufacturer’s instructions (StreptABComplex/HRP Duet, Dako, Ely, UK). In the case
of CD34 and D2-40 reactions, coupled streptavidin-horseradish peroxidase reacted
with 3,3’ diaminobenzidine (DAB) to generate brown staining. For CD68 a permanent
red substrate (Dako) was used to help distinguish macrophages from brown
melanocytes. Sections were counterstained with Gill’s formula haematoxylin (Vector
Laboratories, Peterborough, UK), dehydrated and fixed in histolene. CD34 and D2-40
sections were mounted with Depex mounting medium (Solmedia, Romford, UK ),
Glycergel mounting medium (Dako) was used for CD68 stained sections. Sections of
tonsil and placental tissue were used as controls, primary antibody was omitted for
negative controls. The final tumour section was stained with H+E as described in
section 2.3.3.
Examples of stained sections are presented in Figure 2-10.
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Figure 2-10: Consecutive stains of melanoma sections with haematoxylin and
eosin (H+E) (A), anti-D2-40 (B), anti-CD34 (C) and anti-CD68 (D) (20x
magnification).
A vessel is visible on the H+E slide (arrow) showing invasion by melanoma
tumour cells. Invasion can also be seen in anti-D2-40 stained lymphatic vessels
and anti-CD34-stained blood vessels. Anti-CD68 stained macrophages can be
seen around the vessel invasion. Figure courtesy of Sarah Storr, University of
Nottingham [113].
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2.19.2 Assessment of microvessel density and macrophage
count
Microvessel density and the number of macrophages were measured using the
‘hotspot’ Chalkley 25-point method in three areas on each section as previously
described [398, 399]. To identify ‘hotspots’ of high blood vessel density or
macrophages, sections were reviewed at 10x magnification. Areas with high vascular
concentration or macrophage infiltration were viewed at 20x magnification and a 25-
point Chalkley eyepiece graticule was applied and adjusted so there was maximum
overlap between vessels or macrophages and the graticule points. A Chalkley count for
each tumour was taken as the average of three counts. Twenty percent of the slides
were reviewed by two independent assessors who were blinded to each other’s scores
and clinico-pathological data.
2.19.3 Assessment of lymphatic density
Lymphatic vessel density was determined by counting all positively stained lymphatic
vessels across a whole tissue section as previously described [400]. Sections were
divided into the intratumoural, inner two thirds of a tumour, and peritumoural areas
which represents all normal tissue surrounding the tumour [400]. Stained vessels were
counted across the two areas at 10x magnification, the size of each area was
determined in mm2 by counting the number of fields of view with each field of view
having a surface area of 154mm2. Lymphatic vessel density (vessels/mm2) was
calculated by dividing the number of lymphatic vessels identified in an area by the total
surface area. Total LVD for each section was the sum of intratumoural and
peritumoural lymphatic vessel densities. In these cases, 30% of slides were examined
by two independent assessors.
2.19.4 Assessment of lymphatic vessel invasion and blood
vessel invasion
H+E sections were initially reviewed to determine whether a tumour was vascular
invasion positive, possible or negative. Using IHC stained sections, lymphatic and
blood vessel invasion was determined as presence of tumour cells within a D2-40
stained vessel or a CD34 stained vessel that was negative for D2-40, respectively.
These sections were defined as vascular invasion positive. Lymphatic vessel invasion
was assessed within intratumoural and peritumoural areas. Total vascular invasion was
classified as positive if sections were either lymphatic or blood vessel invasion positive.
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All slides were assessed by two independent assessors. In addition, any positive or
probable cases were reviewed by pathologists, Professor Martin Cook or Professor Ian
Ellis to confirm or refute. Following review, any ‘possible’ invasions, were grouped with
positive cases for analysis.
2.20Summary
This chapter presents methodology used in this thesis. It also reports an assessment of
the WG-DASL HT assay with FFPE melanoma specimens. During my PhD new nucleic
acid extraction and cDNA synthesis kits have been developed and assessed. Results
from these newer products have been good, highlighting the importance of assessing
new technologies to maximise use of precious tissue resources and improve results.
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3 Gene expression profiling of formalin-fixed paraffin-
embedded primary melanoma using the cDNA-mediated
annealing, selection, extension and ligation assay
3.1 Aims
The main aim of this work was to identify genes which are differentially expressed in
primary melanoma tumours in association with relapse or mortality and then validate
these findings in an independent sample set.
Further aims were:
 To assess the utility of the cDNA-mediated annealing, selection, extension and
ligation (DASL) assay to identify gene expression signatures in formalin-fixed
paraffin-embedded (FFPE) primary melanoma tumours.
 To identify factors that influence performance of melanoma samples with the
DASL assay.
3.2 Background
The established predictors of outcome for melanoma patients relate to the histological
characteristics of the primary tumour (Breslow thickness, the presence of ulceration,
mitotic rate), tumour site, sex and age [58, 91]. Histological characteristics are used to
estimate prognosis as part of the AJCC staging system [58] and in various algorithms,
to give a more personalized estimate [133, 401], but much of the variance in survival
remains unexplained. In order to identify prognostic and predictive biomarkers, and
increase the understanding of key biological pathways, molecular studies of primary
melanomas are necessary.
Primary melanomas are small and as the histological characteristics conveying
prognostic information are often focal within the primary tumour, pathologists are
reluctant to cryopreserve tissue. Therefore, until recently genomic expression studies
in primary melanoma tumours have been relatively few in number, limited in size and
focusing on single genes [402, 403]. An increasing body of work has now been
published using gene expression microarrays with cryopreserved melanoma tumours
as presented in Chapter 1, including a number of studies conducted to REporting
recommendations for tumour MARKer prognostic studies (REMARK) standards [161,
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162]. In primary tumours, the only study of reasonable size was undertaken by
Winnepenninckx et al. who used tumours from 58 patients to identify a 254-gene
signature predictive of survival which included mini-chromosome maintenance genes.
This signature was tested in an independent sample set in which 11 out of 17 cases
were correctly classified [178]. Kauffman et al. used bioinformatics analysis of gene
expression data from 60 samples, 58 from the Winnepenninckx study, and found that
DNA repair genes were overrepresented [177]. As reviewed in the Chapter 1, a larger
number of studies have been performed in metastatic tumours specimens [179, 180,
185, 186, 194], which have highlighted the importance of immune response processes
and NRAS-regulation pathways for prognosis [188].
Whilst these studies represent major developments in the field, analysis of FFPE
tumours would enable studies using large numbers of samples, including primary
melanomas, with mature follow-up data. Potentially, studies of this kind would be less
biased as tumours would not be selected based on whether they are deemed suitable
for cryopreservation. Formalin is a fixative which preserves tissue and cellular structure
by cross-linking proteins and nucleic acids [77]. Cross-links cause nucleic acid
degradation during extraction procedures and addition of monomethyol groups to
bases can interfere with downstream reverse transcription and amplification reactions
[292]. Increasing amounts of degradation of nucleic acids have been associated with
longer formalin fixation [404] and higher temperatures during paraffin embedding of
samples [405]. In addition, RNA continues to degrade over time especially when stored
at room temperature, compromising the quality of nucleic acids from older tissue blocks
[291, 316]. Methodological studies have demonstrated that use of an overnight
Proteinase K digestion step to degrade proteins cross-linked with RNA, a high
temperature incubation step (50-55oC [292] or 60-70oC [315, 316]) to remove part of
methylol groups and an on-column DNase digestion step to remove DNA, improves the
quantity and quality of RNA extracted from FFPE tissues and performance in
downstream assays [315, 316, 406]. Despite these modifications to RNA extraction
protocols, RNA can be severely degraded being less than 300 base pairs in length
[291]. Therefore, use of microarray technology has been limited using RNA extracted
from FFPE tissue, restricting the use of this valuable tissue resource.
Illumina’s DASL (cDNA mediated annealing, selection, extension and ligation) assay is
specifically designed for use with degraded RNA, such as that extracted from FFPE
tissue as it uses random priming in cDNA synthesis and a target sequence of only 50
nucleotides is required for probe groups to anneal [293]. Further details of the assay
are included in Chapter 2. Previous studies have demonstrated that the DASL assay
produces reproducible gene expression results from degraded RNA such as that
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extracted from FFPE tissues [293-297]. Gene expression profiles generated from the
assay correlate well with profiles derived for intact RNA extracted from frozen tissue or
cell lines [293-295] and biologically useful results have been obtained from use of this
technology [295, 297].
This chapter describes use of the DASL assay to investigate prognostic biomarkers in
stored primary melanomas. Performance of the assay is highly dependent on the
quality of RNA used and so samples go through a number of quality control procedures
to assess suitability for use in the assay as described in Chapter 2. An assessment of
these investigations as predictive of assay performance is included in this chapter.
A further issue with primary melanomas is melanin, which co-purifies with DNA and
RNA. Melanin absorbs UV light which can lead to unreliable spectrophotometric
quantification of nucleic acids [306] and more importantly, it can inhibit DNA
polymerases leading to failure of downstream PCR reactions [303]. Therefore, assay
performance has also been correlated with melanin content of melanoma tumours.
This chapter reports an evaluation of the DASL assay and confirmation of the
significance of increased SPP1 expression in a large study of FFPE primary melanoma
tumours.
3.3 Detailed methodology
3.3.1 Patient samples and gene expression analysis
As described in Chapter 2, FFPE primary melanoma tumour blocks were identified
from two study sets; the Leeds Melanoma Cohort Study henceforth referred to as the
Cohort study and the Retrospective Sentinel Node Biopsy Study referred to as the SNB
study. In the Cohort study, the first 254 blocks identified from participants within the
cohort with tumours thicker than 0.75mm having the longest follow-up comprised the
test set. In the SNB study (the validation set), the first 218 blocks identified from
participants with the longest follow-up in a study designed to identify predictors of
sentinel node positivity and relapse were sampled. To allow evaluation of the effect of
melanin on gene expression analysis of melanoma samples, cores were graded using
the melanin score. RNA was extracted using the Roche High Pure RNA Paraffin Kit
and quantity and quality of RNA was determined using spectrophotometry. Further
methodological details are in Chapter 2. Sample selection, melanin scoring, tissue
sampling and RNA extraction were performed by Dr Caroline Conway (Cohort study),
Dr Angana Mitra (SNB study) and Samira Lobo.
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The Illumina DASL Human Cancer panel was used for gene expression profiling by
Floor de Kort at the service provider, ServiceXS (Leiden, Netherlands) as described in
Chapter 2.
3.3.2 Target validation using quantitative Real-time PCR (qRT-PCR)
SPP1 expression was identified as significantly associated with relapse and overall
survival (section 3.4.4), and was therefore further investigated by qRT-PCR on
samples from the Cohort study by Dr Caroline Conway. Small fragments of SPP1 and
the endogenous control gene, GAPDH, were amplified using Taqman® Gene
Expression Assay probes (Applied Biosystems, Warrington, UK) as presented in Table
3-1.
Gene Exonstargeted
Amplicon
length
NCBI
Reference
Sequence
Assay Reference
Gene for
relative
quantification
SPP1
1/2 63bp NM_000582.2 Hs00960942_m1
5/6 84bp NM_000582.2 Hs00959010_m1
Endogenous
control gene GAPDH 3 122bp NM_002046.3 Hs99999905_m1
Table 3-1: Taqman® Gene Expression Assay probes used for qRT-PCR of SPP1.
Abbreviations used: NCBI, National Center for Biotechnology Information.
PCRs were performed in duplicate using cDNA previously synthesised from RNA
samples sent for DASL analysis. cDNA was generated using the Invitrogen
Superscript™ First-strand Synthesis System according to the manufacturers protocol as
detailed in Chapter 2. cDNA was diluted 1:1 with nuclease free water and 1l was used
for each qRT-PCR assay. PCRs were performed with Gene Expression Master Mix
(Applied Biosystems) in a 20l final volume on the ABI 7900 Real-time PCR system
(Applied Biosystems). Cycling conditions used were 50oC for 2 minutes, 95oC for 10
minutes and 40 cycles of 95oC for 15 seconds and 60oC for 1 minute. Automatic
settings were used for baseline and threshold determination and cycle threshold (Ct)
values for each target were exported to Excel for further analysis. Mean Ct values from
replicate samples were calculated and ΔCt values were determined using the 
comparative Ct (or ΔCt) method [342], where ΔCt = Ct gene of interest - Ct 
endogenous control. ΔCt values were then converted to 2-ΔCt for the calculation of fold
- 91 -
change between relapsers and non-relapsers where fold change = 2-ΔCt relapsers ÷ 2-
ΔCt non-relapsers. A more detailed assessment of qRT-PCR methods in FFPE
melanoma tumours has been undertaken in Chapter 4.
3.3.3 Statistical methodology
3.3.3.1 Quality control analysis of gene expression data
I performed the statistical analysis reported in this chapter. As reliability of the array
data is critical and there are reasons to expect poorer quality data when generated
from FFPE tissues I looked at age of the tumour block, degree of pigmentation of the
paraffin-embedded tumour and RNA quality as determinants of the array data quality. I
also report consistency between technical and biological replicates.
Previous authors have used the number of genes detected in each sample using the
DASL assay (probe signal significantly greater than average signal from negative
controls with p<0.05) as a measure of the quality of results [294]. Use of number of
detected genes may not be the best measure of result quality as discussed in Chapter
5. However, for the purposes of this assessment, the influence of age of tissue block
and melanin level of the tumour on number of genes detected was investigated using
Spearman’s rank correlation and Kruskal-Wallis tests respectively.
Methods used to measure the quality and quantity of RNA prior to use in the DASL
assay were assessed by correlating the number of genes detected in samples with the
quality measures data using either Spearman’s rank correlation or the Kruskal-Wallis
test. Samples with less than 250 detected genes were classified as ‘failed’ as
suggested by previous authors [294] and excluded from further analysis.
A number of RNA samples from the same extraction were analysed twice using the
DASL assay (technical replicates). Biological replicates were also included which were
RNA samples extracted from tissue cores sampled from adjacent parts of the same
tumour. Equality and correlation between gene expression levels in replicates was
assessed using paired t-tests and Pearson’s correlation coefficients. Mean gene
expression was used for replicate samples in further analysis.
To further monitor variation across plates and runs of the DASL assay, replicate
Stratagene Universal Human Reference RNAs (Agilent Technologies, Edinburgh, UK)
were assessed across DASL plates. Analysis of results from these reference RNAs is
described in detail in Chapter 5.
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3.3.3.2 Descriptive characteristics of the sample set
Patient factors and histological characteristics of the primary tumour were compared
between the two studies using two-sample t-tests, Pearson’s chi squared tests and
Mann-Whitney U tests.
3.3.3.3 Identification of differentially expressed genes
Differential gene expression and survival analyses were performed using data which
had been log-transformed (log2). As some of the raw gene expression levels were
negative values, 1000 was added to all values prior to log-transformation. Survival
analysis was performed using the Cox proportional hazards model to calculate hazard
ratios and 95% confidence intervals for each gene. Significance values were ranked to
identify genes most differentially expressed. Relapse-free survival (RFS) was defined
as the period between diagnosis and date of first relapse at any site. The analysis was
performed on the 11th February 2010 and survival data were censored on this date.
Analyses were performed unadjusted and adjusted for demographic (patient gender,
site of tumour and age of patient at diagnosis) and histological factors of prognostic
importance in melanoma (Breslow thickness, mitotic rate of tumour and ulceration
status). Analyses were also adjusted for whether the patient had undergone a sentinel
node biopsy and the effect of the biopsy result (SNB status) as the use of SNB results
in delay of the date of first relapse in melanoma patients as the usual site of first
recurrence (nodal) is removed.
Correlations between gene expression patterns were identified using linear regression,
adjusting for the study from which patients were recruited to, using the merged dataset
from both studies which was generated as described in Chapter 4.
3.3.3.4 Multiple testing and adjustment of analyses
In view of the number of statistical tests in this analysis (502), a number of significant
findings would be expected to occur by chance. Therefore, to correct for this issue of
multiple testing, the Bonferroni method was used [366] and the significance level was
set at 0.0001 for analyses identifying genes associated with survival. For survival
analyses adjusted for known prognostic factors assessing the expression of a single
gene in each test, the significance level for highlighting results of interest was set as
0.05. All statistical analyses were undertaken using Stata version 10 (StataCorp 2007,
College Station, TX).
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3.3.4 Generation of gene networks using Ingenuity software
Ingenuity Pathway Analysis was performed by Dr Jeremie Nsengimana in the Section
of Epidemiology and Biostatistics. Using the combined data from the studies, fold
changes and significance levels of genes differentially expressed in tumours from
patients with reduced relapse-free survival time were analysed using Ingenuity
Pathway Analysis software (Ingenuity Systems, Redwood City, California,
www.ingenuity.com). The algorithms used by Ingenuity Pathway Analysis software are
described in more detail in Chapter 2. Genes >1.2 times over- or under-expressed with
significance levels <0.05 were interrogated by Ingenuity to find genes most related to
each other and a network of these relationships was generated.
3.4 Results
3.4.1 RNA yields, quality control measures and performance of the
DASL assay
Of the 472 tumours blocks identified from the two studies, 378 (80%) were sampled.
Blocks were not sampled if there was too little residual tumour after sectioning carried
out for diagnostic purposes or other research projects, or if the tumour was necrotic or
too admixed with a large number of lymphocytes or stromal cells. In 17/378 (4.5%) a
tissue core was taken and RNA extracted, but inadequate quantities were extracted
(<20ng/μl) as measured by spectrophotometry. Overall, “adequate” amounts of RNA 
were therefore obtained from 361 (76%) tissue blocks.
A total of 423 RNA samples including replicate samples was sent to the service
provider (ServiceXS) for DASL analysis (359 unique samples and 64 replicate
samples). Six (1.4%) samples failed the assay, defined as less than 250 genes being
detected. The failure rate was 2.1% in the Cohort Study and 0.9% in the SNB study. As
discussed previously, age of tissue block and melanin content of tumours can have an
influence on quality of RNA extracted and performance in PCR reactions. Table 3-2
summarizes the association between quality control measures, age of tissue block and
melanin content of tumour and the number of genes detected in the DASL assay.
Increased block age was negatively correlated with number of genes detected in the
SNB study (p=0.0002), but not the Cohort study, which may be because the range of
block age was much greater in the SNB study (SNB study: 2.23-15.16 years, Cohort
study: 1.48-7.84 years). Melanin score was assessed for all tumours sampled in the
SNB study, but only 102 samples in the Cohort study as the score was not recorded for
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a proportion of samples. Higher melanin score was associated with fewer genes
detected in the Cohort study (p=0.04) but not in the SNB study (p=0.26).
Samples were assessed with quality control measures as described in Chapter 2. RNA
concentrations for all samples were measured using the ND-8000 spectrophotometer
(Nanodrop, Wilmington, DE, USA) before being sent to the service provider. Samples
in the Cohort study were also assessed using the Agilent 2100 Bioanalyzer using a
RNA 6000 nano-chip and standard manufacturer’s protocols by the service provider,
however no data from this analysis was made available to us apart from
electropherogram traces which when assessed subjectively as described in Chapter 2
did not correlate with number of genes detected in the DASL assay (Spearman’s rho -
0.07, p=0.37). Twenty-seven samples from the SNB study were assessed with the
Bioanalyzer. For these cases RNA concentration as determined by the Bioanalyzer
and RNA integrity number (RIN) score [336] was provided for 21 samples. RIN scores
are described in further detail in Chapter 2. qRT-PCR of the housekeeping gene
RPL13a, described in further detail in Chapter 2, was undertaken for all samples but
unfortunately failed for samples from the Cohort study. The quality control procedures
that best predicted number of genes detected in the SNB study were RNA
concentration as determined by spectrophotometry and the Bioanalyser, RIN number
and Ct values determined using qRT-PCR of RPL13a.
Table 3-2 (following page): Associations between quality control procedures,
tumour characteristics and performance with the DASL assay.
Performance with the assay was determined by the number of detected genes.
Columns that present statistical association present the test performed, the test
statistic and the significance value. Significant results are highlighted in bold.
Abbreviations used: n, number; Ct, cycle threshold value; RIN, RNA integrity
number.
Cohort Study
(188 samples)
Association between
measure and number
of detected genes
SNB study
(235 samples)
Association between
measure and number
of detected genes
Number failed samples, n (%) (<250 genes) 4 (2.1) 2 (0.9)
Number detected genes overall, mean (range) 434 (33-472) 457 (180-493)
Age of block, years, mean (range)
Number genes detected, mean (range):
Block <5 years old
Block 5-10 years old
Block >10 years old
4.63 (1.48-7.84)
436 (33-468)
442 (317-472)
None
Spearman’s rho
0.11, p=0.13
6.26 (2.23-15.16)
466 (371-491)
456 (180-493)
441 (376-477)
Spearman’s rho
-0.24, p=0.0002
Melanin score, n (%):
0
1
2
3
In 102 samples:
5 (4.9)
30 (29.4)
42 (41.2)
25 (24.5)
Kruskal-Wallis χ2 8.44,
p=0.04
4 (1.7)
58 (24.9)
63 (27.0)
108 (46.4)
Kruskal-Wallis χ2 4.02,
p=0.26
Nanodrop RNA concentration, ng/L, mean (range) 44.6 (0-87) Spearman’s rho0.09, p=0.23 53.7 (0.4-209.9)
Spearman’s rho
0.13, p=0.05
Bioanalyser RNA concentration, ng/L, mean (range) Not assessed In 27 samples:24.6 (0-56)
Spearman’s rho
0.59, p=0.001
Bioanalyser RIN number, median (range) Not assessed In 21 samples:1.5 (1.0 -2.3)
Kruskal-Wallis χ2
6.90, p=0.03
Ct values, mean (range) Failed 24.3 (19.9-27.3) Spearman’s rho -0.20, p=0.003
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3.4.2 Sample replicates
Table 3-3 summarises results from replicate samples in each study. Correlation
coefficients across technical replicates are good, however the mean correlation
coefficient for biological replicates from the SNB study is lower. I have interpreted this
as representing biological variation across tumours which has been well described and
would explain differences in gene expression profiles in different tissue cores resulting
from true tumour heterogeneity or variation in admixture of inflammatory or stromal
cells [407].
Study
No. of
replicate
samples
(biological
replicates)
No. pairs
with failed
samples
Mean of
correlation
coefficients
across
technical
replicates
(range)
Mean of
correlation
coefficients
across
biological
replicates
(range)
Pairs with
significantly
different mean
gene
expression
(t-test - p <0.05)
Cohort
study 27 (2) 3
0.96
(0.59 - 0.99)
0.96 (only one
pair without
failed samples)
0
SNB
study 37 (12) 1
0.95
(0.68 - 0.99)
0.88
(0.41 - 0.97) 0
Table 3-3: Comparison of technical and biological replicate samples assessed in
each study.
Failed samples were classified as samples in which <250 genes were detected
using the DASL assay. Pearson’s correlation coefficients were calculated for
each pair of replicates (failed samples were removed from this analysis) and
mean gene expression was compared between the replicates using paired t-
tests.
3.4.3 Descriptive statistics of samples sets
Table 3-4 presents a summary of the characteristics of the two sample sets. They are
similar, the differences being that participants in the SNB study were slightly younger,
had a significantly higher mitotic rate (p=0.001) and unsurprisingly had been more
likely to have a sentinel node biopsy (p<0.0001) as this was the key recruitment
characteristic. Patients recruited to the Cohort study had a significantly longer period of
follow up than patients recruited to the SNB study (median 60.7 months and 38.4
months respectively, p<0.00001).
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Variable Cohort study SNB study Test statistic andsignificance value
Number of patients 156 198
Age at diagnosis or at SNB,
years, mean (range) 54.9 (19.9-78.5) 52.0 (14.4-88.0)
t value 1.87
p=0.06
Sex – female, n (%) 81 (51.9) 95 (48.0) χ2 0.54,
p=0.46Sex – male, n (%) 75 (48.1) 103 (52.0)
Site of tumour, n (%)
Arm
Head-neck
Leg
Trunk
Not recorded
31 (19.9)
24 (15.4)
50 (32.0)
49 (31.4)
2 (1.3)
44 (22.2)
17 (8.6)
69 (34.9)
68 (34.3)
0 (0.0)
χ2 4.13,
p=0.25
Breslow thickness, mm,
median (range) 1.9 (0.9-12.0) 2.1 (0.4-19.0)
Mann-Whitney Z
-0.58
p=0.56
Mitotic rate, per mm2, n (%)
<1
1-6
>6
Not recorded
27 (17.3)
76 (48.7)
34 (21.8)
19 (12.2)
21 (10.6)
91 (46.0)
85 (42.9)
1 (0.5)
χ2 13.62
p=0.001
Ulcerated tumours,
n (%) 40 (25.6) 52 (26.3)
χ2 0.02
p=0.90
Sentinel node biopsy status,
n (%)
No SNB performed
Had SNB – negative
Had SNB – positive
Not recorded
106 (67.9)
17 (10.9)
5 (3.2)
28 (17.9)
0 (0)
68 (34.3)
130 (65.7)
0 (0)
χ2 248.78
p<0.0001
Relapsers, n (%) 50 (32.1) 63 (31.8) χ
2 0.02
p=0.88
Deaths, n (%) 40 (25.6) 47 (23.7) χ
2 0.13
p=0.72
Follow-up time, months,
median (range) 60.7 (5.1-105.9)
38.4 (0.03-
111.7)
Mann-Whitney Z 7.38
p<0.00001
Table 3-4: Descriptive statistics of the two samples sets.
Significant results are highlighted in bold. Abbreviations used: n, number; SNB,
sentinel node biopsy.
3.4.4 Genes most predictive of survival
Genes with expression levels most strongly related to RFS in the Cohort study are
presented in Table 3-5. The gene most predictive of RFS was SPP1 which codes for
osteopontin, with increased expression being associated with shorter relapse-free
survival time. In the Cohort study, the hazard ratio (HR) for RFS associated with
doubling of SPP1 expression was 2.64 (p=2.74 x 10-6). This association persisted when
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the analysis was repeated adjusted for host variables known to predict relapse (age,
sex, tumour site and SNB status p=0.001), and when adjusted additionally for Breslow
thickness, mitotic rate and the presence of tumour ulceration (p=0.003) (Table 3-6).
Fold change of expression signal was 1.55 between relapsers and non-relapsers in
unadjusted analysis. Increased SPP1 expression was also predictive of overall survival
(HR 2.74 (95% CI 1.71-4.37), p=9.57 x 10-6) with a fold change of 1.52 between
tumours from patients who had died versus tumours from alive patients. This
association remained significant after adjusting for age, sex and tumour site (HR 2.73
(95% CI 1.68-4.42), p=0.00005) and further for Breslow thickness, mitotic rate and
presence of tumour ulceration (HR 2.23 (95% CI 1.24-4.02), p=0.008). Expression
signals from all three SPP1 probes on the array were comparably predictive of reduced
RFS (HR range 1.95-2.40, significance value range 0.00001-0.0008).
In the SNB study, increased SPP1 expression was also associated with reduced RFS
at the p=0.006 level in unadjusted analyses, with a similar fold change of 1.32 (Table
3-6). When corrected for age, sex, tumour site and SNB status, the significance of the
association was p=0.07, but when the analysis was adjusted further for histological
factors the influence on relapse-free survival was lost. Increased SPP1 expression
furthermore was associated with poorer OS in the SNB study (HR 1.64 (95% CI 1.08-
2.50), p= 0.02) in unadjusted analysis. The fold change between survivors and non-
survivors was 1.26. SPP1 remained associated with OS after adjusting for age, sex
and tumour site (HR 1.72 (95% CI 1.11-2.67), p=0.02), but is no longer associated with
overall survival once the analysis is adjusted for the tumour Breslow thickness, mitotic
rate or ulceration status (HR 1.26 (95% CI 0.79-1.99), p=0.33).
3.4.5 Validation of SPP1 expression using qRT-PCR
qRT-PCR with probes to exons 1/2 and 5/6 showed increased expression of SPP1 with
fold changes of 1.74 and 1.67 respectively in patients who relapsed versus those that
did not relapse in the Cohort study (compared with a fold change of 1.55 in the DASL
analysis).
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Gene
Expression fold
difference between
relapsers and non-
relapsers
Hazard
ratio
95%
confidence
interval
Significance
value
SPP1 1.55 2.64 1.72-4.03 2.74 x 10-6
DSP 0.63 0.59 0.47-0.74 0.00002
RAD54B 1.33 5.89 2.48-13.97 0.00003
GRB7 0.64 0.51 0.38-0.70 0.00004
ITGB4 0.74 0.36 0.22-0.58 0.00005
ING1 1.14 11.34 3.30-38.95 0.00006
HLF 0.72 0.27 0.13-0.54 0.0001
PTPRF 0.76 0.41 0.27-0.64 0.0002
FGFR2 0.67 0.42 0.25-0.71 0.0005
EGFR 0.74 0.39 0.23-0.66 0.0005
RECQL 1.17 5.87 2.13-16.15 0.0005
PML 0.94 0.04 0.005-0.27 0.0009
FGFR3 0.73 0.53 0.36-0.76 0.0009
CDKN2B 0.79 0.43 0.27-0.69 0.0009
HMMR 1.31 2.79 1.50-5.19 0.001
EPHA1 0.74 0.35 0.19-0.67 0.001
FHIT 1.23 3.06 1.53-6.14 0.001
DAB2 1.08 11.88 2.55-55.42 0.001
AR 0.68 0.35 0.18-0.68 0.001
TGFB1 0.76 0.29 0.13-0.65 0.002
Table 3-5: Top 20 genes with expression associated with relapse-free survival
from the Cohort study (unadjusted analysis).
Hazard ratios for reduced RFS are calculated for doubling of gene expression
value. P-values are from the proportional hazards model.
Cohort study
unadjusted
Cohort study
adjusted for age,
sex, site of tumour
and SNB status
Cohort study
adjusted additionally
for histological
measures
SNB study
unadjusted
SNB study
adjusted for age,
sex, site of tumour
and SNB status
SNB study adjusted
additionally for
histological
measures
Mean signal (SD)
relapsers 5172 (2587) 4980 (2567) 4946 (2280) 5812 (2752) 4240 (2623) 3982 (2415)
Mean signal (SD)
non-relapsers 3346 (2156) 3516 (2184) 3845 (1999) 4411 (2818) 3334 (2642) 3480 (2439)
Fold change 1.55 1.42 1.29 1.32 1.27 1.14
Hazard ratio
(95% CI)
2.64
(1.72-4.03)
2.19
(1.40-3.41)
2.49
(1.37-4.54)
1.60
(1.13-2.27)
1.40
(0.97-2.03)
1.11
(0.75-1.70)
Significance value 2.74 x 10-6 0.001 0.003 0.006 0.07 0.55
Table 3-6: The association of SPP1 expression with relapse-free survival in the Cohort and SNB studies.
The unadjusted analysis for the Cohort study is presented in column 1. The association was adjusted for sex, patient age, tumour site and SNB
status in column 2 (mean signal values are presented for a 45 year old female with a tumour on her leg who has not had a sentinel node
biopsy). In column 3, further adjustment is made for known histological predictors of outcome: Breslow thickness, mitotic rate and ulceration
(mean signal values are presented for a 45 year old female patient with a non-ulcerated tumour on her leg which has a Breslow thickness of
2.5mm, a mitotic rate of 1-6/mm2 and has not had a sentinel node biopsy). SNB study analyses are similarly presented, however mean signal
values are presented for a patient who did receive a sentinel node biopsy with a negative result (as all patients in this study had received a
sentinel node biopsy). Abbreviations used: SD, standard deviation; CI, confidence interval; SNB, sentinel node biopsy.
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3.4.6 Co-expression of genes with SPP1
The following analyses were performed by Dr Jeremie Nsengimana in the Section of
Epidemiology and Biostatistics. The expression of genes most closely correlated with
SPP1 expression was studied in the pooled data set for both studies (analysis adjusted
for study) in order to better understand the biological pathways involved. Results are
presented in Table 3-7. Thirty-two genes are listed with expression significantly
correlated (either positively or negatively) with that of SPP1 at the 1.0 x 10-5
significance level or less. These results are further related to relapse status. Genes up-
regulated with SPP1 and associated with reduced RFS were BIRC5, IL-8, TK1, HMMR,
TOP2A, CCNA2, CDC2, RAD51, NQO1, PTPRH and MAPK10. I also present a gene
network for SPP1 derived using Ingenuity Pathway Analysis (Table 3-8 and Figure
3-1). The literature-derived Ingenuity knowledge base identified SPP1 as involved in
cell adhesion, cell proliferation and cell migration. The network demonstrates that
SPP1 is the terminal component of many pathways and therefore over-expression of
SPP1 may reflect combined activity in many of these pathways.
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Gene
Correlation and p
value for pooled
data set
Fold
change
P-value
for RFS
Correlation and p
value for the
Cohort study
Correlation and
p value for the
SNB study
PBX1 -0.34 (3.1 x 10-11) 0.88 0.02 -0.36 (2.9 x 10-6) -0.32 (5.5 x 10-6)
BIRC5 0.33 (2.0 x 10-10) 1.21 0.008 0.40 (2.7 x 10-7) 0.25 (0.0004)
HLF -0.32 (5.5 x 10-10) 0.72 0.0001 -0.35 (7.3 x 10-6) -0.28 (0.00007)
IL8 0.31 (1.4 x 10-9) 1.34 0.03 0.41 (9.7 x 10-8) 0.22 (0.003)
HMMR 0.30 (5.8 x 10-9) 1.31 0.001 0.33 (0.00003) 0.27 (0.00009)
TOP2A 0.29 (1.7 x 10-8) 1.13 0.007 0.30 (0.0001) 0.28 (0.00007)
TK1 0.29 (2.0 x 10-8 1.13 0.01 0.28 (0.0004) 0.30 (0.00002)
CTSL 0.29 (2.8 x 10-8) 1.08 0.004 0.34 (0.00001) 0.24 (0.0006)
CCNA2 0.28 (5.6 x 10-8) 1.19 0.01 0.33 (0.00003) 0.24 (0.0006)
BCL6 -0.28 (8.3 x 10-8) 0.93 0.02 -0.33 (0.00003) -0.24 (0.0007)
CDC2 0.27 (2.2 x 10-7) 1.17 0.03 0.31 (0.00008) 0.24 (0.0008)
RAD51 0.27 (3.3 x 10-7) 1.25 0.004 0.29 (0.0002) 0.23 (0.001)
ERCC5 -0.26 (5.1 x 10-7) 0.97 0.13 -0.17 (0.03) -0.31 (9.2 x 10-6)
NQO1 0.26 (5.8 x 10-7) 1.12 0.09 0.28 (0.0005) 0.26 (0.0002)
CBFA2T1 -0.26 (7.6 x 10-7) 0.95 0.53 -0.28 (0.0003) -0.24 (0.0007)
MMP1 0.26 (1.1 x 10-6) 1.07 0.45 0.44 (1.2 x 10-8) 0.13 (0.06)
PTPRH 0.26 (1.1 x 10-6) 1.15 0.21 0.27 (0.0006) 0.24 (0.0006)
FGFR2 -0.25 (1.2 x 10-6) 0.67 0.0005 -0.33 (0.00002) -0.17 (0.02)
EGFR -0.25 (1.2 x 10-6) 0.74 0.0005 -0.27 (0.0007) -0.23 (0.0009)
TIMP1 0.25 (1.5 x 10-6) 1.03 0.24 0.18 (0.02) 0.29 (0.00003)
GAS1 -0.25 (1.6 x 10-6) 0.93 0.03 -0.27 (0.0006) -0.23 (0.001)
FLT3 -0.25 (1.8 x 10-6) 0.97 0.57 -0.24 (0.003) -0.26 (0.0002)
RBL2 -0.25 (2.1 x 10-6) 1.00 0.59 -0.27 (0.0007) -0.25 (0.0004)
ETS2 -0.25 (2.5 x 10-6) 0.87 0.003 -0.27 (0.0006) -0.20 (0.005)
NUMA1 -0.25 (2.9 x 10-6) 0.97 0.17 -0.31 (0.00009) -0.18 (0.01)
EPHA1 -0.24 (4.3 x 10-6) 0.74 0.001 -0.23 (0.003) -0.21 (0.002)
MAP3K8 -0.24 (4.7 x 10-6) 0.95 0.23 -0.30 (0.0002) -0.20 (0.005)
VEGF 0.24 (5.0 x 10-6) 1.02 0.73 0.31 (0.0001) 0.20 (0.004)
CCND3 -0.24 (7.5 x 10-6) 0.96 0.29 -0.27 (0.0006) -0.21 (0.003)
AR -0.23 (9.4 x 10-6) 0.68 0.001 -0.43 (2.7 x 10-8) -0.15 (0.04)
FGFR3 -0.23 (0.00001) 0.73 0.0009 -0.24 (0.003) -0.20 (0.006)
MAPK10 0.23 (0.00001) 1.48 0.005 0.19 (0.02) 0.29 (0.00003)
Table 3-7: Gene expression correlations for SPP1.
Analysis was undertaken in merged dataset from the two studies and adjusted for
study. Fold differences in gene expression between relapsers and non-relapsers
and significance values (from the proportional hazards model) for association with
RFS are also presented. Abbreviations used: RFS, relapse-free survival.
Gene
Correlation and p
value for pooled data
set
Fold difference gene
expression between
relapsers and non-
relapsers
Significance
level for RFS
Correlation and p value
for the Cohort study
Correlation and p
value for the SNB
study
IL8 0.31 (1.4 x 10-9) 1.26 0.04 0.41 (9.7 x 10-8) 0.22 (0.003)
CDC25C 0.21 (0.00009) 1.28 0.005 0.18 (0.03) 0.17 (0.02)
TERT 0.13 (0.02) 1.40 0.0005 0.19 (0.02) 0.09 (0.23)
RARB 0.11 (0.04) 1.12 0.80 0.07 (0.35) 0.09 (0.20)
IL3 0.06 (0.25) 1.39 0.009 -0.06 (0.42) 0.15 (0.04)
IL6 0.05 (0.37) 1.27 0.46 0.09 (0.26) -0.01 (0.84)
E2F5 0.06 (0.25) 1.26 0.004 0.05 (0.50) 0.02 (0.77)
MCF2 0.02 (0.70) 1.45 0.03 -0.01 (0.86) -0.02 (0.79)
CDKN2B -0.00 (0.93) 0.86 0.004 -0.10 (0.21) 0.05 (0.52)
Table 3-8: Correlations and differences in gene expression for genes identified in the Ingenuity network as being linked to SPP1.
Fold differences in gene expression between relapsers and non-relapsers and significance values (from the proportional hazards model) for
association with RFS are also presented. Abbreviations used: RFS, relapse-free survival.
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Figure 3-1: Gene network involving SPP1 from Ingenuity Pathway Analysis in
pooled data (showing only direct interactions except those involving SPP1).
Molecules are represented as nodes and the biological relationship between
nodes is represented as a line (edge). Each edge is supported by at least one
reference from the literature, from a textbook, or from canonical information
stored in the Ingenuity Knowledge Base. The intensity of the node colour
indicates the degree of up- (red) or down- (green) regulation.
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3.5 Discussion
3.5.1 Use of the Illumina DASL assay with FFPE melanoma tissue
Gene expression studies in melanoma have hitherto been few in number and small in
size. This is largely because platforms required good quality RNA which is rarely
available for melanoma where primaries are very small and therefore pathologists are
reluctant to cryopreserve tumours. This chapter describes my methodological
assessments of a platform designed to allow gene expression from FFPE tissue
thereby potentially giving access to large-scale sample sets with mature follow up data.
I have also described the key findings of the study which identified up regulation of
SPP1 as poor prognostic biomarker.
As presented in Chapter 1 there have been a number of publications using cDNA
microarray technology in cryopreserved tumours [177-180, 185, 194]. Many of these
studies have been performed in metastatic samples from patients with advanced
disease because of limited banks of cryopreserved primary tumours, therefore gene
expression data has only been generated from a highly selected proportion of
melanoma samples. There has been limited work identifying gene expression profiles
with independent prognostic value in primary tumours [177, 178]. This study was
designed to fill that gap and was started before many of the more recent studies using
cDNA microarrays with cryopreserved tissues were published [187].
Concerns about the use of fixed tumours derive from the degradation of RNA.
Increasingly however it has been suggested that technical modification of platforms,
such as the Illumina DASL assay, can allow profiling of gene expression and micro-
RNAs [408-411]. In this chapter, I report the generation of expression data from 74% of
consecutive formalin-fixed melanomas, suggesting that future studies designed to
identify predictive or prognostic biomarkers for melanoma would generate results from
approximately 75% of samples depending on the age of the blocks, and the proportion
that were deeply pigmented.
The Illumina DASL assay was originally described in 2004 [323]. The original assay
permitted 1536 oligonucleotide pairs to be multiplexed in a single reaction, using a
significantly smaller amount of template RNA than required for older cDNA microarray
assays. An additional advantage was that the assay was suitable for use with
degraded RNA because of short target gene sequences and random priming during
cDNA generation [293, 323, 412]. This platform was developed into a 502-gene Human
Cancer Panel targeting genes using three probes, using the Sentrix Array Matrix to
allow processing of 96 arrays in one experiment [296, 413]. The assay has been
further developed to combine the PCR and labelling steps from the DASL assay with
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the whole-genome probe set of Illumina’s Direct Hybridization Assay to allow profiling
of over 29,000 transcripts using the HumanHT-12 Expression Beadchip (whole-
genome DASL HT assay, further described in Chapter 2) [326, 414]. This chapter
describes use of the 502-gene Human Cancer Panel, in work carried out to assess
factors that may influence performance with the assay, such as age of tissue samples
and melanin content of samples.
RNA is known to degrade over time especially when paraffin blocks are stored at room
temperature [291, 316]. Melanin can lead to unreliable spectrophotometric
quantification of nucleic acids [306] and can inhibit DNA polymerases in downstream
PCR reactions [303]. In this study, gene expression data were derived from 98.6% of
RNA samples extracted from FFPE melanoma tissue. Using the number of detected
genes with the DASL assay as a quality control measure, increased block age (SNB
study) and higher melanin score (Cohort study) were indeed negatively correlated with
number of genes detected. Overall however the DASL platform performed well and age
of block was not an issue, probably as ‘failed’ samples in this sample set (<250 genes
detected) were less than 10 years old age. This is consistent with previous findings that
RNA becomes increasingly degraded with storage time of tumour blocks as
demonstrated by higher Ct values generated using qRT-PCR [293], but this does not
appear to severely compromise the performance with the assay as one study has
reported successful gene expression profiling using tumour blocks stored for over 24
years [295]. A number of ‘failed’ samples had high melanin scores in this analysis. To
avoid melanin contamination, we could avoid sampling heavily pigmented tumours. In
this study however, 24.5% of tumours from the Cohort study and 46.4% of tumours
from the SNB study had a melanin score of 3, so being densely pigmented tumour.
Exclusion of these samples would greatly reduce the number of tumours assessed and
would seriously bias tumour sampling for the study. There are increasing data
suggesting that pigmented tumours behave differently in terms of progression and
even response to chemotherapy [304, 305, 415], therefore exclusion of these samples
would compromise the quality of results. Melanin and DNA polymerase preferentially
form a complex with decreased DNA polymerase activity [303]. Inhibition can be
reduced by diluting these complexes or adding other proteins, such as bovine serum
albumin which scavenge and inactivate inhibitors of polymerase [303, 416, 417]. As
concentrations of eluted RNA are low from tissue cores, dilution is not an option,
however addition of bovine serum albumin to eluted RNA may improve performance
with the DASL assay and this will be tested in future experiments.
Prior to commencement of gene expression studies using DASL, in order to avoid use
of RNA of insufficient quality, a number of quality control procedures were assessed to
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identify measures that would predict sample performance with the assay. The
measures that best predicted performance of the SNB study samples were RNA
concentration as determined by the ND-8000 spectrophotometer, data generated using
the Bioanalyser, (the Bioanalyser RIN number and RNA concentration) and Ct values
generated by qRT-PCR of RPL13a. Unfortunately, spectrophotometry RNA
concentration did not predict sample performance in the Cohort study and limited
quality control assessment did not allow confirmation of Bioanalyser findings in the
Cohort sample set. Many authors have suggested criteria that predict assay
performance based on spectrophotometry, Bioanalyser results and qRT-PCR of
RPL13a as discussed further in Chapter 2 [293, 294, 296, 297]. Illumina recommend
these quality control measures are performed prior to using an RNA sample in the
assay, however in this analysis the majority of samples with an RNA concentration
over 20ng/μl as determined by spectrophotometry performed successfully with the 
assay irrespective of other quality control results. My conclusion was therefore that use
of precious sample for quality control measures other than RNA concentration did not
appear worthwhile based on these analyses.
A number of technical and biological replicate samples were assessed using the assay.
Generally there was good correlation between gene expression for sample replicates
as has been previously reported, with higher correlation coefficients for technical
replicates than biological replicates. This was expected as biological replicate samples
were derived from two extractions from different tissue cores from different parts of the
tumour and so heterogeneity of the tumour would account for gene expression
differences [407]. Good correlation between technical replicate samples demonstrates
that the DASL assay provides reproducible results in FFPE melanoma tissue as
previously demonstrated for other tumour types [293-297]. This chapter does not
describe extensive comparisons between results from frozen or fresh and formalin
fixed tumours as previous studies have addressed this in many tissues including
melanoma [187, 293-295]. Both of these observations demonstrate that the DASL
assay can be used to generate reproducible gene expression data from FFPE
melanoma tissue.
The technical limitations of this study are related to the presence of a limited number of
genes on the DASL Cancer Panel, and to sampling of tumours using tissue microarray
(TMA) cores. Using a TMA core does not allow confirmation of the tumour content
throughout the core and therefore there is potentially greater contamination with normal
cells than in laser microdissected samples. Furthermore, by using this technique we
were unable to sample very small tumours and so there is a bias towards sampling of
larger tumours. The use of this method however, has allowed a far greater range of
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tumours to be examined than in previous research based upon cryopreserved tumours.
Using a TMA core results in extraction of both DNA and RNA yet preserves the
architecture of the block for the clinical service which we viewed as crucial in this
research programme. The use of microdissection would address some of these
concerns but would be very much more time consuming for large-scale studies.
The work described in this chapter remains the largest assessment of gene expression
in primary melanomas where a marker with independent prognostic value has been
validated in an independent sample set of FFPE cutaneous primary melanoma
tumours. It has demonstrated that gene expression studies using FFPE tumours are
possible and a recent study has expanded on this work assessing expression in 223
FFPE primary melanoma tumours using the whole-genome DASL assay to assess
whether expression signatures associated with outcome in metastatic tumours are also
associated with survival in primary tumours [335]. The authors found that this was the
case, with “high-grade” tumours, associated with poorer survival, expressing a
proliferative/pigmentation signature and “low-grade” tumours with a high-
immune/normal-like gene expression profile [335]. These findings were validated in two
publically available gene expression datasets [178, 179, 335].
3.5.2 Identification of SPP1 as a prognostic biomarker in primary
melanomas
Fortunately, melanoma has a good prognosis in the majority of patients, but a
proportion of patients with low risk disease go onto relapse with advanced disease
being extremely difficult to treat. Therefore, identification of new prognostic biomarkers
would assist in identification of patients likely to benefit from more aggressive treatment
and allow clinicians to provide better prognostic information.
SPP1 was identified as the gene with increased expression most strongly associated
with reduced RFS and overall survival. The validity of this finding was tested by
comparison of test and validation sample sets. qRT-PCR detected similar fold changes
associated with relapse in the test set. SPP1 expression continued to be an
independent predictor of relapse in the test set when analysis was adjusted for patient
factors and histological factors of known prognostic value in melanoma. In the
validation set, SPP1 was less significantly associated with RFS and overall survival in
unadjusted analyses (p=0.006 and p=0.02, respectively), however over-expression
was associated with increased risk of relapse and death as in the test set. We did not
go on to confirm the findings using immunohistochemistry because a large study
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recently reported that osteopontin staining predicts sentinel node positivity and relapse
in melanoma [163].
Osteopontin is a glycophosphoprotein cytokine with pleiotropic effects. There are two
forms, secreted and intracellular, and post-translational modifications explain the large
number of actions associated with this protein [418]. In normal tissues, osteopontin
plays a role in inflammation, immune regulation, vascular and bone remodelling and
wound repair [418]. In tumour cells, it has a role in cell adhesion, chemotaxis,
prevention of apoptosis, invasion, migration and anchorage-independent growth [419,
420]. Osteopontin has a key role in the regulation of cell signalling which controls
neoplastic and malignant transformation and has been identified as a possible drug
target [421]. It is known to modulate several signalling pathways such as growth factor
and receptor pathways via interactions with cell surface receptors such as CD44 and
integrins [422, 423]. Osteopontin regulates v3 integrin mediated P13K/Akt/NFk
dependent urokinase plasminogen activator and metalloproteinase expression, which
is associated with tumour cell invasiveness [422, 424, 425]. This relationship between
osteopontin and the NF complex is pictured on the Ingenuity network (Figure 3-1).
There is in vitro evidence that melanoma cells that secrete osteopontin are more
aggressive [419, 426]. Transfection of KZ-28 melanoma cells with osteopontin siRNA
leads to reduced cell proliferation, whereas stimulation of B16 melanoma cells with
osteopontin from human milk enhances growth [424].
Osteopontin also increases epidermal growth factor receptor activation [427] and is
thought to provide the molecular link between degradation of the extra-cellular matrix,
tumour progression and vascularization [427]. In the data analysed in this chapter,
there was commensurate increased expression of genes involved in the interaction
between tumour cells, the extra-cellular matrix and angioneogenesis such as MMP1,
IL8 and VEGF. In relation to the role of osteopontin in inhibition of apoptosis, increased
expression of SPP1 correlated with increased expression of BIRC5 (survivin, p=2.0x10-
10), which was also over-expressed in tumours from patients with poorer RFS. Survivin
is recognized as a mediator of resistance to apoptosis, increased cell proliferation and
invasiveness in melanoma [428, 429].
As presented in Figure 3-1, osteopontin is downstream of a number of pathways and
therefore expression is influenced by a number of signalling cascades [430].
Osteopontin expression is regulated by the protein tyrosine kinase, Src, Wnt and T-cell
factor 4 signalling, steroid hormones and receptors, such as oestrogen receptors and
the vitamin D receptor, growth factors, for example platelet-derived growth factor and
epidermal growth factor, p53, BRCA1, Ets and activator protein-1 (AP-1) transcription
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factors [430-435]. A proportion of melanomas have NRAS mutations [436] and in
these, SPP1 transcription may be increased by a RAS-activated enhancer [437].
In the current analysis, increased SPP1 expression was associated with increased
expression of genes involved in cell cycling (CCNA2, CDC2); DNA replication and
repair (TOP2A, RAD51); cell signalling (PTPRH, MAPK10); cell division and
proliferation (BIRC5, TK1), observations that would be consistent with the known
biological functions of osteopontin. HMMR expression was also positively correlated
and is associated with cell motility and the cell cycle and expression levels have been
shown to increase with melanoma progression [438]. Increased SPP1 expression was
associated with reduced expression of the tumour suppressor gene GAS1, which was
also under-expressed in tumours from patients who relapsed. GAS1 has been
identified as a possible melanoma metastasis suppressor gene using a genome wide
‘short hairpin’ RNAi (shRNAi) screen, a finding which supports the observations in this
dataset [439, 440].
Increased expression of osteopontin has been demonstrated in a number of different
cancers and in some, secreted blood levels have prognostic value [422, 441, 442].
Osteopontin expression in plasma may also have prognostic utility in melanoma as
osteopontin has been proposed as a marker of metastatic disease [443, 444].
The association between SPP1 expression in human tumours and melanoma
progression at both the transcriptomic and proteomic level has been observed
previously. In a study using microarray analysis to assess 19,740 loci, SPP1 was one
of the most over-expressed genes in 6 cryopreserved primary melanomas in
comparison with 9 benign naevi [182]. In a further study assessing expression of
14,000 genes, SPP1 expression was found to be significantly higher in 4
cryopreserved metastatic melanomas versus 4 naevi [192]. This over-expression was
confirmed in a further sample set using immunohistochemistry, where osteopontin
expression was greater in primary and metastatic melanomas versus normal naevi,
dysplastic naevi or melanoma in situ [192]. However, in this study there was no
correlation between protein expression and Breslow thickness or patient survival, and
there were also no significant differences in staining between primary or metastatic
lesions [192]. A more recent study using 22,215 probe sets, found significantly higher
levels of SPP1 expression in 22 cryopreserved metastatic specimens in comparison
with 19 primary tumours [176]. This was quickly followed by a large
immunohistochemical study of 345 patients, in which increased osteopontin expression
was associated with reduced relapse-free and overall survival and increased
probability of sentinel node positivity [163]. Increased expression was also associated
with greater tumour thickness, higher invasive (Clark) level and higher mitotic rate
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[163]. Osteopontin protein expression has been incorporated into a multimarker assay
including two further markers not present on the DASL Cancer panel (NCOA3 and
RGS1), this assay was the most significant factor predicting disease specific survival in
this study and this finding was validated in an independent cohort [161, 172].
The relationship between SPP1 gene expression levels and sentinel node biopsy
positivity has been further investigated in data from the SNB study described in this
chapter. In this dataset, SPP1 expression was the best predictor of SNB positivity,
remaining significant in multivariate analyses adjusting for prognostic clinico-
pathological characteristics [445]. Given the role of osteopontin in degradation of
extracellular matrix, cellular adhesion, invasion and tumour growth [419] increased
expression of SPP1 is likely to enhance propensity to lymphatic metastases, for
example to sentinel lymph nodes, as has been noted in animal models of breast cancer
and breast cancer tumours [446].
In summary, the work I have reported in this chapter provides strong corroborative
evidence for SPP1 expression as a prognostic biomarker in melanoma. The utility of
pathway analysis in relation to SPP1 expression has been limited, however it has
provided a list of genes in the dataset with altered expression with evidence of
association to SPP1 based on the literature. It has also produced a network diagram
which assists in understanding the relationship between SPP1 and other genes. Use of
pathway analysis is explored further for groups of genes in Chapter 4. This study is the
largest in primary melanomas to date which identifies a biologically relevant biomarker
validated in an independent test set. It also demonstrates that FFPE tissue can be
used to identify prognostic markers in melanoma enabling further use of this invaluable
tissue resource.
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4 Patterns of DNA repair gene expression in primary
melanoma tumours
4.1 Aims
The main aim of this work was to identify genes which are differentially expressed in
primary melanoma tumours in relation to relapse in a large sample set generated by
merging data from two smaller studies.
Additional aims were to:
 Assess use of gene ontology (GO) and pathway analysis with microarray gene
expression data.
 Assess whether genes associated with survival were also differentially expressed
in tumours with different histological features associated with a poor prognosis
(increased Breslow thickness and higher mitotic rate).
 Develop a technique for validating cDNA-mediated annealing, selection,
extension and ligation (DASL) assay findings using quantitative Real-time PCR
(qRT-PCR) in formalin-fixed paraffin-embedded (FFPE) melanoma tumour
tissue.
4.2 Background
A biomarker is a measurable factor that can be used to indicate a biological process
such as the presence of a disease [155]. Prognostic biomarkers offer information about
outcome from a disease, and a number of prognostic biomarkers already exist for
melanoma, such as tumour Breslow thickness, mitotic rate, ulceration or nodal
involvement [58]. Additional biomarkers may help further refine prognostic information.
As reviewed in the introduction, a number of candidate prognostic biomarkers have
been assessed in melanoma tumours using approaches such as
immunohistochemistry and qRT-PCR. Use of microarray technology has greatly
increased the number of genes assessed as potential prognostic biomarkers, and this
chapter presents gene expression results from microarray analysis for a large number
of FFPE primary melanoma tumours in relation to survival and prognostic tumour
histological features. Generating gene expression data of this sort has led me to
investigate methods for analysis of this data, for example, use of pathway software. I
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also sought to confirm our findings using a different gene expression platform (qRT-
PCR), which has led to an assessment of the use of this technology in FFPE
melanoma samples as presented in this chapter.
Researchers have previously used cDNA microarray platforms to identify single genes
and groups of genes with expression patterns associated with relapse and survival
[161, 178, 180, 185]. Identification of differentially expressed genes can be performed
in a ‘supervised’ fashion where characteristics of a sample or patient are known.
Differences in gene expression can be based on simple identification of fold changes
between two distinct groups, for example relapsers and non-relapsers or by using
statistical tests, such as t-tests or modified tests, such as significance analysis of
microarrays (SAMic) [447-450]. In Chapter 3 we have used survival analysis to
generate a list of genes associated with relapse and so identified SPP1 expression as
an independent predictor of survival [187]. However, these techniques merely generate
lists of genes, which require interrogation to identify the biological implications of genes
differentially expressed. Identification of groups of genes with related biological
functions can be more useful, especially in cases where hundreds to thousands of
genes are differentially expressed [451]. Comparison of a gene list with Gene Ontology
(GO) terms can be used to understand the function of genes that are over-represented
[451]. GO terms were developed to describe the roles of genes in terms of associated
biological processes, cellular components and molecular functions [451, 452].
Biological process terms refer to a series of events using one or more combinations of
molecular functions; molecular function terms describe activities of genes, such as
catalytic or binding activities, and cellular component terms describe the location of a
gene product or a subcomponent of a larger cellular assembly [452]. To extend deeper
into the biology of gene lists, options are to analyse at the molecular level using
promoter and regulatory network analysis or use knowledge from the literature to
perform pathway analysis [451]. Pathway analysis assesses interactions between
genes, whereas GO terms represent gene function [453]. Pathway analysis also allows
mapping of gene lists onto existing pathways, usually using databases of pathways
generated from literature analysis [451].
In relation to cDNA microarray experiments with melanoma, many authors have utilised
GO terms and pathway analysis to identify groups of genes with expression levels
related to survival. Kauffmann et al. applied “searching for a biological interpretation of
microarray experiments” (SBIME) with Gene Ontology (GO) annotations to a
microarray dataset generated in an experiment to identify genes that differentiated
between primary tumours that would or would not metastasise within 4 years [177,
178]. SBIME performs analysis of variance (ANOVA) on logarithmic gene expression
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by metastasis status at 4 years. For each GO category, SBIME then compares the
proportion of genes with an ANOVA P-value lower than 1.0 x 10-2 within that category
with what would be expected if there was no relationship between the category and the
genes [177]. Using this analysis, Kauffmann and colleagues showed that genes
involved in DNA repair and genomic stability were over-represented among genes
differentially expressed in primary melanomas that would metastasise and that over-
expression of these genes was associated with metastasis [177]. In a study using
lymph node metastases, gene expression profiles were compared between tumours
from patients with “poor-prognosis” disease, progressing within 24 months of lymph
node dissection, and patients with “good-prognosis” disease who did not progress
within 24 months [185]. In this study, differentially expressed genes were grouped
according to GO terms, and Mann-Whitney tests were performed to compare
differentially expressed genes with existing GO-based gene lists to identify significant
over-representation of GO terms [185]. Using this method, of the 2140 differentially
expressed genes, genes involved in apoptosis, pathways associated with nuclear
factor-κB, Wnt/Frizzled signalling, immunologic signalling and developmental 
processes were over-represented [185].
An alternative approach to analysis of microarray data is ‘unsupervised’, where genes
or samples are clustered based on expression patterns [449]. Jonsson and colleagues
performed unsupervised hierarchical clustering of gene expression data from stage IV
melanoma and identified four subgroups of tumours [180]. They then used SAMic to
identify genes differentially expressed in each tumour subgroup and used DAVID (the
database for annotation, visualisation and integrated discovery) to determine gene
function [180, 369, 372]. DAVID, in common with many other publicly available tools,
maps a gene list to the associated biological annotation (e.g. GO terms) and then
highlights the most over-represented annotation [369-371]. In terms of the pathway
analysis, DAVID provides links for searching a number of pathway databases [369]. A
review of recent microarray studies used MetaCore (from GeneGo, St Joseph, MI) to
compare gene lists from six studies to identify common subsets of genes followed by
GO enrichment analysis [188, 454]. This highlighted immune response genes and the
NRAS-pathway as significant biological processes across microarray studies in
melanoma [188].
This chapter describes identification of a group of genes whose expression levels are
associated with survival and adverse prognostic factors. In Chapter 3 we have
described identification of a single gene (SPP1) with expression associated with
survival and have used Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood
City, California) to generate a network of genes associated with SPP1, based on the
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expression dataset. In this chapter, DNA repair genes and genes associated with these
processes, were easily identified as being associated with survival by simple review of
the gene list; however GO and pathway analysis has been used to confirm these
observations. Furthermore, IPA has been used in association with principal
components analysis to identify a network of genes with expression correlated with
DNA repair gene expression.
This chapter also describes an assessment of methods used for qRT-PCR with small
FFPE melanoma specimens. This has been undertaken to ensure accuracy of results
using precious samples, and I present experiments designed to identify the most
suitable experimental design and endogenous control genes for use in this work. The
two experimental designs for relative quantification of gene expression using qRT-PCR
are the relative standard curve method and the comparative Ct method [342]. The
relative standard curve method involves having a set of relative standards from which
the unknown samples are quantified. This quantity is then reported as relative to a
selected sample, which acts as a calibrator. Serial dilutions of cDNA, RNA or genomic
DNA can be used to generate standard curves, which need to be accurately diluted,
but do not need to be quantified. A standard curve is generated on each PCR plate for
each probe (including endogenous controls), therefore more reagents and space are
needed. However, this method is very accurate and requires the least amount of
validation as the PCR efficiencies of probes for the endogenous controls and test
genes do not need to be equal [341]. The comparative Ct (2-ΔΔCt) method is described
in Chapter 2 and does not require use of standard curves, so fewer reagents are used.
However, it is essential that PCR efficiencies of probes for test genes and endogenous
control genes are similar in order to use comparative Ct (2-ΔΔCt) method [340, 455].
Taqman® Gene Expression assays used in the qRT-PCR work presented in this
chapter have amplification efficiencies of 100% (+/-10%) when used in high quality
RNA [456]; specifically there is doubling of PCR product during every PCR cycle [340,
457], although this is likely to be less in degraded RNA from melanoma FFPE tissue.
Therefore, before deciding on an experimental design to use, an assessment of the
amplification efficiencies of the assays was made.
The comparative Ct method requires quantification of an endogenous control gene,
which will be used to normalise gene expression levels of unknown genes for the
amount of mRNA used in each reaction. When choosing which gene to use as a
control it is essential that the expression of this gene does not vary in response to an
intervention or in certain biological states, that the amplification efficiency is similar to
genes of interest and that the abundance of the reference gene is similar to that of the
gene of interest [458]. A “housekeeping” gene is often used as an endogenous control,
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however expression of these genes can vary considerably between different cell types
and between identical cell types from different individuals [459-461]. Also, some genes
used as endogenous control genes, for example GAPDH and beta-actin, have a
number of pseudogenes (genomic sequences which often lack introns similar to
transcribed mRNA sequences) which can amplify even when trace amounts of
genomic DNA are present in a PCR mixture [462-464]. This has prompted authors to
suggest that for experiments where internal control genes are used, these genes need
to be assessed to ensure there is minimum variability of gene expression [465].
Extensive studies have suggested that for more reliable and accurate normalisation of
data, multiple control genes are required from which a normalisation factor can be
calculated [343, 466]. Software has been developed to select genes with most stable
expression within the tissue of interest, such as geNorm [343] or Normfinder [467].
GeNorm calculates a gene stability measure based on the principle that the expression
ratio of two ideal control genes is the same in all samples. For each control gene, the
software determines the average pairwise variation with all other control genes as the
standard deviation of the log-transformed expression ratios and defines an internal
control gene-stability measure, M. Genes with the lowest M value have the most stable
expression. GeNorm then excludes genes with the highest M value and recalculates
new M values for the remaining genes, resulting in identification of the two endogenous
control genes with the most stable expression in tested samples [343]. Vandesompele
and colleagues suggested use of the geometric mean of control gene expression levels
as a normalisation factor [343]. Most authors recommend that at least three genes are
required for normalisation of data [343, 466], however a balance must be struck
between practical considerations of analysing control genes and accuracy of data
normalisation [343]. GeNorm can assist in identification of the number of genes
required for normalisation. When additional genes are added to calculate the
normalisation factor, GeNorm can calculate the pairwise variation between the original
normalisation factor and the new normalisation factor (pairwise variation =
normalisation factor using n genes ÷ normalisation using n+1 genes) to identify
whether addition of another gene significantly contributes to the normalisation factor
[343]. If there is large difference between the normalisation factor calculated using the
additional gene and the original normalisation factor, this suggests that the additional
gene has a significant effect on the factor and should be included to calculate the most
accurate normalisation factor [343]. Further genes can be added until there is little
difference between normalisation factors indicating that additional genes do no
contribute to calculation of an accurate normalisation factor. Vandesompele and
colleagues suggest that a pairwise variation of <0.15 with addition of a further gene
indicates that this control gene is not required for accurate normalisation [343]. In this
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chapter, this software has been used to identify genes with the most stable expression
in FFPE melanoma samples for use as endogenous control genes and the number of
genes needed for accurate normalisation of qRT-PCR data.
In summary, this chapter describes use of the DASL assay to identify DNA repair
genes and genes related to this process associated with relapse-free survival (RFS)
and adverse histopathological tumour features. Pathway analysis was used to further
investigate the data and DASL results were validated using qRT-PCR.
4.3 Identification of genes associated with prognosis and
histological features
4.3.1 Detailed methodology
4.3.1.1 Samples and generation of data set
As described in Chapter 3, FFPE primary melanoma tumour blocks were identified
from two study sets; the Leeds Melanoma Cohort Study (Cohort Study) and the
Retrospective Sentinel Node Biopsy Study (SNB Study). Tissue blocks were sampled
as described previously and RNA was extracted. Sample selection, tissue sampling
and RNA extraction were performed by Dr Caroline Conway (Cohort study), Dr Angana
Mitra (SNB study) and Samira Lobo. The Illumina DASL Human Cancer panel was
used for gene expression profiling by Floor de Kort at the service provider, ServiceXS
(Leiden, Netherlands). Data generated from the DASL array from the two sample sets
were normalised separately as described in Chapter 2 before the two data sets were
merged for analysis to identify differentially expressed genes. Gene expression data
from 354 primary melanoma samples was used for analysis.
4.3.1.2 Statistical methodology
4.3.1.2.1 Identification of differentially expressed genes
Gene expression analyses were performed by myself using data which had been log-
transformed (log2). As some of the normalised gene expression levels were negative,
1000 was added to all values prior to log-transformation. Within the sample sets, mean
expression of each gene was compared between samples with differing Breslow
thicknesses and mitotic rates using linear regression. For survival analysis, relapse-
free survival (RFS) was defined as the period between diagnosis and date of first
relapse at any site. Death from any cause was used for overall survival analyses.
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Analysis was performed on the 11th February 2010, and survival data was censored at
this date. Survival analysis was performed using the Cox proportional hazards model to
calculate hazard ratios and 95% confidence intervals for each gene. Significance
values were ranked to identify genes most differentially expressed between groups of
interest.
Survival analysis identified a number of genes significantly associated with survival that
were either DNA repair genes or genes linked to these processes. To identify which of
the DNA repair genes independently predicted survival, a multivariate Cox proportional
hazards model was generated using all DNA repair genes significantly (p<0.0001)
associated with Breslow thickness, mitotic rate or survival in the previous analyses.
Fold changes for gene expression between groups of interest were calculated using
normalised gene expression data which had not been log transformed. The
associations between expression of different DNA repair genes were identified using
Spearman’s rank correlation.
4.3.1.2.2 Multiple testing and adjustment of analyses
To correct for multiple testing, the Bonferroni method was used [366] and the
significance level was set at 0.0001. For survival analyses assessing the expression of
single genes in each test, the significance level for highlighting results of interest was
set as 0.05.
In view of non-biological variation that was present between the two DASL studies, all
gene expression analyses were adjusted for the study from which the patients were
recruited. Survival analyses were also adjusted for whether the patient had undergone
a sentinel node biopsy and the effect of the biopsy result (SNB status), as the use of
SNB results in delay of the date of first relapse in melanoma patients since the usual
site of first recurrence (nodal) is removed. Analyses were further adjusted for
demographic and histological factors of prognostic importance in melanoma. All
statistical analyses were undertaken using Stata version 10 (StataCorp 2007, College
Station, TX).
4.3.1.2.3 Gene ontology (GO) and pathway analysis of genes associated with survival
To further investigate differentially expressed genes, GO analysis was performed by
Binbin Liu and Lee Hazelwood of the Bioinformatics Group in the Cancer Research UK
Centre, Leeds Institute of Molecular Medicine. Cytoscape v2.8.1 [362, 363] and its
plug-in, BiNGO v2.44 [364, 365] were used to search a custom built GO database with
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gene lists generated from analyses described above. Further details of this software
are included in Chapter 2. For this study a customized gene reference and annotation
databank were built, as gene expression data was based on the 502-gene Human
Cancer panel rather than a genome-wide platform. Therefore, the databank used
contained GO terms associated with the 502 genes only.
DAVID [368] [369, 371, 372], was also used to identify over-represented gene
functions and pathways in our gene lists. I performed this analysis myself. Further
details of the algorithms used by DAVID are described in Chapter 2. For the purposes
of enrichment analysis, a background population of genes from the Human Cancer
panel has been inputted for comparison with the annotation composition of the inputted
gene list [368].
Genes associated with survival in analyses described in section 4.3.1.2.1 were ranked
in three ways according to hazard ratio, significance level and fold change in
expression between relapsers and non-relapsers for input into the analysis software.
4.3.1.2.4 Principal components analysis and Ingenuity Pathway analysis
Principal components analysis and Ingenuity Pathway Analysis was performed by
Jeremie Nsengimana in the Section of Epidemiology and Biostatistics. Ingenuity
Pathway Analysis (IPA, Ingenuity Systems, Redwood City, California
(www.ingenuity.com)) was used to identify the pathways and networks of genes co-
regulated with the most significant DNA repair genes [468]. Principal components
analysis was first applied to the dataset to summarize into one variable the expression
of the DNA repair genes most strongly associated with RFS [468]. A Pearson’s
product-moment correlation coefficient was then calculated between the first principal
component (summary variable) and each of the genes on the cancer panel. Finally IPA
was interrogated using algorithms described in Chapter 2 to find pathways and
networks involving genes significantly correlated with the principal component at a level
of p<1x10-10.
4.3.2 Results
4.3.2.1 Genes predictive of survival
Genes with expression levels most strongly related to RFS in the merged dataset from
354 primary melanoma samples are presented in Table 4-1 when analysis is adjusted
for study type and SNB status only.
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Gene
Mean fold
difference
between relapsers
and non-relapsers
Hazard
ratio
95%
confidence
interval
Significance
value
RAD51 1.22 2.99 1.84-4.85 8.34 x 10-6
TK1 1.12 4.70 2.30-9.61 0.00002
ING1 1.11 5.86 2.58-13.31 0.00002
RAD52 1.16 4.49 2.23-9.01 0.00002
TFAP2C 0.83 0.49 0.35-0.69 0.00004
CCNA2 1.16 2.66 1.67-4.23 0.00004
BIRC5 1.19 2.75 1.67-4.52 0.00007
TOP2A 1.12 3.85 1.97-7.55 0.00008
CDH13 0.80 0.48 0.33-0.70 0.0002
HLF 0.78 0.45 0.30-0.69 0.0002
SPP1 1.41 1.67 1.26-2.21 0.0003
ITGB4 0.79 0.58 0.43-0.79 0.0004
MLF1 1.15 2.74 1.55-4.83 0.0005
FLI1 0.83 0.51 0.35-0.75 0.0005
EPHB4 0.89 0.41 0.25-0.69 0.0008
VEGFB 1.04 9.83 2.57-37.64 0.0009
ELK3 0.95 0.20 0.07-0.53 0.001
RAD54B 1.18 2.08 1.33-3.25 0.001
E2F1 1.10 2.79 1.47-5.27 0.002
TERT 1.29 1.80 1.25-2.59 0.002
CDC2 1.22 1.85 1.26-2.70 0.002
CCNH 1.08 3.39 1.58-7.26 0.002
WNT2 1.34 2.49 1.41-4.41 0.002
IFNGR1 0.89 0.47 0.29-0.76 0.002
PML 0.96 0.21 0.07-0.58 0.003
Table 4-1: Top 25 genes associated with relapse-free survival (analysis adjusted
for study and SNB status).
Fold difference in gene expression between relapsers and non-relapsers is
presented. Hazard ratios for reduced RFS are calculated for doubling of gene
expression value, for example doubling of tumour RAD51 levels is associated
with a three times greater hazard of relapse. P-values are from the proportional
hazards model. The significance level following a Bonferroni correction is
indicated by a dashed line. DNA repair genes or those associated with this
process are highlighted in dark green and genes involved in the cell cycle or cell
proliferation are highlighted in light green.
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A number of the genes which were differentially expressed in association with relapse
in univariate analysis are DNA repair genes or involved in this process. Within this
group, over-expression of RAD51, RAD52 and TOP2A were most predictive of poor
RFS (Table 4-2) with hazard ratios of 2.99 (p=8.34x10-6), 4.49 (p=0.00002) and 3.85
(p=0.00008) respectively for a doubling of expression levels. These genes continued to
be predictive of RFS when the analysis was repeated and adjusted for factors of
prognostic importance in melanoma (age of patient at diagnosis, sex of the patient and
body site of tumour) and when adjusted further for tumour characteristics of prognostic
importance (Breslow thickness, mitotic rate (number/mm2) and presence of tumour
ulceration), confirming that these genes are independent predictors of relapse (Table
4-2, part (i)). Expression of RAD51 was 1.22 times greater in tumours from patients
who relapsed versus those that did not; the fold changes between tumours from
relapsers and non-relapsers for RAD52 and TOP2A were 1.16 and 1.12 respectively
(Table 4-1). RAD54B, RAD52, TOP2A and RAD51 were also over-expressed in
tumours from patients who died versus surviving patients (fold changes of 1.15, 1.11,
1.09 and 1.10, respectively).
4.3.2.1.1 Multivariate models including DNA repair genes associated with relapse,
Breslow thickness and mitotic rate
RAD52 and TOP2A continued to significantly influence survival in a Cox proportional
hazards model when considered with all the other DNA repair genes identified as being
significantly associated with Breslow thickness, mitotic rate or RFS (listed in Table 4-3)
(multivariate model Table 4-2, part (ii) and Figure 4-1). In the multivariate model
adjusted for study and SNB status only, hazard ratios (HR) for RAD52 and TOP2A
were 4.72 (p=0.0004) and 3.07 (p=0.009), respectively, for a doubling of levels. When
analysed by quartiles of RAD52 and TOP2A gene expression adjusted for study type
and SNB status only, HRs generally increased for each quartile of gene expression
(Figure 4-1). Both RAD52 and TOP2A continued to have a significant independent
predictive influence on RFS when analyses were adjusted for host variables (age, sex
and tumour site) and histological factors (Breslow thickness, mitotic rate and
ulceration) of prognostic importance (Table 4-2 part (ii)).
Gene
(i) Association between single gene expression and relapse free survival (ii) Multivariable model with expression of all DNA repair genes
predictive of RFS, Breslow thickness or mitotic rate
1.
Analysis adjusted for study
and SNB status only
(n=326)
2.
Analysis further
adjusted for age and
sex of patient and
site of tumour
(n=325)
3.
Analysis further
adjusted for Breslow
thickness, ulceration
and mitotic rate of
tumour (n=305)
1.
Analysis adjusted for
study and SNB status
only (n=326)
2.
Analysis further
adjusted for age and
sex of patient and site
of tumour (n=325)
3.
Analysis further
adjusted for Breslow
thickness, ulceration
and mitotic rate of
tumour (n=305)
Fold
HR
(95% CI) P-value
HR
(95% CI) P-value
HR
(95% CI) P-value
HR
(95% CI) P-value
HR
(95% CI) P-value
HR
(95% CI) P-value
RAD51 1.22 2.99(1.84-4.85) 8.34x10
-6 3.23
(1.96-5.33) 4.45x10
-6 2.45
(1.41-4.24) 0.001
1.91
(0.98-3.72) 0.06
2.13
(1.09-4.19) 0.03
1.79
(0.88-3.67) 0.11
RAD52 1.16 4.49(2.23-9.01) 0.00002
4.32
(2.12-8.80) 0.00006
2.50
(1.15-5.46) 0.02
4.72
(1.99-11.23) 0.0004
4.19
(1.77-9.92) 0.001
2.67
(1.08-6.61) 0.03
TOP2A 1.12 3.85(1.97-7.55) 0.00008
3.87
(1.97-7.63) 0.00009
3.29
(1.58-6.85) 0.001
3.07
(1.33-7.08) 0.009
2.79
(1.20-6.47) 0.02
2.86
(1.16-7.06) 0.02
Table 4-2: The association of genes involved in DNA repair with relapse free survival in multivariate models.
Part (i) of the table shows the association between single gene expression and survival. Data adjusted for study and SNB status only are
presented in column 1. The association was adjusted for sex, patient age and tumour site (as known predictors of outcome) in column 2. In
column 3, further adjustment is made for known histological predictors of outcome: Breslow thickness, mitotic rate and ulceration. Part (ii) of
the table presents results of a multivariate Cox proportional hazards model with expression of DNA repair genes identified as being predictive
of RFS, Breslow thickness or mitotic rate (listed in Table 4-3). Significance values for genes that are independent predictors of survival within
this model are highlighted in bold. Abbreviations used: RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval; SNB, sentinel node
biopsy.
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Expression
level HR 95% CI P-value HR 95% CI P-value
<25%
25-50%
50-75%
>75%
1
1.58
1.79
2.90
0.80-3.10
0.95-3.37
1.57-5.36
0.19
0.07
0.001
1
2.82
2.67
3.59
1.45-5.47
1.34-5.29
1.78-7.25
0.002
0.005
<0.0001
Figure 4-1: Kaplan Meier survival function estimates for RAD52 and TOP2A gene expression.
Survivor functions have been estimated for each quartile of gene expression. Hazard ratios compared with the lowest quartile increase for
each successive quartile. Analysis is adjusted for study and SNB status. Abbreviations used: HR, hazard ratio; CI, confidence interval.
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4.3.2.2 Gene expression in tumours with poor prognostic
histopathological features
Genes involved in DNA repair were also over-expressed in tumours with greater
Breslow thickness and mitotic rate, which are associated with a poorer prognosis in
melanoma (Table 4-3). Generally, expression increased with each category of
increasing Breslow thickness and mitotic rate. This association remains significant
when the analysis was repeated and adjusted for host factors of prognostic importance
(age of patient at diagnosis, sex of patient and site of tumour).
4.3.2.3 Correlations in expression levels between DNA repair genes
Expression of the majority of DNA repair genes identified as being associated with
reduced survival or poor prognostic histological features correlated well with each other
(Table 4-4). An exception was RAD52, with expression levels that did not correlate with
the levels of RAD54L, BRCA2 and TOP2A.
4.3.2.4 GO analysis and pathway analysis using DAVID
When the gene list was ranked in order of hazard ratio for association with RFS, 33
genes had significance values ≤0.01 and were used for GO analysis. Ten GO terms 
were significantly associated with expression of these genes (Table 4-5). Many of
these terms describe cellular components, however eight genes are involved in the
biological process of M-phase (mitosis) in the cell cycle (CDC2, RAD54B, BIRC5,
RAD52, CDC25C, CCNA2, CDK2 and RAD51).
Analysis based on ranking genes in order of fold change allowed input of 280 genes
with fold changes greater than 1. In this analysis, genes were associated with four GO
terms which described biological processes: DNA recombination (corrected p-value
0.005) and DNA replication (corrected p-value 0.007) which are subsets of DNA
metabolic processes (corrected p-value 0.005), genes were also associated with M-
phase (corrected p-value 0.02) (Figure 4-2). Sixty-two (22%) of the genes were
associated with the term “DNA metabolic process”. The limitation of these analyses is
that only genes which increased risk of relapse or that were over-expressed in
relapsers were assessed. Reduced relapse risk and under-expression of genes may
also be of interest however as DNA repair genes were over-expressed, this analysis
was most relevant. Analysis based on ranking of genes according to significance levels
did not yield any significant results associations in GO analysis.
Gene
Breslow thickness Mitotic rate
Fold difference in gene
expression between
indicated group and tumours
≤1mm thick (n=24) 
Significance
level
(adjusted for
study only)
Significance
level – adjusted
for age and sex
of patient and
site of tumour
Fold difference in gene
expression between
indicated group and
tumours with mitotic rate
<1/mm2 (n=48)
Significance
level
(adjusted for
study only)
Significance
level – adjusted
for age and sex
of patient and
site of tumour
>1-2mm
(n=163)
>2-4 mm
(n=118)
>4 mm
(n=46)
1-6/mm2
(n=167)
>6/mm2
(n=119)
RAD52 1.05 1.16 1.30 1.88 x 10-8 9.53 x 10-8 1.10 1.16 0.02 0.03
MSH2 1.03 1.20 1.36 2.18 x 10-8 2.24 x 10-7 1.20 1.29 0.0009 0.002
RAD51 1.06 1.30 1.48 5.53 x 10-8 2.16 x 10-7 1.26 1.59 4.61 x 10-10 3.67 x 10-9
RAD54B 1.20 1.45 1.66 6.30 x 10-8 7.61 x 10-7 1.19 1.50 5.94 x 10-6 0.00006
CHEK1 1.04 1.35 1.44 9.44 x 10-6 0.0001 1.17 1.38 0.0005 0.005
BRCA1 1.19 1.42 1.54 0.00002 0.00007 1.12 1.45 1.23 x 10-6 3.19 x 10-6
TOP2A 1.00 1.10 1.22 0.00003 0.00008 1.20 1.38 5.43 x 10-9 1.36 x 10-8
RAD54L 0.94 1.18 1.28 0.00005 0.0004 1.11 1.34 0.0007 0.004
BRCA2 1.13 1.27 1.41 0.00006 0.0004 1.06 1.24 0.0006 0.002
MSH6 0.94 1.01 1.03 0.001 0.002 1.08 1.16 0.00003 0.00003
Table 4-3: DNA repair genes differentially expressed in relation to Breslow thickness and mitotic rate.
Genes listed were identified as significantly differentially expressed (p<0.0001) in tumours with either greater Breslow thickness or mitotic rate
using linear regression. Fold changes in gene expression are presented for each tumour thickness and mitotic rate group compared to
baseline groups. Analyses are adjusted for study only and further adjusted for age of patient at diagnosis, site of tumour and sex of patient.
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RAD51 RAD52 RAD54B RAD54L BRCA1 BRCA2 MSH2 MSH6 CHEK1
RAD52 0.22<0.0001
RAD54B 0.39<0.0001
0.25
<0.0001
RAD54L 0.29<0.0001
0.05
0.39
0.24
<0.0001
BRCA1 0.40<0.0001
0.29
<0.0001
0.46
<0.0001
0.25
<0.0001
BRCA2 0.34<0.0001
0.06
0.28
0.25
<0.0001
0.25
<0.0001
0.39
<0.0001
MSH2 0.23<0.0001
0.21
0.0001
0.43
<0.0001
0.27
<0.0001
0.41
<0.0001
0.36
<0.0001
MSH6 0.33<0.0001
0.26
<0.0001
0.31
<0.0001
0.21
0.0001
0.32
<0.0001
0.16
0.0029
0.33
<0.0001
CHEK1 0.46<0.0001
0.19
0.0005
0.29
<0.0001
0.32
<0.0001
0.39
<0.0001
0.29
<0.0001
0.37
<0.0001
0.27
<0.0001
TOP2A 0.61<0.0001
0.05
0.40
0.36
<0.0001
0.31
<0.0001
0.37
<0.0001
0.34
<0.0001
0.20
0.0002
0.25
<0.0001
0.30
<0.0001
Table 4-4: Gene expression correlations for DNA repair genes adjusted for study and relapse status.
Spearman’s rho and significance value are presented.
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GO-ID
Corrected
significance
value
Description
44428 0.013 nuclear part
5654 0.013 nucleoplasm
31981 0.013 nuclear lumen
43233 0.015 organelle lumen
31974 0.015 membrane-enclosed lumen
70013 0.015 intracellular organelle lumen
44446 0.016 intracellular organelle part
44422 0.017 organelle part
279 0.028 M phase
5634 0.031 nucleus
Table 4-5: Gene ontology terms associated with genes that influence relapse-free
survival.
Many of these terms describe cellular components, terms which describe a
biological process are highlighted in green. The P-value has been corrected using
the Benjamini and Hochberg correction [367].
A list of 109 genes significantly associated with RFS (p<0.05) were entered into DAVID
software, 102 genes were recognised by the software and compared with a
background of 479 recognised genes from the Human Cancer panel to identify
enriched gene ontology terms or pathways in this dataset. Forty-six Kyoto Encylopedia
of Genes and Genomes (KEGG) pathways [469, 470] were identified which contained
66 of the input genes, the top 10 pathways are presented in Table 4-6.
Unsurprisingly, as a cancer panel was used for gene expression measurement, the
majority of genes were involved in the cancer pathway. Genes were also significantly
enriched in the cell cycle pathway (Table 4-6) and the homologous recombination
pathway (17th most significant pathway) following adjustment of significance values
using either the Bonferroni correction [366] or the Benjamini and Hochberg correction
[367]. Genes were also present in the non-homologous end-joining pathway when the
less stringent Benjamini and Hochberg correction was used (25th most significant
pathway). The melanoma pathway contained four genes, but these genes were not
significantly represented. This analysis suggests that genes involved in focal adhesion
and cytokine-cytokine receptor interactions are also over-represented in this gene list.
This result is useful as it may not have been appreciated on simple review of the gene
list.
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Figure 4-2: Hierarchical display of biological process GO terms associated with
genes with expression fold change >1 between relapsers and non-
relapsers.
GO terms associated with the gene list are highlighted in yellow.
Pathway
Number of
genes in
pathway
% of genes
inputted P-Value
Bonferroni
corrected P-
value
Benjamini
corrected P-
value
False
discovery
rate
hsa05200:Pathways in cancer 26 25.5 1.29x10-18 1.03x10-16 1.03x10-16 1.37x10-15
hsa04510:Focal adhesion 14 13.7 5.87x10-12 4.70x10-10 2.35x10-10 6.24x10-09
hsa04110:Cell cycle 12 11.8 8.71x10-11 6.96x10-09 2.32x10-09 9.26x10-08
hsa04060:Cytokine-cytokine receptor interaction 13 12.8 9.07x10-11 7.25x10-09 1.81x10-09 9.64x10-08
hsa05212:Pancreatic cancer 9 8.8 2.40x10-07 1.92x10-05 3.84x10-06 2.55x10-04
hsa05210:Colorectal cancer 8 7.8 4.63x10-06 3.70x10-04 6.17x10-05 0.005
hsa04144:Endocytosis 7 6.9 8.14x10-06 6.51x10-04 9.30x10-05 0.009
hsa05215:Prostate cancer 8 7.8 1.36x10-05 0.001 1.36x10-04 0.019
hsa04520:Adherens junction 6 5.9 1.84x10-05 0.002 1.64x10-04 0.02
hsa04810:Regulation of actin cytoskeleton 7 6.9 8.09x10-05 0.007 6.47x10-04 0.09
Table 4-6: KEGG (Kyoto Encylopedia of Genes and Genomes) pathways associated with genes that influence relapse-free survival.
Significance values for representation of genes in the pathway without correction for multiple testing are presented, along with corrected
significance values using the Bonferroni correction [366] and the Benjamini and Hochberg correction [367]. The false discovery rate is also
presented.
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4.3.2.5 Principal components and Ingenuity Pathway Analysis (IPA)
Principal components analysis of the top 10 significant DNA repair genes (listed in
Table 4-3) identified one component which explained 40% of total variance in DNA
repair gene expression whilst each of the other components explained 10% or less
(analysis adjusted for study). Principal component 1 was also the only one that
correlated with each of the 10 genes from which it was generated (Pearson’s
correlation coefficient ranging from 0.40 to 0.74). Table 4-7 presents the remaining
genes from the cancer panel with expression that correlated with the first principal
component at a level of p<1x10-10. A large number of these genes are associated with
cell cycle control or DNA repair (Table 4-7).
The 37 genes presented in Table 4-7 were used in IPA to infer cellular and molecular
functions and to build gene networks. IPA built a gene network which contains 35
genes (Figure 4-3), among which 22 were correlated with the principal component of
DNA repair genes at a significance level of p<1x10-10. The major cellular and molecular
functions making up this network were cell cycle and cell death, confirming the strong
association between these processes and DNA repair.
4.3.3 Summary of gene expression associated with prognosis and
histological features of tumours
Over-expression of DNA repair and related genes in 354 primary melanomas was
prognostic and associated with shorter relapse-free survival time and poor
histopathological features of the tumour. RAD51, RAD52 and TOP2A are independent
predictors of RFS in analyses adjusted for patient and tumour factors of prognostic
importance. RAD52 and TOP2A remained predictive of survival in multivariate analysis
with other DNA repair genes. Expression of the majority of DNA repair genes was
correlated and was also associated with expression of genes associated with cell cycle
control and cell death.
Table 4-7 (following page): Remaining genes from the Human Cancer panel most
correlated with principal component 1.
Correlation coefficients are adjusted for study. The National Center for
Biotechnology Information Entrez Gene database was interrogated to identify
gene function [471]. DNA repair genes or those associated with this process are
highlighted in dark green and genes involved in the cell cycle or cell proliferation
are highlighted in light green.
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Gene Correlation P value Role
CDC2 0.54 1.3x10-27 Cell cycle
TYMS 0.51 8.4x10-25 DNA repair and replication
BIRC5 0.50 1.2x10-23 Inhibitor of apoptosis
HMMR 0.49 1.8x10-22 Cell motility
CCNA2 0.48 9.0x10-22 Cell cycle
CDC25A 0.48 1.1x10-21 Cell cycle
TK1 0.48 1.7x10-21 Cell cycle
PCNA 0.45 2.8x10-19 DNA repair and replication
CDC25C 0.45 5.6x10-19 Cell cycle
DEK 0.45 8.6x10-19 Chromatin organisation
DCN -0.44 5.0x10-18 Role in connective tissue
CDK4 0.42 7.1x10-17 Cell cycle
WEE1 0.42 9.9x10-17 DNA replication and cell cycle
ETS2 -0.41 4.9x10-16 Transcription factor
PDGFRA -0.41 8.9x10-16 Tyrosine kinase receptor
BLM 0.40 7.2x10-15 DNA repair and replication
ITGB4 -0.39 2.4x10-14 Cell adhesion
CDKN2C 0.39 2.4x10-14 Cell cycle
E2F1 0.38 1.5x10-13 DNA replication and cell cycle
XRCC2 0.38 2.4x10-13 DNA repair
MYBL2 0.37 3.8x10-13 Cell cycle
FYN -0.37 5.7x10-13 Cell growth
XRCC4 0.37 1.2x10-12 DNA repair
PDGFRB -0.37 1.3x10-12 Tyrosine kinase receptor
BCL6 -0.36 2.8x10-12 Transcriptional repressor
CDH11 -0.36 4.0x10-12 Cell adhesion
FOSL2 -0.36 4.4x10-12 Cell proliferation
MAF -0.36 5.5x10-12 Transcriptional repressor/activator
MLF1 0.36 5.9x10-12 Haemopoietic cell development
COL18A1 -0.36 6.3x10-12 Collagen component
PBX1 -0.35 6.8x10-12 Osteogenesis and steroidogenesis
JUNB -0.35 1.1x10-11 Response to growth factors
IFNGR1 -0.35 2.2x10-11 Interferon γ receptor 
AXL -0.34 3.5x10-11 Tyrosine kinase receptor
E2F3 0.34 4.2x10-11 DNA replication and cell cycle
MCF2 0.34 7.7x10-11 Guanine nucleotide exchange factor
RECQL 0.34 9.0x10-11 DNA repair
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Figure 4-3: Gene network significantly correlated with principal component 1
from Ingenuity Pathway Analysis: cancer, cell cycle and cell death.
Molecules are represented as nodes and the biological relationship between
nodes is represented as a line (edge). Each edge is supported by at least one
reference from the literature, from a textbook or from canonical information stored
in the Ingenuity Knowledge Base. The intensity of the node colour indicates the
degree of positive (red) or negative (green) correlation with the principal
component.
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4.4 Validation of DASL results
Results generated from microarray analysis require validation to ensure that results are
reproducible (and not platform specific) and warrant further investigation. To check the
results using a different gene expression assay, a qRT-PCR experiment was
performed to confirm expression levels of RAD52, RAD54B and TOP2A using samples
from patients recruited to the Cohort Study.
To ensure that accurate results were being obtained from these precious samples,
methodological work was undertaken to identify the best methods for qRT-PCR
experiments with FFPE melanoma samples.
4.4.1 Study to optimise methods for qRT-PCR using FFPE
melanoma samples
4.4.1.1 Assessment of amplification efficiencies of Taqman® Gene
Expression assays and choice of experimental design
4.4.1.1.1 Methods
An assessment of the amplification efficiencies of Taqman® Gene Expression assays
for unknown genes and endogenous control genes was performed to decide whether
the comparative Ct method could be used with FFPE melanoma samples and
Taqman® Gene Expression assays. cDNA was generated using the Invitrogen
Superscript™ First-strand Synthesis System with a modified protocol, as described in
Chapter 2, from RNA extracted from a FFPE metastatic melanoma sample as
described in Chapter 2. cDNA concentration was measured using spectrophotometry
and standard samples were prepared using a 1:2 dilution to generate standard curves
for each assay assessed. Applied Biosystems (Warrington, UK) recommend that
amplification efficiencies are assessed over a broad dilution (5-6 logs) [456], however
previous experiments suggested that cDNA produced from RNA extracted from FFPE
melanomas is too dilute to amplify in a concentration less than 100ng/μl so a 1:2 
dilution was used to ensure enough results would be obtained to assess amplification
efficiency.
Fragments of genes were amplified using Taqman® Gene Expression assays as
detailed in Table 4-8.
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Gene Exonstargeted
Amplicon
length
NCBI Reference
Sequence Assay Reference
Genes for
relative
quantification
RAD52 2/3 65bp NM_134424.2 Hs00172536_m1
RAD54B 1/2 64bp NM_012415.2 Hs00610716_m1
TOP2A 23/24 72bp NM_001067.2 Hs03063307_m1
Endogenous
control genes
GAPDH 3 122bp NM_002046.3 Hs99999905_m1
IPO8 20/21 71bp NM_006390.2 Hs00183533_m1
Table 4-8: Details of Taqman® Gene Expression assays for DNA repair gene
qRT-PCR experiments.
Abbreviations used: NCBI, National Center of Biotechnology.
PCRs were performed using standard methods described in Chapter 2. Automatic
baseline and threshold levels were used to generate cycle threshold (Ct) values, and
amplification efficiencies for each probe were calculated by the ABI 7500 Fast Real-
time PCR System software (Applied Biosystems).
4.4.1.1.2 Results and conclusions
Ct values for replicate samples were plotted against sample cDNA amount. A line of
best fit through the data points for each probe is applied by the software to generate
standard curves from which probe efficiency can be calculated using the formula:
efficiency = 10(-1/slope) -1 [456]. Probe efficiencies as calculated by the software are
presented in Table 4-9.
Assay
Slope of
standard
curve
Efficiency (%)
Genes for
relative
quantification
RAD54B -4.92 59.7
RAD52 -5.44 52.7
TOP2A -5.33 54.1
Endogenous
control genes
IPO8 -5.60 50.9
GAPDH -4.68 63.5
Table 4-9: Taqman® Gene Expression assay probe efficiencies in cDNA
generated from RNA extracted from an FFPE metastatic melanoma sample.
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Applied Biosystems report that Taqman® Gene Expression assays are 100% (+/-
10%) in high quality RNA. This experiment showed that the assays were less efficient
with degraded RNA extracted from FFPE tissue, but were comparable in efficiency with
each test probe being within 10% of the efficiency of one of the endogenous control
probes. Therefore I concluded that use of a comparative Ct method to assess the
relative quantities of RAD54B, RAD52 and TOP2A when using GAPDH and IPO8 as
endogenous control genes would be appropriate and this was used as the
experimental design for validation of DASL results.
4.4.1.2 Identification of suitable endogenous controls
4.4.1.2.1 Methods
To identify endogenous control genes for use in qRT-PCR experiments using FFPE
melanoma tissue, cDNA was generated using the Invitrogen Superscript™ First-strand
Synthesis System using a modified protocol from RNA extracted from four FFPE
melanoma metastases samples as described in Chapter 2. For a comparative
experiment, a calibrator sample is also required to generate relative quantity values,
and assessment of endogenous control gene expression in this sample was also
made. For this work, a sample from an intradermal naevus was identified as a
calibrator sample, RNA was extracted from 12 cores of tissue using the Roche High
Pure RNA Paraffin Kit as described in Chapter 2 and cDNA was generated from
calibrator RNA as described previously. Taqman® Express Endogenous Controls
plates (Applied Biosystems, Warrington, UK) are 96-well MicroAmp® optical reaction
plates with Taqman® Gene Expression Assays for 32 endogenous control genes dried
into wells in triplicate (full list in Figure 4-4). One plate was used to assess each of the
5 samples. Each well was reconstituted to a final volume of 20μl with 10μl of Gene 
Expression Master Mix, 8μl DNase-free water and 2μl cDNA sample (total 1 
microgram). PCRs were performed using the ABI 7500 Real-time PCR system (Applied
Biosystems) using standard cycling conditions described in Chapter 2. Data from each
of the 5 plates was imported into a single study and automatic settings were used for
baseline and threshold determination across the samples. Ct values were exported to
Excel for further analysis. Mean Ct values from replicate samples were used, and
standard deviations were calculated for each gene across all samples. Data was
uploaded into geNorm software (J. Vandesompele, Center for Medical Genetics,
Ghent, Belgium) following conversion into non-normalised quantities. These quantities
were calculated as follows: ΔCt values were calculated for each gene where ΔCt = 
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mean Ct value melanoma sample – mean value Ct calibrator sample, non-normalised
values were calculated using 2-ΔCt [340].
4.4.1.2.2 Results and conclusions
A number of gene expression assays failed to amplify with some of the samples, those
being HMBS, HPRT1 and TBP. Figure 4-4 shows the spread and mean Ct values for
each gene across the five samples assessed. The genes with the lowest standard
deviations were HMBS (for which a number of samples failed), PPIA1, POP4, IPO8
and CDKN1B.
Figure 4-5 shows the average gene-stability measure (M values) of remaining control
genes during stepwise exclusion of the least stable control gene using geNorm
software [343]. The two genes with the lowest M value and hence the least average
pairwise variation, have the most stable gene expression.
Based on these analyses PPIA1, POP4, IPO8, CDKN1B, CASC3 and PES1 would be
candidates for endogenous control genes. In view of the limited amounts of RNA
available to perform qRT-PCR validation work the lowest number of genes to allow
accurate normalisation were identified. The calculated pairwise variation between a
normalisation factor using 2 genes and 3 genes was only 0.097 (and therefore <0.15
[343]), indicating that normalisation using two genes would be adequate. GAPDH is
commonly used as an endogenous control gene for normalisation. GAPDH had the 6th
lowest standard deviation between samples of 0.61 and was the 6th most stably
expressed gene as identified by geNorm, so was used as the first control gene. As
discussed previously, an ideal control gene should be of similar abundance to the
unknown genes. Figure 4-4 demonstrates that GAPDH is more abundant than many of
our unknown genes with a lower Ct value, therefore it would be sensible to choose a
gene of lower abundance as the second gene for normalisation. IPO8 was identified as
being the 3rd most stably expressed gene by geNorm and had low standard deviation
between samples of 0.40. In this experiment, IPO8 had a Ct value of 36.5 and GAPDH
had a Ct value of 35.1, therefore IPO8 was chosen as the second control gene for
further qRT-PCR work to validate DASL results. As discussed previously, ideally three
or more control genes are used and this represents a limitation of this work. However,
in view of the small amounts of RNA available it cannot be justified to use more than
two control genes to assess expression of three unknown genes.
.Figure 4-4: Dot-plot of cycle threshold values for cDNA samples generated from RNA extracted from four metastatic melanoma samples
and one intradermal naevus (calibrator sample).
The mean is indicated by the plus sign. Abbreviation used: Ct, cycle threshold.
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Figure 4-5: Average gene stability values (M values) of control genes during stepwise exclusion of least stable control genes.
CASC3 and PES1 have the lowest M value and therefore have the most stable gene expression in four melanoma samples and one
intradermal naevus sample .
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4.4.2 Expression of RAD52, RAD54B and TOP2A in tumours from
patients recruited to the Leeds Melanoma Cohort Study
4.4.2.1 Detailed methodology
cDNA was generated using the Invitrogen Superscript™ First-strand Synthesis System
using a modified protocol as described in Chapter 2 from RNA extracted from 156
primary melanoma tumours from patients recruited to the Cohort Study and sent for
DASL analysis. Thirteen samples from patients treated with chemotherapy were not
included in the analysis as these samples were required for another study (Chapter 8).
RNA was not available for two samples, one of which was from a patient treated with
chemotherapy, leaving a total of 142 samples for analysis. Chemotherapy treated
patients had all relapsed, leaving a total of 24 patients who had relapsed in the sample
set assessed. cDNA was generated in two 96-well plates for all samples in the same
reaction. cDNA generated from RNA extracted from an intradermal naevus sample, as
described in section 4.4.1.2.1, was used as a calibrator sample.
Small fragments of RAD52, RAD54B, TOP2A and the endogenous control genes,
GAPDH and IPO8 were amplified using Taqman® Gene Expression Assay probes
(Applied Biosystems, Warrington, UK) as listed in Table 4-8. PCRs were performed
using standard conditions described in Chapter 2.
A total of 25 96-well plates were used for this experiment. The calibrator sample was
amplified for all probes on 4 plates across the experiment to allow assessment of
variability across the plate runs. Each 96-well plate was set up using the Corbett CAS4
robot (Qiagen Ltd, Crawley, UK) with the assistance of Dr Mark Harland, to minimise
pipetting variation. Template negative controls for each assay and reverse
transcriptase negative cDNA controls were rotated across the plates.
Following each run, results were assessed and any failed samples were omitted from
the analysis. Groups of replicates with standard deviations greater than 0.5 cycles
were reviewed to identify outliers. If a sample result was clearly erroneous when
compared to other replicates (sample with Ct value >0.5 cycles different to other two
samples), this sample was omitted from the analysis. When it was unclear which
sample was the outlier (all Ct values within 0.5 cycles of each other) all samples were
retained to generate a mean Ct value for replicates. All plates were imported into a
single study, and automatic settings were used for baseline and threshold
determination across all samples. Ct values were exported to Excel for further analysis.
Reproducibility between sample replicates was calculated using intraclass correlation
coefficients, which describe how strongly replicate samples within each group
resemble each other. A value of 1 indicates perfect correlation, with lower values
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representing more variation between samples within a group [472]. Mean Ct values
were calculated for each sample for each gene from replicates and data were
normalised using expression of GAPDH and IPO8 according to the method of
Vandesompele et al. [343], which is described in Chapter 2. Normalised gene
expression quantities were used to calculate a fold change in expression between
samples from patients that had relapsed and non-relapsers. The statistical significance
of gene expression differences between the groups was assessed using the Mann-
Whitney U test with the significance level being set at 0.05.
Non-normalised values for gene expression are given by the formula (1+efficiency of
amplification)-ΔCt [340]. For probes with 100% efficiency this equates to the formula 2-
ΔCt, however as the efficiency of the assays in FFPE melanoma tissue was shown in
Table 4-9 to be a mean value of 56%, the calculation was repeated using the formula
1.56-ΔCt prior to normalisation. To compare gene expression results generated using
different normalisation approaches, data was also normalised to GAPDH and IPO8
separately using the 2-ΔΔCt method as previously described in Chapter 2. Gene
expression data from qRT-PCR was compared with that from the DASL assay using
Spearman’s rank correlation.
4.4.2.2 Results
4.4.2.2.1 Validation of DASL results
Nine samples failed to amplify with the probes for all genes assessed. Two further
samples failed to amplify with the RAD52 probe and three samples for the RAD54B
probe. Negative controls failed to amplify as expected. Table 4-10 presents summary
information about the assays used in this experiment. Mean Ct values for RAD52 and
RAD54B probes were higher than those for other genes and the intraclass correlation
coefficients for replicate samples were lower. Mean Ct values were calculated from all
calibrator samples for each probe for further analysis.
Table 4-11 presents the fold changes in mean gene expression between tumours from
patients who relapsed (n=24) versus those that do not relapse (n=118). Table 4-11
also shows the different values obtained when analysis was normalised using the
geometric mean of two control genes and each control gene separately, and the
difference in values obtained when the lower efficiency of probes was taken into
account when calculating relative quantities. The samples used for this analysis were
from the Leeds Cohort study only, therefore Table 4-11 also presents the DASL results
for the 142 samples used in this qRT-PCR validation for comparison with the merged
dataset results in Table 4-1.
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Gene
Mean Ct
value for
calibrator
samples
(n=4)
(outliers
removed)
Mean Ct
value for
test samples
(n=133)
(outliers
removed)
Intraclass
correlation
coefficient
for samples
(outliers
present)
Intraclass
correlation
coefficient
for samples
(outliers
removed)
GAPDH 32.83 32.21 0.99 0.99
IPO8 35.36 35.26 0.94 0.97
RAD52 36.83 36.57 0.49 0.91
RAD54B 38.80 37.57 0.45 0.87
TOP2A 37.91 35.58 0.93 0.97
Table 4-10: Mean cycle threshold values and intraclass correlation coefficients
for sample replicates for each qRT-PCR assay.
Mean Ct values for calibrator samples and test samples are presented following
removal of outliers (156 values were classified as outliers from 2043 original Ct
values). Intraclass correlation coefficients for replicate samples have been
calculated before and after outliers have been removed.
Gene
Geometric mean
normalisation,
mean fold change
(significance
level)
Geometric mean
normalisation -
efficiency 0.56,
mean fold change
(significance
level)
Normalised to
GAPDH only
2-ΔΔCT, mean
fold change
(significance
level)
Normalised
to IPO8 only
2-ΔΔCT, mean
fold change
(significance
level)
No. in DASL
Cohort list
of
differentially
expressed
genes
Fold
change in
DASL
cohort
samples
Significance
level in DASL
cohort data
RAD52 0.72 (0.006) 0.81 (0.006) 0.56 (0.005) 0.80 (0.07) 125 1.09 0.08
RAD54B 1.08 (0.42) 1.07 (0.42) 0.80 (1.00) 1.38 (0.07) 4 1.35 0.00008
TOP2A 1.37 (0.01) 1.27 (0.009) 0.94 (0.26) 1.82 (0.0003) 29 1.16 0.004
Table 4-11: Fold changes in mean gene expression of RAD52, RAD54B and TOP2A in tumours of patients who relapse compared to non-
relapsers as determined using qRT-PCR.
Column 1 presents results when normalised to the geometric mean of GAPDH and IPO8 assuming the efficiency of the assays is 100%.
Column 2 presents results when probe efficiency of 56% is used (as determined in FFPE melanoma tissues in section 4.4.1.1.2). Column 3
present results when normalised to the endogenous control gene, GAPDH, only using the 2-ΔΔCt method. Column 4 presents results for data
normalised to IPO8 only (both columns assume probe efficiency of 100%). The Mann Whitney U test has been used to identify statistically
significant differences between expression results between relapsers and non-relapsers and the significance value is presented. The final
three columns show results from DASL analysis of 142 samples used in the qRT-PCR experiment, the first column shows the position of the
gene on the list of most differentially expressed genes in relapsers versus non-relapsers, the second column show the fold change between
relapsers and non-relapsers and the final column show the significance value from survival analysis using the proportional hazards model.
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Expression of RAD54B and TOP2A was greater in tumours from relapsers versus non-
relapsers using geometric mean normalisation and normalisation to IPO8. TOP2A was
statistically significantly over-expressed, which is consistent with the DASL results,
although over-expression of RAD54B did not reach statistical significance. RAD52 was
significantly under-expressed in tumours from relapsers versus non-relapsers, a result
which therefore does not correlate with DASL results. Use of lower probe efficiencies to
calculate relative quantities does not alter these results. To investigate the different
results obtained for RAD52 using these two methods, I looked at data from each of the
three probes used in the DASL assay for RAD52. As presented in Table 4-12,
expression results for RAD52 from the DASL assay using the mean expression values
from three probes do not correlate significantly with qRT-PCR results using Taqman
assays (Spearman’s rho 0.15, p=0.08). Two of the DASL probes are located on exon
12 of the RAD52 gene and results from these probes correlated poorly with the qRT-
PCR data (Spearman’s rho -0.05 and 0.08, p=0.59 and 0.37, respectively). When a fold
change in gene expression between relapsers and non-relapsers is calculated for
these DASL probes, RAD52 is over-expressed (fold change 1.05 and 1.08,
respectively). The other RAD52 probe is located on exon 4, closer to the Taqman
assay which targets exons 2/3. DASL expression results correlate better with qRT-PCR
results for this probe (Spearman’s rho 0.26, p=0.003); however the fold change in gene
expression for relapsers and non-relapsers for this DASL probe is smaller at 1.01.
There may be a number of factors contributing to the lack of consistency across DASL
results and qRT-PCR results. Results from the DASL or the qRT-PCR assay may be
erroneous, which is supported by the lack of correlation between DASL expression
results and qRT-PCR data for two of the three DASL assay probes. In addition, the fold
change in gene expression between relapsers and non-relapsers was very small (1.01)
for the probe which correlated with qRT-PCR results, decreasing the likelihood that this
fold change would have been detected in the qRT-PCR experiment. Another factor that
may also contribute to these results is the samples selected for qRT-PCR validation.
As presented in Table 4-11, when DASL data for the 142 samples used in the qRT-
PCR experiment is analysed, RAD52 is the 125th gene most associated with RFS and
expression is not significantly associated with RFS (p=0.08, fold change between
relapsers and non-relapsers 1.09). In contrast, RAD52 is the 4th gene most significantly
associated with RFS in the merged dataset analysis (p=0.00002, fold change 1.16)
(Table 4-1). Therefore, I could not validate DASL results for RAD52 using qRT-PCR,
likely due to lack of correlation between qRT-PCR results and DASL probes and lack of
power within the dataset to identify gene expression differences between relapsers and
non-relapsers.
GAPDH and IPO8 geometric
mean normalisation -
efficiency 100%,
Spearman’s rho (p)
GAPDH and IPO8 geometric
mean normalisation -
efficiency 56%,
Spearman’s rho (p)
GAPDH only normalisation
2-ΔΔCT, Spearman’s rho (p)
IPO8 only normalisation
2-ΔΔCT, Spearman’s rho (p)
RAD52 RAD54B TOP2A RAD52 RAD54B TOP2A RAD52 RAD54B TOP2A RAD52 RAD54B TOP2A
RAD52 0.15(0.08)
0.15
(0.08)
0.06
(0.48)
0.16
(0.07)
RAD54B 0.13(0.13)
0.13
(0.13)
0.009
(0.92)
0.26
(0.003)
TOP2A 0.55(<0.0001)
0.52
(<0.0001)
0.34
(<0.0001)
0.72
(<0.0001)
Table 4-12: Correlations between DNA repair gene expression data derived from qRT-PCR and DASL.
Spearman’s rho values and significance levels are presented for each gene. The first column compares gene expression results from qRT-
PCR using the geometric mean of GAPDH and IPO8 expression and assuming assay efficiency of 100%. The second column presents
correlations between data when efficiency of assays is set at 56%. The third and fourth columns present correlations when qRT-PCR data has
been normalised to GAPDH or IPO8 respectively, using the 2-ΔΔCtmethod and assuming a probe efficiency of 100%.
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4.4.2.2.2 Comparison of normalisation methods
Table 4-12 presents the correlations between relative gene expression quantities
calculated using qRT-PCR and gene expression values from DASL data. Irrespective
of normalisation method or efficiency used to calculate relative quantities, expression of
TOP2A using qRT-PCR correlated significantly with expression levels from DASL. Only
when normalised to IPO8 alone did expression of RAD54B correlate significantly
between qRT-PCR and DASL. As discussed previously, expression of RAD52 as
determined by qRT-PCR is positively correlated with DASL expression data based on
three probes, but not significantly. This is not altered by normalisation method and may
contribute to the lack of correlation between fold changes in gene expression in
relapsers and non-relapsers between the two methods. There are clearly differences in
results depending on which normalisation method is used. Normalisation to GAPDH
only decreases the differences between relapsers and non-relapsers with regards to
RAD54B and TOP2A expression (Table 4-11), and decreases the correlation between
qRT-PCR results and DASL results (Table 4-12). Normalisation to IPO8 only increases
the differences in gene expression of RAD54B and TOP2A and improves the
correlation between DASL results and qRT-PCR results. This highlights the importance
of correct normalisation. In view of these results it would be sensible to use genes
which we have identified as being most stably expressed in melanoma samples in
4.4.1.2.2 (CASC3 or PES1) instead of GAPDH in future work and undertake a similar
assessment to compare results obtained with different normalisation techniques.
4.4.3 Summary of qRT-PCR methodological work
The work I have presented demonstrates that although the efficiencies of Taqman®
Gene Expression assays are lower in RNA extracted from FFPE melanoma tissue, use
of the comparative Ct method for gene quantification is valid. The importance of correct
normalisation has been demonstrated and a number of suitable endogenous control
genes (PPIA1, POP4, IPO8, CDKN1B, CASC3 and PES1) for normalisation have been
identified. DASL results for two genes have been validated using qRT-PCR (TOP2A
and RAD54B), however results for RAD52 could not be replicated.
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4.5 Discussion
4.5.1 Development of methodology for qRT-PCR with FFPE
melanoma tissue
The potential for reporting an erroneous result as a consequence of using a single
gene expression platform, such as the DASL assay, is always a concern in gene
expression work, thus it is important to confirm findings using another approach. I
therefore attempted corroboration using qRT-PCR. This technique requires
optimisation for use in different tissue types as amounts of starting material may vary,
enzymatic efficiencies may differ and transcriptional activity can be highly variable
[343]. “Housekeeping” genes, commonly used for normalisation, have expression
which can vary considerably [459-461], leading authors to recommend that control
genes are assessed for suitability in each experimental protocol [465]. In the case of
FFPE melanoma tissue, optimisation is even more essential in view of the degraded
RNA extracted from FFPE materials [291] and the presence of melanin which can
interfere with PCR reactions [303].
This chapter therefore presents methodological work to investigate and optimise
methods for qRT-PCR in FFPE melanoma tumours. The data described above show
that there is not doubling of PCR product with every PCR cycle (100% efficiency) [340,
457] using Taqman® Gene Expression Assays in our degraded samples. However the
efficiency of endogenous control genes is similar to those of test genes, and therefore
a comparative Ct method is appropriate [340, 455]. This work has demonstrated that
different normalisation strategies alter gene expression results. Using DASL gene
expression data to compare qRT-PCR results using different normalisation strategies,
use of GAPDH as a control gene decreases correlation between DASL and qRT-PCR
results and fold changes in gene expression between relapsers and non-relapsers.
This assessment is limited, as DASL results may themselves be subject to error;
however in our assessment of candidate control genes, GAPDH was not as uniformly
expressed as other genes, for example CASC3 or PES1, making these genes more
sensible choices for future gene expression work. Use of more than one control gene
with uniform expression is more likely to yield accurate gene expression results so that
many authors recommend use of at least three genes [343, 466]. This work represents
a compromise using two genes, considering lack of available RNA and the number of
genes quantified.
Despite efforts to optimise methods, validation of DASL results was only possible for
two of the three genes assessed. This may be because of erroneous results from the
DASL assay or the qRT-PCR assay; however it may also be because of a lack of
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power to detect differences in gene expression level as a limited number of samples
were used. This has not be assessed further as limited samples are available, but
highlights the importance of a large sample set when attempting to identify small
differences in gene expression levels.
4.5.2 Over-expression of DNA repair genes in melanoma tumours as
a prognostic marker
Using the Illumina DASL assay, a group of genes has been identified with prognostic
significance in melanoma. This technology has been used in a number of previous
studies to identify prognostic markers using FFPE tissue using the Human Cancer
panel [297, 473] and on a genome-wide scale [180, 474]. Genes of prognostic
significance have been identified in uveal [475] and cutaneous melanoma (SPP1)
(Chapter 3) [187].
The work described in this chapter represents the largest study to date using gene
expression profiling to identify prognostic markers in melanoma, made possible by
utilising FFPE primary melanoma tumours. A number of bioinformatics resources have
been used to interrogate the data presented in this chapter. These systems are
inherently biased as they are based on information currently available in the literature,
however DNA repair genes and genes related to these processes were easily identified
as a group of important genes by simple review of the list of genes significantly
associated with survival. GO analysis confirmed the importance of these genes in DNA
recombination, DNA replication and the M-phase of the cell cycle. Pathway analysis
using DAVID highlighted that the data was derived from a cancer related gene panel,
but also confirmed enrichment of genes involved in the cell cycle and DNA repair. Use
of Ingenuity pathway analysis has identified correlations between genes associated
with cell cycle control or DNA repair and the DNA repair genes identified in this
analysis and has allowed generation of a network to visualise associations within the
dataset. In summary, pathway analysis has helped to categorise and visualise the
biological functions of genes within this dataset. The advantages of this are limited for
gene expression data derived from a 502-gene cancer panel, but DAVID pathway
analysis has highlighted the importance of focal adhesion and cytokines in our list of
differentially expressed genes which may not have been identified by review of the list.
Use of bioinformatics resources would be invaluable when using large, unbiased
genome-wide data.
For this analysis we have assessed the data in a ‘supervised’ fashion to identify genes
differentially expressed in tumours or patients with well documented characteristics,
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such as relapse or Breslow thickness [448, 449]. This is the approach used in most
previous microarray studies in melanoma tumours addressing gene expression
associated with survival [177, 185], the exception being the recent report by Jonsson
and colleagues which used unsupervised hierarchical clustering to identify groups of
samples with similar gene expression profiles and then assessed prognosis between
these groups [180]. With the detailed histological and survival data available in
association with the samples analysed in this study, a supervised approach appears
most sensible. Unsupervised analysis would also have been likely to identify groups of
tumours within this dataset, however previous work indicates that most clustering
performed in microarray datasets is not reproducible or reflective of patterns in a larger
population [449, 476]. Identification of genes associated with survival can only be
confirmed by validation in an independent sample set, an approach described in
Chapter 3. Lack of validation of findings presented in this chapter represents a
significant limitation of this work. We have been unable to identify a sample set of
sufficient size to replicate these findings to date, however the development of
microarray analysis in FFPE tissues will facilitate this in time.
There has been interest in the role of over-expression of DNA repair genes which has
been associated with poorer prognosis in melanoma and metastasis in candidate gene
[477, 478] and microarray studies [175, 177, 178]. These results are in agreement with
those of Kauffman et al. who identified that over-expression of genes involved in
recovery of stalled replication forks, especially genes involved in repair of double-
stranded DNA breaks, were associated with melanoma metastasis in a study of 60
frozen melanoma tumours [177]. It has been suggested that in order for a melanoma
cell to continue to divide and give rise to metastases, cells up-regulate genes
associated with DNA repair processes to maintain genomic integrity [264]. This has
been noted in other cancers such as bladder [479] and breast cancer [480, 481],
however the proportion of DNA repair genes that are over-expressed in melanoma
tumours that will metastasise is particularly high (90%) compared with bladder cancers
(82%) and breast cancers (58-80%) [264]. Over-expression of DNA repair genes may
help to explain why melanoma tumours are so especially resistant to chemotherapy
and radiotherapy [264], a hypothesis which will be further investigated in Chapter 8.
The majority of genes identified in this work are involved in double-strand break (DSB)
repair by homologous recombination (RAD51, RAD52, RAD54B, RAD54L, BRCA1 and
BRCA2) [264, 482]. (Figure 4-6). To repair DSBs, DNA is resected to expose single-
stranded DNA (ssDNA) to which RAD51 binds, a process enhanced by direct
interaction of RAD51, RAD52 [483-485] and the ssDNA binding protein replication
protein A (RPA) [482]. RAD51 wraps around DNA to form a nucleoprotein filament in
Figure 4-6: DNA repair mechanisms.
Adapted from reference [486]. DNA damage leads to a number of responses and repair mechanisms within a cell. The genes identified in this
work are mostly related to double-stranded break repair and mismatch repair.
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which DSB repair takes place [487], RAD52 is also involved in single strand annealing
independently of RAD51 [488]. During DSB repair, ssDNA invades into double-
stranded DNA (dsDNA) within the nucleoprotein filament, a process that requires
binding of a cofactor such as ATP [489, 490]. Studies with yeast proteins have
revealed that the efficiency of this binding is dependent on RAD54 [491]. The RAD54
gene has significant homology with the human RAD54B gene [492]: RAD54L is also
known as human RAD54 and has similar functions to those of RAD54 in yeast [493].
Once ssDNA has paired with dsDNA, strand exchange can occur. RAD51 and RAD52
promote capture of the other ssDNA tail, and DNA is synthesized using the two ssDNA
ends as primers. Once DNA synthesis is complete, crossovers between DNA duplexes
are resolved to allow repaired chromosomes to separate [482]. BRCA2 interacts with
both RAD51 [494] and BRCA1. BRCA1 and BRCA2 are required for DSB repair by
homologous recombination in cell lines, probably via RAD51-mediated DNA repair
[482, 495, 496]. CHEK1 is part of the cell-cycle checkpoint pathway; it is a protein
kinase activated by DNA damage such as DSBs and stalled DNA replication forks,
which prevent progress from the G2 to M phase of the cell cycle [177, 497]. MSH2 and
MSH6 are not involved in DSB repair, but are mismatch repair genes that produce
proteins which repair errors made in base-pairing by DNA polymerases during
replication [177, 498]. TOP2A is another gene not involved in repair of DSBs, but
induces transient DNA breaks to allow changes in DNA topology during DNA
replication [499]. Expression of TOP2A closely reflects the proliferative activity of cells
[499].
Formation of DSBs and DNA damage occurs during replication of cells, so it is
unsurprising that DNA repair genes are over-expressed in more aggressive tumours
with greater mitotic rate and Breslow thickness. As discussed above, it has been
suggested that more aggressive tumours up-regulate DNA repair genes to allow more
error-free cell division [264]. However an actively dividing tumour may well have higher
levels of DNA repair gene expression secondary to DNA replication, an observation
supported by the fact that TOP2A expression reflects the proliferative activity of non-
malignant cells [499]. It is likely that a combination of these factors contributes to
higher DNA repair gene expression. Using principal component analysis of genes
associated with RFS, Breslow thickness and mitotic rate, we have shown that many of
the genes with expression levels that correlate with the first principal component are
involved in DNA repair processes and the cell cycle, indicating that over-expression of
genes involved in these pathways is common in tumours with poorer prognosis,
perhaps reflecting increased proliferation in these cells. RAD52 is an exception, as
expression levels were not correlated with expression of other genes involved in DSB
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repair such as RAD54L and BRCA2. This may reflect the additional function of RAD52
in repair by single strand DNA damage [488]. The correlation between genes involved
in cell cycle control and genes identified in this analysis associated with prognosis is
expected, given the importance of tumour mitotic rate as a prognostic marker [58].
RAD51 is the central protein involved in the DSB process and is over-expressed in
many tumours [500]. Previous reports have identified the association between TOP2A
expression and aggressive tumour features in prostate [501], hepatocellular carcinoma
[502] and colorectal cancer [503]. More recent work has confirmed that high TOP2A
gene expression is associated with shorter metastasis-free interval in breast cancer
[504]. A recent study, published following the work described in this chapter [505], in
223 FFPE primary melanoma tumours has confirmed the association between poorer
survival, prognostic tumour factors (Breslow thickness, ulceration and mitotic rate) and
over-expression of BRCA1 and DNA damage signalling genes [335].
In summary, in this large study of FFPE primary melanoma tumours, over-expression
of DNA repair genes is associated with poorer survival and adverse histopathological
features. The fact that over-expression of a number of the genes identified has already
been published in the literature using gene expression profiles from frozen melanoma
tumours [177] provides evidence that this finding is biologically relevant in melanoma
and that the DASL assay is yielding results from FFPE tissue which corroborate with
results using other microarray platforms with intact RNA. Expression of RAD52 and
TOP2A have independent prognostic value, even when analysis is adjusted for host
factors known to be of prognostic importance in melanoma. A limited sample set was
used to validate the over-expression of a number of genes in tumours from patients
who relapse versus non-relapsers using qRT-PCR. RAD52 was under-expressed in
relapsers from qRT-PCR data, in contradiction with DASL data. However, over-
expression of TOP2A was confirmed, and in view of the independent prognostic value
of over-expression of TOP2A, this could be a candidate for a prognostic biomarker in
melanoma requiring validation in an independent sample set.
Using FFPE tissue for gene expression analysis is challenging, however these efforts
enable analysis of large numbers of samples with mature survival data and well-
annotated tumour and patient characteristics. Studies of this kind will undoubtedly
improve our understanding of the biological processes associated with melanoma
progression and allow identification of prognostic biomarkers.
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5 Identification of differentially expressed genes in matched
formalin-fixed paraffin-embedded primary and metastatic
melanoma tumour pairs
5.1 Aims
The main aim of this study was to assess the performance of the cDNA-mediated
annealing, selection, extension and ligation (DASL) assay using very small formalin-
fixed paraffin-embedded (FFPE) sentinel node biopsy (SNB) samples. Additional aims
were:
 To identify tissue factors of small SNB samples which determine performance
with the DASL assay.
 To clarify which quality control measures and sample characteristics determine
performance on the array using small/ SNB samples.
 To assess use of number of detected genes as a quality control measure of
sample performance with the DASL assay.
 To compare gene expression profiles between matched primary and SNB
samples to identify differentially expressed genes.
These data have been published in part [506].
5.2 Introduction
Current predictors of outcome for melanoma fail to identify a proportion of patients with
“low-risk” melanoma who go on to relapse [58, 121]. Therefore, there is a need to
investigate the somatic genetic changes in the primary tumour which determine
metastatic capacity. A number of studies have used naevi, primary melanomas and
metastatic melanomas to assess alterations in gene expression profiles during
melanoma progression [176, 182, 190, 193, 507, 508]. However, many of these studies
have used limited numbers of samples because of lack of cryopreserved tissue for
genomic work, and have often assessed gene expression in primary and metastatic
tumours from different patients for the same reason [176, 190, 507]. Heterogeneity of
primary melanoma tumours, germline genetic variation and epigenetic influences are
postulated to modify gene expression profiles in melanoma tumours [509], therefore
- 153 -
assessment of gene expression profiles in matched primary and metastatic tumours
from the same patient may yield more insight into the mechanisms of melanoma
progression.
The sentinel lymph node is the usual site of initial metastasis in melanoma, with
sentinel lymph node status being the single most important prognostic factor for
patients without any other evidence of metastatic spread [58, 80]. The identification of
gene expression differences between primary and nodal metastases is desirable in
order to identify key pathways involved in this pattern of metastasis. Koh and
colleagues compared whole-genome expression profiles in four matched FFPE primary
and sentinel node biopsy samples, which were either macrodissected or sampled using
laser capture microdissection, along with 11 unpaired specimens [510]. This study
identified differential expression of 576 genes in unpaired samples, with most
differences reflecting lower gene expression in metastatic samples compared to
primary samples. This pattern was replicated in the matched specimens. Genes
differentially expressed were typically associated with processes relevant to tumour
metastasis, such as apoptosis, cell adhesion and the cell cycle [510].
This chapter reports a pilot study designed to assess the utility of the DASL assay to
identify differentially expressed genes in extremely small FFPE SNB samples. In
contrast to our sampling method for primary melanoma samples using a tissue
microarray needle, laser capture microdissection (LCM) was used to sample these very
small tissues. This technique has the advantage that single melanoma cells can be
identified and sampled [511], although it is time consuming for large numbers of
samples. LCM is discussed in further detail in Chapter 2.
Data from SNB samples have been compared with gene expression data from
matched primary melanoma tumours where possible to explore the feasibility of using
the DASL assay to identify genes differentially expressed between primary and early
metastatic tumours which has the potential to give insight into early metastatic
processes. In our previous work using primary melanomas, we have used the number
of genes detected in each sample using the DASL assay (probe signal significantly
greater than average signal from negative controls with p<0.05) as a measure of the
quality of results [294], indeed we have deemed a sample as “failed” with less than 250
(50%) genes expressed. This was a somewhat arbitrary cut off derived from previous
reported studies [294]. My work with nodal biopsies has highlighted significant
differences in the number of genes detected across different tissues and control RNA
samples along with different patterns of “failed” probes, leading to a reappraisal of use
of number of detected genes as a quality control measure.
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5.3 Further methodological details
5.3.1 Sampling of nodal and primary tumours
FFPE SNB samples and primary tumours were identified from The Leeds Melanoma
Cohort Study (Cohort study) and the Retrospective Sentinel Node Biopsy Study (SNB
study) which are fully described in Chapter 2. From the Cohort study eight positive
SNB samples were identified and from the SNB study, seventeen positive SNB
samples were identified, from patients whose primary tumours had already been
sampled for DASL studies as described in Chapters 3 and 4.
There was much variation in tissue availability between samples ranging from 8 cells
(as detailed in the histopathology report) to large parenchymal deposits and we elected
to test the sensitivity of DASL by attempting to extract RNA from all. For eight nodal
samples, tumour was sampled using LCM from two new 5 micron sections cut from the
nodal tumour block. For three samples no tumour remained on the nodal tumour block
so a diagnostic haematoxylin and eosin (H+E) slide was used for tumour sampling
following removal of the coverslip. For the remainder of the samples, archival
unstained sections were available from Professor Martin Cook at the Royal Surrey
County Hospitals NHS Foundation Trust. Details of coverslip removal, sectioning,
section staining, LCM and RNA extraction are included in Chapter 2 and were
undertaken by myself. LCM was performed under the supervision of Dr Andy Boon
who is a dermatopathologist.
Primary tumour blocks were sampled using a tissue microarray (TMA) needle. Tissue
cores were de-waxed and RNA extracted using the High Pure Paraffin RNA kit
according to the manufacturer’s protocol. Further methodological details are included in
Chapter 2. Tissue sampling and RNA extraction of primary samples were performed by
Dr Caroline Conway (Cohort study), Dr Angana Mitra (SNB study) and Samira Lobo.
RNA concentration for nodal and primary samples was assessed using the ND-8000
spectrophotometer (NanoDrop, Wilmington, DE, USA).
5.3.2 Gene expression profiling using the DASL assay
The Illumina DASL Human Cancer panel was used for gene expression profiling as
previously described in Chapter 2 by Floor de Kort at ServiceXS (Leiden, Netherlands).
As a final quality control measure, quantitative Real-time PCR (qRT-PCR) of the
housekeeping gene, RPL13a, was performed for each sample as described in Chapter
2 by Floor de Kort.
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RNA samples derived from nodal specimens were sent for DASL analysis with RNA
from primary specimens from the SNB study. Primary samples from the Cohort study
were analysed in a separate DASL experiment. Data from the Cohort study and SNB
study were normalised separately and merged for analysis as described in Chapter 4.
Gene expression data from nodal samples were normalized with primary samples.
To monitor variation across plates and runs of the DASL assay, technical replicates
were placed across plates within each run as described in Chapter 2 and a total of 10
replicate Stratagene Universal Human Reference RNAs (Agilent Technologies,
Edinburgh, UK) were assessed across the two DASL experiments. These reference
RNAs are composed of RNA from 10 human cell lines, including a melanoma cell line
[512].
5.3.3 Statistical methodology
Associations between the area of tissue microdissected, reported size of tumour
deposit and concentration of extracted RNA were investigated using Spearman’s rank
correlation.
In the DASL assay, the number of genes detected in each sample (probe signal
significantly greater than average signal from negative controls with p<0.05) was used
as a measure of the quality of the results for our initial analysis. The influence of area
of tissue microdissected, reported metastasis size, age of tissue block and age of the
tissue slide on the number of genes detected was assessed using Spearman’s rank
correlation. The association between type of tissue section used for microdissection
(new sections, diagnostic H+E slides or archival unstained sections) was assessed
using the Kruskal-Wallis test. Quality control methods used to measure quality and
quantity of RNA prior to use in the DASL assay were assessed by correlating the
number of genes detected in samples with the quality measure data using Spearman’s
rank correlation. To assess reproducibility across the DASL runs, Spearman’s rank
correlation was used to assess gene expression across reference RNA samples.
The number of genes detected using the DASL assay in each sample has been
traditionally used as a measure of the quality of the results with authors excluding
samples with <50% genes detected [294]. To assess use of this measure in further
detail in different tissue types, the mean number of genes detected in each tissue type
(primary, nodal and reference RNA) was calculated and based on the cumulative
distribution of number of detected genes, nodal samples with <166 genes detected and
primary samples with <400 genes were excluded from further analyses. Genes which
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failed across all samples of a particular tissue type (primary, nodal and reference RNA)
were also identified.
Negative expression values for genes were removed for further analysis. Mean gene
expression was used for any replicate samples. Correlation between gene expression
levels in matched nodal and primary samples was assessed using Spearman’s rank
correlation. For each matched primary and nodal pair, the fold change in gene
expression between nodal and primary sample was calculated for each gene. Genes
were ranked in order of mean fold change in gene expression between primary and
nodal samples across the matched pairs. Primary tumour details were derived from
central pathology review as described in Chapter 2, SNB histology details were derived
from histopathology reports. Patient details were available from study databases with
survival variables assessed on 19th December 2011.
5.4 Results
5.4.1 Areas of nodal tumour sampled and RNA yields
Twenty-five nodal samples were selected for sampling (Figure 5-1). The size of
deposits ranged from 8 cells seen within a section to 14mm in diameter. The majority
of samples had both parenchymal and subcapsular deposits (55%), with smaller
numbers having parenchymal (32%) or subcapsular deposits (9%) only (site of
metastases was not recorded on the histopathology report for one sample). The area
of tumour microdissected varied from 157 μm2 to over 6x106 μm2 which correlated well
with the reported size of tumour deposit (Spearman’s rho 0.76, p=0.0001). The mean
concentration of RNA extracted was 32.5ng/μl (range 0.4-73.1ng/μl) but this measure 
did not correlate with area of tissue microdissected (Spearman’s rho 0.08, p=0.70) or
metastasis size as reported by the histopathologist (Spearman’s rho 0.25, p=0.31).
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Figure 5-1: Representative nodal sample before laser capture microdissection
(A) and following laser capture microdissection (B).
A.
B.
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5.4.2 Quality control measures, tissue characteristics and
performance of samples with the DASL assay
One nodal RNA sample, microdissected from a diagnostic H+E slide, was not sent for
DASL analysis because of low RNA concentration (0.37 ng/μl), therefore a total of 26 
nodal samples (including 2 replicate samples) were supplied to ServiceXS who
performed the DASL assay. The mean number of genes detected from nodal samples
(mean 242 (range 36-369)) was significantly less than number of genes detected from
primary tumours (mean 434 and 457 from the Cohort and SNB studies, respectively),
as reported in Chapter 3.
The characteristics of nodal samples and results of quality control measures are
summarized in Table 5-1. Neither the area of tissue microdissected, RNA
concentration as measured using spectrophotometry or cycle threshold (Ct) values
generated from qRT-PCR of RPL13a correlated with number of genes detected in the
DASL assay. However, the age of the FFPE tumour block (Spearman’s rho -0.50,
p=0.01) and the age of the tissue section prior to RNA extraction (Spearman’s rho -
0.51, p=0.01) both negatively correlated with number of genes detected (Table 5-1).
The mean number of genes detected from the oldest tumours (>4.47 years) was 72
less than from the newer specimens (<2.29 years) (Table 5-1)
The type of section used for tumour sampling also influenced the number of genes
detected (Table 5-2), with a lower proportion of samples failing the assay and a higher
mean number of genes detected in newly cut sections (280 genes) or diagnostic H+E
sections (301 genes) than from archival unstained sections (219 genes). The stored
unstained sections were stored without a cover slip at room temperature.
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Nodal samples
Associations between
sample factors and
number of genes
detected. Test statistic
and significance value.
Area of tissue microdissected,
median (range), μm2
Number of genes detected for
each quartile of area dissected,
mean (range):
<25%
25-50%
50-75%
>75%
223124 (157-6051771)
262 (182-365)
229 (167-275)
260 (209-314)
237 (166-369)
Spearman’s rho -0.18,
p=0.41
RNA concentrations, median
(range), ng/μl 
30.3 (0.4-73.1) Spearman’s rho 0.18,p=0.39
Ct value, median (range) 24.1 (20.8-25.2) Spearman’s rho -0.05,p=0.83
Age of tissue block, median
(range), years
Number of genes detected for
each quartile of block age,
mean (range):
<2.29 years
2.29-3.76 years
3.77-4.36 years
>4.47 years
3.8 (1.1-6.9)
299 (249-365)
253 (193-369)
217 (166-290)
227 (182-325)
Spearman’s rho -0.50,
p=0.01
Age of tissue slide (before RNA
extraction), median (range),
months
41.5 (0.3-75.5) Spearman’s rho -0.51,p=0.01
Slide type, number (mean
number of genes detected):
New section
Old unstained section
Diagnostic H+E slide
8 (280)
14 (219)
3 (301)
Kruskal-Wallis χ2 8.79,
p=0.01
Number of genes detected,
mean (range) 242 (36-369)
Table 5-1: Characteristics of nodal samples and extracted RNA.
Associations between these factors and the number of genes detected in the
DASL assay are presented. Significant results are highlighted in bold.
Abbreviations used: Ct, cycle threshold; H+E, haematoxylin and eosin.
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Table 5-2: Characteristics of sections used for tissue sampling.
The numbers of samples that yielded sufficient RNA for DASL analysis and were
successful with the assay are presented in addition to the mean number of genes
detected and area of tissue microdissected. Abbreviations used: H+E,
haematoxylin and eosin.
5.4.3 Exclusion of samples
As discussed previously, in the DASL assay, the number of genes detected in each
sample has been traditionally used as a measure of result quality with authors
excluding samples with <50% genes detected [294]. The number of genes detected in
nodal samples is much less than in primary samples (Figure 5-2) which from the
literature was expected in a biological sense, but might also reflect poorer quality of
gene expression data related to the smaller tissue sample. Based on the cumulative
distribution of the number of genes detected (Figure 5-2), nodal samples with <166
genes detected and primary samples with <400 genes detected were excluded from
further analyses. One nodal sample was excluded, however as this sample was a
replicate, data from the other specimen could be used for analysis. No primary
samples were excluded.
Slide type Number ofsamples
Number RNA
successfully
extracted and
sent for
analysis (%)
Number of
genes
detected,
mean (range)
Number
successful with
DASL (≥240 
genes detected)
(% of samples
assayed)
Area
microdissected
median (range),
μm2
Diagnostic
H+E slide 3 2 (67) 301 (236-365) 1 (50)
138253 (13529-
654932)
Archival
unstained
section
14 14 (100) 219 (166-325) 4 (29) 277555 (157-6051771)
New section 8 8 (100) 280 (227-369) 6 (75) 302413 (65346-2007508)
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Figure 5-2: Cumulative distribution of number of detected genes in nodal and
primary samples.
The cumulative distribution for primary samples is based on the larger sample
sets previously assessed with the DASL assay as described in Chapter 3.
To assess whether our approach of excluding nodal samples with <166 genes detected
was valid, we performed further analyses to identify genes differentially expressed
between matched samples when the threshold for detection was higher. Samples were
excluded when less than 240 genes were detected allowing assessment of 10 matched
pairs and less than 200 genes allowing assessment of 18 matched pairs. Reassuringly,
12 of the most differentially expressed genes (presented in Figure 5-4) identified in
these analyses matched those from the current analysis with MMP2 remaining the
gene most over-expressed in primary samples and CSF3 the gene most over-
expressed in nodal samples in all tumour pairs. This suggests that our results are
representative of a larger sample set and that exclusion of nodal samples with <250
genes detected as suggested by previous authors [294] is an over-conservative
approach to this particular analysis.
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5.4.4 Reproducibility and detected genes across reference RNA
samples
Across the two DASL runs, for the Cohort samples and the SNB primary and nodal
samples, gene expression profiles across the ten reference RNAs were reproducible
(Spearman’s rho 0.90-0.99 (p<0.00001)) and the mean number of genes detected in
reference RNA samples was 479 (Cohort study) and 472 (SNB study).
5.4.5 Genes detected across tissue types
Eight genes were not detected across all 10 reference RNA samples including genes
identified as being over-expressed in nodal samples in this analysis (CSF3, FGF3,
FGF6, FGF8 and MOS). I would argue this is because those genes were simply not
expressed in the reference RNA samples chosen rather than because of a
methodological issue. Only one gene (MYCL2) was not detected across all nodal
samples assessed and there were no genes that were not detected across the primary
samples assessed. The 502 genes on the Human Cancer panel were selected
because of their importance in the cancer literature and therefore it is not perhaps
surprising that some genes were not detected in the control RNAs but were seen in
nodal and primary samples from a particular cancer type.
5.4.6 Correlations between matched primary and nodal samples
Of the samples successfully yielding gene expression data, 22 had matched primary
samples for which gene expression data were available. Gene expression from 21 of
the matched pairs was correlated to varying degrees (Spearman’s rho 0.15-0.80, all
significance values ≤0.001) (Figure 5-3). 
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Figure 5-3: Association between gene expression levels for 502 genes from the
Human Cancer panel for a matched primary and nodal sample from the
same patient.
5.4.7 Genes differentially expressed in matched primary and nodal
pairs
Table 5-3 and Figure 5-4 present genes most differentially expressed between nodal
tumours and their matched primary tumours. For genes most over-expressed in nodal
tumours, 9 out of 10 genes were over-expressed in all nodal samples from all matched
pairs assessed (fold changes presented in Table 5-3). Gene expression data from
nodal samples were normalized with primary samples. As the number of genes
detected and pattern of gene expression differs between these tissue types,
normalization procedures will have altered the magnitude of expression differences
and absolute fold changes should be interpreted with caution.
A number of genes were differentially expressed in nodal metastases across all
matched pairs including genes involved cellular proliferation and survival (FGF3, FGF5,
FGF6 and FGF8).
Spearman’s rho 0.80
p<0.00001
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Higher gene
expression Gene
Mean fold difference
(nodes/primaries)
Min fold
change
across
matched
pairs
Max fold
change across
matched pairs
Primaries
MMP2 0.40 0.12 1.04
ETV6 0.41 0.17 1.17
PDGFRB 0.44 0.15 1.28
KIT 0.46 0.13 1.20
FYN 0.47 0.18 1.02
EMS1 0.47 0.10 1.42
PRCC 0.47 0.16 1.19
CREBBP 0.48 0.24 1.20
MXI1 0.48 0.02 1.10
GAS7 0.48 0.22 1.34
Nodes
CSF3 34.67 2.53 269.72
ERBB4 29.53 1.99 169.66
FGF3 26.22 2.96 160.62
PLG 25.63 4.33 162.57
PLA2G2A 15.90 1.65 196.99
MOS 15.27 0.92 32.04
FGF8 15.01 1.41 77.26
TFF1 14.09 2.41 45.97
FGF6 13.74 5.26 38.00
FGF5 13.34 2.30 84.54
Table 5-3: Genes most differentially expressed across matched primary and
sentinel node biopsy samples.
The mean fold difference in gene expression between nodal and primary samples
and range of fold differences across 22 matched pairs is presented.
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Figure 5-4: Genes most differentially expressed across matched primary and
sentinel node biopsy samples.
Box-plots are presented for genes most over-expressed in primary (A) and nodal
(B) samples. Outside values are excluded for clarity from graph B.
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5.4.8 Patient and primary tumour characteristics
To provide some information regarding the final sample set analysed for this study,
details of patients and key tumour characteristics are presented in Table 5-4.
Characteristic
Breslow thickness, mm, median (range) 2.6 (0.9-6.0)
Mitotic rate, mm2, median (range) 9 (1-39)
Ulceration, number (%):
Absent
Present
Not recorded
14 (63.6)
7 (31.8)
1 (4.6)
Histological subtype, number (%):
Superficial spreading
Nodular
Other
Not recorded
15 (68.2)
2 (9.1)
3 (13.6)
2 (9.1)
Tumour site, number (%):
Trunk
Leg
Arm
Head or neck
Sun-protected site
9 (40.9)
8 (36.4)
1 (4.6)
3 (13.6)
1 (4.6)
Age at diagnosis, years, median (range): 56.8 (23.2-77.7)
Patient gender, number (%):
Female
Male
10 (45.5)
12 (54.5)
Relapse status, number (%):
Not relapsed
Relapsed
13 (59.1)
9 (40.9)
Relapse-free survival time, years, median (range) 2.7 (0.2-6.0)
Survival status, number (%):
Alive
Died
12 (54.6)
10 (45.5)
Overall survival time, years, median (range) 3.4 (0.7-6.0)
Table 5-4: Clinical characteristics of patients and key primary tumour
histological features of the samples assessed in analysis of matched
primary and sentinel node biopsy specimens.
In primary samples used in this analysis, the median Breslow thickness (2.6mm),
mitotic rate (9/mm2) and proportion of ulcerated tumours (32%) were greater than in the
larger sample sets used for gene expression analysis in Chapter 3, reflecting the fact
that these patients had higher risk disease associated with a positive sentinel node
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biopsy. This is also reflected by the high proportion of patients who subsequently
relapsed (41%) and died (46%). Most tumours were of the commonest superficial
spreading subtype (68%) and from the trunk (41%) or leg (36%) in common with the
larger gene expression sample set. There were more men than women in this sample
set (55% and 45%, respectively).
5.5 Discussion
5.5.1 Use of the DASL assay with small sentinel node biopsy
samples
This pilot study had a number of aims, the first of which was to identify the lower limits
of volume of small tumour samples which can be used to generate gene expression
data from the DASL assay. A deposit reported as being only 8 cells in size provided
data, suggesting that very small FFPE tumour samples can be used to assess gene
expression.
Quality control measures have been used to assess the relative performance in
primary versus smaller nodal tumours. The traditional measure of performance is the
total number of genes detected and in this respect, the assay did not perform as well
with these samples as with RNA extracted from larger primary tissue cores. Other
studies however provide some evidence to support the view that the number of genes
expressed in metastases is smaller than in primaries, consistent perhaps with Fidler’s
hypothesis that metastases occur from sub clones of the primary [513, 514]. Previous
gene expression studies in melanoma furthermore have demonstrated that the
predominant change in advanced malignancy is decreased gene expression [176,
193]. Decreased expression has also been found in less advanced SNB metastases in
comparison with primary tumours [510]. Therefore, number of genes detected may not
be the best measure of assay performance and consequently we have included all
nodal samples with a reasonable number of detected genes in this analysis.
Despite the problems using number of detected genes as a quality control measure,
there are no other options for assessing the performance of a sample with the DASL
assay. It is likely that a smaller number of genes would be detected in a poorly
performing sample relative to other samples of the same tissue type, therefore we have
used this measure to assess current RNA quality control measures. I found no
relationship between the number of detected genes and RNA concentration by
spectrophotometry or Ct values generated using qRT-PCR of RPL13a. We did find that
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the age of the tissue sample and the age of tissue section used for sampling influenced
the number of detected genes, suggesting that newer tissue blocks with freshly cut
sections would be most likely to yield gene expression data. Previous published
studies using the DASL assay have used a number of tissue sections with or without
macrodissection or tissue cores for RNA extraction [296, 297, 474, 475], therefore it is
likely that use of a larger number of freshly cut tissue sections for microdissection may
have yielded better results. Previous evidence suggests that measures such as storing
sections at 4oC or coating with paraffin preserves tissue antigenicity for use in
immunohistochemistry [515, 516]. This work supports the hypothesis that similar
measures may also preserve utility of stored cut sections for genomic work.
5.5.2 Genes differentially expressed in matched primary and SNB
samples
Gene expression data derived from SNB samples were compared with those from
matched primary tumour from the same patient. There was good correlation overall
between gene expression profiles from matched primary and nodal samples as has
been reported previously in a number of tumour types including melanoma [507, 508,
514, 517], which is reassuring methodologically. However, there were some interesting
differences. Significant differences in gene expression profiles between primary
tumours and matched metastases have been identified in melanoma [510], breast
[518, 519] and colorectal cancer [520, 521] previously and in this current study a
number of genes were differentially expressed in nodal metastases across all 10
matched pairs assessed. Genes coding for fibroblast growth factors were amongst
these genes.
Fibroblast growth factors (FGFs) signal through FGF receptors (FGFRs) and regulate
developmental pathways as well as wound repair and angiogenesis [522]. With broad
mitogenic and angiogenic activities [523], FGFs are frequently overexpressed in a
number of tumour types [524-526]. Furthermore, increased expression of FGF3 and
FGF8 has been associated with higher grades of prostate cancer [527] and recurrence
of hepatocellular carcinoma [528]. In melanoma, there has been interest in FGF2 as
there is over-expression of FGF2 protein and FGF2 transcripts in melanoma cell lines
compared to melanocytes [529, 530] and in melanoma tumours [531]. Over-expression
of FGF2 leads to transformation of melanocytes [532], with inhibition leading to
regression of tumours in mice due to lack of angiogenesis in the tumour [533]. It has
also been shown that FGF5 transcripts and FGF5 protein are also over-expressed in
cell lines compared to normal melanocytes [530]. There is little in the literature
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investigating the function or expression levels of FGF3, FGF6 and FGF8 in melanoma
cells, however this group of molecules is closely related to tumourigenesis and
progression suggesting that over-expression of this family of genes may represent an
important step in the early metastatic processes of malignant melanoma, which
warrants further investigation in a larger sample set.
This study also identified lower expression of matrix metalloproteinase-2 (MMP2) in the
majority of nodal samples compared to their matched primaries. Interestingly, Koh and
colleagues also identified under-expression of another matrix metalloproteinase
(MMP1) in SNB samples in their study of matched primary and SNB samples [510].
Matrix metalloproteinases degrade extracellular matrix causing release of growth
factors and cytokines. Consequently, they are important in invasion and metastasis
and regulate cell growth, survival, angiogenesis and inflammation [534, 535]. MMP2 is
a gelatinase, along with MMP9 which can lyse numerous components of extracellular
matrix [534]. A meta-analysis of studies aiming to identify protein markers of melanoma
progression, found that over-expression of MMP2 in primary tumours was associated
with poorer prognosis [160, 169]. There is also evidence that MMP2 expression
increases as melanocytic tumours become more atypical [536]. There have been
suggestions however that the predominant source of MMP2 is not tumour, but stromal
cells [537, 538]. In a syngenic in vivo mouse model which spontaneously develops
metastases, MMP2 was predominantly expressed by stromal cells at the border
between tumour and stroma of subcutaneous tumours, however in spontaneous lymph
node or lung metastases, tumour and stromal cells were largely negative for MMP2
[538]. Therefore, the data reported in the literature suggest that increased expression
detected in the primary tumours in my study relative to that in nodal metastases might
in fact reflect overexpression by stromal cells in primaries destined to metastasise to
nodes.
The gene most over-expressed in nodal tumours compared to primary tumours was
CSF3 which codes for granulocyte colony stimulating factor (GCSF). GCSF is
predominantly produced by immune cells, but also endothelium, and stimulates bone
marrow to produce granulocytes, such as neutrophils, and release them into the blood
[539, 540]. This finding may reveal a potential problem when trying to sample tiny
melanoma deposits from lymphoid tissue full of lymphocytes. The range of fold change
in gene expression across the sample set in nodal samples compared to primary
samples is very wide for CSF3 (2.5-269.7) and the box-plot in Figure 5-4 shows the
great range of fold changes. Very high levels of CSF3 in some nodal samples may be
related to sampling of immune cells from nodal tissue as well as tumour cells. It could
be hypothesized that lymphocytes would up-regulate CSF3 expression markedly in
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response to tumour invading the lymph node. Sampling was carried out under the
supervision of a expert dermatopathologist, however single tumour cells can reside
amongst numerous lymphocytes making sampling difficult even when using fresh
tissue sections on slides specifically designed for LCM. In this study, the majority of
sections were archival sections on normal glass slides, therefore multiple laser pulses
were used to remove tissue piece by piece reducing the accuracy of sampling further.
Use of fresh tissue samples on slides designed to allow accurate sampling of intact
tumour deposits would improve accuracy in future studies. In summary, greater
expression of CSF3 in the nodal samples may simply reflect contamination by
inflammatory cells even in these laser microdissected samples.
It is important to acknowledge that the patient and primary tumour characteristics of
this sample set were not representative of our larger cohort, reflecting the small
numbers of samples assessed and the fact that all these patients had a positive SNB
associated with poor prognostic factors. Therefore the applicability of these gene
expression results to better prognosis tumours is limited.
This study is clearly also limited by the small number of samples assessed and the
number of additional factors present in the study design that influence performance
with the assay, such as age of tissue block, differences in tissue age between matched
samples and sample availability for microdissection. Factors such as age of tissue
blocks will continue to be a challenge for studies using FFPE tissue, but this work
indicates that use of new sections yields superior results over archival unstained
sections, and that storage of sections may be critical, storage under paraffin or a cover
slip at 4oC would appear sensible.
In summary, this study demonstrates that very small, laser dissected, FFPE SNB
samples can be used for RNA extraction for gene expression analysis, although with a
higher fail rate than with larger samples, as defined by number of genes detected
overall. The study produced interesting data on a possible role for FGFs in metastasis
which should be explored in larger studies. The work also reflects the observation
made by others that gene expression profiles may reflect expression by non-tumour
cells [301, 302]. Further work will help clarify which sample characteristics will predict
performance with the DASL assay and enable more extensive studies to assess
alterations in gene expression profiles between primary and early metastatic tumours
from the same patient.
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6 Identification of associations between somatic mutations in
BRAF and NRAS in formalin-fixed melanoma tumours,
clinico-pathological factors and gene expression profiles
6.1 Aims
The aims of this chapter are:
 To identify mutations in BRAF and NRAS in a large number of formalin-fixed
paraffin-embedded (FFPE) primary melanoma tumours.
 To identify tumour or patient characteristics associated with these mutations.
 To identify gene expression profiles associated with BRAF or NRAS mutation
status.
The secondary aims were:
 To assess use of cDNA, generated in the course of gene expression studies in
primary melanoma, rather than DNA as a substrate for mutation screening to
maximise use of precious tumour material.
6.2 Background
The mitogen-activated protein kinase (MAPK) pathway (Figure 6-1) is a key signalling
pathway activated in melanoma, which regulates a number of processes within cancer
cells including cell survival, growth and migration [28, 29].
RAS is membrane bound and is activated by cytokines, growth factors and hormones
[29]. RAS activates three closely related RAF proteins, ARAF, BRAF and CRAF, which
when activated phosphorylate the MAP-kinases, Mek1 and Mek2, which then
phosphorylate and activate Erk1 and Erk2 [30, 541] (Figure 6-1). Erk protein kinase
activation regulates cellular proliferation, survival, invasion, differentiation and
apoptosis [30, 541].
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Figure 6-1: The mitogen-activated protein kinase (MAPK) and
phosphatidylinositol-3-kinase (PI3K) pathways.
NRAS mutations activate both pathways. The MAPK pathway can also be
activated by mutations in BRAF. In addition, ERK can be constitutively active in
absence of NRAS and BRAF mutations. The PI3K-Akt pathway may be activated
by loss of the inhibitory function of PTEN, or by gene amplification of AKT3 [35].
Figure adapted from [541].
Mutations in genes within this pathway are frequently found in melanoma tumours and
in this chapter, I will present my work identifying BRAF and NRAS mutations in FFPE
tumours and an investigation of the clinico-pathological features and gene expression
profiles associated with these mutations.
The reported frequency of BRAF mutations in melanoma tumours is variable ranging
from 20-80%, however a recent meta-analysis of studies published between 1989 and
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2010 found BRAF mutations in 41% of melanomas [30, 31]. A large proportion of
mutations are due to a single substitution where adenine (A) replaces thymine (T) in
codon 600 of exon 15 (V600E, c.1799T>A) leading to substitution of glutamic acid for
valine [30, 32].
It is unclear why this site is so frequently mutated. BRAF mutations have been
demonstrated in acquired melanocytic naevi (incidence of 21-82% in larger series) [25,
542] and naevus number is strongly associated with sunny holidays [15] so induction
by sun exposure seems logical. However the T>A substitution is not characteristic of
the cytosine (C)>T and CC>>TT pyrimidine dimer mutations more commonly found
following UVB-damage [541, 543]. There have been suggestions that mutations may
occur secondary to UVB-induced DNA photoproducts and subsequent errors in DNA
synthesis which develop near to the V600 site [544]. There has also been some
evidence that UVA, which is the predominant portion of sunlight, can trigger
photosensitization reactions causing oxidative DNA damage, typical UV-induced DNA
lesions and DNA cross-links [545, 546]. These lesions can lead to mutations, such as
BRAF V600 mutations, in experimental systems [545]. Further support for the role of
UVA is that V600E mutations are also common in colonic cancers in which oxidative
stress is thought to play an aetiological role [32, 547, 548]. Despite these findings, the
relationship between sunlight and development of BRAF mutations is still unclear.
Until relatively recently, V600E mutations were thought to account for over 90% of
BRAF mutations, however studies have found that the V600K mutation
(c.1798_1799delinsAA) can account for up to 30% of mutations in melanoma tumours
[549-551]. The majority of BRAF mutations destabilize the structure of inactive BRAF
kinase domains leading to activation and higher protein kinase activity causing
activation of the MAPK pathway [32, 35, 552-555], along with insensitivity to negative
feedback mechanisms [556]. V600E mutations can transform immortalized
melanocytes [557] and cause growth and improved survival in melanoma cells in vitro,
with inhibition of mutant BRAF in vivo leading to delay in tumour growth [558, 559].
Mutant BRAF also appears to have a role in angiogenesis, as blockade of mutant
BRAF activity prevents further vascular development in established tumours via
decreased secretion of vascular endothelial growth factor [560]. In mice, expression of
BRAFV600E in melanocytes at physiological levels, cause naevus development, which
after a period of latency can develop into melanoma tumours [561]. However, when
PTEN is lost in addition to BRAFV600E expression, metastatic tumours develop quickly in
all cases [562].
In humans, the fact that V600E BRAF mutations are commonly found in naevi is
consistent with the view that those mutations drive proliferation. The majority of
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melanocytes however subsequently senesce and there is evidence that in the normal
cell, BRAFV600E induces tumour suppressor proteins such as p16INK4a which mediate
the senescence of those melanocytes [36, 37]. Therefore, it appears that additional
factors are required to act alongside mutated BRAF to cause progression to melanoma
[563]. Animal data described above suggest that loss of PTEN is a potent means of
inducing progression.
With regards to the morphological features of tumours, primary BRAF mutated tumours
have been reported to have distinct appearances with larger, rounder and more
pigmented tumour cells with increased upward scatter and nest formation of
intraepithelial melanocytes [564]. The tumours are also associated with thickened
epidermis and are more clearly circumscribed [564]. These features suggest that BRAF
mutated tumours are biologically distinct which may prove to be reflected in gene
expression profiles that differ to those of wild-type tumours.
Recently, the BRAF kinase inhibitor (BRAFi), vemurafenib, has been developed which
has been shown to prolong progression-free and overall survival with a relative
reduction of 74% in risk of either death or disease progression and a 48% response
rate in patients with metastatic melanoma with a BRAF V600E mutation versus
standard care with dacarbazine [199]. Vemurafenib also appears to produce clinical
responses in patients with tumours harbouring the rarer V600K mutation [565].
Although relapse rapidly occurs in the majority of treated patients, this represents a
major development in the treatment of advanced melanoma, where previous treatment
achieved poor responses rates [243, 244] and highlights the importance of this
pathway in melanoma development and progression. In tumours without BRAF
mutations, there are usually mutations elsewhere in the MAPK pathway, such as NRAS
in cutaneous melanomas (18%) [30, 31], KIT in acral or mucosal melanomas [33] and
GNAQ in uveal melanomas [34].
The NRAS protein is encoded by one of the three RAS genes which encode four RAS
proteins, HRAS, KRAS4A, KRAS4B and NRAS [566]. The NRAS gene is also
frequently mutated in melanoma tumours with mutations most commonly occurring in
codon 61 of exon 3 [30]. Again these mutations are not characteristic of UV-induced
changes, but codon 61 preferentially forms pyrimidine dimer mutations following
exposure to UV radiation and following transfection into a non-tumourigenic rat
fibroblast cell line, Q61R and Q61R mutations develop, similar to those found in
melanoma samples [567, 568]. Other sites which rarely form these dimers are codons
12 and 13, where again NRAS mutations are found [568]. NRAS mutations cause
constitutive activation of the MAPK pathway [31] and in addition to signalling via RAF
proteins, mutant NRAS can increase signalling via the phosphatidylinositol-3-kinase
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(PI3K) pathway, the Ral guanine exchange factors (RalGEFs) and other signal
transduction pathways [569-571]. Mutant RAS has transforming ability in a variety of
cell types [572]. Many studies of RAS in melanoma models have used transgenic
expression of HRAS, but have shown that RAS mutations alone are insufficient to
cause melanomas in mice [573, 574] . However in a melanoma mouse model null for
the tumour suppressor, p16INK4a, expression of mutant HRAS in melanocytes leads to
melanoma development [574]. In this model, subsequent loss of activated HRAS in
established tumours leads to tumour shrinkage, suggesting that HRAS is required for
tumour maintenance [575].
That BRAF mutations are commonly found in benign or dysplastic naevi and NRAS or
BRAF mutations are generally maintained in paired primary and metastatic samples [2,
25, 576] has led to the suggestion that these mutations occur early in melanoma
development [18]. Despite the early appearance of mutations, there is evidence
however to suggest that the proportion of mutated cells increases as a melanoma
becomes increasing invasive, for example in tumours moving from the radial to vertical
growth phase or when they metastasise [577-579].
Generally, BRAF and NRAS mutations are not found in the same tumour [32, 541].
However, infrequent double mutations have been identified in naevi [25], melanoma
cell lines [580, 581], melanomas from patients with germline CDKN2A mutations [582]
and in small numbers of primary and metastatic melanomas [550, 577, 583]. Recent
studies have demonstrated that primary melanomas, naevi and circulating tumour cells
display heterogeneity, with some cells harbouring mutant BRAF and others wild-type
BRAF [357, 579, 584-586]. Therefore, as the presence of both an NRAS and BRAF
mutation does not confer any advantage in a single cell and has not been identified
[580], detection of double mutations within a tumour may represent heterogeneity, with
some cell clones containing mutant NRAS and others mutant BRAF [25].
A numbers of studies have attempted to identify relationships between tumour features,
patient characteristics and mutation status. These findings are summarised in Table
6-1. It is clear in a large meta-analysis of studies involving tumours from 4493 patients
that tumours with BRAF mutations are more commonly of the superficial spreading
subtype in sun-protected sites, with NRAS mutations being more commonly found in
tumours of the nodular subtype in sun-exposed sites [30, 31]. There is also strong
evidence that patients with BRAF mutated tumours are diagnosed at a younger age
than patients with wild-type tumours [549, 587, 588].
Tumour or
patient
characteristic
Association with BRAF
mutations
Association with NRAS
mutations Strength of evidence References
Histological
subtype
Commoner in superficial
spreading melanomas
Commoner in nodular
melanomas
Meta-analysis of data from primary melanomas from
4493 patients (studies from 1989-2010) [31]
Tumour site Commoner on intermittentlysun-exposed skin, e.g. trunk
Commoner on sun-
exposed sites e.g. head or
neck, extremities
Meta-analysis of data from primary melanomas from
4493 patients (studies from 1989-2010) [31]
Patient age at
diagnosis
Younger age at diagnosis
than patients with wild-type
tumours
No associations identified
BRAF mutations identified in FFPE metastatic tumours
from 197 patients with unresectable stage IIIC or IV
melanoma
BRAF mutations identified in primary melanoma
tumours from 544 patients
NRAS and BRAF mutations identified in 365 primary
melanoma tumours
[549]
[587]
[588]
Primary tumour
mitoses
More common in primary
tumour when BRAF
mutation found in metastatic
tumour
Higher mitotic rate
compared to BRAF
mutated or wild-type
tumours
BRAF mutations identified in FFPE metastatic tumours
from 197 patients with unresectable stage IIIC or IV
melanoma
NRAS and BRAF mutations identified in primary
melanoma tumours from 249 patients
[549]
[589]
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Tumour or
patient
characteristic
Association with BRAF
mutations
Association with NRAS
mutations Strength of evidence References
Primary tumour
Breslow thickness
Greater than in wild-type
tumours
Greater than in BRAF
mutated or wild-type
tumours
NRAS and BRAF mutations identified in primary
melanoma tumours from 249 patients
NRAS and BRAF mutations identified in 223 primary
melanoma tumours
[589]
[583]
Primary tumour
ulceration
Increased incidence
compared to NRAS mutated
or wild-type tumours
No associations identified NRAS and BRAF mutations identified in 223 primarymelanoma tumours [583]
Stage at diagnosis
More likely to present with
stage III (nodal metastases)
disease than wild-type
tumours
More likely to present with
stage III disease (nodal
metastases) than wild-type
tumours
NRAS and BRAF mutations identified in 223 primary
melanoma tumours [583]
Table 6-1: Patient and tumour characteristics associated with BRAF or NRAS mutations in melanoma tumours.
Associations between mutation status and tumour or patient characteristics are presented with details of the studies describing these
relationships. Where data from meta-analyses is available, this has been referenced in preference to single studies.
-177
-
- 178 -
It is generally accepted that there is no relationship between BRAF or NRAS mutation
status in primary tumours and either relapse-free survival or overall survival in
melanoma patients [436, 555, 576, 583, 588, 590, 591]. An exception to this is in
metastatic melanoma (stage III and IV), where there does appear to be some
association with mutation status and survival. This was initially noted by Houben and
colleagues where mutations were identified in 86 metastatic lesions and the presence
of a BRAF or NRAS mutation was associated with shorter survival, whereas mutations
in 114 primary melanoma tumours did not impact on progression-free or overall
survival [555]. This has been subsequently confirmed in other studies [186, 549, 550,
592].
In summary, there is evidence that presence of a BRAF or NRAS mutation is
associated with tumour histological subtype, tumour site and age at diagnosis.
Presence of mutations in metastatic tumour negatively impacts survival, with no
association between survival when a mutation is identified in the primary tumour.
There has been increasing interest in the biological relevance of non-V600E BRAF
mutations. Menzies and colleagues obtained BRAF mutation status preferentially from
FFPE metastatic melanoma tissue for 308 patients [593]. Mutations were identified in
tumours from 46% of patients, with 73% being V600E mutations and 10% V600K
mutations. The authors determined the prevalence of BRAF mutations according to
each decade of diagnosis. In common with findings in primary melanoma, presence of
a BRAF mutation was associated with a significantly younger age at diagnosis of
metastatic disease, however the proportion of mutations which were not V600E,
including V600K mutations, increased with each age-decade of diagnosis. There was
no difference in the age of diagnosis between patients with wild-type tumours or V600K
mutated tumours. The study also found increased evidence of cumulative sun damage,
as determined by degree of solar elastosis, in skin from patients with V600K mutated
tumours, but not V600E mutations which correlated with their finding that V600K
mutant tumours were found more commonly on the head and neck, typically a sun-
exposed site, with V600E tumours on the limbs. The distant metastasis disease-free
period from diagnosis of the primary tumour was shorter for patients with a V600K
mutation versus a V600E mutation, but there was no difference in overall survival. The
number of V600K mutations identified in this study was 27, therefore these analyses
were based on limited numbers, however these findings suggest that V600K mutations
may have a different aetiology and behaviour to V600E mutations [593]. In a study
where 229 tumour specimens were genotyped from patients with advanced cancer,
168 of which had melanoma, 13 V600K mutations were detected, one in a patient with
colorectal cancer and the rest in melanoma tumours. Presence of a V600K mutation
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was associated with more brain and lung metastases, earlier metastasis and shorter
overall survival following diagnosis [594]. These data albeit in relatively small studies
suggest that the V600K mutant may be biologically more deleterious than the V600E
mutation. In common with V600E mutations, V600K mutations cause elevated kinase
activity and ERK activation, but there is evidence that the kinase activity associated
with V600K mutations is lower than that of V600E mutations [554]. Reduced survival
associated with V600K mutations maybe related to modified kinase activity along with
other, as yet unidentified, factors.
It is important to consider both the pathogenesis of melanomas driven by different
oncogenes and the impact on biological pathways. The importance of fully
understanding how BRAF and NRAS mutations alter downstream biological pathways
is particularly important with the development of BRAFi which offer the first major
targeted treatment option for advanced melanoma. Despite the initial responses seen
with vemurafenib, treatment is associated with side effects, such as development of
cutaneous squamous cell carcinomas and keratoacanthomas [199, 206]. Of greater
concern, is that resistance to vemurafenib almost invariably develops and
understanding the mechanism by which a BRAF mutation modifies gene expression
will greatly assist the intensive efforts currently underway investigating mechanisms of
resistance [199, 206, 242].
A number of studies have attempted to identify gene expression signatures related to
mutation status using melanoma cell lines and frozen tumour specimens as
summarised in Table 6-2. Another approach has been to study gene expression in
melanocytes where activated BRAFV600E has been introduced, this work has identified
over-expression of genes involved in cell growth and motility, inflammation and
apoptosis including matrix metalloproteinase-1 (MMP1) [595]. As technologies have
developed, cDNA sequencing (RNA-seq) has been used to compare gene expression
in normal human melanocytes with and without BRAFV600E expression and two V600E
BRAF mutated tumours to identify genes more specifically altered in cancer tissues
[196]. BRAFV600E was associated with differential expression of 1027 protein-coding
transcripts along with other unannotated transcripts, which were thought to represent
new unidentified long non-coding RNAs (lncRNA) and specifically highlighted BANCR
as a lncRNA which potentially regulated melanoma cell migration [196].
Study design and
sample type
Number and
type of
samples
Comparisons
made Analysis method Significant results References
Cell lines genotyped for
BRAF and NRAS and
gene expression
assessed with 18,107
microarray.
61 cell lines. BRAF mutant
versus wild-type
and NRAS mutant
versus wild-type
cell lines.
Mann-Whitney U test to
compare groups and support
vector machines to develop a
classifier to predict presence of
BRAF mutations.
135 differentially expressed clones in BRAF mutant
samples, 48 in NRAS mutant samples with 19
clones overlapping.
Differential expression of genes encoding enzymes
which regulate signal transduction pathways, e.g.
protein tyrosine phosphatase receptor type A
(PTPRA).
[596]
Cell lines genotyped for
BRAF and NRAS and
gene expression
assessed with
microarray targeting
22,277 transcripts
(Affymetrix HG-U133A
2.0).
10 cell lines. BRAF mutant
versus NRAS
mutant versus
wild-type cell
lines.
Pairwise comparisons, SAMic
and marker analysis to identify
genes correlated with a
genotype.
61 differentially expressed genes in BRAF mutated
samples and 109 in NRAS mutant samples with 56
overlapping.
Genes which encode regulators of the MAPK
pathway and genes involved in metastasis or
invasion were differentially expressed.
[597]
Cells genotyped for
BRAF and NRAS and
gene expression
assessed with Affymetrix
microarrays (various HG-
U133 arrays).
86 melanoma
cell lines.
BRAF mutant
versus NRAS
mutant versus
wild-type cell
lines.
ANOVA with correction for
multiple testing, hierarchical
clustering.
No differentially expressed genes.
Data from study of Pavey and colleagues was
reanalysed using correction for multiple testing and
only one gene differentially expressed (identity not
reported).
[598]
Mutations in BRAF
identified and whole-
genome Affymetrix
microarray (HG-U133
plus 2.0).
63 melanoma
cell lines.
BRAF mutant
versus wild-type.
Support vector machines to
develop a classifier to identify
BRAF mutations and SAMic.
Classifier identified in two thirds of samples and
validated in the other third. Classifier predicted
BRAF mutation status in a subset of the dataset
from Hoek and colleagues.
Overexpressed genes included T box 3 (TBX3),
SPRY domain containing 5 (SPRYD5) and v-erb-b2
erythroblastic leukaemia viral oncogene homolog 3
(ERBB3).
[599]
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Study design and
sample type
Number and
type of
samples
Comparisons
made Analysis method Significant results References
BRAF and NRAS
mutations identified and
whole-genome Agilent
array was used for gene
expression profiling.
69 frozen
primary
melanomas.
BRAF mutant
versus wild-type.
Two-sample t-test with control
of the false discovery rate.
34 genes overexpressed in BRAF mutated tumours,
including genes involved in immune responses and
cell motility. These genes were not differentially
expressed in NRAS mutated tumours.
[591]
BRAF and NRAS
mutations identified and
expression profiling
using the Affymetrix HG-
U133 plus 2.0 (main
study aim to determine if
a single metastatic lesion
has a similar expression
profile to other lesions to
allow use of a single
lesion to determine
responsiveness to
chemotherapy).
55 frozen in-
transit
metastatic
melanomas
from 29
patients.
BRAF mutant
versus NRAS
mutant versus
wild-type tumours.
Unsupervised hierarchical
clustering, ANOVA and
regression.
Unsupervised hierarchical clustering revealed two
groups with one group containing BRAF mutated
tumours and the other NRAS mutated tumours or
wild type BRAF genes. 2168 genes correlated with
mutation status including under-expression of
micropthalmia-associated transcription factor
(MITF) and a member of the transient receptor
potential cation channel family (TRPM1) in mutant
tumours.
Top 200 differentially expressed genes similarly
expressed in BRAF mutant and NRAS mutant
tumours.
[508]
Table 6-2: Summary of studies assessing gene expression profiles in tumours with BRAF or NRAS mutations.
Abbreviations used: SAMic, significance analysis of microarrays; MAPK, mitogen-activated protein kinase; ANOVA, analysis of variance.
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To summarise gene expression studies, there has been much variation in reported
gene profiles in mutant tumours which is likely to reflect tumour heterogeneity in
association with different analysis methods and small numbers of samples assessed.
The identification of gene expression profiles associated with NRAS mutated tumours
has been particularly limited because of the lower frequency of mutations in melanoma
cell lines and tumours. Where differentially expressed genes have been identified in
mutant tumours, genes fall into common themes such as those involved in cell growth
and motility [196, 591, 595, 597, 599] and regulators of the MAPK pathway [597, 599].
There has been some overlap in differentially expressed genes in BRAF and NRAS
mutated tumours, perhaps reflecting similar alterations in biological pathways [508,
596, 597]. The exception to this statement is the study by Kannengiesser and
colleagues which found no overlap in gene expression profiles of BRAF and NRAS
mutated genes in the largest study of primary melanomas to date [591]. Use of FFPE
tissue, as in the current study, will allow assessment of a larger number of tumours to
identify gene expression signatures associated with BRAF and NRAS mutation status.
This chapter presents BRAF and NRAS mutation results from FFPE primary melanoma
sample sets previously used for gene expression work in Chapters 3 and 4. I report the
identification of BRAF and NRAS mutation status of primary melanomas and
subsequent studies performed in order to identify patient and tumour factors which are
associated with these mutations. Furthermore, mutation associated gene expression
profiles were identified in the largest study of primary melanoma tumours to date and
the only study using FFPE tissue.
The main method used for BRAF and NRAS mutation testing described in this chapter
was pyrosequencing. This method is described in detail in Chapter 2, but briefly the
technique uses primers to direct a polymerase extension reaction where nucleotides
are added sequentially to the reaction and incorporation of a nucleotide causes light to
be released which is detected to determine the DNA sequence [352-355]. This
technique has been shown to be more sensitive than Sanger sequencing for detecting
the V600E BRAF mutation [356] and has been previously used by a number of groups
to identify BRAF and NRAS mutations in FFPE and frozen melanoma tissues [353,
356, 436, 600]. In order to preserve precious stocks of tumour DNA, mutation
screening of NRAS and BRAF has been attempted using cDNA produced as part of
concurrent gene expression studies and these results are also presented.
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6.3 Identification of BRAF and NRAS mutations in FFPE
primary melanoma tumours
6.3.1 Detailed methodology
6.3.1.1 Patients and samples
FFPE melanoma metastases and cell line samples were used for initial methodological
testing; these sample sets are described further in Chapter 2. From metastatic
samples, RNA was extracted from a single tissue core using the Roche High Pure RNA
Paraffin Kit, cDNA was generated using 200ng of RNA using the Invitrogen
Superscript™ First-strand synthesis system using a modified protocol. DNA was
extracted from a single tissue core from the same tumour block used for RNA
extraction using the Qiagen QIAamp DNA FFPE kit. RNA was extracted from pelleted
cells of SkMel28 and MeWo melanoma cell lines using the Qiagen RNeasy® Mini kit.
cDNA was generated using the standard protocol and one microgram of RNA using the
Invitrogen Superscript™ First-strand synthesis system. DNA was extracted from
pelleted cells of cell lines from the same flask used for RNA extraction using the
Qiagen QIAamp DNA Mini kit. Details of extraction and cDNA synthesis methods used
are included in Chapter 2.
Samples for the larger study were from patient study sets described in Chapter 3.
cDNA had been synthesised from tumour RNA for use in gene expression studies from
patients recruited to the Leeds Melanoma Cohort Study (Cohort Study) and a small
number of samples from patients recruited to the Retrospective Sentinel Node Biopsy
Study (SNB study) using the Invitrogen Superscript™ First-strand cDNA system using
a modified protocol as described in Chapter 2. This stored cDNA was used to test the
feasibility of using cDNA for mutation screening. DNA was extracted from available
tumour tissue cores from patients recruited to both the Cohort and SNB study using
either the Qiagen QIAamp DNA FFPE kit or the Qiagen AllPrep® RNA/DNA FFPE kit
using methods described in Chapter 2 for mutation testing using DNA.
6.3.1.2 BRAF and NRAS mutation detection
Using methods described in Chapter 2, pyrosequencing was initially used to identify
common BRAF and NRAS mutations in cDNA from melanoma metastases, cell line
samples and the larger cohort of primary tumour samples. All pyrosequencing analyses
were performed by Dr Phil Chambers in the Genomics Facility, Cancer Research UK
Centre, Leeds Institute of Molecular Medicine. The “mutation percentage” calculated
from pyrosequencing data reflects the number of mutated alleles in cells assessed, but
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as tumour is heterogeneous it will also reflect the number of non-mutated tumour cells
along with contaminating normal stromal cells. Pyrosequencing analysis was repeated
using DNA from metastases samples and cell lines. For the larger study, cDNA and
DNA from a proportion of samples were screened for BRAF and NRAS mutations using
the Applied Biosystems PRISM® SNaPshotTM Multiplex system using methods
described in Chapter 2 to confirm results from pyrosequencing. SNaPshot analysis was
performed by myself. Finally, the BRAF and NRAS mutation status of DNA from
samples in the larger cohort were assessed using pyrosequencing.
Correlations between percentage mutation results between cDNA and matched DNA
samples were assessed using Spearman’s rank correlation.
6.3.1.3 Identification of patient and tumour factors associated with
mutation status
Patient factors and histological characteristics of the primary tumour were compared
between samples with differing mutation status using Pearson’s Chi squared (χ2) tests
or Fisher’s exact test (where the frequency of observations in a subgroup was less than
5) for categorical variables and Kruskal-Wallis tests for continuous variables. For
survival analysis, relapse-free survival (RFS) was defined as the period between
diagnosis and date of first relapse at any site. Death from any cause was used for
overall survival analyses with death from melanoma only used for melanoma-specific
survival. Analysis was performed on the 19th December 2011 and survival data were
censored at this date. Associations between mutation status and survival were
assessed using plots of Kaplan-Meier estimates of survival function. Furthermore,
survival analysis was performed using the Cox proportional hazards model to calculate
hazard ratios and 95% confidence intervals for each group of patients with tumours of a
particular genotype. Analysis was performed unadjusted and adjusted for factors of
prognostic importance in melanoma. A significance level of 0.05 was set for these
analyses.
6.3.1.4 Identification of gene expression profiles associated with mutation
status
Gene expression data were generated using the Illumina DASL Human Cancer panel
and the merged dataset from the Cohort and SNB studies as described in Chapter 4.
Differential gene expression analysis was performed using data which had been log-
transformed (log2). As some of the raw gene expression levels were negative values,
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1000 was added to all values prior to log-transformation. Within the sample sets, mean
expression of each gene was compared between samples with differing mutation
status using linear regression. Significance values were ranked to identify genes most
differentially expressed between groups of interest. In view of non-biological variation
that was judged to be present between the two DASL studies, all gene expression
analyses were adjusted for study from which the patients were recruited. To correct for
multiple testing, the Bonferroni method was used [366] and the significance level was
set at 0.0001. Fold changes in mean gene expression between tumours with different
genotype were calculated using data that had not been log-transformed. Statistical
analyses were undertaken using Stata version 10 (StataCorp 2007, College Station,
TX).
To allow comparison of gene lists generated using different analysis methods for gene
expression data, analysis was also performed using two-group significance of
microarray analyses (SAMic) [450] (Stanford University, Stanford, CA) using a Δ 
threshold to keep the false discovery rate at zero. Data used from this analysis had
been log2 transformed without addition of the constant value and then residuals from a
linear regression model adjusting for study from which the patients were recruited were
used for further analysis. Any missing values following log-transformation were imputed
by SAMic using a K-Nearest Neighbor algorithm [601]. SAMic identifies statistically
differentially expressed genes using a set of gene-specific t-tests, where a small
constant is added to the denominator during calculation of the T-statistic to reduce the
influence of genes with a small variance [450, 599]. Each gene is given a score based
on its change in gene expression relative to the standard deviation of repeated
measurements for that gene. Genes with a score greater than a particular threshold
(Δ), set by the user, are significantly differentially expressed. The false discovery rate is 
estimated by analysing permutations of the measurements, in this case 5000, which
will identify false positive results [450]. This analysis generates a q-value, which is the
lowest false-discovery rate at which a gene is significant [602].
6.3.2 Results
6.3.2.1 Use of cDNA for mutation detection
When this work began, extraction of either DNA or RNA from tumour samples required
use of a tissue core. A single tissue core can represent all, or a large proportion, of the
tumour available for research. To avoid having to extract DNA from precious stored
tumour material, experiments were performed to assess whether stored cDNA
produced in the course of gene expression studies could be used for BRAF and NRAS
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mutation screening. Initial experiments assessed use of high-quality nucleic acids from
cell lines followed by assessment of nucleic acids from FFPE melanoma samples.
6.3.2.1.1 Pyrosequencing of cell line DNA and cDNA
To compare results generated using pyrosequencing with cDNA and DNA to screen for
BRAF and NRAS mutations in high quality nucleic acids, pyrosequencing was used to
screen DNA and cDNA from SkMel28 cells, which have a homozygous V600E BRAF
mutation, and MeWo cells which do not have a BRAF or NRAS mutation as recorded
by the Catalogue of Somatic Mutations in Cancer (COSMIC) [361]. Results were
similar from DNA and cDNA, however an unexpected V600E BRAF mutation was
identified in the MeWo cells in both cDNA and DNA. The A allele (mutant allele)
percentage was higher when cDNA was analysed. For MeWo cells the A allele
percentage was 72% for DNA and 76% for cDNA, and for SkMel28 cells, 95% for DNA
and 98% for cDNA. No NRAS mutations were identified in these samples. DNA and
cDNA from the cell line samples was also sequenced by Dr Phil Chambers using
methods described in Chapter 2 and these results were confirmed.
6.3.2.1.2 Pyrosequencing of FFPE melanoma metastasis DNA and cDNA
To compare results from cDNA and DNA in degraded nucleic acids using
pyrosequencing, a panel of five melanoma metastases samples were selected and
results for BRAF and NRAS mutation screening using DNA and cDNA were compared.
Two samples had V600E BRAF mutations identified in both cDNA and DNA. For
samples with a mutation, the percentage A allele was higher when assessed with
cDNA than DNA. One sample had an NRAS mutation (c.182A>G (p.Q61R)) which was
found using both cDNA and DNA. DNA samples were sequenced by Dr Phil Chambers
using methods described in Chapter 2 and these results were confirmed, however
confirmatory sequencing of the cDNA samples failed.
6.3.2.1.3 Pyrosequencing of cDNA from tumour samples
As these initial results from cDNA and DNA were comparable, a larger number of
cDNA samples were screened for mutations using pyrosequencing. cDNA samples had
previously been generated from RNA extracted from FFPE primary tumours of patients
recruited to the Cohort Study for use in quantitative Real-Time PCR (qRT-PCR)
analysis as described in Chapter 4. A total of 154 cDNA specimens were available,
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cDNA was also generated from 20 tumour RNA samples from patients recruited to the
SNB study who were treated with chemotherapy (see Chapter 8), 6 of these samples
were also sent for pyrosequencing with samples from the Cohort study. Therefore a
total of 160 cDNA samples were screened for BRAF and NRAS mutations using
pyrosequencing. A summary of results is presented in Table 6-3.
Sample status Number of samples(%)
BRAF
V600E
Total with BRAF mutation (A allele ≥10%) 
0% A allele
>0% and <5% A allele
≥5% and <10% A allele 
≥10% and <20% A allele 
≥20% A allele 
No data
105 (65.6)
28 (17.5)
12 (7.5)
8 (5.0)
19 (11.9)
86 (53.8)
7 (4.4)
NRAS Total with NRAS mutation 47 (29.4)
NRAS
Codon 61
Mutation
No data
44 (93.6)
11 (6.9)
NRAS
Codon
12/13
Mutation
No data
3 (6.4)
7 (4.4)
Double mutations (BRAF A allele ≥10%) 25 (15.6)
Table 6-3: Summary of BRAF and NRAS mutation screening results from cDNA
synthesised from RNA extracted from 160 primary melanoma samples.
The percentage values for BRAF and NRAS mutations overall, percentage A
allele, missing data and double mutations were calculated as a percentage of the
total number of samples assessed. For mutations in separate NRAS codons, the
percentage value was calculated as a proportion of the number of samples with
an NRAS mutation.
Overall, 65.6% of samples had a V600E BRAF mutation with a percentage A allele
level over 10%. All BRAF mutations identified were V600E. A total of 29.4% of samples
had a mutation in NRAS, with the majority of mutations being p.Q61R (40.4%) and
pQ61K (40.4%). Both of these results are consistent with published results, however
15.6% of samples had mutations both in BRAF and in NRAS which is uncommon and
inconsistent with previous reports [30].
On review of the data in more detail, samples with double mutations appeared to have
lower A allele percentage levels than samples without an NRAS mutation (Figure 6-2).
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Figure 6-2: Distribution of A allele levels for V600E BRAF mutations in cDNA
samples with and without NRAS mutation.
A single dot represents each sample. % BRAF mutation refers to A allele
percentage levels. An orange line of pluses represents the median for the two
groups; dashed lines indicate the upper and lower quartiles.
In order to confirm whether the results identified in cDNA samples were correct,
pyrosequencing was repeated and similar results were obtained. A selection of
samples were selected with different percentage A allele mutation results for
sequencing to confirm the presence of these mutations, however the samples failed in
this analysis. Therefore in order to confirm or refute these results, an Applied
Biosystems PRISM® SNaPshotTM Multiplex system assay was developed to screen for
BRAF and NRAS mutations in cDNA samples using methods described in Chapter 2.
6.3.2.1.4 Mutation screening of cDNA and DNA samples using the Applied
Biosystems PRISM® SNaPshotTM Multiplex system for samples identified as
having both BRAF and NRAS mutations in cDNA using pyrosequencing
cDNA samples identified as having double mutations using pyrosequencing were
reassessed using the SNaPshot system. A further six samples with low levels of BRAF
A allele levels (<10%) along with NRAS mutations were also assessed, therefore a
total of 31 samples were analysed. Where there were further tissue cores available,
DNA was extracted using the Qiagen QIAamp DNA FFPE kit from a matched core for
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comparison of results using the SNaPshot system and pyrosequencing. A total of 25
samples had matched DNA samples available.
When cDNA was assessed using the SNaPshot system, four samples failed the BRAF
assay. In the remainder, V600E BRAF mutations were detected in samples where the
percentage A allele level using pyrosequencing was greater than 23%. Generally, in
samples with lower percentage mutations, mutations were not detected, although for
one sample, a V600E mutation was detected using the SNaPshot system when the
mutation percentage was only 19% in the pyrosequencing assay. No V600K or K601
mutations were identified in these samples. No samples failed the NRAS assay and
there was better concordance across the SNaPshot system and pyrosequencing for
NRAS mutation results using cDNA, with mutation results being the same across the
two assays for the majority of samples. The exception was that a c.182A>G mutation
(Q61R) in codon 61 was identified in one sample using the SNaPshot system, whereas
a c.181C>A mutation (Q61K) had been detected using pyrosequencing. Therefore,
pyrosequencing appeared to be detecting low levels of V600E BRAF mutations in
cDNA samples which could not generally be replicated using a different method of
mutation detection, albeit a less sensitive detection method.
In order to investigate further, DNA was available for 25 samples for which we had
previously tested the cDNA and this was assessed using both pyrosequencing and the
SNaPshot system. Only one sample failed the BRAF and NRAS assay in
pyrosequencing. There was excellent concordance between results across the two
assays when DNA was used with all mutation results matching. Only one sample had a
V600E BRAF mutation, which was the same sample identified as having a mutation in
cDNA using the SNaPshot system and pyrosequencing where the A allele level was
19%. This sample was wild-type for NRAS when DNA was used for analysis, whereas
a mutation was found in cDNA. No V600K or K601 mutations were identified in these
samples. NRAS mutations were detected in all the samples assessed, except for the
sample discussed previously, and the mutation spectrum was the same as results from
cDNA. The sample with a different mutation identified using the SNaPshot system and
pyrosequencing using cDNA was found to have a c.182A>G mutation (Q61R) in DNA
using the SNaPshot system, however it failed in the pyrosequencing assay.
To summarise, using DNA from FFPE tumour specimens, samples previously identified
as harbouring both NRAS and BRAF mutations when cDNA was assessed using
pyrosequencing, were found to have only one mutation which is much more consistent
with the published literature. Results for NRAS mutation screening were more
concordant across cDNA and DNA, however using cDNA for BRAF mutation screening
yielded inaccurate results, specifically low levels of mutation are identified in samples
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where no mutation can be detected in matched DNA samples. Therefore to ensure
accuracy of results, DNA was used for subsequent mutation screening.
6.3.2.2 BRAF and NRAS mutation results from FFPE primary melanoma
specimens using DNA
6.3.2.2.1 Samples
Following completion of work using cDNA samples, the Qiagen AllPrep® RNA/DNA
FFPE kit became available for use allowing us to extract DNA and RNA from a single
core, thereby removing the necessity to consider mutation screening in cDNA. DNA
was subsequently extracted using this kit by myself from 88 available primary tissue
cores from patients recruited to the Cohort Study and 166 cores from patients recruited
to the SNB study. DNA was used to identify BRAF and NRAS mutations using
pyrosequencing as described previously. Results from this analysis were added to
results for 25 tumours assessed in previous methodological work, therefore a total of
279 tumours were genotyped.
6.3.2.2.2 Mutations identified
Table 6-4 summarises the results of the pyrosequencing analysis. A total of 50.5% of
the samples assessed had a BRAF mutation, the majority (83.7%) V600E mutations,
which is consistent with levels quoted in the literature. A total of 27.2% of tumours had
an NRAS mutation, most of which were in codon 61 as previously described. We were
unable to obtain results for 3.2% of the samples assessed because of repeated PCR
failure. No samples had both a NRAS and BRAF mutation.
The percentage mutation levels for V600E and NRAS mutations remained high in DNA
samples analysed with pyrosequencing. Forty-one (15%) of tumours with V600E
mutation had a percentage mutation levels over 50% and in the 75 tumours with NRAS
mutations where mutation percentage could be calculated (p.G12N due to
c.34_35delinsAA excluded), 38 (51%) of tumours had mutation percentage levels over
50%.
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Gene Mutation Number of samples (%)
BRAF
All
V600E
V600K
V600D
K601E
141 (50.5)
118 (83.7)
18 (12.8)
4 (2.8)
1 (0.7)
NRAS
All
p.Q61R
p.Q61K
p.Q61L
p.Q61H
p.G13R
p.G12V
p.G12N
76 (27.2)
37 (48.7)
22 (29.0)
8 (10.5)
2 (2.6)
5 (6.6)
1 (1.3)
1 (1.3)
Samples with double mutations 0
No mutation 53 (19.0)
Data not available 9 (3.2)
Table 6-4: Summary of BRAF and NRAS pyrosequencing results for DNA
extracted from 279 primary melanoma tumours.
For each gene, the percentage number of samples is calculated for the whole
sample set tested. For each separate mutation, the percentage number of
samples is calculated as a proportion of samples with a mutation in the gene.
6.3.2.2.3 Correlations between results derived from pyrosequencing of matched cDNA
and DNA samples
As discussed previously, there were discordant mutation results obtained from cDNA
and matched DNA samples using pyrosequencing in the small sample set assessed in
section 6.3.2.1.4. Whilst this discordance was thought likely to result from erroneous
results from pyrosequencing, I investigated the relationship between cDNA and DNA
results further to assess whether pyrosequencing was detecting small numbers of
mutant BRAF cells in NRAS mutant tumours. Therefore, a comparison was made
between results derived using pyrosequencing from matched cDNA and DNA samples
in the larger sample set. All BRAF mutations detected in cDNA were V600E, however
V600K mutations were detected in six DNA samples where V600E mutations have
been previously identified in cDNA. In addition, a V600K mutation was identified in
DNA where no mutation had been detected in the matched cDNA sample previously.
Generally there was good concordance in the mutation spectrum detected in matched
cDNA and DNA samples for NRAS, but mutations were detected in DNA, but not cDNA
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for 4 samples, with mutations detected in cDNA and not DNA for 2 samples.
Percentage mutation levels for V600E BRAF mutations and NRAS mutations were also
compared between matched cDNA and DNA samples in the larger sample set. Results
are presented in Figure 6-3.
There were significant correlations between the level of mutation detected in matched
cDNA and DNA samples for V600E BRAF (Spearman’s rho 0.50) and NRAS
(Spearman’s rho 0.71) mutations, however it is clear from Figure 6-3 that for BRAF,
high levels of mutant allele were detected in cDNA samples which are not replicated in
DNA samples. The association between NRAS mutation levels was better between
matched cDNA and DNA samples. Discordant results between cDNA and DNA
samples demonstrate that cDNA cannot be used for accurate detection of mutations in
BRAF and NRAS and this analysis confirms that DNA should be used for mutation
screening in melanoma samples. I was unable to generate any data which explained
this discordance.
6.3.2.2.4 Associations with clinico-pathological features
Table 6-5 presents results of analyses carried out to identify associations between
mutation status and tumour histological features or patient characteristics.
There were a greater proportion of tumours with BRAF mutations in the SNB study,
and NRAS mutations in the Cohort study. A higher proportion of superficial spreading
melanomas were BRAF mutated, with a marginally greater proportion of nodular
tumours being NRAS mutated. A higher proportion of truncal tumours had BRAF
mutations, with NRAS mutations being more predominantly found in head and neck
tumours or tumours on the limbs. A higher proportion of tumours on sun-protected sites
were wild-type, however mutations were identified in four acral tumours (three BRAF
and one NRAS mutation). The median age at diagnosis of patients with NRAS mutated
tumours was significantly higher (61 years) than for patients with wild-type tumours (53
years) which was greater than for patients BRAF mutated tumours (51 years). This
analysis found that patients with a positive SNB were more likely to have a BRAF
mutated primary tumour, but these data are difficult to interpret given the observation
that BRAF mutations were more common in people who elected to have a SNB rather
than to decline it.
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A.
B.
Figure 6-3: Scatter plots showing percentage mutation levels for V600E BRAF (A)
and NRAS (B) levels from matched cDNA and DNA samples using
pyrosequencing.
BRAF mutations are detected in cDNA samples, where none were found in DNA
samples.
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Spearman’s rho 0.50
(p<0.00001)
Spearman’s rho 0.71
(p<0.00001)
Factor No mutation(n=53)
BRAF mutation
(n=141)
NRAS mutation
(n=76) Test statistic and significance value
Study type, n (%):
Cohort study
SNB study
23 (21.7)
30 (18.3)
45 (42.5)
96 (58.5)
38 (35.9)
38 (23.2)
χ2 (2) 7.3, p=0.03
Breslow thickness, mm, median (range) 2.1 (0.7-11.0) 2.0 (0.8-13.0) 2.5 (0.8-19.0) Kruskal-Wallis χ2 (2) 2.9, p=0.24
Mitotic rate per mm2, median (range) 4 (0-37) 5 (0-40) 4 (0-32) Kruskal-Wallis χ2 (2) 0.8, p=0.67
Ulceration, n (%):
None
Present
38 (73.1)
14 (26.9)
103 (73.6)
37 (26.4)
50 (67.6)
24 (32.4)
χ2 (2) 0.9, p=0.63
Tumour infiltrating lymphocytes, n (%):
None
Present
15 (29.4)
36 (70.6)
20 (15.5)
109 (84.5)
17 (25.0)
51 (75.0)
χ2 (2) 5.2, p=0.08
Vascular or lymphatic invasion, n (%):
None
Present
44 (89.8)
5 (10.2)
121 (90.3)
13 (9.7)
67 (90.5)
7 (9.5)
χ2 (2) 0.02, p=0.99
Perineural infiltration, n (%):
None
Present
28 (90.3)
3 (9.7)
93 (98.9)
1 (1.1)
41 (97.6)
1 (2.4)
Fisher’s exact p=0.05
Regression, n (%):
No
Yes
38 (80.9)
9 (19.2)
105 (84.0)
20 (16.0)
64 (91.4)
6 (8.6)
χ2 (2) 3.0, p=0.22
Microsatellites, n (%)
None
Present
40 (83.3)
8 (16.7)
110 (90.2)
12 (9.8)
60 (90.9)
6 (9.1)
χ2 (2) 2.0, p=0.37
Histological subtype, n (%):
SSM
NM
Other
28 (53.9)
17 (32.7)
7 (13.5)
104 (76.5)
25 (18.4)
7 (5.2)
40 (54.1)
27 (36.5)
7 (9.5)
χ2 (4) 15.5, p=0.004
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Factor No mutation(n=53)
BRAF mutation
(n=141)
NRAS mutation
(n=76) Test statistic and significance value
Age at diagnosis or SNB, median (range) 52.6 (19.9-79.0) 51.2 (14.4-80.2) 60.8 (26.7-88.0) Kruskal-Wallis χ2 (2) 17.6, p=0.0002
Patient gender, n (%)
Female
Male
31 (58.5)
22 (41.5)
68 (48.2)
73 (51.8)
36 (47.4)
40 (52.6)
χ2 (2) 1.9, p=0.38
Site of tumour, n (%):
Trunk
Limbs
Head/neck
Sun protected
12 (22.6)
28 (52.8)
5 (9.4)
8 (15.1)
61 (43.3)
65 (46.1)
12 (8.5)
3 (2.1)
18 (23.7)
48 (63.2)
9 (11.8)
1 (1.3)
Fisher’s exact, p<0.0001
SNB status, n (%)
No SNB
SNB performed – negative
SNB performed – positive
19 (37.3)
15 (29.4)
17 (33.3)
36 (25.5)
31 (22.0)
74 (52.5)
29 (38.7)
21 (28.0)
25 (33.3)
χ2 (4) 10.2, p=0.04
Relapse status, n (%)
Not relapse
Relapsed
34 (64.2)
19 (35.9)
88 (64.2)
49 (35.8)
49 (64.5)
27 (35.5)
χ2 (2) 0.002, p=1.00
Overall survival, n (%)
Alive
Died
36 (67.9)
17 (32.1)
88 (62.4)
53 (37.6)
49 (64.5)
27 (35.5)
χ2 (2) 0.52, p=0.77
Table 6-5: Associations between tumour BRAF and NRAS mutation status and clinico-pathological features.
Significance values quoted for Fisher’s exact tests are 2-sided. Percentage values for study type are reported as the proportion within each
study, with other percentage levels being the proportion of tumours with each mutation. Significant results are highlighted in bold.
Abbreviations used: SNB, sentinel node biopsy; n, number.
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In view of the increasing interest in the biological significance of V600K BRAF
mutations, in Table 6-6 I compared the clinico-pathological features associated with
V600E mutated tumours and V600K mutated tumours.
V600K mutations were more commonly found in tumours from older and male patients.
There were also a higher proportion of patients with V600K mutated tumours who had
died, which was investigated further using survival analysis in section 6.3.2.2.5.
A comparison was also made between clinico-pathological features of tumours with the
two commonest NRAS mutations (p.Q61R and p.Q61K), but there were no significant
differences in features between these two groups.
6.3.2.2.5 Associations with survival
The influence of mutation status on survival was investigated further using survival
analysis. Figure 6-4 presents Kaplan-Meier plots for relapse-free survival (RFS), overall
survival (OS) and melanoma-specific survival (MSS) for patients with tumours of
differing mutational status. Hazard ratios and 95% confidence intervals generated
using the Cox proportional hazards model are also presented. Use of sentinel node
biopsy results in delay of the date of first relapse in melanoma patients since the usual
site of first recurrence (nodal) is removed, therefore analysis of RFS was adjusted for
whether the patient had undergone a sentinel node biopsy and the effect of the biopsy
result (SNB status). This analysis shows that mutation status did not modify RFS, OS
or MSS in this sample set.
Survival analysis was also performed to identify associations between type of BRAF
mutation (V600E or V600K) and RFS, OS or MSS. Patients with rare BRAF mutations
(V600D in 4 patients and K601E in 1 patient) were excluded from this analysis. Figure
6-5 presents Kaplan-Meier plots for these analyses and results of survival analyses
using the Cox proportional hazards model.
This analysis demonstrated that patients with a V600K positive tumour had a shorter
RFS than patients with a wild-type tumour (HR 2.64, p=0.02, median RFS V600E 3.3
years, V600K 2.4 years) when the analysis was adjusted for sentinel node biopsy
status. There was also some evidence that V600K mutations shorten OS (HR 2.03,
p=0.07) and MSS (HR 1.97, p=0.09).
To investigate the association between mutation status and RFS further, the Cox
proportional hazards model was adjusted in multivariate analysis for demographic and
histological factors of prognostic value in melanoma, the results of which are presented
in Table 6-7.
Factor V600E mutation(n=118)
V600K mutation
(n=18) Test statistic and significance value
Study type, n (%):
Cohort study
SNB study
36 (81.8)
82 (89.1)
8 (18.2)
10 (10.9)
χ2 (1) 1.4, p=0.24
Breslow thickness, mm, median (range) 2.0 (0.8-12.0) 2.2 (0.9-5.2) Mann-Whitney z -0.87, p=0.38
Mitotic rate per mm2, median (range) 4 (0-40) 6.5 (1-28) Mann-Whitney z -1.79, p=0.07
Ulceration, n (%):
None
Present
86 (72.9)
32 (27.1)
13 (76.5)
4 (23.5)
Fisher’s exact, p=1.00
Tumour infiltrating lymphocytes, n (%):
None
Present
17 (15.7)
91 (84.3)
2 (12.5)
14 (87.5)
Fisher’s exact, p=1.00
Vascular or lymphatic invasion, n (%):
None
Present
101 (89.4)
12 (10.6)
15 (93.8)
1 (6.3)
Fisher’s exact, p=1.00
Perineural infiltration, n (%):
None
Present
80 (98.8)
1 (1.2)
9 (100.0)
0
Fisher’s exact, p=1.00
Regression, n (%):
No
Yes
87 (83.7)
17 (16.4)
14 (82.4)
3 (17.7)
Fisher’s exact, p=1.00
Microsatellites, n (%)
None
Present
93 (90.3)
10 (9.7)
13 (92.7)
1 (7.1)
Fisher’s exact, p=1.00
Histological subtype, n (%):
SSM
NM
Other
88 (77.2)
19 (16.7)
7 (6.1)
13 (76.5)
4 (23.5)
0
Fisher’s exact, p=0.54
-197
-
Factor V600E mutation(n=118)
V600K mutation
(n=18) Test statistic and significance value
Age at diagnosis or SNB, median (range) 50.5 (14.4-80.2) 60.7 (32.8-79.1) Mann-Whitney z -2.8, p=0.005
Patient gender, n (%)
Female
Male
63 (53.4)
55 (46.6)
4 (22.2)
14 (77.8)
Fisher’s exact, p=0.02
Site of tumour, n (%):
Trunk
Limbs
Head/neck
Sun protected
48 (40.7)
56 (47.5)
11 (9.3)
3 (2.5)
11 (61.1)
6 (33.3)
1 (5.6)
0
Fisher’s exact, p=0.47
SNB status, n (%)
No SNB
SNB performed – negative
SNB performed – positive
31 (26.3)
23 (19.5)
64 (54.2)
4 (22.2)
8 (44.4)
6 (33.3)
Fisher’s exact, p=0.08
Relapse status, n (%)
Not relapse
Relapsed
77 (67.5)
37 (32.5)
8 (44.4)
10 (55.6)
χ2 (1) 3.6, p=0.06
Overall survival, n (%)
Alive
Died
78 (66.1)
40 (33.9)
7 (38.9)
11 (61.1)
χ2 (1) 4.9, p=0.03
Table 6-6: Associations between tumour V600E and V600K BRAF mutations and clinico-pathological features.
Significance values quoted for Fisher’s exact tests are 2-sided. Percentage values for study type are reported as the proportion within each
study, with other percentage levels being the proportion of tumours with each mutation. Significant results are highlighted in bold.
Abbreviations used: SNB, sentinel node biopsy; n, number.
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A.
Genotype (analysis
adjusted for SNB status) HR 95% CI P-value
No mutation
BRAF mutation
NRAS mutation
1
0.94
0.89
0.54-1.62
0.49-1.62
0.81
0.70
B.
Genotype HR 95% CI P-value
No mutation
BRAF mutation
NRAS mutation
1
1.29
1.01
0.74-2.23
0.55-1.86
0.37
0.97
0.
00
0.
25
0.
50
0.
75
1.
00
P
ro
po
rti
on
of
pa
tie
nt
s
al
iv
e
0 2 4 6 8 10
Analysis time (years)
No mutation BRAF mutation
NRAS mutation
Overall survival
- 200 -
C.
Genotype HR 95% CI P-value
No mutation
BRAF mutation
NRAS mutation
1
1.27
0.96
0.72-2.23
0.51-1.81
0.42
0.89
Figure 6-4: Kaplan-Meier plots and results of survival analyses used to identify
associations between relapse-free (A), overall (B) and melanoma-specific
survival (C) and tumour genotype.
Hazard ratios and 95% confidence intervals generated using a Cox proportional
hazards model are presented. For relapse-free survival, the analysis is adjusted
for influence of sentinel-node biopsy status. Abbreviations used: HR, hazard ratio;
CI, confidence interval; SNB, sentinel node biopsy.
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A.
Genotype (analysis
adjusted for SNB status) HR 95% CI P-value
No mutation
V600E mutation
V600K mutation
NRAS mutation
1
0.80
2.64
0.89
0.45-1.42
1.20-5.80
0.49-1.62
0.45
0.02
0.69
B.
Genotype HR 95% CI P-value
No mutation
V600E mutation
V600K mutation
NRAS mutation
1
1.17
2.03
1.02
0.66-2.06
0.95-4.33
0.55-1.86
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C.
Genotype HR 95% CI P-value
No mutation
V600E mutation
V600K mutation
NRAS mutation
1
1.15
1.97
0.96
0.64-2.06
0.89-4.34
0.51-1.81
0.65
0.09
0.90
Figure 6-5: Kaplan-Meier plots and results of survival analyses used to identify
associations between relapse-free (A), overall (B) and melanoma-specific
survival (C) and tumour genotype where V600E and V600K BRAF mutations
were analysed separately.
Hazard ratios and 95% confidence intervals generated using a Cox proportional
hazards model are presented. For relapse-free survival, the analysis is adjusted
for influence of sentinel-node biopsy status. Significant results are highlighted in
bold. Abbreviations used: HR, hazard ratio; CI, confidence interval; SNB, sentinel
node biopsy.
Mutation status
Analysis adjusted SNB
status only
(n=258)
Analysis further adjusted for
age and sex of patient and site
of tumour
(n=258)
Analysis further adjusted for
Breslow thickness, ulceration
and mitotic rate of tumour
(n=245)
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
No mutation 1.00 1.00 1.00
V600E BRAF mutation 0.80 (0.45-1.42) 0.45 0.89 (0.49-1.63) 0.71 1.04 (0.54-2.01) 0.90
V600K BRAF mutation 2.64 (1.20-5.80) 0.02 2.25 (0.97-5.19) 0.06 2.58 (1.03-6.48) 0.04
NRAS mutation 0.89 (0.49-1.62) 0.69 0.80 (0.42-1.52) 0.50 0.82 (0.41-1.65) 0.58
Table 6-7: Associations between tumour mutation status and relapse-free survival in multivariate analysis.
The first model is adjusted for sentinel node biopsy status only; the second further adjusted for demographic variables of prognostic
importance (patient gender, age at diagnosis and site of tumour) in melanoma and finally the model is further adjusted for histological
prognostic factors (Breslow thickness, mitotic rate and ulceration status). Presence of a V600K mutation was significantly associated with
reduced relapse free survival time in the first model and the model fully adjusted for other prognostic factors. Significant results are highlighted
in bold. Abbreviations used: HR, hazard ratio; CI, confidence interval; SNB, sentinel node biopsy.
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In the multivariable analysis presented, the presence of a V600K mutation was
significantly associated with reduced RFS time even when adjusted for prognostic
factors in melanoma, indicating that presence of a V600K mutation was independently
associated with RFS. As only 18 tumours had a V600K mutation, this study is limited in
power to identify relationships with survival, however I have identified an association
with RFS suggesting that this effect is significant and warrants further investigation in a
larger sample set. Presence of a V600E mutation did not influence RFS, suggesting
that V600K mutations may induce different biological properties in a tumour.
6.3.2.2.6 Gene expression patterns associated with mutation status
Genes differentially expressed between groups of tumours based on genotype were
identified using linear regression adjusted for the study from which patients were
recruited. This analysis was also performed using significance analysis of microarrays
(SAMic) analysis, to allow comparison of gene lists, but the results were very similar,
therefore the results of analysis based on linear regression are presented in Table 6-8.
6.4 Discussion
6.4.1 Use of cDNA specimens for mutation detection
In this chapter I have described experiments to assess whether cDNA could be used
as an alternative to DNA for mutation screening from small volume FFPE melanoma
specimens. This investigation was initiated to try and limit the amount of precious
tumour material required for mutation screening by using available cDNA that had been
previously generated for use in gene expression experiments. Despite promising initial
results, further investigation demonstrated that different results are generated when
cDNA and DNA are used for mutation detection of BRAF and NRAS using
pyrosequencing. The spectrum of BRAF mutations identified and the percentage
mutation levels differed in cDNA and DNA. There was better concordance for NRAS,
however differences do exist and without accurate BRAF mutation screening, further
analysis is limited.
BRAF mutated tumours compared
to tumours with no mutation (fold
difference in gene expression for
BRAF mutated tumours/wild-type
tumours)
NRAS mutated tumours compared
to tumours with no mutation (fold
difference in gene expression for
NRAS mutated tumours/wild-type
tumours)
NRAS mutated tumours compared
to BRAF mutated tumours (fold
difference in gene expression for
NRAS mutated tumours/BRAF
mutated tumours)
V600K BRAF mutated tumours
compared to V600E BRAF
mutated tumours (fold change in
gene expression for V600K
mutations/V600E mutations)
Gene Mean folddifference P-value Gene
Mean fold
difference P-value Gene
Mean fold
difference P-value Gene
Mean fold
difference P-value
ETV1 1.34 9.75x10-7 TYRO3 1.44 1.90x10-7 NRAS 1.16 1.04x10-7 TFAP2C 0.54 0.00001
ERBB3 1.20 1.63x10-6 CTNNB1 1.08 3.27x10-7 THBS2 0.69 1.50x10-7 BRAF 1.11 0.0001
CDK6 1.22 2.29x10-6 NRAS 1.17 6.10x10-6 VHL 1.09 2.15x10-7 CDK2 1.21 0.0002
PTPRG 1.30 2.60x10-6 PTPRG 1.30 7.58x10-6 WNT5A 0.67 2.08x10-6 DVL3 1.12 0.002
TYRO3 1.33 5.90x10-6 CDK6 1.23 7.70x10-6 RAP2A 1.09 0.00001 TRAF3 1.25 0.002
CD59 1.13 0.00003 ETV1 1.37 0.00001 PTEN 1.06 0.00003 EVI2A 0.77 0.002
CEACAM1 1.54 0.00004 TGFBR1 1.13 0.00002 CTNNB1 1.03 0.00003 JUN 1.10 0.003
MAP3K8 1.54 0.00004 ERBB3 1.23 0.00003 QARS 1.08 0.00004 EXT1 1.07 0.003
CAV1 1.12 0.0001 TRAF4 1.19 0.00004 BIRC2 1.08 0.00007 PDGFA 0.80 0.004
NFKB2 0.83 0.0001 TNFRSF5 0.80 0.00005 ERCC6 1.13 0.0001 MSF 1.12 0.004
Table 6-8: The top 10 most differentially expressed genes between wild-type tumours, tumours with BRAF mutations and NRAS
mutations.
The top ten most differentially expressed genes are listed for each comparison. Significance values are from linear regression analyses
adjusting for study from which patients were recruited to. Genes highlighted in bold appear on more than one list. Cells highlighted in green
shading contain genes which are part of the mitogen-activated protein kinase (MAPK) or phosphatidylinositol-3-kinase (PI3K) signalling
pathway.
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cDNA has been previously used for mutation screening in frozen tumour samples to
allow detection of small numbers of mutant BRAF and NRAS alleles in heterogeneous
tissues where both wild-type and mutant genes are present [603, 604]. The methods
used cDNA amplified using PCR primers designed to introduce new site-directed
restriction sites into the PCR amplicon when a mutation is present. Restriction
enzymes then cut the cDNA and fragments are identified [603, 604]. These analyses
identified mutations at a comparable frequency to other methods, with no double
mutations identified [603, 604]. This technique has been used to screen for mutations
in DNA extracted from small numbers of FFPE melanoma specimens, but not cDNA
synthesised from mRNA extracted from FFPE materials [604]. A similar method which
utilises a series of PCR amplifications and the presence of a restriction site to
preferentially digest wild-type BRAF sequences in cDNA has been used for mutation
detection in circulating tumour cells from peripheral blood, frozen and FFPE tumour
specimens [605, 606]. Seventy melanoma tumour biopsies from frozen and FFPE
tissue have been assessed previously with varying degrees of V600E BRAF mutation
positivity identified. The authors report that this method using mRNA as template in
association with PCR amplification, increases sensitivity compared to DNA based
assays, especially in melanoma cells with high levels of V600E BRAF mRNA
expression, however NRAS mutation status was not determined in this study to allow
further comparison with our results [605].
cDNA synthesized from mRNA reflects the transcribed genes within the cell. RNA
extracted from FFPE materials is degraded, leading to short cDNA sequences. This, in
combination with the PCR amplification step used in pyrosequencing, has the potential
to introduce errors, which may be detected as mutations in the highly sensitive
pyrosequencing assay. The other possibility is that there is increased expression of
BRAF transcripts in melanoma cells harbouring BRAF mutations. If these mutations
are present in a small proportion of cells, this may not be detected using DNA based
analysis, however if expression is increased in mutant cells, mutant transcripts may be
detected in cDNA. There is evidence that there is copy number gain in association with
BRAF activating mutations in short-term melanoma cultures, established cell lines and
tumour samples with both gain across the entirety of chromosome 7 and in the specific
7q34 region which harbours the BRAF locus [44, 356, 607-611]. There also appears to
be preferential amplification of mutant BRAF alleles [356, 609, 612]. As
pyrosequencing is quantitative, the higher levels of mutation detected in cDNA samples
may reflect greater transcription of mutant alleles, with detection of both NRAS and
BRAF mutations in cDNA from a single tumour resulting from tumour heterogeneity. A
number of factors argue against this hypothesis: low level BRAF mutations identified
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using pyrosequencing in cDNA were not detected using the SNaPshot system,
although this method is less sensitive that pyrosequencing [360]; we did not see
differential expression of BRAF transcripts in BRAF mutated tumours compared with
NRAS mutated or wild-type tumours and in NRAS mutated tumours with high levels of
mutation detected in DNA and over-expression of NRAS (discussed in section 6.4.3),
results from cDNA and DNA were more comparable. Therefore, it is likely that poor
quality cDNA used in a highly sensitive assay has produced erroneous results.
6.4.2 Associations between mutation status and clinico-
pathological features and survival
In this study, 50.5% of tumours had a BRAF mutation and 27.2% had an NRAS
mutation. These frequencies are higher than those quoted in a recent meta-analysis of
studies using various mutation detection methods (BRAF 41% and NRAS 18%) [31],
but are comparable to studies that have used more sensitive pyrosequencing for
mutation detection (BRAF 53%, NRAS 29%) [436] (NRAS 32%) [353].
This study has identified associations between mutation status and a number of clinico-
pathological features, the majority of which have been previously described in the
literature [30, 31, 549, 587, 588]. BRAF mutations were found more frequently in
tumours of the superficial spreading subtype, with NRAS mutations more commonly in
nodular tumours. Truncal tumours, on intermittently sun-exposed skin, were most likely
to have a BRAF mutation, with NRAS mutations found more commonly on head and
neck tumours or tumours of the limbs of chronically sun-exposed skin. These data are
consistent with other studies and Whiteman’s two route theory of carcinogenesis where
intermittent excessive sun exposure is postulated to be associated with melanoma risk
on the trunk in individuals with a tendency to develop naevi [152]. Tumours on sun-
protected sites were less likely to harbour a BRAF or NRAS mutation, although
mutations were identified in four acral tumours. In this study, BRAF mutations were
more likely to be found in patients who were younger at diagnosis, with NRAS
mutations in older patients.
I did not find any associations between tumour Breslow thickness, mitotic rate or
ulceration and mutation status as has been described in other studies [549, 583, 589]. I
report some evidence that patients with a positive SNB were more likely to have a
BRAF mutated primary tumour. A recent study found that patients with a NRAS or
BRAF mutated tumour were more likely to present with stage III disease, the
association being strongest for palpable nodal disease [583]. My study indicates there
may also be an association between presence of a BRAF mutation and
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micrometastases identified using sentinel node biopsy, although a smaller proportion of
patients with BRAF positive tumours appeared to have elected not to have a SNB
(26% compared with 37% for patients with wild-type tumours and 39% for patients with
NRAS mutated tumours) so these data are difficult to interpret.
There appeared to be differences in the clinical characteristics of patients with V600K
BRAF positive tumours. Albeit, in a small sample, I found that V600K mutations are
more commonly found in primary tumours from patients diagnosed at a later age
(median 60.7 years versus 50.5 years with V600E mutations, p=0.005) and in male
patients (77.8% tumours with V600K mutation were in male patients). As discussed in
the background to this chapter, the association between age at diagnosis of metastatic
disease and mutation status has been previously identified in a study of metastatic
melanoma [593]. This study also found an association between V600K mutations and
sun-induced damage, as determined by degree of solar elastosis, and V600K tumours
were more commonly found in tumours on the head or neck, a sun-exposed site, with
V600E tumours more commonly on the limbs [593]. In the current study, a higher
proportion of V600K mutations were found in tumours on the trunk with V600E
mutations more commonly on the limbs. This was a non-significant finding and I was
unable to investigate the association between sun-damage and presence of V600K
mutation based on the data available currently (pending central pathology review). The
relationship between sun exposure and development of V600E mutations is not clear,
however the evidence presented by Menzies and colleagues suggests that chronic sun
exposure may be related to the pathogenesis of V600K mutations [593]. This is further
supported by the higher incidence of V600K mutations in geographical locations with
higher UV exposure [436, 550, 593]. Again, the V600K mutation is not characteristic of
UVB DNA damage [541, 543], however there are suggestions that UVA and UVB
radiation may cause mutations at the BRAF V600 site [544, 545]. Menzies and
colleagues suggested that a number of factors are likely to contribute to V600K
mutations, including sun-exposure on the background of genetic alterations related to
the age of the patient [593]. Also, V600E mutations are predominantly found in young
patients, suggesting that these mutations may be more likely have a specific aetiology,
whether that is environmental or genetic, compared to V600K mutations [593]. My
findings that V600K mutations are commoner in primary melanoma in older patients
supports the hypothesis that chronic sun exposure may be important, however I found
no further evidence to support this in my data. Menzies and colleagues did not report a
difference in prevalence of V600K mutations in males and females [593]. My study
suggests that V600K mutated tumours are commoner in male patients, however this
requires confirmation in a larger sample set. This may be related to the higher
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proportion of truncal tumours with V600K mutations in this dataset, with tumours on the
trunk more commonly diagnosed in men [3]. However, the presence of these mutations
may be contributing to the poor prognosis in male patients [85, 91, 613], which despite
intensive investigation is thought to be due to biological differences between men and
women, remains largely unexplained [144].
With regards to survival, consistent with previous reports, this study found no
association between presence of a BRAF or NRAS mutation and RFS, OS or MSS
[436, 555, 576, 583, 588, 590, 591]. However, there was a significant reduction in RFS
for patients with a V600K positive tumour (HR 2.64 (95% CI 1.20-5.80), p=0.02), which
remains significantly associated in multivariable analysis adjusted for prognostic factors
in melanoma (HR 2.58 (95% CI 1.03-6.48), p=0.04). In metastatic melanoma, presence
of a V600K mutation has been associated with shorter distant metastasis-free survival
time and OS [593, 594]. My study is the first to assess this relationship in primary
melanoma specimens, and therefore the identification of an independent association
with RFS is clearly a significant finding. Differences in patient characteristics and RFS
in patients with V600K mutated primary tumours supports the hypothesis that there
may be different aetiology and biological behaviour of V600K mutated tumours
compared with commoner V600E mutated tumours [593].
6.4.3 Gene expression patterns associated with mutation status
As discussed in the introduction to this chapter, identification of expression signatures
in tumours associated with NRAS mutations has been particularly limited with more
focus on the identification of signatures associated with BRAF mutated tumours [508,
591, 596-599]. The strength of this study is that we have been able to look at
expression profiles in a large number of primary melanoma samples with differing
mutations.
My study has shown that a number of genes are over-expressed in tumours with either
a BRAF or NRAS mutation compared with wild-type tumours. Differentially expressed
genes are ets variant 1 (ETV1), TYRO3 protein tyrosine kinase (TYRO3), v-erb-b2
erythroblastic leukaemia viral oncogene homolog 3 (ERBB3 or HER3), cyclin-
dependent kinase 6 (CDK6) and protein tyrosine phosphatase, receptor type G
(PTPRG). As discussed in previous chapters, in order to confirm these results,
validation of gene expression results is required within this sample set and in an
independent validation study. However, a number of the genes are biologically
interesting and I shall discuss them in further detail.
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ETV1 and TYRO3 are the most differentially expressed genes in BRAF and NRAS
mutated tumours, respectively. ETV1 is an ETS transcription factor and has been
recently identified as an oncogene in melanoma [614]. ETV1 is situated on 7p21 and is
frequently amplified in primary and metastatic tumours [614]. In immortalized
melanocytes and mouse models, over-expression of ETV1 in combination with over-
expression of NRASG12D or BRAFV600E oncoproteins stimulated cell growth and
tumourigenesis, an effect which was not seen when ETV1, NRASG12D or BRAFV600E
were over-expressed alone [614, 615]. Therefore, on the background of MAPK
pathway activation by BRAF or NRAS mutations, ETV1 over-expression can transform
immortalized melanocytes [614]. The authors of the study also found that over-
expression of ETV1 in melanocytes over-expressing NRASG12D increased expression of
the microphthalmia-associated transcription factor gene (MITF) and MITF protein and
this increased level of MITF was required for cell growth [614]. MITF is a transcription
factor required for melanocyte development which activates multiple downstream
factors important for normal melanocyte physiology and survival, cell cycle regulation,
and cellular growth [616]. Germline MITF mutations have been associated with
melanoma development [617, 618] and MITF is amplified in around 20% of
melanomas, where it can act as an oncogene [615]. MITF can also contribute to
melanoma progression when not highly expressed by having tumour promoting
actions, stimulating cell cycle progression but also inhibitory actions, by pushing the
cell towards terminal differentiation or apoptosis, depending on protein levels within the
cell [619, 620]. Multiple signalling pathways regulate MITF expression, for example the
MAPK pathway, melanocyte-stimulating hormone acting via the melanocortin 1
receptor (MC1R) and KIT [616, 621]. Ectopic MITF expression in melanocytes
expressing BRAFV600E causes transformation [615], however in melanoma cells MITF
expression is carefully controlled by mutated BRAF to allow survival and proliferation,
as low MITF levels lead to apoptosis and high levels to terminal differentiation [622].
Previous studies suggest that ETS factors are activated by MAPK pathway mediated
phosphorylation [623] and ETV1 is a target of ERK signalling via MAPK activation
[556]. Inhibition of MEK, which is downstream of NRAS and BRAF or inhibition of
mutant BRAF, in V600E-mutated melanoma cell lines leads to down-regulation of gene
expression in members of the ETS family, including ETV1 [556, 563]. In cells where the
MAPK pathway is driven by receptor tyrosine kinases without mutant BRAF, MEK
inhibition does not cause altered gene expression [556]. These observations suggest
that over-expression of ETV1 enhances an oncogenic signal which functions, and is
also enhanced, by MAPK activation [614]. It also appears that MITF activation
participates in this pathway [614]. I have identified significant over-expression of ETV1
in NRAS or BRAF mutated tumours compared with wild-type tumours which supports
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the hypothesis that mutated tumours drive expression of ETV1 which enhances the
oncogenic effect of NRAS or BRAF mutations. MITF was not present on the Human
Cancer panel used for gene expression profiling, so this association could not be
assessed in my sample set. This study would suggest that ETV1 is a strong driving
force for oncogenesis in mutated tumours, indicating that this may be a candidate for
therapeutic targeting.
TYRO3 was significantly over-expressed in BRAF and NRAS mutated tumours
compared with wild-type tumours. TYRO3 is a member of the TAM (TYRO3, AXL and
MER) receptor tyrosine kinase family which have been shown to have effects on
cellular migration and invasion, angiogenesis, cell survival and tumour growth in cancer
[624]. In melanoma cell lines, TYRO3 has been shown to be a positive regulator of the
MITF-M isoform [625] and is over-expressed in primary tumour samples compared to
normal tissues [625]. Over-expression of TYRO3 in primary melanocytes overcomes
BRAFV600E induced senescence and knockdown in melanoma cells inhibits proliferation
in vitro and reduces tumorigenic potential in mice [625]. Therefore, my study has
identified another gene which is differentially expressed in NRAS and BRAF mutated
tumours which has been shown to have a role in oncogenesis of BRAF mutated
tumours and is also a regulator of MITF expression. Direct therapeutic targeting of
MITF or ETV1 may be difficult as they are transcription factors and difficult to target
using small molecules [626], however TYRO3 may represent a molecule more
amenable to targeted therapies [616, 625].
ERBB3 is a transmembrane receptor which binds to molecules, such as transforming
growth factor- and epidermal growth factors leading to intracellular signalling causing
cellular proliferation, organ development and repair [627, 628]. It lacks innate kinase
function, but can dimerise with other ERBB receptors and is important in activation of
the MAPK pathway [628, 629] and the PI3K-Akt pathway [627]. In melanoma, ERBB3
signalling can inhibit expression of differentiation genes and increase expression of
proliferation genes in melanocytes and melanoma cells, leading to proliferation and
invasion [630]. I did not identify any differential expression of other members of the
ERBB family, specifically ERBB2, which is the usual binding partner for ERBB3 [627,
629]. As dimerisation of receptors is required for action this is perhaps surprising,
however over-expression of ERBB3 in mutated tumours, which is closely related to
activation of MAPK and PI3K-Akt signalling is clearly of interest.
When our results are compared against other gene expression profiles identified in
previous gene expression studies, it is reassuring to see that there is overlap between
genes identified. I have confirmed the finding of Johansson and colleagues in tumour
samples, that ERBB3 was over-expressed in BRAF mutated cell lines versus wild-type
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cell lines [599]. ETV1 was found to be highly differentially expressed in BRAF mutated
tumours in the EORTC study using frozen primary melanoma tumours. This has been
confirmed in this dataset and I have also found that ETV1 is differentially expressed in
NRAS mutated tumours [591].
There is significant overlap between genes differentially expressed in BRAF and NRAS
mutated tumours compared to wild-type tumours which is not unexpected, indicating
that similar genes are dysregulated in cells harbouring a NRAS or a BRAF mutation.
Studies identifying gene expression profiles in tumour tissue have been performed in
small numbers of samples, with some studies showing overlap in gene expression
profiles [508] and others no concordance in gene expression between NRAS and
BRAF mutated tumours [591]. My study represents the largest study to date using
primary melanoma tumours and indicates significant overlap in cancer-related genes
differentially expressed in NRAS or BRAF mutated tumours compared to wild-type
tumours. I have then gone on to compare gene expression between NRAS and BRAF
mutated tumours, the results of which I will discuss now.
As this comparison in gene expression in NRAS mutated tumours with wild-type and
BRAF mutated tumours has been limited to small numbers of tumour and cell lines, the
results I present here are novel and will require extensive validation. One of the most
interesting findings is that NRAS expression was significantly greater in NRAS mutated
tumours compared with BRAF mutated tumours. NRAS is also highly expressed in
NRAS mutated tumours when compared with wild-type tumours. NRAS mutations in
melanoma are activating and these results indicate that expression is also increased.
Changes in gene expression can be due to mutation, alteration in genomic
organisation such a translocations, changes in DNA copy number or epigenetic
alterations [631]. In common with BRAF mutations there is evidence of copy number
gain at the NRAS locus associated with activating mutations in short-term melanoma
cultures, but this is less well documented than in BRAF mutated tumours [607, 608,
610]. Therefore mutation in combination with copy number alteration may cause
altered expression in NRAS mutated tumours. The pyrosequencing assay used for
mutation screening in my study was quantitative with mutation levels in NRAS mutated
tumours being greater than 50% in over half of the tumours. These results indicate an
abundance of the mutated gene in these tumours, which could be due to a number of
mechanisms such as homozygosity, preferential copy gain of the chromosome with the
mutant gene or because of amplification of the mutant allele [609]. This hypothesis
makes many assumptions about the accuracy of mutation levels detected using
pyrosequencing and DASL gene expression results making it highly speculative;
- 213 -
further intensive investigation is needed to clarify the number of NRAS alleles in the
samples and the expression levels.
PTEN was also over-expressed in NRAS mutated tumours compared with BRAF
mutated tumours. PTEN is inhibitory to the PI3K pathway and resides in a commonly
deleted area in melanoma on chromosome 10q [151]. PTEN is inactivated by mutation
in approximately 10% of melanoma tumours [21, 632, 633]. NRAS and PTEN
mutations rarely occur in the same tumour, but PTEN mutations are commonly found
associated with BRAF mutations as are lower PTEN copy numbers [43, 44, 151].
Therefore, the over-expression of PTEN in NRAS mutated tumours may reflect normal
levels when compared to lower levels of PTEN that may be found in BRAF mutated
tumours. We have not assessed the copy number or mutation status of PTEN in these
tumours, but this knowledge would help confirm or refute this hypothesis. It is also
likely that PTEN expression would be elevated in an NRAS mutated tumour in an
attempt to reduce signalling via the PI3K pathway.
The final comparison I have made is between gene expression in V600K BRAF
mutated tumours versus V600E tumours. As the numbers involved in this analysis are
small, there is limited power to detect differential gene expression but I will briefly
discuss some observations. Once a correction had been made for multiple testing, only
two genes were differentially expressed, TFAP2C was significantly under-expressed in
V600K tumours and BRAF significantly over-expressed. Both V600K and V600E
mutations cause high BRAF kinase activity, but this is greater in association with the
V600E mutation [554]. In view of the differences in the prognostic influence of these
mutation types, age-distribution and association with sun-damaged skin, there appear
to be biological differences in tumours with these differing mutations [593]. The
similarity in gene expression profile may suggest otherwise, but this analysis is limited
by the small numbers of tumours with V600K mutations. In a previous study which
assessed gene expression profiles in melanoma cell lines with a V600E mutation
following inhibition with BRAFV600E or MEK inhibitors, TFAP2C was down-regulated
after treatment indicating that this is a direct transcriptional target of the activated
pathway [563]. TFAP2C encodes AP2γ, which is a member of the activating protein 
family 2 (AP2) family of transcription factors. Loss of AP2 transcription factors,
specifically AP2 is associated with transition from radial growth phase melanomas to
vertical growth phase, with re-expression in highly metastatic melanoma cells leading
to tumour growth inhibition and reduction in metastatic potential [634-637]. TFAP2C is
the only AP2 factor on the Human Cancer Panel, so we could not assess expression in
other AP2 factors. BRAF expression was also greater in V600K mutated tumours,
suggesting that the level of pathway activation would be greater than in V600E mutated
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tumours. As TFAP2C is a direct transcriptional target of the activated pathway [563],
levels of TFAP2C would be expected to be greater if activation of the pathway was
increased by higher BRAF levels. This suggests that over-expressed BRAF in V600K
cells may not act to increase signalling through the pathway or that the relationship
between signalling and TFAP2C expression may be more complicated than previously
thought. In view of the relationship between AP2 loss and progression in melanoma
tumours, under-expression of TFAP2C in V600K mutated tumours compared with
V600E may contribute to the biological properties of the V600K mutated tumour.
I have already alluded to some of the limitations of this work, such as poor power to
assess relationships between tumour features, patient characteristics, gene expression
profiles and the rarer V600K BRAF mutation. Gene expression data in this study was
also limited to 502 cancer-related genes; assessment of gene expression on a
genome-wide scale would yield further biological information, and with successful trial
runs using the WG-DASL HT assay (described in Chapter 2) the hope is that this will
be possible using FFPE melanoma tissue in the near future. A final limitation is related
to the issue of tumour heterogeneity as tumours can contain a population of wild-type
and mutant cells [357, 579, 584, 585]. Separate tissue cores, usually taken in close
proximity to each other, from the same tumour were used to generate gene expression
data and screen for mutations in a proportion of samples. Therefore it is possible that
gene expression may be related to a wild-type part of the tumour which was found to
be BRAF mutated in a separate tissue core. To reduce these errors, ideally RNA and
DNA would be extracted from the same tissue core, extraction kits allowing extraction
of both nucleic acids from a single FFPE specimen have recently been developed and
will be used for future work of this type (as discussed in Chapter 2).
6.4.4 Summary and conclusions
This work has shown that cDNA is not suitable for mutation screening.
Results using DNA samples confirmed the associations between mutation status and
clinico-pathological features previously identified in the literature and identified an
independent association between the presence of V600K BRAF mutations in primary
tumours and shorter RFS.
A large number of genes were found to be differentially expressed in BRAF and NRAS
mutated tumours compared to wild-type tumours, some of which have been identified
in previous gene expression studies, with overlap between the two lists suggesting
similar biological processes are active in the tumours with BRAF or NRAS mutations.
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The two most differentially expressed (ETV1 and TYRO3) both have roles in
oncogenesis in association with MAPK pathway activation in and MITF expression.
Presence of an NRAS mutation was associated with significantly greater NRAS and
PTEN expression, a finding that requires validation. There were also small differences
in the gene expression profile of V600K and V600E mutated tumours. This analysis
has been performed in small numbers of tumours requiring extensive further
investigation, but there is a suggestion of higher BRAF expression in V600K tumours
with lower expression of a direct transcriptional target of the MAPK pathway, TFAP2C.
This, in association with differing clinical features and modified prognosis in patients
with a V600K mutated tumour supports the suggestion that these tumours may be
aetiologically and biologically distinct from V600E mutated tumours [593]. If this
hypothesis is proven, this may have relevance to use of BRAFi.
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7 Primary melanoma tumour ulceration: relationship with
gene expression profiles, tumour features and patient
characteristics
7.1 Aims
The aims of this chapter are to:
 Identify tumour histological features and patient characteristics associated with
primary melanoma ulceration in a large patient cohort.
 To identify whether lymphovascular invasion, microvessel density or
macrophage infiltration assessed using immunohistochemistry (IHC) are
associated with ulceration in a subset of tumours.
 To identify tumour gene expression profiles associated with ulceration.
Results of these analyses will be related to both the prognostic and predictive influence
of tumour ulceration status in melanoma.
7.2 Background
Ulceration of a primary melanoma is defined as absence of intact epidermis, including
stratum corneum and basement membrane [94]. Traumatic loss of epidermis can
occur, but this can be distinguished because of a number of additional features which
can be seen in spontaneous cases of ulceration, namely thinning, reactive hyperplasia
or effacement of surrounding epidermis and evidence of a host response, such as
neutrophil infiltration [94, 638]. As discussed in Chapter 1, ulceration of a primary
melanoma tumour is a poor prognostic factor and is integral to the American Joint
Committee on Cancer (AJCC) staging guidelines [58]. The prognostic influence of
ulceration is apparent even in stage III disease, highlighting its strong influence on
patient outcome [58, 59].
More recently, somewhat paradoxically, primary tumour ulceration has been associated
with improved benefit in terms of longer relapse-free survival (RFS), distant metastasis-
free survival (DMFS) and overall survival (OS) following treatment with adjuvant
interferon- (IFN) [204, 231, 639]. The meta-analysis of interferon trials demonstrates
that IFN does provide benefit in terms of RFS, with less clear benefit in terms of OS
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[203, 204]. When individual patient data from IFN randomised controlled trials, not
including the European Organisation for Research and Treatment of Cancer (EORTC)
18991 trial of pegylated IFN, are analysed separately for patients with ulcerated
tumours and non-ulcerated tumours in meta-analysis the positive effect on RFS and
OS is lost for patients with non-ulcerated tumours but is greater for those with ulcerated
tumours (RFS, odds ratio (OR) 0.76; OS, OR 0.77) with evidence of interaction
between IFN effect and ulceration status (p=0.03) [204]. A further meta-analysis of the
two largest IFN adjuvant trials, EORTC 18952 and 18991, showed similar results with
evidence of interaction between IFN therapy and ulceration status for RFS (p=0.02),
DMFS (p<0.001) and OS (p<0.001) [231]. In this study, greatest survival benefit was
seen in patients with ulcerated tumours and stage IIb or III disease with microscopic
nodal metastases [231]. The overall HR for OS in ulcerated patients was 0.77 [204,
231, 638]. Therefore, ulceration is a poor prognostic factor, but appears to be a
beneficial predictive factor for IFN therapy. To assess efficacy of IFN therapy in
patients with ulcerated tumours, a randomized phase III trial is planned in patients with
stage II ulcerated primaries (EORTC 18081) [638]. As discussed in the introduction,
there are currently no other confirmed predictive biomarkers for IFN therapy, therefore
the association between ulceration and IFN benefit is unique and warrants further
investigation to unravel the association [638].
Despite the profound prognostic influence of ulceration, very little is known about how
or why a tumour ulcerates and the biological explanation for its impact on prognosis
[155, 640]. Ulceration may be a feature that represents some characteristic of the
tumour such as greater proliferative activity or superior metastatic capacity [155, 640].
Other hypotheses are that ulceration is associated with adverse host/tumour interaction
which might be determined by innate characteristics of the host or tumour [155, 640]. I
will explore the evidence for these hypotheses below.
Ulceration may simply result from increased proliferative activity which erodes the
epidermis during tumour expansion and makes the tumour more likely to metastasise.
However mitotic rate and ulceration are independently associated with prognosis in
stage I/II melanoma, suggesting that a distinct biological process, in addition to cell
proliferation, is occurring in ulcerated tumours, which contributes to poorer prognosis
[58, 96, 98, 155, 640, 641].
The presence of ulceration may indicate differences in the way that tumour cells modify
the local tumour environment, thereby contributing to spread of the tumour [155, 640,
642]. Once melanoma cells pass across the epidermal-dermal junction in skin, their
ability to metastasise is greatly increased [643]. Normal melanocytes are linked by cell-
cell adhesion molecules, such as E-cadherin and desmoglein, and gap junctions to
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keratinocytes in the epidermis which control melanocyte cell growth and dendricity via
paracrine growth factors, intracellular and intercellular mechanisms [53, 643-646].
When uncoupled from keratinocytes and their control mechanisms, melanoma cells
communicate with each other and fibroblasts via N-cadherin, cell adhesion molecules
from the immunoglobulin gene superfamily, integrins and connexins [53, 642].
Melanoma cells thus down-regulate receptors which mediate interaction with
keratinocytes, such as E-cadherin and desmoglein, and up-regulate molecules that
mediate melanoma cell communication or interactions between melanoma cells and
fibroblasts, such as N-cadherin [53, 644]. Deranged expression of integrins which bind
to extracellular matrix can also contribute to loss of keratinocyte communication by
allowing separation from the basement membrane [53]. Lack of intact epidermis in
ulcerated tumours may represent a mechanism by which a tumour directly modifies the
microenvironment to further evade keratinocyte control [642]. In addition, there is
evidence that deranged expression of proteins which influence tumour and extracellular
matrix interaction are associated with tumour progression such as osteopontin (as
discussed in Chapter 3) and CCN3 (nephroblastoma overexpressed or NOV) [640,
647]. Invasion of melanoma tumours with deranged expression of matrix proteins is
likely to be enhanced by the lack of keratinocyte control within an ulcerated tumour
[642], however there is little evidence currently to support this theory.
It has been hypothesised that the presence of tumour ulceration may modify immune
responses, as suggested in a study of 537 sentinel lymph nodes containing micro-
metastatic deposits of tumour [648]. Nodes were stained for mature dendritic cells
(DCs); lower DC densities were found in nodes in association with an ulcerated primary
tumour [648]. DCs are vital for antigen presentation to T-cells thereby initiating specific
adaptive immune responses, and immature plasmacytoid DCs are the largest
producers of type I interferons, such as IFN [212, 649]. Therefore, it was suggested
that ulceration might be associated with a defect in stimulation of adaptive immunity,
which is likely to contribute to its prognostic and perhaps predictive influence [155,
640]. Whether the biology of an ulcerated tumour causes less mature DCs in sentinel
nodes or whether host factors modify this response requires investigation [155, 640]. A
further observation related to immune responses is provided by gene expression
profiling of primary melanoma tumours from 58 patients [178]. A very different gene
expression pattern was found in ulcerated tumours versus non-ulcerated tumours, and
the authors specifically highlighted that the gene encoding the pro-inflammatory
cytokine interleukin-6 (IL6) was differentially expressed [178]. The relationship between
inflammation and cancer development and metastasis is known to be important [650,
651]. These data suggest that ulceration may contribute to this inflammatory process in
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primary melanoma tumours. In addition, higher serum levels of pro-inflammatory
cytokines, such as IL6, IL1 and IL1, detected prior to IFN treatment have been
associated with longer RFS following therapy [652], with higher serum levels of IL6
being associated with poorer prognosis in advanced disease [653-655]. The prognostic
and predictive influence of serum IL6 levels requires confirmation; however levels of
this cytokine appear to have very similar prognostic and predictive associations to
tumour ulceration.
A number of poor prognostic primary tumour histological features have been
associated with ulceration. Greater Breslow thickness was associated with higher
incidence of ulceration in the large study of 17,600 patients used to validate the 6th
edition of AJCC staging [91], and from the same database, higher mitotic rate,
recorded for 13,296 patients, was also associated with ulceration status [98]. Kashani-
Sabet and colleagues studied 417 primary tumours and found increased tumour
vascularity in ulcerated tumours [111]. Recently, lymphovascular invasion has also
been associated with ulceration in a study of 2183 patients, 171 of whom had evidence
of tumour lymphovascular invasion [656]. These studies have used routine
haematoxylin and eosin (H+E) staining to assess lymphovascular invasion and
vascular density; however use of specific antibodies for vessels increases detection
rates versus H+E slides alone [110, 382-384]. Studies using immunohistochemical
staining of D2-40 or LYVE-1, for lymphatic vessels, and CD34, to assess all vessels, in
primary melanoma tumours have also found that lymphovascular invasion and
lymphatic density is associated with ulceration [110, 657]. The association between
lymphovascular invasion and ulceration suggests that there may be common biological
processes, perhaps related to tissue hypoxia and host/tumour interaction, causing both
ulceration and vascular invasion [110]. What is unclear is whether vascular invasion or
ulceration contributes most to tumour invasion [110]. As discussed previously,
ulceration remains prognostic in stage III disease, therefore it is unsurprising that in a
study of 1526 patients primary tumour ulceration is independently associated with
positive sentinel node biopsy in multivariate analyses with primary tumour histology
[658]. In summary, ulceration is associated with poor prognostic features in the primary
tumour and tumour deposits in sentinel lymph nodes.
In order to gain some further insight into the biological processes within ulcerated
tumours and how this relates to prognosis and IFN action, this chapter presents results
of analyses designed to identify primary tumour and patient characteristics associated
with tumour ulceration in a large cohort of patients. Gene expression data were
generated for 502 cancer-related genes from a subset of the primary tumours, allowing
identification of genes differentially expressed in ulcerated tumours. Furthermore,
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immunohistochemical staining was performed at the University of Nottingham on a
further subset of tumours to identify blood and lymphatic vascular invasion (D2-40 and
CD34), vessel density and presence of tumour-associated macrophages (CD68), to
allow examination of associations between these factors and ulceration [113]. Analysis
of patient information, tumour histology, immunohistochemical staining and tumour
gene expression data has allowed an extensive and integrated investigation of factors
associated with ulceration. It has allowed identification of factors independently
associated with ulceration in multivariate analyses and has revealed insight into
biological processes within ulcerated tumours that are directly related to the influence
of ulceration on prognosis and treatment response.
7.3 Methods
7.3.1 Patients and primary melanoma samples
Samples and data from patients recruited to the Leeds Melanoma Cohort Study
(Cohort study) and Retrospective Sentinel Node Biopsy Study (SNB study) were used
for this work. These studies are described in further detail in Chapter 2. Histology data
for the majority of cases were derived from histology reports. For a subset of tumours
diagnostic H+E slides were reviewed by Dr Andy Boon (Cohort study) or Professor
Martin Cook (SNB study), described in further detail in Chapter 2, to standardize
reporting across the specimens. Gene expression data were derived from formalin-
fixed paraffin-embedded (FFPE) primary melanoma tumours from a subset of patients
recruited to each of the two studies.
From the SNB study, H+E slides from FFPE primary tumours blocks were reviewed by
Dr Angana Mitra to assess whether they would be suitable for IHC staining, based
upon the need to sample representative areas of the tumour without excessive damage
to the clinical block. Where two tumour blocks were available with similar tumour
features from the same patient, one block was used for tumour sampling for gene
expression analysis as described in Chapter 2 and the other was used for IHC. If only
one block was available, the block was cored first for gene expression analysis and
then sections were taken for IHC staining. Some blocks were not sampled because of
size. Tumour blocks containing only punch or curettage specimens were not used for
IHC staining as these specimens were not representative of the larger tumour. From
the selected specimens, four consecutive 4μm sections were cut from each tumour 
block by Filomena Esteves, using a microtome. This process is summarised in Figure
7-1. Adjacent sections were carefully retained so that the IHC staining was of
contiguous tumour.
Figure 7-1: Assessment of tumour samples for tissue sampling for gene
expression and immunohistochemical studies.
The process is described in further detail in the text.
haematoxylin and eosin; IHC, immunohistochemistry.
7.3.2 Immunohistochemistry (I
IHC staining and measurement of vessels and macrophages was performed by Sarah
Storr and Sabreena Safuan at University of Nottingham by a Academic Oncology
research group who perform studies primarily addressed to understanding the role of
tumour vasculature in breast cancer progression. Sections were stained with D2
CD34, and a CD68 antibodies and microvessel density, macrophage count, lymphatic
density and vascular invasion were assessed using methods described in Chapter 2.
We were unable to assess subtypes of tumour
limited tissue availability.
Very small
amounts of
tumour
Not sampled
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7.3.3 Gene expression data
Gene expression data were generated for 502 cancer-related genes using the Human
Cancer panel and the cDNA-mediated, annealing, selection, extension and ligation
(DASL) assay as described in Chapter 2. The samples selected for gene expression
analysis are described in Chapter 3 and processing of gene expression data to
generate a merged dataset from the two studies is described in detail in Chapter 4.
7.3.4 Statistical analysis
To identify associations with ulceration status and histological (including IHC) or patient
factors, Pearson’s Chi-squared (χ2) tests or Fisher’s exact tests (where the frequency
of observations in a subgroup was less than 5) were performed for categorical
variables and Mann-Whitney U tests for continuous variables. For the subset of
samples with H+E sections centrally reviewed by expert pathologists, analyses were
repeated to confirm results found in the larger datasets. For IHC data, vessel density
and macrophage counts were categorised into high and low groups around the median
value. To identify factors independently associated with ulceration status, multiple
logistic regression was performed using factors significantly associated with ulceration
in univariate analysis. For these analyses, Breslow thickness and mitotic rate were
analysed as categorical variables based on AJCC staging criteria, and results of a test
for trend across the groups is presented. For Breslow thickness, categories were
≤1mm, >1 to ≤2mm, >2 to ≤4mm and >4mm. For mitotic rate, categories were <1 
mitosis/mm2, 1-6 mitoses/mm2 and >6 mitoses/mm2. To maximise the number of
observations assessed in each analysis, multiple logistic regression was performed
separately for clinico-pathological data and IHC data provided by the University of
Nottingham. The significance level for these analyses was set at 0.05.
Gene expression analysis was performed using the dataset generated as described in
Chapter 4. Differential gene expression analysis was performed using log-transformed
(log2) data. As some of the raw gene expression levels were negative values, 1000 was
added to all values prior to log-transformation. Associations between gene expression
and ulceration status were identified using linear regression adjusting for the study type
to which the patient was recruited. Fold changes in mean gene expression between
ulcerated and non-ulcerated tumours were calculated using data that had not been log-
transformed. A Bonferroni correction was used to adjust for multiple testing as
described in Chapter 4, with significance level being set at 0.0001. All statistical
analyses were undertaken using Stata version 10 (StataCorp 2007, College Station,
TX).
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7.3.5 Pathway analysis
Pathway analysis of gene expression data was performed using DAVID (the database
for annotation, visualisation and integrated discovery) [368] to identify overrepresented
pathways in the list of differentially expressed genes [369, 371, 372]. Further detail of
algorithms used by DAVID software are described in Chapter 2. For this analysis, the
502-gene Human Cancer panel of genes was inputted as the background population of
genes for comparison with the list of genes differentially expressed in ulcerated
tumours. From the 502-gene background list, 479 genes were recognised by DAVID. A
list of 109 differentially expressed genes (significance values <0.05) were inputted into
DAVID, with 103 genes being recognised by the software for analysis. Enrichment
analysis was performed to identify KEGG (Kyoto Encylopedia of Genes and Genomes)
[469, 470] pathways enriched in the gene list.
7.4 Results
7.4.1 Patients and tumour samples
A total of 1804 patients recruited to the Cohort study and SNB study had the ulceration
status of primary tumour recorded, and these data were used for analysis of clinico-
pathological features associated with ulceration status. Of these patients, 368 (20%)
had centrally reviewed primary tumour histopathological data. Gene expression data
was available for 348 primary tumours from this patient group, 339 (97%) of which had
had central pathology review.
Out of the 218 tumour blocks received for the SNB study, 202 were suitable for
sectioning for IHC staining. Of these 130 (64%) tumour blocks had also been cored for
use in gene expression work described in Chapters 3 and 4. Of the 202 tumours
stained, lymphovascular and macrophage measurements were successfully taken for
the majority of samples, and 195 tumours had ulceration status recorded for use in the
analyses described in this chapter. One hundred and eighty six (95%) of these tumours
had had diagnostic H+E slides centrally reviewed.
7.4.2 Effect of central histology review on ulceration status
Figure 7-2 describes changes that were made to ulceration status following central
histology review. This analysis demonstrates that a significant proportion of ulceration
status in histopathology reports generated in clinical practice are changed following
review, highlighting the importance of central review and the variability that can be
found in reporting between pathologists
the number of cases for which ulceration status is reported, increasing the power of the
following analyses. Following this review, a total of 25% of tumours from the larger
dataset were ulcerated.
Figure 7-2: Changes in reported ulceration status of melanoma primary tumours
following central histological review.
7.4.3 Univariate analyses of clinico
ulceration
Table 7-1 presents results of univariate analyses for the large dataset and the smaller
centrally reviewed sample set.
mitotic rate were associated w
tumour factors were associated with ulceration such as presence of vascular invasion
(p<0.0001), perineural infiltration (p=0.003) and microsatellites (p<0.0001). Nodular
tumours and tumours on sun
and patients were more likely to be older (p<0.00001) and male (p=0.001) if the tumour
was ulcerated. In view of the prognostic influence of ulceration, it is unsurprising that
patients with ulcerated tumours were more likely to have positive sentinel node
biopsies (p<0.0001) and were more likely to relapse and die (p<0.0001). The majority
of these factors were also associated with ulceration in the smaller centrally reviewed
dataset. Presence of pe
gender (p=0.21) and sentinel node biopsy status (p=0.20) were no longer statistically
significant in the smaller dataset, which likely reflects lower power, however the trends
were similar to those in the larger dataset.
Cohort study: 175
samples
5 had ulceration status
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[298, 299]. This process has also increased
-pathological factors and
In the large dataset, greater Breslow thickness and
ith ulceration (p<0.00001). In addition, other prognostic
-protected sites are more likely to be ulcerated (p<0.0001)
rineural infiltration (p=0.61), microsatellitosis (p=0.05), patient
changed (3%)
4 samples from
ulcerated to not
ulcerated
32 samples with
ulceration status not
recorded (18%): all
reclassified as not
ulcerated
SNB study: 193
samples
18 had ulceration status
changed (9%)
14 samples from
ulcerated to not
ulcerated
54 samples with
ulceration not recorded
(28%): 4 classified as
ulcerated, 50 as not
ulcerated
Whole dataset Centrally reviewed dataset
Factor
Non-
ulcerated
(n=1357)
Ulcerated
(n=447)
Test statistic
and P-value
Non-ulcerated
(n=276)
Ulcerated
(n=92)
Test statistic
and P-value
Study type, n (%):
Cohort study
SNB study
1008 (74.3)
349 (25.7)
311 (69.6)
136 (30.4)
131 (47.5)
145 (52.5)
44 (47.8)
48 (52.2)
Breslow thickness, mm
median (range) 1.4 (0.2-24.0) 3.0 (0.5-19.0)
Mann-Whitney
z -19.1, p<0.00001 1.7 (0.4-12.0) 3.2 (1.0-19.0)
Mann-Whitney
z -8.1, p<0.00001
Mitotic rate per mm2
median (range) 2 (0-52) 6 (0-84)
Mann-Whitney
z -11.3, p<0.00001 3.0 (0-39) 7 (0-40)
Mann-Whitney
z -5.1, p<0.00001
Tumour infiltrating lymphocytes, n (%):
None
Present
177 (15.7)
951 (84.3)
59 (15.6)
319 (84.4)
χ2 (1) 0.002, p=0.97 54 (21.9)
193 (78.1)
14 (16.1)
73 (83.9)
χ2 (1) 1.3, p=0.25
Vascular or lymphatic invasion, n (%):
None
Present
839 (95.5)
40 (4.6)
250 (82.8)
52 (17.2)
χ2 (1) 50.2, p<0.0001 253 (93.0)
19 (7.0)
75 (85.2)
13 (14.8)
χ2 (1) 5.0, p=0.03
Perineural infiltration, n (%):
None
Present
345 (98.0)
7 (2.0)
121 (92.4)
10 (7.6)
χ2 (1) 9.0, p=0.003 154 (97.5)
4 (2.5)
49 (96.1)
2 (3.9)
χ2 (1) 0.3, p=0.61
Regression, n (%):
No
Yes
980 (83.3)
197 (16.7)
286 (82.2)
62 (17.8)
χ2 (1) 0.2, p=0.64 211 (86.8)
32 (13.2)
68 (80.0)
17 (20.0)
χ2 (1) 2.3, p=0.13
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Whole dataset Centrally reviewed dataset
Factor
Non-
ulcerated
(n=1357)
Ulcerated
(n=447)
Test statistic
and P-value
Non-ulcerated
(n=276)
Ulcerated
(n=92)
Test statistic
and P-value
Microsatellites, n (%)
None
Present
791 (96.6)
28 (3.4)
273 (90.7)
28 (9.3)
χ2 (1) 16.0, p<0.0001 219 (92.4)
18 (7.6)
75 (85.2)
13 (14.8)
χ2 (1) 3.8, p=0.05
Histological subtype, n (%):
SSM
NM
Other
887 (68.3)
234 (18.0)
177 (13.6)
177 (41.8)
175 (41.3)
72 (17.0)
χ2 (2) 111.8,
p<0.0001
198 (72.8)
52 (19.1)
22 (8.1)
46 (50.0)
35 (38.0)
11 (12.0)
χ2 (2) 16.8, p<0.0001
Age at diagnosis, median (range) 53.3(14.4-87.0)
58.8
(18.1-88.5)
Mann-Whitney
z -6.7, p<0.00001
52.6
(14.4-87.0)
57.2
(22.7-88.0)
Mann-Whitney
z -2.5, p=0.01
Patient gender, n (%)
Female
Male
778 (57.3)
579 (42.7)
217 (48.6)
230 (51.5)
χ2 (1) 10.5, p=0.001 144 (52.2)
132 (47.8)
41 (44.6)
51 (55.4)
χ2 (1) 1.6, p=0.21
Site of tumour, n (%):
Trunk
Leg
Arm
Head/neck
Sun protected
Unknown
484 (35.7)
440 (32.4)
268 (19.8)
133 (9.8)
31 (2.3)
1 (0.07)
170 (38.0)
112 (25.1)
67 (15.0)
46 (10.3)
52 (11.6)
0
χ2 (5) 74.9, p<0.0001
91 (33.0)
94 (34.1)
58 (21.0)
26 (9.4)
7 (2.5)
0
34 (37.0)
21 (22.8)
16 (17.4)
14 (15.2)
7 (7.6)
0
χ2 (4) 10.4, p=0.04
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Whole dataset Centrally reviewed dataset
Factor
Non-
ulcerated
(n=1357)
Ulcerated
(n=447)
Test statistic
and P-value
Non-ulcerated
(n=276)
Ulcerated
(n=92)
Test statistic
and P-value
SNB status, n (%)
No SNB
SNB performed – negative
SNB performed – positive
725 (54.5)
386 (29.0)
219 (16.5)
203 (47.1)
108 (25.1)
120 (27.8)
χ2 (2) 27.1, p<0.0001 98 (35.8)78 (28.5)
98 (35.8)
34 (38.2)
17 (19.1)
38 (42.7)
χ2 (2) 3.2, p=0.20
Relapse status, n (%)
Not relapse
Relapsed
1138 (84.3)
212 (15.7)
263 (59.0)
183 (41.0)
χ2 (1) 125.4,
p<0.0001 204 (75.3)67 (24.7)
42 (45.7)
50 (54.4)
χ2 (1) 27.6, p<0.0001
Overall survival, n (%)
Alive
Died
1147 (84.5)
210 (15.5)
275 (61.5)
172 (38.5)
χ2 (1) 106.6,
p<0.0001 200 (72.5)76 (27.5)
47 (51.1)
45 (48.9)
χ2 (1) 14.3, p<0.0001
Table 7-1: Associations between clinico-pathological features and ulceration in univariate analysis.
Results are presented for the larger dataset and the smaller centrally reviewed dataset. Statistical tests (degrees of freedom) and significance
values are presented for association between the factor and ulceration status. Generally speaking analyses in the large and the much smaller
centrally reviewed data sets produced similar results. Statistically significant results are highlighted in bold. Abbreviations used: SNB, sentinel
node biopsy; n, number.
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7.4.4 Factors independently associated with ulceration
Factors found to be associated with ulceration in the larger dataset in univariate
analysis were analysed using multiple logistic regression to identify factors
independently associated with ulceration. Perineural infiltration was omitted from the
model because of small numbers of observations. The results for the larger dataset are
presented in Table 7-2 with results for the smaller centrally reviewed dataset in Table
7-3.
Univariate logistic regression of the larger dataset confirmed that factors identified in
Table 7-1 were associated with ulceration status. In multivariate analysis, greater
Breslow thickness (test for trend across a categorical variable based on AJCC staging
criteria, odds ratio (OR) 2.62 (95% CI 2.07-3.32) p<0.0001), mitotic rate (test for trend,
OR 1.53 (95% CI 1.12-2.09) p=0.008) and tumours of sun-protected sites (OR 4.70
(95% CI 2.05-10.80) p<0.0001) were independently associated with ulceration status.
Overall, 63% of tumours from sun-protected sites were ulcerated, with the majority of
tumours being from acral skin of the palms or soles of feet (60%) or subungual (21%).
In the smaller centrally reviewed dataset, the only factor independently associated with
ulceration status in multivariate analysis was greater Breslow thickness (test for trend,
OR 2.93 (95% CI 1.94-4.45) p<0.0001).
.
Univariate analysis Multivariate analysis (n=892)
Factor
No. in non-
ulcerated
group
No. in
ulcerated
group
OR (95% CI) P-value OR (95% CI) P-value
Breslow thickness, mm 1354 442 3.26 (2.84-3.74) p<0.0001 2.62 (2.07-3.32) p<0.0001
Mitotic rate per mm2 831 291 3.01 (2.39-3.79) p<0.0001 1.53 (1.12-2.09) p=0.008
Tumour infiltrating lymphocytes:
None
Present
177
951
59
319
1.0
1.01 (0.73-1.39)
p=0.97
Vascular or lymphatic invasion:
None
Present
839
40
250
52
1.0
4.36 (2.82-6.75)
p<0.0001 1.0
1.60 (0.89-2.88) p=0.12
Perineural infiltration:
None
Present
345
7
121
10
1.0
4.07 (1.52-10.94)
p=0.005
Not included
because of low
numbers of
observations
Regression:
No
Yes
980
197
286
62
1.0
1.08 (0.79-1.48)
p=0.64
Microsatellites:
None
Present
791
28
273
28
1.0
2.90 (1.69-4.98)
p<0.0001 1.0
1.20 (0.57-2.54) p=0.63
Histological subtype:
SSM
NM
Other
887
234
177
177
175
72
1.0
3.75 (2.91-4.83)
2.04 (1.48-2.80)
p<0.0001
p<0.0001
1.0
1.14 (0.75-1.75)
1.06 (0.60-1.88)
p=0.54
p=0.84
Age at diagnosis, years 1357 447 1.03 (1.02-1.04) p<0.0001 1.01 (1.00-1.02) p=0.13
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Univariate analysis Multivariate analysis (n=892)
Factor
No. in non-
ulcerated
group
No. in
ulcerated
group
OR (95% CI) P-value OR (95% CI) P-value
Patient gender
Female
Male
778
579
217
230
1.0
1.42 (1.15-1.77)
p=0.001 1.0
1.28 (0.88-1.86) p=0.19
Site of tumour:
Trunk
Leg
Arm
Head/neck
Sun protected
484
440
268
133
31
170
112
67
46
52
1.0
0.73 (0.55-0.95)
0.71 (0.52-0.98)
0.99 (0.68-1.44)
4.78 (2.96-7.70)
p=0.02
p=0.04
p=0.94
p<0.0001
1.0
1.13 (0.71-1.81)
1.02 (0.61-1.70)
0.90 (0.49-1.65)
4.70 (2.05-10.80)
p=0.60
p=0.96
p=0.73
p<0.0001
SNB status:
No SNB
SNB performed – negative
SNB performed – positive
725
386
219
203
108
120
1.0
1.00 (0.77-1.30)
1.96 (1.49-2.57)
p=1.00
p<0.0001
1.0
1.14 (0.72-1.81)
0.78 (0.50-1.21)
p=0.57
p=0.27
Table 7-2: Results of univariate and multivariate logistic regression analyses in the larger dataset identifying clinico-pathological factors
associated with ulceration status.
Breslow thickness, mitotic rate and origin in a sun-protected site were all independently associated with ulceration status. Odds ratios, 95%
confidence intervals and significance values are presented for the associations between each factor and ulceration in the univariate setting and
then significant factors were included in a multiple logistic regression model. Results for Breslow thickness and mitotic rate are from a test for
trend across categorical variables based on American Joint Committee on Cancer staging criteria as described in 7.3.4. Statistically significant
results are highlighted in bold. Abbreviations used: OR, odds ratio; CI, confidence interval; SNB, sentinel node biopsy.
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Univariate analysis Multivariate analysis (n=343)
Factor
No. in non-
ulcerated
group
No. in
ulcerated
group
OR (95% CI) P-value OR (95% CI) P-value
Breslow thickness, mm 276 91 3.36 (2.39-4.73) p<0.0001 2.93 (1.94-4.45) p<0.0001
Mitotic rate per mm2 268 87 2.17 (1.48-3.20) p<0.0001 1.32 (0.85-2.07) p=0.22
Tumour infiltrating lymphocytes:
None
Present
54
193
14
73
1.0
1.46 (0.76-2.79)
p=0.25
Vascular or lymphatic invasion:
None
Present
253
19
75
13
1.0
2.31 (1.09-4.89)
p=0.03 1.0
1.03 (0.43-2.47) p=0.96
Perineural infiltration:
None
Present
154
4
49
2
1.0
1.57 (0.28-8.84)
p=0.61
Regression:
No
Yes
211
32
68
17
1.0
1.65 (0.86-3.15)
p=0.13
Microsatellites:
None
Present
219
18
75
13
1.0
2.11 (0.99-4.51)
p=0.05
Histological subtype:
SSM
NM
Other
198
52
22
46
35
11
1.0
2.90 (1.70-4.95)
2.15 (0.98-4.75)
p<0.0001
p=0.06
1.0
1.37 (0.72-2.62)
2.12 (0.82-5.46)
p=0.34
p=0.12
Age at diagnosis, years 276 92 1.02 (1.01-1.04) p=0.01 1.02 (1.00-1.04) p=0.09
Patient gender
Female
Male
144
132
41
51
1.0
1.35 (0.85-2.18)
p=0.21
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Univariate analysis Multivariate analysis (n=343)
Factor
No. in non-
ulcerated
group
No. in
ulcerated
group
OR (95% CI) P-value OR (95% CI) P-value
Site of tumour:
Trunk
Leg
Arm
Head/neck
Sun protected
91
94
58
26
7
34
21
16
14
7
1.0
0.60 (0.32-1.11)
0.74 (0.37-1.46)
1.44 (0.67-3.08)
2.68 (0.87-8.20)
p=0.10
p=0.38
p=0.35
p=0.09
SNB status:
No SNB
SNB performed – neg
SNB performed – pos
98
78
98
34
17
38
1.0
0.63 (0.33-1.21)
1.12 (0.65-1.92)
p=0.16
p=0.69
Table 7-3: Results of univariate and multivariate logistic regression analyses with the significantly smaller data set subjected to central
review of histology: clinico-pathological factors associated with ulceration status.
The results were similar to those in the larger data set but were statistically less robust probably related to sample size. Odds ratios, 95%
confidence intervals and significance values are present for the associations between each factor and ulceration in the univariate setting and
then significant factors were included in a multiple logistic regression model. Results for Breslow thickness and mitotic rate are from a test for
trend across categorical variables based on American Joint Committee on Cancer staging criteria as described in 7.3.4. Statistically significant
results are highlighted in bold. Abbreviations used: OR, odds ratio; CI, confidence interval; SNB, sentinel node biopsy.
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7.4.5 Associations between IHC data and ulceration status
A comparison between IHC and H+E staining methodologies and the relationship
between vascular invasion and clinico-pathological data, including ulceration, using the
data presented in this chapter has been previously published [113] and will not be
described in further detail. Results presented here concentrate in more detail on the
relationship between ulceration and tumour factors identified using IHC.
Results of univariate and multivariate analyses to identify associations between
tumours factors determined by IHC and ulceration status are presented in Table 7-4.
The variable “any vessel invasion” was not included in the multivariate model as it was
generated from the “blood vessel invasion” and “lymphatic vessel invasion” variables.
In addition, the variable “lymphatic invasion” was used in preference to “intratumoural
lymphatic invasion” and “peritumoural lymphatic invasion” in the multivariate model as
these variables were highly correlated with “lymphatic invasion” which was most
associated with ulceration in univariate pairwise analysis. Univariate analyses showed
that lymphatic invasion, both intratumourally (inner two thirds of the tumour) and
peritumourally (all normal tissue surrounding tumour) was associated with tumour
ulceration (p <0.0001). Higher microvessel density and macrophage count were also
associated with tumour ulceration (p<0.0001). In the multivariate model, presence of
lymphatic invasion (OR 3.59, 95% CI 1.64-7.87, p=0.001), greater microvessel density
(OR 2.59, 95% CI 1.16-5.80, p=0.02) and macrophage count (OR 2.42, 95% CI 1.07-
5.50, p=0.03) remain independently associated with ulceration status.
Univariate logistic regression Multivariate logisticregression (n=169)
Factor
Not
ulcerated
(n=145)
Ulcerated
(n=50)
Test statistic
and P-value OR (95% CI) P-value OR (95% CI) P-value
Invasion on H+E slide, n (%):
No
Present/possible
129 (90.9)
13 (9.2)
48 (96.0)
2 (4.0)
Fisher’s exact
p=0.36 1.00.41 (0.09-1.90) p=0.26
Blood vessel invasion (CD34), n (%):
Negative
Positive
130 (97.0)
4 (3.0)
46 (93.9)
3 (6.1)
Fisher’s exact
p=0.39 1.02.12 (0.46-9.83) p=0.34
Lymphatic invasion (D2-40), n (%):
Negative
Positive/possible
109 (82.6)
23 (17.4)
22 (46.8)
25 (53.2)
χ2 (1) 22.6,
p<0.0001 1.05.39 (2.60-11.16) p<0.0001
1.0
3.59 (1.64-7.87) p=0.001
Any vessel invasion using IHC, n (%):
Both negative
Either positive/possible
103 (79.8)
26 (20.2)
22 (45.8)
26 (54.2)
χ2 (1) 19.5,
p<0.0001 1.04.68 (2.30-9.55) p<0.0001
Intratumoural lymphatic invasion, n (%):
Negative
Positive/possible
121 (89.0)
15 (11.0)
31 (64.6)
17 (35.4)
χ2 (1) 14.7,
p<0.0001 1.04.42 (1.99-9.83) p<0.0001
Peritumoural lymphatic invasion, n (%):
Negative
Positive/possible
119 (91.5)
11 (8.5)
29 (65.9)
15 (34.1)
χ2 (1) 17.0,
p<0.0001 1.05.60 (2.33-13.46)
p<0.0001
Lymphatic density, n (%):
Low
High
69 (50.7)
67 (49.3)
23 (47.9)
25 (52.1)
χ2 (1) 0.1,
p=0.74 1.01.12 (0.58-2.16)
p=0.74
Intratumoral lymphatic density, n (%):
Low
High
69 (50.7)
67 (49.3)
21 (43.8)
27 (56.3)
χ2 (1) 0.7,
p=0.41 1.01.32 (0.68-2.57)
p=0.41
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Univariate logistic regression Multivariate logisticregression (n=169)
Factor
Not
ulcerated
(n=145)
Ulcerated
(n=50)
Test statistic
and P-value OR (95% CI) P-value OR (95% CI) P-value
Peritumoural lymphatic density, n (%):
Low
High
66 (50.8)
64 (49.2)
21 (47.7)
23 (52.3)
χ2 (1) 0.1,
p=0.73 1.01.13 (0.57-2.24)
p=0.73
Microvessel density, n (%):
Low
High
80 (59.7)
54 (40.3)
12 (24.5)
37 (75.5)
χ2 (1) 17.8,
p<0.0001 1.04.57 (2.19-9.55)
p<0.0001 1.0
2.59 (1.16-5.80)
p=0.02
Macrophage count, n (%):
Low
High
79 (56.8)
60 (43.2)
14 (28.0)
36 (72.0)
χ2 (1) 12.2,
p<0.0001 1.03.39 (1.68-6.84)
p=0.001 1.0
2.42 (1.07-5.50)
p=0.03
Table 7-4: Results of univariate and multivariate analyses identifying associations between lymphovascular parameters and macrophage
count (determined using immunohistochemistry), and ulceration status in primary melanoma tumours.
Statistical tests (degrees of freedom) and significance values are presented for association between the factor and ulceration status in pairwise
tests. For logistic regression analyses, odds ratios, 95% confidence intervals and significance values are presented for the associations
between each factor and ulceration in the univariate analysis and then significant factors were included in a multiple logistic regression model.
Additional details of variables included in the multivariate model are included in the text. Vessel density and macrophage counts were
categorised into high and low groups around the median value. Significance values quoted for Fisher’s exact tests are 2-sided. Statistically
significant results are highlighted in bold. Abbreviations used: H+E, haematoxylin and eosin; n, number.
.
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7.4.6 Gene expression profiles associated with tumour ulceration
The top 20 genes differentially expressed in ulcerated tumours for the 348 tumours for
which gene expression data were available are listed in Table 7-5.
Gene
Mean fold difference in
gene expression
(ulcerated/non-ulcerated)
Significance value
HLF 0.67 1.73x10-08
FGFR3 0.73 3.96x10-08
DSP 0.68 5.26x10-08
GRB7 0.67 2.21x10-07
FGFR2 0.59 4.17x10-07
MAF 0.92 3.69x10-06
ITGB4 0.78 6.39x10-06
IL6 1.73 0.00001
RAD52 1.15 0.00001
EPHA1 0.74 0.00001
FGF7 1.35 0.00002
SPP1 1.34 0.00002
CEBPA 0.77 0.00002
CDH1 0.83 0.00003
OSM 1.80 0.00004
MMP1 1.52 0.00005
EGFR 0.74 0.0001
PTGS1 0.80 0.0001
EPO 0.81 0.0001
Table 7-5: Top 20 genes differentially expressed in ulcerated tumours.
Significance value is derived from linear regression adjusting for the study to
which patients were recruited. Genes involved in cell adhesion are highlighted in
dark green, fibroblast growth factors and their receptors are highlighted in
medium green and the pro-inflammatory cytokine interleukin-6 is highlighted in
light green.
This list shows that a number of genes involved in cell adhesion (DSP, ITGB4 and
CDH1) were down-regulated in ulcerated tumours. Fibroblast growth factor 7 (FGF7),
otherwise known as keratinocyte growth factor, was up-regulated in ulcerated tumours,
with fibroblast growth factors receptors (FGFR2 and FGFR3) being down-regulated.
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The pro-inflammatory cytokine gene interleukin-6 (IL6) was over-expressed in
ulcerated tumours.
Pathway analysis was performed using DAVID software to identify enriched pathways
in this dataset. Table 7-6 presents the top five most enriched KEGG (Kyoto
Encylopedia of Genes and Genomes) pathways out of a total of 52 pathways identified
containing 70 of the inputted genes [469, 470]. The top five enriched KEGG pathways
included ‘Pathways in cancer’, which is unsurprising as a cancer panel of genes was
used for gene expression profiling, but also the ‘Cytokine-cytokine receptor interaction’
pathway, the ‘Jak-STAT signalling pathway’ and the ‘Focal adhesion’ pathway. Type 1
interferons act via Jak-STAT signalling [213, 220], therefore identification of deranged
gene expression for components of this pathway in ulcerated tumours is of great
interest. Genes involved with focal adhesion were identified by review of the gene list
with pathway analysis confirming their importance. Figure 7-3 presents visually which
genes are under- and over-expressed in ulcerated tumours in the Jak-STAT KEGG
pathway.
7.5 Discussion
7.5.1 Relationship between ulceration and clinico-pathological
factors
Tumour ulceration has a profound influence on the likelihood of survival for melanoma
patients [58] and is reported to have a predictive influence on benefit received from IFN
therapy [204, 231]. It is therefore important to understand the biology of this
phenomenon.
In this study, analysis of clinico-pathological features associated with ulceration in a
large sample set and the smaller centrally reviewed set has shown that a number of
poor prognostic tumour features, such as Breslow thickness, mitotic rate and presence
of lymphovascular invasion, were associated with the presence of ulceration. Ulcerated
tumours were more likely to be of the nodular subtype, arising in a sun-protected site
and found in older patients. The association with age was not independently significant,
but the statistical power to detect a small effect was limited. As I discuss below chronic
.
KEGG Pathway Numberof genes
% of
genes P-Value
Bonferroni
corrected P-
value
Benjamini
corrected
P-value
False
discovery
rate
hsa05200: Pathways in cancer 31 30.10 5.78x10-24 4.97x10-22 4.97x10-22 6.23x10-21
hsa05219: Bladder cancer 11 10.68 4.04x10-11 3.47x10-09 1.74x10-09 4.36x10-08
hsa04060: Cytokine-cytokine receptor interaction 13 12.62 2.14x10-10 1.84x10-08 6.15x10-09 2.31x10-07
hsa04630: Jak-STAT signalling pathway 11 10.68 1.20x10-09 1.03x10-07 2.58x10-08 1.29x10-06
hsa04510: Focal adhesion 12 11.65 4.46x10-09 3.84x10-07 7.67x10-08 4.81x10-06
Table 7-6: Top 5 KEGG (Kyoto Encylopedia of Genes and Genomes) pathways containing differentially expressed genes in ulcerated
tumours.
The number and percentage of genes in the gene list associated with each term is presented. Significance values for representation of genes
in the pathway without correction for multiple testing are presented with corrected significance values using the Bonferroni correction [366] and
the Benjamini and Hochberg correction [367]. The false discovery rate (FDR) is also presented.
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Figure 7-3: The KEGG (Kyoto Encylopedia of Genes and Genomes) ‘Jak-STAT signalling pathway’ adapted to demonstrate fold changes in
gene expression between ulcerated and non-ulcerated tumours.
Blue arrows indicate under-expression of genes in ulcerated tumours, with over-expression indicated by red arrows. The diagram has been
adapted from the KEGG hsa04630: Jak-STAT signalling pathway diagram [469, 470, 659].
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inflammation is postulated to be a mechanism involved in determining ulceration which
is more frequent with age, which is perhaps of some interest [660, 661].
The factors which remained independently associated with ulceration in multivariate
analysis of the large sample set were Breslow thickness, mitotic rate and tumour site,
with ulceration being more frequently present in tumours arising in a sun-protected site,
with only Breslow thickness remaining significant in the smaller centrally reviewed set.
Breslow thickness and mitotic rate are the other two primary tumour features which
contribute to current AJCC staging in stage I and II disease [58]. Therefore, it is
perhaps unsurprising that these prognostic tumour features, representing an
aggressive, proliferative tumour, are associated with the poorly prognostic tumour
feature of ulceration. The association between thicker primary melanoma tumours and
greater mitotic rate and presence of ulceration has been previously identified in large
sample sets [91, 98]. However, no previous studies have attempted to identify tumour
or patient features independently associated with ulceration. In this study, the
independent association of ulceration with Breslow thickness and mitotic rate may
contribute to the prognostic influence of ulceration status. Mitotic rate was not
significantly associated in the smaller centrally-reviewed dataset, probably due to there
being less power to detect this association.
I have found that tumours of sun-protected sites, such as acral, subungual and
mucosal tumours were more likely to be ulcerated. In this study, 4.6% of tumours were
from sun-protected sites and of these 63% were ulcerated compared with a proportion
of 25% of ulcerated tumours overall. The majority of tumours (81%) in this group were
subungual and from acral skin of the palms or soles of feet. In studies of acral and
subungual tumours in Caucasian populations, the proportion of ulcerated tumours is
greater at 30-33% [662, 663] than in cohorts including tumours from all sites, such as
the AJCC staging dataset where approximately 27% of tumours were ulcerated [58].
Therefore, the literature provides support for my observation that the proportion of
ulcerated tumours was higher in tumours from sun-protected sites. Further, my work
demonstrates that the association with site is independent of Breslow thickness and
mitotic rate, indicating that aggressiveness of the tumour or delay in diagnosis, which
have been suggested as contributing factors to the poorer prognosis of acral tumours,
does not fully explain the association with ulceration [131, 132].
It is possible that trauma to tumours on the sole of the foot or under the nail may have
led to separation of the epidermis from the dermis and a failure of pathologists to
distinguish this from true ulceration. To support this hypothesis the comparison I made
between histopathology reports from routine clinical practice and review by expert
dermatopathologists (Figure 7-2) showed that of the 23 tumours which had ulceration
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status changed in review, 18 (78%) were reclassified as not being ulcerated. In the
analysis of centrally reviewed data, the association of sun-protected tumour site and
ulceration was less significant in pairwise analysis (p=0.04) and not significant in
univariate logistic regression (p=0.09) suggesting that perhaps trauma-induced loss of
epidermis being reported as ulceration may be a factor contributing to the association
in the larger dataset. However, the more likely scenario is that the smaller dataset does
not have the power to detect associations between tumour site and ulceration status.
My conclusions therefore are that:-
 Ulceration of melanoma primaries is associated with other poor prognostic
factors.
 Ulceration was more common in older patients in the larger data set although
this was not an independent predictor.
 Breslow thickness and mitotic rate were independent predictors of ulceration.
 Tumours in sun-protected sites were more frequently ulcerated than in other
sites and there was support for this observation in the literature. It was not
possible to exclude erroneous categorisation of traumatic damage, but I
conclude that this is likely a real observation.
7.5.2 Ulceration status and immunohistochemical pathological
factors
Analysis of IHC data identified associations between ulceration and presence of
lymphatic invasion, greater microvessel density and macrophage infiltration in
univariate and multivariate analyses. It must be acknowledged that multiple
comparisons have been assessed in these analyses, which increases the chance of
detecting false-positive results [367]. A significance level of 0.05 was chosen to
highlight interesting findings and associations identified with clinico-pathological
features in the large dataset were strongly significant, however the statistical
significance of results from the smaller immunohistochemical dataset were less strong
and would require validation in another sample set.
This study has found that presence of lymphatic invasion, when assessed using IHC, is
independently associated with ulceration. Lymphatic invasion appears to predominate
over vascular invasion in primary tumours [110, 113], and there was no evidence of an
association between blood vessel invasion, assessed using IHC, and ulceration status
in this sample set. There was also no association found between lymphatic vessel
density and ulceration. Presence of lymphovascular invasion in primary tumours has
been associated with poorer prognosis in a number of studies [110, 112], therefore this
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association is likely to contribute to increased propensity to metastasis associated with
ulcerated tumours. It has been suggested that there is likely to be a common biological
process causing lymphovascular invasion and ulceration, which may be related to
hypoxia [110]. The study also found that greater microvessel density was
independently associated with tumour ulceration. This is a marker of tumour
angiogenesis and may again be related to a hypoxic tumour environment. Normal skin
is mildly hypoxic [664], and as a melanoma tumour grows, hypoxic regions appear
which can promote tumour progression by supporting cell survival, enhancing
metastatic spread as well as stimulating new blood vessel formation [665-667]. Under
hypoxic conditions, there is induction of hypoxia-inducible factor 1 (HIF-1) and HIF-2
heterodimers [667]. HIF-1 is the predominant hypoxic factor produced in the majority of
tissues and binds to hypoxia-response elements in the promoters of genes, such as
vascular endothelial growth factor (VEGF), the expression of which is up-regulated in
hypoxic conditions enhancing angiogenesis [667-669]. There are data in other cancers
to support the hypothesis that hypoxic tumour microenvironments contribute to tumour
invasiveness, by causing down-regulation of E-cadherin and disordered expression of
genes involved in cell motility and invasion, such as metalloproteinase-2 (MMP2) and
keratins [668-670]. To support this, expression of the  subunit of HIF-2 (HIF-2)
assessed with IHC in melanoma tumours is a poor prognostic marker in association
with high levels of VEGF and greater vascular density [671].
My study has shown that microvessel density is greater in ulcerated tumours. Higher
microvessel density has been noted focally in breast tumours, where in some areas
necrosis has occurred secondary to ischaemia, but in other areas there are regions of
greater vascular density [672]. There is likely to be a similar process occurring in
ulcerated tumours, where there is cell death as the tumour out-grows its blood supply,
but there are focal areas with greater vascular density associated with less profound
hypoxic conditions. In gene expression data analysed in this chapter, expression of
HIF1A, which encodes the HIF-1 subunit, was greater in ulcerated tumours, although
not significantly following correction for multiple testing (fold change 1.06, p=0.004).
This result supports the hypothesis that ulcerated tumours are more hypoxic than non-
ulcerated tumours, which is likely to stimulate angiogenesis in areas where necrosis
has not taken place. In breast tumours, tumour macrophage infiltration has been
associated with greater microvessel density in necrotic tumours [672], and this
association in melanoma will be further discussed below.
Microvessel density determined by review of H+E sections, has been identified as an
independent predictor of overall survival [111]. There is controversy in the literature
regarding the association between microvessel density and prognosis in melanoma
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when IHC staining is used [396], with some authors reporting an association between
higher microvessel density and poor prognosis or tumour progression [673-678],
whereas others show no relationship or an association with better prognosis [679-681].
With regards to the association with ulceration status, studies using factor-VIII related
antigen and anti-CD31 have found associations between higher microvessel density
and tumour ulceration [673, 678]. A smaller study using anti-CD34 did not show any
difference in microvessel density between ulcerated and non-ulcerated tumours [396].
My analyses are the first to identify microvessel density as a factor independently
associated with ulceration in a multivariate model with other detailed tumour IHC data.
Macrophage count was independently associated with ulceration status. Macrophages
are phagocytic cells which form part of the innate, non-specific, inflammatory immune
response [651, 682]. They present antigen to components of the adaptive immune
system and produce cytokines, such as interleukin-1, interleukin-6 and tumour-necrosis
factor- [682, 683]. There are two distinct macrophage phenotypes. Bacterial
components and interferon-γ cause macrophages to become M1 macrophages which 
are associated with normoxic tissues, are antiangiogenic and are associated with
tissue destruction, tumour cell killing and amplification of T helper type 1 (TH1) immune
responses [684-686]. M2 macrophages are polarized by tumour and T-cell derived
cytokines and are usually found in association with tissue remodelling and hypoxic
environments [684, 686, 687]. M2 macrophages are the subtype usually found in
tumours [687-689] and release proangiogenic growth factors, support tumour growth,
improve attachment of melanoma cells to extracellular matrix, suppress anti-tumour T-
cell dependent adaptive immune responses and modify inflammatory responses,
leading to chronic inflammation [651, 682, 684, 690-693]. The association between
inflammatory processes and cancer has been well documented [651, 693]. Acute
inflammation is rapid and usually self-limiting with later phases characterised by tissue
remodelling and repair [693]. It is apparent that chronic inflammation contributes to the
pathogenesis of many diseases associated with older age, including cancer, and M2
macrophages are key in development of chronic inflammation [651, 693]. M2
macrophages suppress adaptive immune responses via production of
immunosuppressive indoleamine dioxygenase (IDO) metabolites [694], inhibition of
dendritic cell maturation and stimulation of T regulatory cell infiltration into the tumour,
which subsequently suppress effector T-cell activity and other inflammatory cells [695-
697]. The presence of tumour-associated macrophages or a greater proportion of
macrophages within tumour-infiltrating immune cells has been associated with poorer
prognosis in a number of cancers, including uveal and metastatic cutaneous melanoma
[684, 698-701]. In primary melanoma, these associations have been identified using
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CD68 staining and when the more M2 macrophage specific CD163 antigen has been
used [393, 394, 702-704]. With regards to ulceration, an earlier smaller study failed to
find any association between CD68 stained macrophage levels in primary tumours and
ulceration status [396]. In uveal melanoma, an association has also been identified
between the presence of CD68-positive macrophages and greater microvessel density
in tumours which is relevant to my findings [700].
In summary, ulcerated tumours, associated with tissue remodelling and hypoxia, were
infiltrated by more macrophages, as detected using IHC in this current study. Although
this could not be confirmed using the limited IHC performed, I postulate that these were
M2 macrophages and that the pro-angiogenic effect of these macrophages may have
contributed to the higher microvessel density in ulcerated tumours. The presence of M2
macrophages is likely to have profound effects on the tumour environment, enhancing
tumour growth, angiogenesis, leading to a chronic inflammatory state and suppressing
the adaptive immune system [393, 682, 684, 690-692]. Evidence exists that both
higher microvessel density and macrophage count in melanoma tumours are
associated with poorer prognosis; therefore the presence of these factors may
contribute to prognostic significance of ulceration. Suppression of adaptive immune
responses by M2 macrophages may also contribute to why ulcerated tumours are
more amenable to the effects of exogenous IFN therapy (Figure 7-4).
In summary:
 Presence of lymphatic invasion and higher microvessel density, but not greater
lymphatic density or blood vessel tumour invasion, are independently
associated with ulceration. These factors may be secondary to the hypoxic
tumour environment and macrophage infiltration. Higher microvessel density
and presence of lymphatic invasion is associated with poor prognosis in
melanoma, so contributing to the prognostic significance of ulceration.
 Higher macrophage count was independently associated with ulceration.
Infiltration of M2 macrophages increases angiogenesis and leads to a chronic
inflammatory state that suppresses adaptive immune mechanisms and is
associated with poorer prognosis. I postulate that the presence of M2
macrophages may contribute to the prognostic and also predictive influence of
ulceration on benefit from IFN therapy.
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Figure 7-4: The prognostic and predictive implications of greater macrophage
infiltration and microvessel density in ulcerated tumours.
I postulate that macrophages are polarized to the M2 phenotype in ulcerated
tumours by release of cytokines and chemokines from immune cells (TH2 cells,
Treg cells and B cells), fibroblasts and tumour cells. M2 macrophages can
enhance tumour growth and produce pro-angiogenic factors which may stimulate
higher microvessel density in ulcerated tumours. They also suppress adaptive
immune responses. Both tumour macrophage infiltration and microvessel density
are associated with poorer prognosis in melanoma which may contribute to the
prognostic influence of ulceration. Suppression of adaptive immunity may be
modified by exogenous IFN therapy, explaining some of the predictive influence
of ulceration. Figure adapted from [684, 705]. Abbreviations used: TH2, T helper
type 2 cells; Treg, T regulatory cells; ECM, extracellular matrix; VEGF, vascular
endothelial growth factor; EGF, epidermal growth factor; MVD, microvessel
density; IFN, interferon-α.  
7.5.3 Gene expression and ulceration status
A number of genes shown in this study to be down-regulated in ulcerated tumours are
known to be involved in cell adhesion, such as genes encoding desmoplakin (DSP),
the integrin β4 subunit (ITGB4) and E-cadherin (CDH1). DSP is part of intercellular
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junctions called desmosomes, which are important in cellular adhesion, especially in
the epidermis [706, 707]. In the skin, altered expression of parts of the desmosome can
alter keratinocyte structure and function via modification of signalling pathways [708].
Another component of the desmosome, desmoglein 1, is down-regulated during
melanoma progression, allowing melanoma cells to un-couple from keratinocyte
mediated growth control [53, 709]. A study of gene expression of skin at the wound
edge of venous ulcers found under-expression of DSP at the edge of non-healing
ulcers versus healing ulcers [710]. However, there are no previous published reports
which have identified under-expression of desmosome components in association with
melanoma tumour ulceration. Down-regulation of DSP may cause breakdown of
cellular adhesion and subsequent ulceration of the tumour. Melanoma cells are then
released from keratinocyte control, enabling them to invade and progress.
It has been well established that the adherens junction protein, E-cadherin, is down-
regulated in melanoma cells as the tumour progresses [53, 644]. Cadherin based
junctions arrange microfilaments to maintain cell adhesion and integrate signalling
within the cell and between cells [711, 712]. This study demonstrates that E-cadherin
down-regulation occurs to a greater extent in ulcerated tumours. Ulceration of normal
skin is believed to be due to cycles of hypoxia and then re-oxygenation leading to
breakdown of skin integrity [713]. Previous studies assessing alterations in expression
of cell adhesion molecules in models of skin ulceration have found that E-cadherin
protein expression is dramatically down-regulated in response to hypoxia [713].
Interestingly, DSP expression is unaltered by exposure to hypoxic conditions [713].
Again, down-regulation of CDH1 in ulcerated melanoma tumours has not been
reported in the literature. However, cancer cells subjected to hypoxic conditions,
especially those which up-regulate HIF-1 expression, have lower E-cadherin levels
[714, 715], indicating that a more profoundly hypoxic, ulcerated tumour would have
lower levels of E-cadherin expression than a more normoxic, non-ulcerated tumour.
Lower levels of E-cadherin provide a further mechanism by which cells of ulcerated
tumours evade keratinocyte control, contributing to tumour aggressiveness.
ITGB4 encodes the integrin β4 subunit, which usually associates with the 6 subunit to
mediate binding between keratinocytes and laminins in hemidesmosomes situated
between the epidermal cells and dermis of normal skin [716, 717]. In mice models,
where 64 integrin is knocked-out, the epidermis separates from dermis, in a similar
fashion to ulceration in primary melanoma tumours [716, 718]. Lack of the β4 subunit 
also alters cell motility of keratinocytes, via modification of laminin organisation in
extracellular matrix [719]. It has also been noted that 64 integrin, along with other
integrin subunits, is usually up-regulated during wound healing [716]. There is little in
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the literature investigating the role of the integrin β4 subunit or the ITGB4 gene in
melanoma; however my study indicates that under-expression is associated with
ulceration, a finding which correlates well with the known biological function of this
integrin subunit in keratinocytes. We were unable to assess expression of the ITGA6
gene as this gene was not on the 502-gene Human Cancer panel used for gene
expression work. However it is likely that this would also be under-expressed in
ulcerated tumours.
Figure 7-5 summarizes my hypothesis as to how down-regulation of genes involved in
cell adhesion could lead to ulceration of primary melanoma tumours. Loss of cell
adhesion and keratinocyte control mechanisms in ulcerated tumours is associated with
increased motility of melanoma cells [53], which may be directly related to greater
invasion of lymphatic vessels by tumour cells as detected using IHC.
DSP and the integrin β4 subunit have roles in wound healing [716, 720, 721], and 
another gene involved in wound healing which is over-expressed in ulcerated tumours
in my study is fibroblast growth factor 7 (FGF7), otherwise known as keratinocyte
growth factor [722]. FGF7 expression is up-regulated after tissue damage, and this
growth factor acts through fibroblast growth factor 2b (FGFR2b), which is a splice
variant of FGFR2 found on epithelial cells [722, 723]. FGFs and FGFRs are
proangiogenic and can stimulate cell proliferation and survival; they are often over-
expressed or overactive in many cancers, secondary to a number of mechanisms,
including gene amplification and mutations [522, 724, 725]. FGF7 promotes
proliferation of epidermal cells in association with improved survival and motility
Figure 7-5 (following page): Loss of molecules involved in cell adhesion leading
to epidermal loss and ulceration of primary melanoma tumours.
(A) Keratinocytes and melanocytes are normally held together in the epidermis by
desmosomes and E-cadherin (CDH-1). Adhesion of epidermal cells to the
basement membrane is facilitated by hemidesmosomes which contain integrin
subunits. As melanoma cells develop, E-cadherin is down-regulated along with
components of the desmosome, such as desmoglein. Melanoma cells bind to
each other by up-regulating N-cadherin and integrins, connexins and cell
adhesion molecules (CAM). These molecules also allow binding to fibroblasts
and endothelial cells. (B) In this study, there is down-regulation of DSP, which is
a component of the desmosome, CDH1 and the integrin subunit, ITGB4 in
ulcerated tumours. (C) Loss of these molecules would decrease cell adhesion in
the epidermis leading to ulceration. Figure adapted from [53].
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[726, 727] and is normally produced by mesenchymal cells, for example fibroblasts
[728, 729]. There is evidence that normal and malignant melanocytes express FGF7
transcripts; however it is unclear whether this has a role in epidermal cell proliferation
and may be related to normal melanocyte development [730]. The current study has
identified under-expression of FGFR2, which codes for the FGF7 receptor, in ulcerated
tumours. In contrast to many other gain of function FGFR mutations identified in
cancer, loss of function mutations have been reported in FGFR2 in melanoma cell
lines, primary and metastatic tumours [731-733]. Decreased expression of FGFR2 has
been associated with progression of astrocytomas, prostate and bladder cancers,
indicating that FGFR2 can act as a tumour suppressor gene [734-736]. Over-
expression of FGF7 by ulcerated tumours in association with tissue damage may be
expected to initiate wound healing. We have not assessed levels of FGFR2 in
keratinocytes, however in ulcerated tumours, FGFR2 is markedly down-regulated, and
FGF7 would be unable to act via the FGFR2b receptor on melanoma cells in an
ulcerated tumour. The role of FGF7 in melanocytes and melanoma cells has not been
elucidated [730], so further significance of these findings is unclear. In addition to
higher FGF7 expression secondary to tissue damage, pro-inflammatory cytokines,
such as interleukin 6 (IL6), can stimulate FGF7 production in dermal fibroblasts [737],
therefore over-expression of IL6 in ulcerated tumours may be contributing to the
overexpression of FGF7. The current study has identified under-expression of FGFR3
in ulcerated tumours. FGFR3 binds to both basic and acidic fibroblast growth factors
and is important in bone development [738]. FGFR3 may be a tumour suppressor gene
in melanoma [738, 739], so lower expression in ulcerated tumours would contribute to
the prognostic significance of this tumour feature.
IL6 was over-expressed in ulcerated tumours in this study. A previous gene expression
study using frozen tumour specimens has also reported differential expression of IL6
[178]. IL6 is a pro-inflammatory cytokine which can stimulate growth and survival of
tumour cells and polarize immune cells, including macrophages, to aid tumour
progression [740-742]. Melanoma tumours appear to produce IL6 [652, 743-745] and
as discussed previously, higher serum levels of IL6 are related to poor survival and
predictive of benefit from IFN therapy, which closely parallels the effects of tumour
ulceration [652-655, 746]. This association indicates that production of this pro-
inflammatory cytokine by ulcerated tumours may be an important factor determining
disease progression and IFN action. Other proinflammatory cytokine genes, such as
interleukin-1 and interleukin-1, were also over-expressed in my analyses in
ulcerated tumours (fold change ulcerated/non-ulcerated tumours 1.32 (p=0.03) and
- 250 -
1.74 (p=0.0006), respectively), although not significantly following a Bonferonni
correction for multiple testing.
Pathway analysis has highlighted pathways containing genes differentially expressed
in ulcerated tumours. Genes involved in focal adhesion and cytokine-cytokine receptor
interaction pathways are clearly over-represented, as already discussed. However the
over-representation of genes involved in Jak-STAT signalling is of great interest, as the
anti-proliferative, immune, cytotoxic and anti-angiogenic effects of type 1 interferons
are predominantly mediated by this pathway [213, 220]. Components of this pathway
have been assessed in melanoma tumours in relation to benefit obtained from
interferon therapy. As discussed in the introduction, binding of type 1 IFNs to receptors
causes activation of STATs which then move to the nucleus activating gene expression
[263]. STAT1 is thought to play a key role in promoting antiproliferative, proapopotic
and antiangiogenic effects on tumours by IFN therapy, and protein expression of
phosphorylated STAT1 (pSTAT1) is increased by IFN therapy [747-749]. Defects within
the Jak-STAT pathway are associated with resistance to IFN in melanoma cell lines
[748, 750]. In this study, STAT1 was not differentially expressed, but STAT5B, the
gene which encodes one of the two highly related STAT5 proteins, was over-
expressed in ulcerated tumours (fold change 1.08, p=0.005), although not significantly
following a Bonferroni correction. Despite this non-significant result, the biological
action of STAT5 is of interest and so will be further discussed. Studies investigating the
role of STAT5 in melanoma cell lines have yielded conflicting results. STAT5 protein
expression has been shown to be greater in IFN resistant melanoma cell lines with
over-expression of STAT5 reducing the anti-proliferative ability of IFN in a normally
IFN-sensitive cell line and depletion of STAT5 in resistant lines improving interferon
responsiveness [751]. The authors of this study concluded that STAT5 inhibits STAT1
activation, with some inhibition occurring via involvement of suppressor of cytokine
signalling (SOCS/CIS) factors [751]. A more recent study, again in melanoma cell lines,
failed to find a relationship between phosphorylation of STAT1 following IFN treatment
and the expression of STAT5 or levels of phosphorylated STAT5 [747]. The authors
suggested that there are likely to be additional factors involved in regulation of STAT1
activation along with STAT5, following IFN exposure [747]. In the current study, non-
statistically significant over-expression of STAT5B has been identified in the relatively
IFN-sensitive group of ulcerated tumours, accompanied by down-regulation of factors
downstream of STAT1 (Figure 7-3), such as PIM1 (fold change 0.88, p=0.02), MYC
(fold change 0.95, p=0.008) and CCND3 (or cyclin D3, fold change 0.92, p=0.01).
These findings indicate that STAT1 signalling is being suppressed in ulcerated
tumours, and that STAT5 over-expression may be contributing to this; however other
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factors are likely to be involved which may explain why these results appear
contradictory to previous cell line data [751]. There is evidence that patients with
melanoma have defects in IFN signalling in blood lymphocytes due to reduced
phosphorylation of STAT1 following IFN stimulation [222, 223]. This defect can be
improved by high-dose IFN therapy and the level of STAT1 activation in T-cells with
IFN therapy correlates with the clinical outcome [223, 224]. A similar defect may be
found in ulcerated tumours with deranged expression of components of the Jak-STAT
signalling pathway, perhaps explaining the predictive nature of ulceration with IFN
therapy. Exogenous IFN may enhance normal signalling through the pathway, leading
to anti-tumour and immunomodulatory effects. Non-ulcerated tumours may have less
deranged signalling via this pathway, which is not modified by IFN therapy, and hence
little benefit is derived from the therapy. This hypothesis is speculative and may
represent over-interpretation of my results. However it seems clear that deranged
expression of components of this IFN signalling pathway must bear some relationship
to why ulcerated tumours show greater benefit from IFN therapy and warrants further
investigation.
To summarise, in ulcerated tumours:
 There is under-expression of genes involved in cell adhesion, which may be a
primary event or secondary to other biological processes.
 Expression of fibroblast growth factors and receptors are deranged.
 Pro-inflammatory cytokine genes are over-expressed, which may contribute to
the prognostic and predictive influence of tumour ulceration.
 There is evidence of deranged signalling via the Jak-STAT pathway, which is
likely to modify responses to exogenous IFN therapy.
7.5.4 Summary
A number of poorly prognostic tumour features were shown to be independently
associated with ulceration status, as was lymphatic invasion, higher microvessel
density and macrophage count. I postulate therefore that tumour ulceration is
associated with new blood vessel formation in the tumour, lymphatic invasion by
tumour cells and polarization of macrophages to the M2 phenotype. I have been
unable to confirm that the increased numbers of macrophages seen in ulcerated
tumours were M2 rather than M1 and I would like to prove this in further experiments if
I were able.
My study demonstrated under-expression of genes involved in cell adhesion in
ulcerated tumours, which is an unsurprising finding; however we cannot prove whether
- 252 -
this is a primary process within the tumour, associated with a release from keratinocyte
mediated growth control, or secondary to another biological characteristic of the tumour
which predisposes it both to ulceration and subsequently improved metastatic capacity.
Lack of cell adhesion and keratinocyte control will contribute to increased cell motility,
explaining greater evidence of lymphatic invasion in ulcerated tumours.
My study revealed deranged expression of FGF and FGFR genes in ulcerated tumours
and independent associations with macrophage infiltration, presence of lymphatic
invasion, greater microvessel density, Breslow thickness and mitotic rate. These
associations may explain some of the prognostic effects of tumour ulceration.
There is evidence in these analyses of altered immune mechanisms in ulcerated
tumours. Macrophage infiltration was seen, and the literature would suggest that these
are likely to be M2 cells capable of suppressing adaptive immunity. I also showed
novel findings indicative of deranged expression of components of the Jak-STAT
pathway and confirmed previously reported over-expression of pro-inflammatory genes
such as IL6 in melanomas.
Effects of the IFN used therapeutically are mediated by Jak-STAT signalling. Down-
regulation of genes downstream to STAT1 suggests that signalling via this pathway is
supressed in ulcerated tumours, perhaps by increased STAT5 in association with other
factors. I postulate that deranged signalling via this pathway may be modified by
exogenous IFN therapy, enhancing antitumour effects of IFN and leading to prolonged
survival following IFN therapy.
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8 DNA repair gene expression and response to chemotherapy
in stage IV melanoma
8.1 Aims
In a pilot study, gene expression data generated using the cDNA-mediated annealing,
selection, extension and ligation (DASL) assay and the Human Cancer panel provided
evidence that increased expression of a number of DNA repair genes was associated
with resistance to treatment with alkylating agents, dacarbazine (DTIC) and
temozolomide (TMZ) [505]. These findings were confirmed and the association
between DNA repair gene expression and chemotherapy response was further
explored using the Chemo-sensitivity Gene Expression Array (CGEA-1) [505]. These
results were consistent with the published data related to this issue.
The primary aims of the of the work described in this chapter were:
 To explore the pilot data in a larger sample set in order to identify whether
expression of DNA repair genes might prove to be a useful predictive biomarker
of DTIC or TMZ response.
 To investigate the use of the Fluidigm quantitative Real-time PCR (qRT-PCR)
system for the first time using formalin-fixed paraffin-embedded (FFPE)
melanoma tumour to carry out multiple PCR reactions to measure gene
expression.
To achieve these primary aims, this chapter also describes the:
 Concept, set-up and development of the “Predicting Response to
Chemotherapy in Malignant Melanoma” study. These data (clinical and
genomic) are nearing completion in July 2012 and here I report those data to
which I currently have access.
8.2 Background
A number of effective treatments have been recently developed for advanced
melanoma, however use of vemurafenib against mutant BRAF is limited to patients
with a BRAF mutated tumours (40%) and resistance can develop [199]. Use of the
second “revolutionary” agent, ipilimumab is also associated with improved survival but
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only in a small number of patients and with considerable toxicity [60, 61]. Therefore, a
proportion of patients still receive DTIC or TMZ chemotherapy for stage IV disease and
are likely to be so treated in the future, especially if a predictive biomarker can be
identified. Response rates are low at 7-13%, with a further 15-28% having stable
disease during treatment, but few of these responses are long-lasting [243, 244]. DTIC
is an alkylating agent which methylates DNA at the O6-position of guanine. O6-
methylguanine often mispairs with thymine instead of cytosine during replication and
this is recognised by the mismatch repair system which removes a section of DNA with
the thymine molecule. Replication of this gapped structure leads to double-stranded
breaks in DNA which eventually lead to cell death via apoptosis [247] (Figure 8-1).
TMZ is also an alkylating agent used in melanoma with similar efficacy to DTIC [243,
249]. TMZ undergoes spontaneous conversion to the active alkylating agent 5-(3-
methyltriazen-1-yl)imidazole-4-carboximide (MTIC) which has similar actions to DTIC
[248]. TMZ can be administered orally and has been used for the treatment of brain
metastases as it crosses the blood-brain barrier [243, 249].
It has been suggested that over-expression of genes related to DNA repair is linked to
the chemoresistance of melanoma [264, 752]. Increased activity of the DNA repair
gene O6-methylguanine-DNA-methyltransferase (MGMT), which removes alkyl groups
from DNA, is associated with resistance to alkylating agents in glioblastoma tumours
[753, 754] and in melanoma cell lines [265, 755]. An inverse relationship between
MGMT protein expression and gene expression with DTIC response in melanoma
tumours has also been identified [267, 756] which supports the view that MGMT
expression might be a predictive biomarker. Gene silencing by promoter methylation
has also been associated with improved responses to TMZ therapy in metastatic
tumours [757]. The relationship between melanoma response to alkylating agents and
MGMT is not entirely clear however, as other studies have failed to show that MGMT
activity [268, 269], protein expression [270], promoter methylation [271, 758] or MGMT
polymorphisms [267] are associated with response to TMZ or DTIC. Disappointingly,
clinical trials using extended dose TMZ to deplete MGMT levels and use of MGMT
inactivators or pseudosubstrates did not enhance activity of TMZ in melanoma [271-
273, 759].
The mismatch repair pathway is also important for the toxicity of alkylating agents. A
deficiency in this pathway results in failure of cells to recognise and repair O6-
methylguanine adducts produced by TMZ or DTIC and so double stranded breaks do
not occur and DNA replication continues without apoptosis occurring [248, 274].
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Figure 8-1: Mechanism of action of dacarbazine.
Further detail is provided in the text. Adapted from [247]. Abbreviations used:
DTIC, dacarbazine; O6-meG, O6-methylguanine; T, thymine; MMR, mismatch
repair; ds, doubled-stranded.
Studies using melanoma cell lines have demonstrated that the mismatch repair system
in melanoma appears to be largely intact, so contributing little to TMZ resistance [265,
275].
The base excision repair (BER) pathway has also been reported to be related to
resistance to TMZ and DTIC, as the DTIC-induced adducts, 3-methyladenine and N7-
methylguanine can be processed and repaired by the BER pathway [760]. Inhibition of
poly(ADP-ribose) polymerase (PARP) in cell lines has been reported to improve
cytotoxicity of alkylating agents [276, 277, 761], but again this pathway appears to
have minimal effect on TMZ resistance in melanoma cell lines [265]. A phase I study in
advanced solid tumours, including melanoma, demonstrated that use of a PARP
inhibitor (AG014699) with TMZ caused PARP inhibition with increased single-strand
breaks and minimal toxicity suggesting that these agents could be used therapeutically
alone or in combination with chemotherapy [278]. However, in another phase I trial
using the PARP inhibitor Olaparib (AZD2281, KU0059436), the authors concluded
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there was no clinical advantage over use of DTIC alone [762]. Haemotoxicity appeared
to be an issue in phase II trials and further results are awaited [762]. Inhibitors of other
DNA repair genes in the BER pathway, such as APE1 (or APEX-1), enhance alkylating
agent toxicity in melanoma and glioma cell lines, again highlighting the potential
importance of this pathway [763].
Development of in vitro assays that assess chemosensitivity will help isolate further
candidates of chemotherapy resistance. When chemosensitivity of cutaneous
melanomas has been assessed and correlated with quantitative gene expression of
putative chemotherapy resistance genes, gene expression signatures associated with
resistance to DTIC, treosulphan and cisplatin revealed that genes involved in DNA
repair (ERCC1, XPA, XRCC1, XRCC6) were over-expressed [764].
In summary, DNA repair genes have been reported to be associated with poor
response to alkylating agents in a number of studies, but the relationships are not clear
and a more comprehensive assessment is required. Identification of biomarkers of
treatment response will provide insight into tumour biology and in the long-term, may
assist clinicians and patients in making informed decisions about treatment options.
This chapter describes the process by which I have explored the significance of
expression of DNA repair genes as being associated with DTIC or TMZ chemotherapy
response. Results from the DASL assay were validated using a different gene
expression platform and then further explored in a larger separate sample set.
For the validation of DASL data, this chapter describes use of a customized Taqman®
Array microfluidic qRT-PCR card (Chemo-sensitivity Gene Expression Array, CGEA-1,
CanTech Ltd, Portsmouth, UK). This array contains 92 genes known or hypothesized
to be involved in cytotoxic resistance or sensitivity based on the current literature [289]
(Table 8-1). Mechanisms of resistance to chemotherapy include under-expression of
target genes, altered drug metabolism, presence of membrane drug pumps, altered
apoptotic sensitivity, deranged DNA repair and altered cellular growth or differentiation
[289]. The CGEA-1 has been designed to assess gene expression of candidates within
these pathways and was used in this chapter to validate microarray gene expression
data. Taqman® array cards (Applied Biosystems, Warrington, UK) are 384-well
microfluidic cards which allows 384 simultaneous PCR reactions using Taqman® gene
expression assays which are described in more detail in Chapter 2 [344]. The ability to
perform multiple reactions using one array reduces variability across plates so
improving the reliability of results [344]. It also allows assessment of either multiple
genes for a limited number of samples or assessment of a smaller number of genes for
multiple samples [344].
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Apoptosis Pumps/Detox DNA repair Proliferation Normalisationgenes
AKT
APAF1
BAD
BAX
BCL2
BCL-x(L)
BID
c-FLIP
FAS
FASL
HSP60
HSP70
HSP90
IAP2
IGF1
IGF1R
IGF2
IGR2R
IGFBP1
IGFBP2
MCJ
MCL1
mTOR
NFκB 
PIK3CA
PTEN
STAT3
SURVIVIN
XIAP
ATP7B
BCRP
CES1
CES2
cN II
DPD
FPGS
γH2AX 
GCLC
GCLM
GSTπ 
hENT1
hENT2
MDR1
MRP1
MRP2
MRP3
MRP4
MRP5
MRP6
MRP8
MTII
MVP
OPRT
RRM1
SOD1
TAP1
TAP2
TAP4
ATM
BRCA1
ERCC1
ERCC2
GTF2H2
MGMT
MLH1
MSH2
MSH6
RAD51
TOPO I
TOPO IIa
TOPO IIb
TS
XPA
XRCC1
XRCC5
XRCC6
APC C-term
APC N-term
β-TUBULIN III 
COX2
EGFR
HER2
HER3
HER4
HIF1A
KI67
P16
P21
P27
P53
VEGF
18S
HPRT
PBGD
SDHA
TBP
Table 8-1: Genes on the Chemo-sensitivity Gene Expression Array (CGEA-1).
Genes are listed according to biological function. Table adapted from [289].
On a larger scale, the Fluidigm Biomark HD quantitative PCR chip (Fluidigm, San
Francisco, CA) allows assessment of up to 96 genes in 96 samples in a total of 9216
PCR reactions in a single experiment. I used this technology to assess expression of
43 DNA repair genes (and 5 control genes) in a larger sample set from patients
recruited to the “Predicting Response to Chemotherapy in Malignant Melanoma” study.
This study will be further described in section 8.5. Fluidigm microfluidic technology
uses integrated fluidic circuits (IFC) containing valves and channels which
automatically assemble individual PCR reactions, enabling the simultaneous
performance of PCR reactions in nanolitre volumes. Fluidigm technology is further
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described in Chapter 2 [345, 346]. Each PCR reaction takes place in a volume of only
10nl versus the 10μl volume used for routine qRT-PCR reactions described elsewhere 
in this thesis [345-347]. Previous work has demonstrated that the Fluidigm system
provides reproducible results for gene and micro-RNA expression when compared to
traditional qRT-PCR experiments using Taqman® gene expression assays [346, 347]
and results from micro-RNA analysis correlate well when fresh-frozen tissues or FFPE
tissues are used for RNA extractions [346].
The Fluidigm systems can be used with Taqman® assays, but for the purposes of this
study, we have used gene specific primers (DELTAgene™ assays, Fluidigm) in
conjunction with the DNA-binding dye, EvaGreen. EvaGreen is a flurophore, which
when bound to double-stranded DNA emits a strong fluorescent signal, the intensity of
which is directly proportional to the increase in the amount of double-stranded DNA
during a PCR reaction [349, 350]. Use of EvaGreen significantly reduces the cost of
the experiment, however the specificity of the reaction is reduced as only a primer pair
are used for PCR, the additional probe present in Taqman® based assays (described
in Chapter 2) being absent [349]. To our knowledge, this is the first experiment using
cDNA derived from FFPE material for gene expression using the Fluidigm qRT-PCR
system and so a thorough assessment of the quality of the assays has been made in
FFPE melanoma tumour material. I have specifically assessed the efficiencies of the
primers in a similar fashion to that described in Chapter 4 for Taqman® gene
expression assays and the specificity of the amplicon using melt curve analysis.
8.3 Identification of genes associated with response to
chemotherapy using the DASL assay
8.3.1 Further methodological details
8.3.1.1 Statistical methodology
Chemotherapy analysis was performed using the merged dataset generated from two
sample sets (the Leeds Melanoma Cohort Study (Cohort study) and the Retrospective
Sentinel Node Biopsy Study (SNB study)) described in further detail in Chapter 4. Log-
transformed normalised data (log2) were used for analysis, expression of genes of
interest was compared between responders and non-responders to chemotherapy
using linear regression. Response to chemotherapy was defined as those with stable
disease, a mixed response, partial response or regression of disease determined using
computed tomography (CT) scanning following 2 or 3 cycles of chemotherapy. In some
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instances, response data was recorded according to Response Evaluation Criteria in
Solid Tumours (RECIST) version 1.1 criteria by the reporting radiologist [290], in others
response data was provided by review of the radiology assessed formally at the
melanoma multidisciplinary team meeting. As expression of single genes were
assessed, the significance level for highlighting results of interest was set at 0.05. In
view of non-biological variations that were present between the Cohort and SNB
studies, analyses were adjusted for the study to which patients were recruited. All
analyses were undertaken using Stata version 10 (StataCorp 2007, College Station,
TX).
8.3.2 Results
Forty-three patients, 23 from the SNB study and 20 from the Cohort study had received
chemotherapy (11.9%). Of these patients, tumour response following chemotherapy
had been recorded for 36 patients. The majority of patients received DTIC with three
patients receiving treosulphan as first line chemotherapy. Six patients (17%)
responded to DTIC chemotherapy as defined above. RAD51 and TOP2A were
significantly over-expressed in tumours from non-responders compared to responders
(RAD51 fold change 1.66, p=0.01; TOP2A fold change 1.43, p=0.03). BRCA1 was also
over-expressed in tumours from non-responders (fold change 1.36), but this difference
was of borderline significance (p=0.05). In order to validate these findings and explore
expression of other genes associated with chemotherapy response using a different
platform, the CGEA-1 array was used as described below.
8.4 Validation of DASL results and further assessment of
genes associated with chemotherapy response
8.4.1 Rationale
In order to validate DASL results and assess gene expression of other genes
postulated to be associated with response to chemotherapy, a sample of tumour RNAs
from patients treated with chemotherapy were also analysed using the CGEA-1 array
in collaboration with the Translational Oncology Research Centre, Queen Alexandra
Hospital, Portsmouth. The experimental work was performed by Dr Katharine Parker.
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8.4.2 Further methodological details
8.4.2.1 The Chemo-sensitivity Gene Expression Assay (CGEA-1)
Table 8-1 lists the genes present on the array. Of the 36 patients from whom
chemotherapy response data were available, 33 received DTIC and samples from
these patients were selected for assessment with the CGEA-1 array. cDNA was
generated from RNA using the Invitrogen Superscript™ First-strand Synthesis System
with increased reagent volumes as described in Chapter 2. Two cDNA samples were
unavailable as they were used in other studies. Therefore a total of 31 samples from
patients treated with chemotherapy (5 from responders) were sent for qRT-PCR
analysis using the CGEA-1 array in Portsmouth. The CGEA-1 was run according to
manufacturer’s instructions as previously reported [289] and described in further detail
in Chapter 2. Cycle threshold (Ct) values from the experiment were sent to myself for
further analysis. A calibrator sample was chosen with the lowest Ct value for a highly
expressed gene, 18s, to allow relative quantification of gene expression. This sample
was selected to reduce the number of missing values for analysis. Five endogenous
control genes were present on the array for normalisation of data. Expression levels of
18s were much higher than unknown genes and as the abundance of a reference gene
should be similar to that of the gene of interest [458], 18s was not used for
normalisation. A large number of samples did not amplify using the HPRT assay and
so PBGD, SDHA and TBP were used as reference genes for normalisation according
to the method described by Vandesompele et al. [343] and described in further detail in
Chapter 2. The normalised gene quantities were used to calculate a fold difference in
mean gene expression between chemotherapy non-responders and responders.
Statistical significance was determined using a Mann-Whitney U test, with a
significance level of 0.05. Statistical analysis was undertaken using Stata version 10
(StataCorp 2007, College Station, TX).
8.4.3 Results
Genes from which there were less than 10 results overall were deemed to have failed
and were removed from further analyses (n=13). To allow a meaningful comparison
between gene expression in responders and non-responders, genes for which there
were less than 2 results for responders were also excluded from further analyses
(n=2). All of the 17 genes involved in DNA repair on the array were over-expressed in
tumours from patients who did not respond to chemotherapy (Table 8-2). These genes
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Gene
Number of
non-
responders/
number of
responders
Mean fold
difference in
expression between
non-responders and
responders
Test statistic
and significance
value
DNA repair
genes
MSH6 17/4 4.61 Z 1.4, p=0.15
TOPO1 21/4 3.15 Z 0.2, p=0.82
MSH2 16/4 3.06 Z 1.9, p=0.06
XRCC1 13/4 2.95 Z 1.4, p=0.17
XRCC5 22/5 2.87 Z 0.0, p=1.00
TOP2A 17/3 2.53 Z 0.9, p=0.37
XRCC6 22/5 2.47 Z 1.4, p=0.17
MGMT 9/2 2.21 Z 0.9, p=0.35
RAD51 17/3 2.13 Z 0.6, p=0.56
ERCC1 22/5 2.07 Z 1.1, p=0.29
TOP2B 22/4 1.96 Z 0.0, p=1.00
XPA 20/5 1.87 Z 0.9, p=0.34
ATM 18/3 1.81 Z 0.1, p=0.92
BRCA1 17/3 1.77 Z -0.3, p=0.79
ERCC2 18/4 1.73 Z -0.1, p=0.93
GTF2H2 21/4 1.51 Z -0.9, p=0.37
MLH1 16/2 1.21 Z 0.1, p=0.89
Genes most
over-
expressed in
non-
responding
tumours
TAP4 15/2 24.63 Z 1.3, p=0.18
TS 21/3 24.53 Z 1.6, p=0.11
KI67 9/2 12.06 Z -0.2, p=0.81
MTII 22/5 8.06 Z 1.5, p=0.13
mTOR 21/4 7.33 Z 0.9, p=0.37
cN II 19/5 6.62 Z -0.04, p=0.97
PIK3CA 21/4 5.02 Z 1.2, p=0.24
MSH6 17/4 4.61 Z 1.4, p=0.15
HSP90 22/5 4.51 Z 1.4, p=0.17
SOD 1 22/5 4.40 Z 1.7, p=0.09
Genes most
under-
expressed in
non-
responding
tumours
MCL1 21/4 0.38 Z -0.07, p=0.94
FAS 16/4 0.45 Z 0.4, p=0.71
FPGS 12/2 0.71 Z -0.6, p=0.58
BAX 21/5 0.86 Z -0.9, p=0.35
p53 19/5 0.92 Z -0.1, p=0.92
Table 8-2: Genes differentially expressed in tumours unresponsive to
chemotherapy using the Chemo-sensitivity Gene Expression Array (CGEA-
1).
DNA repair genes on the array are listed followed by genes most over-expressed
and under-expressed in unresponsive tumours. The number of samples from
non-responders and responders is presented with fold difference in gene
expression between non-responders and responders. Significance values are
derived from the Mann-Whitney U test.
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included RAD51 (fold change 2.13), TOP2A (fold change 2.53) and BRCA1 (fold
change 1.77) as well as genes involved in nucleotide excision repair (e.g. ERCC1,
XPA), base excision repair (e.g. XRCC1), removal of damaged DNA bases (MGMT),
mismatch repair (e.g. MLH1, MSH2) and DNA non-homologous end joining (e.g.
XRCC5, XRCC6) [289, 497]. Within the groups of genes encoding proteins associated
with apoptosis, cellular proliferation and membrane transport molecules, some genes
were under- and others over-expressed in tumours which did not respond to
chemotherapy [289, 765]. As a result of the small numbers of samples included in
these analyses, the power was too low to achieve statistical significance but this was
essentially a validation step using different technology and was deemed confirmatory.
8.5 The “Predicting Response to Chemotherapy in Malignant
Melanoma: The role of DNA repair genes” study
In view of the small number of samples available from patients treated with DTIC or
TMZ in the previous analyses described, a larger sample set was required to confirm
the association between DNA repair gene expression and chemotherapy response. A
sample set of sufficient size was not available in the Section of Epidemiology and
Biostatistics, so the “Predicting Response to Chemotherapy in Malignant Melanoma”
study (Chemotherapy study), was developed. The study was started by myself with
assistance from my supervisors and members of the Section, specifically Mr Christy
Walker, who has project-managed the study and coordinated sample collection and Dr
Jon Laye, who has processed and sampled tumours for the study. This study has
permitted collection of a large number of tumours from patients with response and
survival data allowing confirmation of previous findings.
8.5.1 Study design and aims
This retrospective study utilises FFPE primary and metastatic melanoma tumour
samples from patients previously treated with DTIC or TMZ chemotherapy recruited to
clinical trials, well annotated epidemiological studies or as part of routine clinical care in
the UK. RNA has been extracted from tumour samples to assess expression of DNA
repair genes. These data have been linked with chemotherapy response and survival
data to determine gene expression profiles associated with chemotherapy response
and survival after starting chemotherapy. This chapter describes use of tissue for gene
expression analysis for DNA repair genes, however the intention will be to use tissue
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for other techniques, such as whole-genome expression profiling, mutation screening,
immunohistochemistry, micro-RNA expression, methylation analysis and assessment
of copy number variation in the future in order to understand genetic associations with
patterns of metastasis and response to treatment. Given the low response rate to DTIC
and therefore the limited power within any one centre, to maximise the number of
samples for analysis, this is a collaborative study with the European Organisation for
Research and Treatment of Cancer (EORTC) Melanoma group and a European Union-
funded consortium called Chemores. These groups have provided additional tumour
samples and clinical data for analysis with samples collected in the UK. The study is
managed in Leeds. It was hoped that a successful output from this study might
encourage further similar biomarker studies for other cancers using archived FFPE
tumour samples which had previously been supposed to be unsuitable for genomic
studies.
8.5.2 Participants and samples
Patients that were eligible for inclusion in this study were:
 Patients recruited to the “EORTC 18032: Extended schedule, escalated dose TMZ
versus DTIC in stage IV metastatic melanoma: a randomised phase III study” [249].
This study randomised 859 patients to receive oral TMZ or intravenous DTIC. The
study concluded that use of TMZ did not improve overall survival or progression-
free survival when compared to DTIC [249]. Potential participants were identified
from European centres and the Nottingham University Hospitals NHS Trust.
Samples and follow-up data were sent to Leeds for analysis. The use of material
from patients recruited to clinical trials will help to ensure a more accurate
assessment of response to treatment.
 From the Chemores group (www.chemores.org), which is collecting tissue samples
from melanoma patients treated with DTIC and TMZ for identification of biomarkers
of response to chemotherapy. Samples and follow-up data collected by this group
have been sent to us in Leeds for analysis and pooled with other data.
 Patients recruited to cohort studies or case-control studies of melanoma such as
the Leeds Melanoma Cohort Study were also eligible if treated with chemotherapy.
 Patients treated with DTIC or TMZ as part of routine clinical care in Leeds.
A number of patients were excluded following review where tissue was not available for
tumour sampling or where the patient had not received chemotherapy treatment with
DTIC or TMZ. Table 8-3 summarises the number of recruited patients in May 2012.
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Primary and metastatic FFPE melanoma tumour blocks have been traced for eligible
participants. Tumour tissue has been sampled and RNA and DNA extracted from
tumour tissue cores using the Qiagen AllPrep® RNA/DNA FFPE kit as described in
Chapter 2. Gene expression analysis of DNA repair genes has been undertaken using
the Fluidigm qRT-PCR system which will be described in further detail below.
Recruiting centre Total number of patientsfrom each centre
Number recruited to
the EORTC 18032 trial
Leeds 260 6
Nottingham 12 12
Leuvan (EORTC/Chemores) 87 0
Essen (EORTC/Chemores) 135 21
Excluded cases (22) (2)
Total 472 37
Table 8-3: Number of patients recruited to the Chemotherapy study.
The total number of cases is reported with the number recruited to the EORTC
18032 trial. Twenty-two cases were excluded as no tumour tissue was available
or they did not received DTIC or TMZ chemotherapy. Abbreviation used: EORTC,
European Organisation for Research and Treatment of Cancer.
8.5.3 Clinical data
Clinical data have been provided from treating clinicians, with negotiations currently
underway to access trial databases for patients treated as part of clinical trials. For
patients recruited to epidemiological studies in Leeds, data have been extracted from
current study databases. The clinical data recorded include patient demographic
details (age, gender, date and cause of death or last follow-up date), details of the
primary melanoma (date of diagnosis, site of tumour, stage at diagnosis, tumour
histological features), information regarding stage IV diagnosis (date of diagnosis, sites
of disease), details of chemotherapy received (chemotherapy used and regimen, dates
of chemotherapy, dose reductions, severe haemotoxicities) and lactate dehydrogenase
(LDH) levels before, during and after treatment.
For the current study, chemotherapy response data are of paramount importance. For
patients recruited to the EORTC 18032 trial, I hope to access objective response data
based on the original version of RECIST criteria [766] determined using a CT scan
after 3 cycles of treatment and then after 6 cycles if chemotherapy is continued. Overall
response has been defined as complete response, partial response, stable disease or
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progressive disease [766]. As this trial data is currently not available, response data for
patients treated as part of the 18032 trial, other clinical trials or routine clinical care,
have been provided by treating clinicians based on clinical and radiological tumour
response. For example, for patients recruited in Leeds, where possible objective
response has been determined using CT scan after 3 or 6 cycles of therapy. Where
target lesions have been measured, updated RECIST version 1.1 criteria have been
used to determine response to chemotherapy [290]. Where target lesions have not
been measured, response has been determined by the reporting radiologist on CT
scan, the treating clinician if a clinical determination has been made or the
multidisciplinary team based on review of imaging and clinical factors. Where a
response has been recorded by the multidisciplinary team, this has been deemed the
most accurate data and used for analysis. When trial data are available, the source of
response data is recorded to allow separate assessment of the subset of patients
recruited to trials with RECIST criteria response data. In all cases, the best response
whilst on treatment or the scan after the final chemotherapy cycle was recorded as the
response to chemotherapy treatment and used for further analysis.
8.5.4 Power calculations
Power calculations are based on a range of DNA repair genes with varying mean gene
expression levels and standard deviations identified as differentially expressed in
tumours from non-responders to chemotherapy from the DASL gene expression data.
Assumptions made were that 15% of patients respond (complete response, partial
response or stable disease) to chemotherapy. With 450 eligible patients we have 99-
100% power, depending on the differential expression of the gene, to detect a
difference in gene expression level at a 0.001 significance level.
8.5.5 Regulatory approvals
Ethical approval for the study was granted by Yorkshire and Humber Central Research
Ethics Committee on the 23rd August 2010 (10/H1313/72) and support under section
251 of the NHS Act 2006 was granted by the Ethics and Confidentiality Committee by
the National Information Governance Board for Health and Social Care on the 4th
October 2010 (ECC 8-02 (FT2)/2010).
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8.6 Assessment of DNA repair gene expression in FFPE
melanoma tumours using the Fluidigm qRT-PCR platform
Expression of DNA repair genes was assessed in primary and metastatic FFPE
melanoma samples from patients recruited to the Chemotherapy study. Before the
larger sample set was analysed a pilot study was performed to assess the Fluidigm
system and DELTAgene assays when using FFPE melanoma tissue.
8.6.1 Selection of genes for assessment
The aim of this study was to assess gene expression of a larger panel of DNA repair
genes. The Fluidigm IFC arrays allow assessment of 96 genes for 96 samples in a
single reaction, therefore I decided to assess expression of 48 genes (43 test genes
and 5 control genes) in duplicate on each array. DELTAgene assays were used for this
work which were produced by Fluidigm based on RefSeq IDs using standard design
procedures [331]. Table 8-4 lists the genes assessed and details of the DELTAgene
assays. These genes were selected either because they were previously identified as
associated with response to treatment using the DASL assay, were present on the
CGEA-1 array or there was evidence in the literature that these genes were associated
with chemotherapy response in melanoma or other cancers as referred to in Table 8-4.
Five control genes (Table 8-4) were selected based on previous work using Taqman®
gene expression assays as described in Chapter 4, however following the results of
these analyses, GAPDH was not used for normalisation of data.
As these assays had not been used before in an experiment using FFPE melanoma
tissue, a pilot Fluidigm plate was assessed using RNA extracted from melanoma cell
line samples and FFPE metastases samples. This allowed assessment of performance
of the assays, assay specificity and sample reproducibility. As discussed in Chapter 4,
PCR efficiency of endogenous control gene and test genes needs to be comparable to
allow use of the comparative Ct method for relative quantification [340, 455]. To assess
PCR efficiencies of DELTAgene assays in FFPE melanoma samples, standard curves
were generated using serially diluted samples.
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8.6.2 Pilot study
8.6.2.1 Samples
The following experimental work was performed by myself. As a source of high-quality
template RNA, RNA was extracted from 3 melanoma cell lines (SkMel5, Mel Juso and
Mel 624) using the Qiagen RNeasy® Mini kit. RNA was extracted using a single tissue
core from five FFPE melanoma metastasis samples using the Qiagen AllPrep®
RNA/DNA FFPE kit. RNA was also extracted from an FFPE intradermal naevus
sample, which was selected to act as a calibrator sample. The Roche High Pure RNA
Paraffin Kit was used for RNA extraction from this sample. From cell line and FFPE
samples, 400ng and 200ng of RNA, respectively, was used for cDNA synthesis using
the Applied Biosystems High Capacity cDNA reverse transcription kit. Further
methodological details are described in Chapter 2.
8.6.2.2 Methodological details
8.6.2.2.1 Specific target amplification (STA) of samples
Amplification of specific target assays was performed using 18 cycles of pre-
amplification and the standard Fluidigm qRT-PCR protocol as described in Chapter 2.
As GAPDH is already highly expressed, this assay was not included in the primer mix,
therefore the remaining 47 primer pairs were pooled and used for pre-amplification.
Table 8-4 (following 3 pages): Details of genes assessed using the Fluidigm qRT-
PCR platform with DELTAgene assays in samples from the Chemotherapy
study.
Genes are grouped according to biological function [482, 497, 499, 767, 768]. RefSeq
ID used for primer design [331], exons targeted, length of amplicon and primer
sequence of the DELTAgene assays are also presented. The references column
indicates the sources that associate the gene with chemotherapy responses or reasons
why the gene has been included in the panel. Abbreviation used: bp, base pair.
Biological
function Gene
RefSeq ID used
for primer design
Targeted
exons
Amplicon
length
(bp)
Forward primer Reverse primer References
Endogenous
control genes
GAPDH NM_002046.3 2-3 61 ACACCATGGGGAAGGTGAAG GTGACCAGGCGCCCAATA
IPO8 NM_001190995.1 16-17 79 TTCAGTGCAAAGGAAGGGGAA ACCCCTCGAGTTAATCTCTCCA
PES1 NM_014303.2 10-11 81 GCCTGAAGTTCTTCCTGAACC AGGACACTTCCCCACCAAAA
CASC3 NM_007359.4 9-10 75 CCCCTCCAGTGCATATCAGTA GGGTATAGATTGGTCCCTGGAA
SDHA NM_004168.2 11-12 81 ACATCGGAACTGCGACTCA TTCTTGCAACACGCTTCCC
Nucleotide
excision repair
XPA NM_000380.3 4-5 76 ACATCATTCACAATGGGGTGATA ACCCCAAACTTCAAGAGACC [289]
ERCC1 NM_202001.2 5-6 89 GCCGACTGCACATTGATCC TCCGCTGGTTTCTGCTCATA [289, 486]
ERCC2
(XPD) NM_000400.3 2-3 82 TACCCCGAGCAGTTCTCCTA TCCGCTGGTTTCTGCTCATA [289, 486]
ERCC4
(XPF) NM_005236.2 5-6 77 CTTCTGGAATCTCTGAGAGCAA GAGGTGCTGGAGTCAAGAAA [289, 486]
GTF2H2 NM_001515.3 13-14 81 CACAGTGTCGGGCAAAGTAC CCAAGTGGGGAGCAGACA [289]
LIG1 NM_000234.1 19-20 81 TGGGAAGTACCCGGACATCA GCTTCGGTGTCCAGGATGAA [265]
RPA1 NM_002945.3 16-17 80 AGTCAGGGTCAAAGTGGAGAC TGTAGTCCACGGGCTTCAC [769]
Base excision
repair
XRCC1 NM_006297.2 14-15 83 GAGAACACGGACAGTGAGGAA AAGTGCTTGCCCTGGAAGAA [289, 486, 770]
PARP1
(ADPRT) NM_001618.3 12-13 77 TTCTGGAGGACGACAAGGAA GTTGCTACCGATCACCGTAC
[265, 278, 486,
771]
APEX1
(APE1) NM_080649.1 3-4 67 GGGCTTCGAGCCTGGATTA ACAGTATATCTGGGGCTTCTTCC [265, 486, 770]
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Biological
function Gene
RefSeq ID used
for primer design
Targeted
exons
Amplicon
length
(bp)
Forward primer Reverse primer References
Base excision
repair (cont.)
MPG NM_001015054.1 2-3 124 GCCCAAAGGGCCACCTTA CCTCGGAGTTCTGTGCCATTA [265, 772]
OGG1 NM_016829.2 2-3 113 CGTGGACTCCCACTTCCAA CGATGTTGTTGTTGGAGGAACA [486, 773]
Homologous
recombination
BRCA1 NR_027676.1 11-12 74 AAGACTGCTCAGGGCTATCC CAGGTTATGTTGCATGGTATCCC Previous DASLstudy, [289]
BRCA2 NM_000059.3 21-22 130 ATGCAGCAGACCCAGCTTA TCCATGGCCTTCCTAATTTCCA [486]
RAD50 NM_005732.3 2-3 82 TCCCTCCTGGAACCAAAGGAA AGACGAATCTGGGCTCTCACA [264]
RAD51 NM_002875.4 5-6 86 GGGAAGACCCAGATCTGTCA ATGTACATGGCCTTTCCTTCAC Previous DASLstudy, [289, 482]
RAD52 NM_134424.2 11-12 85 GGATCTTGGGACCTCCAAACTTA TCTTCATGTCCTGGCTCTTCC Previous DASLstudy [482]
RAD54B NM_012415.2 12-13 108 GTGGTGTAGGACTTAACCTCA GACCATCTCTCCATACTCTAGAC Previous DASLstudy
RAD54L NM_001142548.1 16-17 73 AAGAAGCGAGCCAAGGTTGTA TGCTGCTCAGCATGAAGACA Previous DASLstudy
MRE11A NM_005590.3 8-9 83 AACCTGGAAGCTCAGTGGTTA CCTCCCTTTAATACGCAGCAAA [774]
NBN
(NBS1) NM_002485.4 8-9 78 GTGATCCTCAGGGCCATCC CAACTGACACGCCTTGTGAAA [769]
Non-homologous
end joining
XRCC5
(Ku80) NM_021141.3 3-4 75 GCTGGAGGACATTGAAAGCA ATGCTCACGATTAGTGCATCC [289, 486]
XRCC6
(Ku70) NM_001469.3 11-12 80 GATTTGATGGAGCCGGAACAA ACCAAGGAGCCCAGTCTTTTA [289, 486]
PRKDC NM_006904.6 23-24 83 GCTTGGATCTCTAGGAGGACAA AGGCCACATAGCTCTTCATCA [486, 769, 775,776]
Mismatch
excision repair
MLH1 NM_000249.3 12-13 68 AGAGGACCTACTTCCAGCAA TCTTCCACCATTTCCACATCA [289, 486, 777]
MSH2 NM_000251.1 15-16 77 CCAGCAGCAAAGAAGTGCTA TCTTCCACCATTTCCACATCA [289, 486, 777]
MSH6 NM_000179.2 1-2 97 CCAAGGCGAAGAACCTCAAC TTGGCCCAAACCAAATCTCC [264, 289, 486,777]
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Biological
function Gene
RefSeq ID used
for primer design
Targeted
exons
Amplicon
length
(bp)
Forward primer Reverse primer References
PMS2 NM_000535.5 6-7 81 GCTCTGTGTTTGGGCAGAA ACTCTTCACACACGGAGTCA [265, 777]
Genes defective
in diseases with
sensitivity to
DNA damaging
agents
ATM NM_000051.3 43-44 83 TACCAAGCAGCATGGAGGAA GATTCATGGTAACTGGTTCCTTCTAC [289, 486]
BLM NM_000057.2 6-7 91 TGTGGGAACGAACTGCTTCA AGCCAAGAAGACTGGCATCA [264, 769]
DNA
polymerases
POLB NM_002690.1 9-10 63 CTACAGTCTGTGGCAGTTTCA TCAGGAGAACATCCATGTCAC [265, 772]
POLH NM_006502.2 7-8 73 GTTCACTGAATCCCAGCTCCA CCCTCGGCACATGGCATATA [177]
PCNA NM_182649.1 1-2 94 TCTGAGGGCTTCGACACCTA CATTGCCGGCGCATTTTAGTA [769]
Direct reversal of
DNA damage MGMT NM_002412.3 3-4 100 CGAGGCTATCGAAGAGTTCCC CACAACCTTCAGCAGCTTCC [289, 486]
DNA helicases RECQL NM_032941.2 5-6 82 TATGCCTACAGGAGGTGGAA TGGGCAAATGACGAGTGTAA [769]
Endonucleases MUS81 NM_025128.4 4-5 76 AGTGATACTGCTGGTGCTCTAC CAGCAGCTCCTCCTTGGTTA [482, 497]
Induction of
transient DNA
breaks
TOP1 NM_003286.2 17-18 87 ACGCTACAGCAGCAGCTAA AGCTCGATTGGCACGGTTA [289]
TOP2A NM_001067.3 21-22 81 GGCGTTTGATGGATGGAGAA GAGCCAGTTCTTCAATAGTACCC Previous DASLstudy, [289]
TOP2B NM_001068.2 20-21 79 GATGCTGCAAGCCCTCGTTA GGTTGTCATCCACAGCAGGAA [289]
Conserved DNA
damage
response genes
CHEK1 NM_001274.4 8-9 76 TGGTACAACAAACCCCTCAA CACTGGGAGACTCTGACAC [778]
CHEK2
(CHK2) NM_007194.3 5-6 102
TGACTGTAGATGATCAGTCAGTT
TA AAGCCAGCTTTACCTCTCC [778]
ATR NM_001184.3 46-47 80 CATTCCAAAGCGCCACTGAA CGCTGCTCAATGTCAAGAACA [486, 779]
Histone H2AFX NM_002105.2 1 83 TGCGGAAGGGCCACTAC CTCAGCGGTGAGGTACTCC [177, 769]
.
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8.6.2.2.2 Standard curve analysis
Following amplification, one of the FFPE melanoma metastases samples was serially
diluted to allow assessment of standard curves, and therefore amplification efficiency,
for each assay. Two standard curves were produced using six standards generated by
a 1:2 and 1:10 serial dilution of the sample. The curve based on 1:10 dilution allowed
assessment of PCR efficiency over a large range, however as many of these samples
were very dilute, the 1:2 standards would allow some assessment of efficiency if 1:10
samples failed to amplify.
8.6.2.2.3 qRT-PCR reaction
Sample and assay pre-mix solutions were prepared using the standard Fluidigm qRT-
PCR protocol as described in Chapter 2. Each sample was assessed in triplicate and a
no template control (water used instead of STA sample) was included. Each assay was
assessed in duplicate. The 96:96 Dynamic Array IFC was loaded and the qRT-PCR
reaction and melt curve analysis was performed as described in the standard protocol
with initial data processing described in Chapter 2. Ct values were exported to Stata
version 10 (StataCorp 2007) for further analysis.
8.6.2.2.4 Analysis of qRT-PCR data
The Fluidigm Real-time PCR Analysis software generated standard curves for diluted
samples based on the mean Ct values across replicate samples and calculated assay
efficiencies using the formula: efficiency = 10(-1/slope) -1 [456]. Melt curves were
assessed for each assay to identify evidence of primer-dimer formation or production of
non-specific PCR products. Reproducibility was assessed between sample replicates
by calculation of the intraclass correlation coefficients (ICC) described further in
Chapter 4.
8.6.2.3 Results
8.6.2.3.1 Amplification efficiencies of DELTAgene assays
No template control samples were assessed and no amplification was seen for any
assay. A number of wells in the IFC had not loaded properly as indicated by absent
ROX passive reference dye in the wells and were excluded from further analysis. Many
of the 1:2 dilution standards had not loaded well meaning there were less data points
for analysis, however the 1:10 diluted samples were more successful, with the first four
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most concentrated standard samples performing well and allowing generation of a
standard curve and calculation of amplification efficiency. GAPDH failed to amplify for
the majority of standard samples, probably because it was not included in the STA
primer mix, therefore a standard curve could not be generated for assessment of assay
efficiency.
Amplification efficiencies for the four control genes assessed (CASC3, PES1, IPO8
and SDHA) ranged from 0.88-1.12. For use of a comparative Ct method for relative
quantification of gene expression, the efficiencies of the test genes needs to be
comparable to that of the control genes. Assuming that +/-10% of the efficiency of
control genes is acceptable, three test assays had efficiencies greater than those of the
control genes (MLH1, OGG1 and RECQL), of these only RECQL was much greater.
Therefore expression of the majority of genes can be assessed using the comparative
Ct method using the endogenous control genes assessed in this panel.
Melt curve analysis demonstrated that the majority of assays generated a specific PCR
product. In some melt curves there was evidence of primer/dimer formation (ERCC1,
MPG and MSH6) and the curve for XRCC6 showed multiple products. We were unable
to redesign primers before starting the larger experiment, however being aware of
these factors will allow a more correct interpretation of results.
Reproducibility across sample replicates was assessed using ICCs. ICC values were
variable across the assays, however there appeared to be a clear inverse relationship
between ICC value and the mean Ct value for the assay across the samples assessed
(Figure 8-2). Following discussion with technical support at Fluidigm, it was decided to
increase the number of pre-amplification cycles to 22 to reduce the mean Ct value for
each probe and improve reproducibility between replicate samples. We also planned to
remove samples with Ct values over 28 from further analysis as there was a lack of
reproducibility between replicate samples, and therefore questionable data accuracy,
at these Ct values. This approach was used in a second pilot plate where the calibrator
sample, a cell line sample and four metastases samples were re-assessed for a limited
panel of assays following 22 cycles of pre-amplification. Table 8-5 summarises the
results of this experiment for the FFPE samples, which confirmed that increasing the
number of pre-amplification cycles, reduced the mean Ct value for the assays and
improved reproducibility across replicate samples.
Following this pilot work, I concluded that the system and assays were working well, so
the larger sample set from the Chemotherapy study was assessed using the Fluidigm
system.
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Figure 8-2: Scatter plot demonstrating the association between sample
reproducibility and mean cycle threshold (Ct) value for the assay.
Reproducibility across replicate samples is reduced as the mean Ct value for the
assay increases.
Probe Mean Ct value18 cycles
Mean Ct value
22 cycles
ICC
18 cycles
ICC
22 cycles
APEX1 13.53 8.86 0.92 1
BRCA1 17.01 13.24 0.99 1
ERCC1 15.48 10.77 0.73 1
MGMT 19.77 13.48 0.45 1
MUS81 18.61 13.09 0.85 1
PARP1 17.79 9.59 0.48 1
POLB 14.74 9.54 0.98 1
RAD51 19.15 14.50 0.71 1
TOP2B 13.42 8.99 0.86 1
Table 8-5: Intraclass correlation coefficients with eighteen and twenty-two pre-
amplification cycles.
Mean Ct values and ICCs are listed for genes following 18 and 22 cycles of pre-
amplification for a limited panel of genes. ICC values are greater with 22 cycles of
pre-amplification indicating improved reproducibility between replicate samples.
Abbreviations used: Ct, cycle threshold; ICC, intraclass correlation coefficients.
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8.7 Assessment of DNA repair gene expression in tumours
from patients recruited to the Chemotherapy study
8.7.1 Further methodological details
8.7.1.1 Samples
From the 450 patients eligible for the Chemotherapy study, samples from 222 patients
were sent to us from European groups and other tissue samples were traced, focusing
on patients who had responded to chemotherapy and completing sets of matched
samples where more than one tumour sample was available. DNA repair gene
expression from 416 tumour samples were assessed in this analysis.
8.7.1.2 Fluidigm qRT-PCR
Tissue cores were sent to us from European groups or tumour blocks were sampled
using a tissue microarray needle and RNA extracted using the Qiagen AllPrep®
RNA/DNA FFPE kit by a service provider, Gen-probe Life Sciences Ltd.
(Wythenshawe, UK) using methods described in Chapter 2. Gen-probe normalised the
RNA samples prior to cDNA synthesis. All RNA samples were used irrespective of
RNA concentration measured using spectrophotometry. Tissue cores from Europe
were much larger than the 0.6mm diameter tissue microarray cores sampled from
tumours in Leeds. Therefore the RNA yield was much greater from European samples
and 1 microgram of RNA was used in each cDNA reaction. For tissue cores sampled in
Leeds with lower RNA yields, 200ng of RNA was used to make cDNA. If RNA yields
were less than 100ng/μl for European samples, or less than 20ng/μl for Leeds tumour 
cores, 10μl of RNA was used to make cDNA. The rationale behind this approach was 
to use as much template RNA as possible, whilst maintaining consistency across the
sample set. For European samples with greater RNA yields, excessive dilution of RNA
to match samples from Leeds was impractical and use of larger amounts of RNA from
Leeds samples would have exhausted RNA stocks from these cores. Accurate
normalisation of gene expression data will correct for differences in template RNA
concentration, therefore this approach was deemed acceptable for this large-scale
study. cDNA was synthesised using the Applied Biosystems High Capacity cDNA
Reverse Transcription kit in 96-well plates and STA of samples was performed using
the standard protocol. Each sample and assay was assessed in duplicate on a 96:96
Dynamic Array IFC using the standard protocol. Further details of methods used are
described in Chapter 2. The intradermal naevus sample used in the pilot study was to
be used as a calibrator sample on each Fluidigm array, however a number of assays
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failed for this sample on the first Fluidigm array so a well performing melanoma sample
was used as calibrator sample on subsequent arrays. For each STA plate, a new
aliquot of cDNA from the calibrator sample was amplified along with the samples for
assessment and then used on the Fluidigm arrays. A number of negative control
samples were rotated across the Fluidigm arrays, these being:
 cDNA control samples generated without reverse transcriptase (RT) and so no
cDNA should be present (RT negative cDNA controls).
 Water used in the STA reaction instead of cDNA (no template samples that
had undergone STA).
 Water used instead of STA product in the qRT-PCR reaction (no template
controls).
A total of nine Fluidigm arrays were used for this experiment. Data were assessed
using the methods described in Chapter 2, with baseline and threshold levels being
calculated by Biomark HD Reader software (Fluidigm, San Francisco, CA) for each
array. Ct values were exported to Stata version 10 (StataCorp 2007, College Station,
TX) for further analysis.
8.7.1.3 Data analysis
Reproducibility between sample replicates was assessed using ICCs and any samples
with Ct values over 28 were excluded from further analysis. Mean Ct values from
sample replicates were calculated and data normalised to the expression of CASC3,
PES1, SDHA and IPO8 according to the method described by Vandesompele [343] as
described in Chapter 2. Data from each Fluidigm array were normalised separately
using the calibrator sample run on the array. Samples failing eight or more assays
were removed from further analysis. Normalised data from the nine arrays were then
merged for further analysis.
8.7.1.4 Statistical analysis
Reproducibility of Ct values generated from the calibrator samples across the arrays
were compared using Spearman’s rank correlation. For the primary analysis, gene
expression data from the first available tumour sample was used. Fold differences in
gene expression were calculated between progressing tumours and tumours showing
any response to chemotherapy (stable disease, partial or complete response). The
Cuzick test for trend [780] was used to identify genes differentially expressed in
tumours from patients in each of the four response groups using un-transformed gene
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expression data. Genes identified as being differentially expressed were assessed
further in linear regression using gene expression data which was log-transformed
(log2).
Survival analysis was performed to identify gene expression patterns associated with
survival after starting chemotherapy. Survival analysis was performed on 25th April
2012 and data was censored on this date. The Cox proportional hazards model was
used to calculate hazard ratios and 95% confidence intervals for each gene using log-
transformed data (log2). Despite transformation, the distribution of data was not normal,
therefore analysis was repeated using expression levels split into eight groups and
survival analysis was repeated using this categorical variable. Significance values were
ranked to identify genes most associated with survival.
Analyses were performed unadjusted and adjusted for prognostic factors in stage IV
disease according to the AJCC staging guidelines [58]. Patients were classified based
on sites of disease and LDH level at start of chemotherapy into M1a (distant skin,
subcutaneous or nodal metastases), M1b (lung metastases) or M1c (all other visceral
metastases or any distant metastasis with elevated LDH level) groups. Regression and
survival analyses were adjusted by this variable (sub-stage) to identify genes
independently associated with chemotherapy response or survival after starting
chemotherapy. Furthermore, survival analysis was adjusted for chemotherapy
response for genes of interest in multivariate analyses.
For these analyses, gene expression from the first available tumour sample was used,
in some cases this was a primary tumour in others a metastatic specimen. As gene
expression profiles are likely to differ between primary and metastatic tumours,
analyses were repeated for primary tumours and metastatic tumours separately. A
minority of patients received combination chemotherapy with an additional agent being
given alongside DTIC or TMZ. Analysis was repeated for patients receiving DTIC or
TMZ monotherapy only to assess differences in gene expression profiles specific to
monotherapy. In view of the multiple testing involved in this study, a stringent
significance value of 0.001 was set for the described analyses.
8.7.2 Results
8.7.2.1 Performance of the Fluidigm system
8.7.2.1.1 Reproducibility of replicate samples
As described above, the calibrator sample was RNA extracted from a melanoma
sample. cDNA was synthesised from this sample and an aliquot of cDNA was used in
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the STA reaction with test samples that were assessed with the calibrator sample on
each Fluidigm array. The calibrator sample was used on all nine Fluidigm arrays and
the Ct values for the 48 genes correlated very well across the arrays (Spearman’s rho
0.97-1.00, all significance values <0.00001) (Figure 8-3).
These results show that reproducibility was excellent across the arrays even when
samples were amplified separately.
Figure 8-3: Scatter plot showing correlation between two replicate samples
assessed on two separate Fluidigm qRT-PCR arrays.
Mean cycle threshold values from replicate samples are plotted for expression of
each gene for the calibrator sample. Abbreviation used: Ct, cycle threshold.
8.7.2.1.2 Control samples
All the control samples where water was used instead of STA product in the qRT-PCR
reaction failed to amplify for any assays as expected. However, some RT negative
controls used in the STA reaction and no template samples that had undergone STA
amplified for some of the genes assessed. These control samples were assessed
across a number of arrays, and amplification was seen in a different spectrum of genes
on each array with no amplification seen for many genes assessed. Across the arrays,
the only two genes where amplification was repeatedly seen were for GAPDH and
TOP1. For all genes, the Ct values generated for the control samples were much
higher than those for the test samples: no template control mean Ct values were 12.9
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cycles higher (range 2.7-22.1) and RT negative control mean Ct values were 5.3 cycles
higher than test samples (range 2.8-12.9). Review of the melt curves from these
control samples showed a product melting at a lower temperature than the test
samples indicating the formation of primer-dimers. For test samples, no primer-dimer
peaks were noted. The formation of primer-dimers only appeared to occur when control
samples had been through the STA process and did not appear consistently for the
majority of genes across the arrays, the exceptions being GAPDH and TOP1. This
phenomenon may be reducing the accuracy of the qRT-PCR data and needs to be
acknowledged. GAPDH was not used in further analysis, however TOP1 is a gene of
interest and therefore, results from this assay should be interpreted with caution.
8.7.2.2 Gene expression analysis
8.7.2.2.1 Samples
From the 416 tumour samples assessed using the Fluidigm system, 41 samples were
not used in the analysis as they failed eight or more of the gene expression assays
assessed. Therefore, 375 (90%) tumour samples yielded gene expression data . Three
samples were removed from further analysis as they either represented a replicate
sample or were samples from a metastasis removed on the same day as another
metastasis. A further seven patients did not have stage IV disease when they received
chemotherapy and two patients proved not to have received DTIC or TMZ. Thus gene
expression data from a total of 363 tumours was analysed (summarised in Table 8-6).
Sample type
Single sample per patient, number (% per total no. patients) 204 (76)
Patients with multiple samples, number (% per total no. patients):
2 samples, number (% of multiple samples)
3 samples, number (% of multiple samples)
4 samples, number (% of multiple samples)
5 samples, number (% of multiple samples)
8 samples, number (% of multiple samples)
66 (24)
50 (76)
10 (15)
4 (6)
1 (1.5)
1 (1.5)
Total number patients 270
Total number of samples 363
Table 8-6: Summary of samples from the Chemotherapy study assessed using
qRT-PCR of DNA repair genes.
The number of patients from whom tumour samples were assessed is presented
along with the number of samples. Multiple samples were from single patients as
indicated in the table.
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For the identification of genes associated with chemotherapy response and survival
following start of chemotherapy, the first sample available from each patient was
analysed so that some were primary tumours and others metastases (Table 8-7). A
total of 270 patients were involved in this analysis.
Tumour or patient characteristic Number or median (% or range)
Type of tumour used for primary analysis:
Primary
Metastasis
89 (33.0)
181 (67.0)
Treatment received:
Dacarbazine
Dacarbazine with other chemotherapy
Temozolomide
133 (49.3)
61 (22.6)
76 (28.1)
Response to chemotherapy:
Progressive disease
Stable disease
Partial response
Complete response
No data available
143 (53.0)
46 (17.0)
25 (9.3)
11 (4.1)
45 (16.7)
AJCC staging IV subgroup:
M1a
M1b
M1c
Missing data
11 (4.1)
22 (8.2)
222 (82.2)
15 (5.6)
Survival status:
Alive
Died
48 (17.8)
222 (82.2)
Survival from start of chemotherapy, years 0.6 (0.003-7.1)
Table 8-7: Summary tumour and patient characteristics for samples used in the
primary analysis for the Chemotherapy study.
See text for further description of AJCC subgroups for stage IV disease.
Abbreviation used: AJCC, American Joint Committee on Cancer.
8.7.2.2.2 Summary characteristics of patients and tumours assessed
Table 8-7 summarises the characteristics of the samples and patients in the primary
analysis for this study. The majority of samples used for the primary analysis were
metastatic samples (67%). The largest proportion of patients received DTIC alone
(49%), however 23% of patients treated in Europe received DTIC in combination with
other chemotherapies, these being the platinum containing agents, cisplatin or
carboplatin. Response data were available for 83% of patients, with the majority
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progressing despite chemotherapy treatment (53%). Response data were missing for
17% of patients, usually because the patients deteriorated clinically or died before an
assessment of response was made. The majority of patients had stage M1c disease
(82%) and 82% of patients had died at the time of analysis.
Gene expression profiles are likely to be different in primary and metastatic tumour
specimens from the same patient (see Chapter 5)[510]. Therefore, assessment of gene
expression in a mixture of primary and metastatic specimens reduces the power of the
study to identify expression patterns specific to either primary or metastatic tumours
alone. Based on the power calculations and assumptions described in section 8.5.4, for
the 270 patients currently involved in this study, we have 93-100% power at a 0.001
significance level to detect a difference in gene expression level across a range of DNA
repair genes. Calculations have been repeated assessing primary and metastatic
tumours separately; for 89 primary samples there is only 28-80% power and for 181
metastatic specimens, this increases to 72-100%. As recruitment to this study
continues, numbers of primary and metastatic samples available for analysis will
increase, so increasing the power of these subgroup analyses.
8.7.2.2.3 Genes associated with response to chemotherapy
Table 8-8 presents the 10 genes most associated with response to chemotherapy in
the whole dataset, primary tumours, metastatic tumours and patients treated with DTIC
or TMZ monotherapy only. Of the 43 DNA repair genes assessed, the gene with
expression most significantly associated with failure to respond in the whole dataset,
metastatic samples and patients treated with DTIC/TMZ monotherapy only was MGMT
(Cuzick test for trend in the whole dataset z=-4.2, p=0.00003). Figure 8-4 shows gene
expression levels for MGMT across the response groups. Expression was greatest in
tumours from patients who did not respond to therapy compared to those with stable
disease, partial or complete responses. MGMT expression remained significantly
associated with response to chemotherapy when analysis was adjusted for sub-stage
at start of chemotherapy treatment in linear regression analysis (regression coefficient -
0.75 (95% CI -1.08 - -0.42), p=0.00001).
When primary tumours were analysed alone, MGMT was less associated with
response (Cuzick test for trend z=-2.5, p=0.01) with a smaller fold change between
tumours from patients with progressive disease compared with patients who responded
(fold change 1.16, compared to 1.46 for the whole dataset and 1.66 for metastases
only). In this group, expression of MLH1 was most associated with chemotherapy
All samples (n=225) Primaries only (n=73) Metastases only (n=152) Monotherapy only (n=165)
Gene Folddifference P-value Gene
Fold
difference P-value Gene
Fold
difference P-value Gene
Fold
difference P-value
MGMT 1.46 0.00003 MLH1 1.25 0.002 MGMT 1.66 0.0008 MGMT 1.44 0.0003
XPA 1.32 0.02 ERCC4 1.36 0.003 PCNA 1.72 0.02 XPA 1.36 0.002
PCNA 1.39 0.07 MGMT 1.16 0.01 BLM 1.45 0.04 ERCC4 1.19 0.009
XRCC5 1.06 0.07 LIG1 0.82 0.02 PARP1 1.18 0.12 MSH6 0.78 0.05
PRKDC 1.02 0.08 TOP1 0.81 0.02 PRKDC 0.97 0.16 MLH1 1.19 0.05
LIG1 0.92 0.09 XPA 1.46 0.02 NBN 1.31 0.21 POLB 0.97 0.06
PARP1 1.13 0.14 POLB 0.81 0.06 MUS81 0.86 0.23 PRKDC 1.01 0.07
NBN 1.20 0.16 BLM 0.90 0.09 XRCC5 1.10 0.24 CHEK1 1.42 0.10
POLB 0.93 0.16 RPA1 1.21 0.09 TOP2A 1.45 0.25 APEX1 1.11 0.11
CHEK1 1.36 0.23 TOP2B 1.10 0.10 XPA 1.26 0.26 XRCC5 1.07 0.11
Table 8-8: Top 10 genes associated with chemotherapy response in the whole dataset and then primary tumours, metastases and patients
treated with dacarbazine or temozolomide monotherapy only.
Significance values are from the Cuzick test for trend across four response groups (progressive disease, stable disease, partial and complete
response). Fold differences are for gene expression in tumours from patients with progressive disease compared with those in which any
response was reported. Abbreviations used: n, number.
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Figure 8-4: Box-plots showing MGMT gene expression in tumours responding
differently to chemotherapy.
response (Cuzick test for trend z=-3.1, p=0.002) followed by ERCC4 (Cuzick test for
trend z=-3.0, p=0.003). The pilot study showed that the amplification efficiency of the
MLH1 assay was not comparable with the endogenous control genes assessed on the
array, therefore it must be acknowledged that the accuracy of the results for this assay
are questionable. There was no association between expression of MLH1 and ERCC4
with response in metastases (MLH1 p=0.68, ERCC4 p=0.77). In metastatic tumours,
PCNA was differentially expressed in tumours from non-responders (Cuzick test for
trend z=-2.4, p=0.02), but not in primary tumours (p=0.85). These findings suggest that
patterns of gene expression associated with treatment response are different in
primary and metastatic samples. This is not surprising but suggests that the value of
predictive biomarkers will be stage specific.
Overall, the majority of the DNA repair genes assessed were over-expressed in
tumours from patients who progressed compared to those who responded (Table 8-8).
There are exceptions to this, for example LIG1 was under-expressed in primary
tumours from patients who progressed with chemotherapy treatment.
8.7.2.2.4 Genes with expression associated with survival after starting chemotherapy
Figure 8-5 presents a Kaplan-Meier plot for survival after starting chemotherapy for
patients in the study, showing the association between response to chemotherapy and
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survival time. As expected, patients with a complete response to chemotherapy
survived longer (median survival time 2.2 years (range 0.6-4.0)) than those with a
partial response (1.1 years (range 0.3-5.4)), stable disease (0.8 years (range 0.2-3.2))
or progressive disease (0.5 years (range 0.003-5.4)) (log-rank test χ2(3) 31.7,
p<0.00001).
Figure 8-5: Overall survival following start of chemotherapy according to
response to chemotherapy treatment.
Table 8-9 lists the genes with expression most associated with survival in analysis
adjusted for the sub-stage of disease at start of chemotherapy treatment, being the
strongest prognostic factor in stage IV disease. Results of survival analysis were
compared using log2 transformed gene expression and data split into a categorical
variable. The gene lists were similar and the results presented are from the analysis of
log2 transformed gene expression data.
In view of the association between MGMT expression and chemotherapy response and
survival, the gene was assessed in further detail. Multivariate survival analysis was
performed further adjusting for the effect of chemotherapy response as this factor
significantly influences survival as shown in Figure 8-5. Results of these analyses are
presented in Table 8-10.
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In the larger dataset, increased expression of ATM (hazard ratio (HR) for doubling of
gene expression 1.30 (95% CI 1.10-1.52), p=0.002), MGMT (Table 8-10), PRKDC (HR
1.34 (95% CI 1.08-1.65), p=0.007) and PARP1 (HR 1.33 (95% 1.08-1.64), p=0.008)
were most associated with reduced overall survival time after starting chemotherapy.
However, these genes were not significantly associated with survival (p<0.001) when
correction is made for multiple testing. In multivariate analysis, MGMT expression
remained associated with shorter survival when analysis was adjusted for prognostic
factors relevant in stage IV disease (stage subset) and when adjusted further, for the
influence of chemotherapy response (Table 8-10).
Again, there appeared to be a difference in the pattern of gene expression associated
with survival in primary tumours compared to metastatic specimens, with MGMT over-
expression associated with larger hazard ratios (HRs) in primary samples compared to
metastatic specimens. Expression in primary tumours is more significantly associated
with survival when adjusted for stage and response to chemotherapy (Table 8-10).
MSH2 and PARP1 over-expression were associated with reduced survival in
metastatic specimens (MSH2 HR 1.44 (95% CI 1.18-1.77), p=0.0004; PARP1 HR 1.37
(95% CI 1.08-1.75), p=0.01). However, there were no associations found between
these genes and survival in primary tumours (MSH2 HR 0.66 (95% CI 0.43-1.03),
p=0.07; PARP1 HR 1.16 (95% CI 0.77-1.76), p=0.48).
Over-expression of ATM appeared to influence survival in both primary (HR 1.40 (95%
CI 1.02-1.91), p=0.04) and metastatic tumours (HR 1.25 (95% CI 1.03-1.51), p=0.02).
Analysis of patients receiving DTIC or TMZ monotherapy showed associations
between expression of PRKDC (HR 1.35 (95% CI 1.09-1.67), p=0.007) and survival,
with MGMT (Table 8-10) and ATM (HR 1.15 (95% CI 0.95-1.39), p=0.15) not
associated with survival in this sample set.
The majority of DNA repair genes were over-expressed in tumours from patients who
had died compared to those who remain alive. Exceptions to this are POLH and POLB
which were under-expressed in tumours from patients who had died and greater
expression of these genes was associated with longer overall survival time (all data
POLB HR 0.81 (95% CI 0.69-0.96), p=0.01; primaries only POLB HR 0.67 (95% CI
0.48-0.95), p=0.02, POLH HR 0.72 (95% CI 0.54-0.95), p=0.02).
All samples (n=270) Primaries only (n=89) Metastases only (n=181) Monotherapy only (n=209)
Gene Folddifference P-value Gene
Fold
difference P-value Gene
Fold
difference P-value Gene
Fold
difference P-value
ATM 1.40 0.002 MGMT 2.31 0.01 MSH2 1.34 0.0004 PRKDC 1.24 0.007
MGMT 1.51 0.006 POLH 0.79 0.02 PARP1 1.36 0.01 ATR 1.08 0.04
PRKDC 1.06 0.007 POLB 0.83 0.02 PRKDC 1.16 0.01 PARP1 1.24 0.05
PARP1 1.30 0.008 ATM 1.50 0.04 RAD54L 0.96 0.02 PMS2 1.01 0.07
POLB 0.81 0.01 OGG1 0.86 0.06 ATM 1.33 0.02 TOP1 0.83 0.08
MSH2 1.19 0.02 ERCC4 1.14 0.06 ATR 1.36 0.02 BRCA2 0.84 0.09
RAD54L 0.89 0.04 MSH2 0.94 0.07 ERCC2 0.97 0.06 MGMT 1.35 0.09
ATR 1.11 0.04 TOP1 0.74 0.09 CHEK2 1.55 0.07 ERCC4 1.13 0.09
MLH1 1.06 0.05 ERCC1 1.02 0.17 POLB 0.79 0.09 MSH2 1.17 0.10
ERCC2 0.89 0.08 XRCC6 1.37 0.19 TOP2A 1.19 0.09 RAD54L 1.30 0.12
Table 8-9: Top 10 genes associated with survival after starting chemotherapy in the whole dataset and then primary tumours, metastases
and patients treated with dacarbazine or temozolomide monotherapy only.
Significance values were from a Cox proportional hazards model adjusting for sub-stage at start of therapy. Fold differences in expression are
for tumours from patients who had died/alive patients. Abbreviations used: n, number.
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Unadjusted analysis Adjusted for sub-stage at start ofchemotherapy
Further adjusted for response to
chemotherapy
Hazard ratio
(95% CI) Significance value
Hazard ratio
(95% CI) Significance value
Hazard ratio
(95% CI) Significance value
Whole dataset 1.10 (1.03-1.18) 0.007 1.12 (1.03-1.21) 0.006 1.10 (1.01-1.20) 0.03
Primaries only 1.13 (0.98-1.31) 0.08 1.24 (1.05-1.46) 0.01 1.27 (1.05-1.53) 0.01
Metastases only 1.09 (1.01-1.18) 0.03 1.07 (0.98-1.17) 0.11 1.06 (0.96-1.16) 0.25
Monotherapy only 1.05 (0.97-1.14) 0.24 1.08 (0.99-1.19) 0.09 1.05 (0.94-1.17) 0.42
Table 8-10: Results of multivariate survival analysis assessing the relationship between MGMT gene expression and survival after starting
chemotherapy in the whole dataset and then primary tumours, metastases and tumours from patients who received DTIC/TMZ
monotherapy only.
Hazard ratios and 95% confidence intervals are from the proportional hazards model and represent risk of death for doubling of MGMT gene
expression. Analysis is presented without adjustment, adjusted for sub-stage at start of chemotherapy and further adjusted for response to
chemotherapy. Significant results are highlighted in bold. Abbreviations used: CI, confidence interval.
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8.8 Discussion
8.8.1 Gene expression profiling in FFPE primary melanoma
tumours
This chapter has described use of a number of gene expression profiling platforms,
namely the DASL assay, a customized Taqman Array microfluidic qRT-PCR card
(the Chemo-sensitivity Gene Expression Array, CGEA-1) and the Fluidigm qRT-
PCR system. The DASL assay is discussed in detail in Chapter 3, I will concentrate
on the other gene expression profiling systems for this discussion.
The analysis of samples using the CGEA-1 array was performed at the
Translational Oncology Research Centre, Queen Alexandra Hospital in Portsmouth.
Therefore, my assessment of sample performance was limited, however Table 8-2
lists the variable and limited number of useable results from the total of 31 samples
sent for analysis, indicating that FFPE melanoma samples did not perform well with
this assay. For the Fluidigm platform, stringent criteria (failing 8 or more assays)
were used to exclude samples from further analysis. This system, using a pre-
amplification step, yielded useable gene expression data from 90% of tumours.
There was also excellent reproducibility between gene expression results from
replicate samples on each array and across arrays. Therefore, the Fluidigm system
performed well, however it is possible that the CGEA-1 array would also have
performed better if pre-amplification of samples had been performed [348].
Despite the good performance of the Fluidigm assay, there was amplification of
control samples in which no cDNA was present and RT negative cDNA control
samples that had been pre-amplified. The spectrum of genes where amplification
was seen differed across the arrays with Ct values in control samples being greater
than test samples. Review of control sample melt curves indicated the formation of
primer-dimers which melt at a lower temperature compared to the specific gene
product. Pre-amplification increases copies of target cDNA using pooled primers for
use in the qRT-PCR experiment. It has been shown that this process does not
introduce bias and decreases Ct values, so improving data quality [316, 348]. To
improve reproducibility between sample replicates for this work, the number of pre-
amplification cycles was increased to 22. This, in combination with a lack of
template cDNA in control samples has led to formation of primer-dimers. As
EvaGreen binds non-specifically to double-stranded DNA [350], it will not
distinguish primer-dimers from the specific PCR product. However, formation of
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primer-dimers is dependent on the cDNA concentration, so when no template is
present, as in control samples, primer-dimers are formed, but when template is
present at higher concentration, the specific product predominates [781, 782]. This
is supported by there being no primer-dimer peaks in test samples. Formation of
primer-dimers will reduce the accuracy of the PCR reaction as fluorescence from
these products will be detected by data collection software and there will be
competition for reaction components between the two products [781, 783, 784].
Amplification was repeatedly seen for GAPDH and TOP1, and ideally these assays
need to be redesigned to remove this problem. Use of Taqman® based assays with
the additional gene specific probe would also reduce amplification detected in
association with primer-dimers [349, 783, 784]. The accuracy of this experiment
does not appear to be severely compromised by this issue as the reproducibility in
the Ct values from the calibrator sample, which was amplified in separate pre-
amplification reactions, was excellent when assessed across different arrays
(Spearman’s rho 0.97-1.00, all significance values <0.00001).
Overall, the Fluidigm platform has worked well in an experiment where gene
expression for a limited number of genes has been assessed in a large number of
samples. The main advantage of this system is the speed with which samples can
be processed, a total of 416 RNA samples have been assessed in a total of 82,944
PCR reactions. Over 850 96-well plates and significant amounts of time would be
needed to perform this study using qRT-PCR methods described in Chapter 4,
therefore we plan to use this system for further gene expression studies within our
group, but refining the technique to reduce apparent amplification of control wells.
8.8.2 DNA repair gene expression and response to chemotherapy
Results from chemotherapy response data suggest that identification of predictive
gene expression profiles is possible using FFPE primary melanoma tumours. In the
small sample set assessed using the DASL assay, over-expression of RAD51 and
TOP2A were associated with poor response to chemotherapy. Using the CGEA-1
array, there was increased expression of genes involved in removal of direct DNA
damage (MGMT), base-excision repair, nucleotide excision repair and DNA non-
homologous end joining [497] in tumours unresponsive to chemotherapy,
suggesting that DNA repair genes involved in other pathways are also relevant. In
contrast, genes encoding proteins involved in apoptosis, cellular proliferation and
membrane drug pumps exhibited both increased and decreased expression in non-
responding tumours. Gene expression studies assessing multiple genes in
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melanoma tumours have previously been small, and not designed to identify
predictive markers, therefore the Chemotherapy study was designed to address
this hypothesis in a larger sample set and allow more detailed analyses of the
relationship between DNA repair genes and response.
In the larger study, over-expression of MGMT was most significantly associated
with progression following chemotherapy treatment and associated with shorter
survival after start of chemotherapy. The association between MGMT expression
appeared however to be more complex than has been previously reported and this
dataset has allowed some assessment of the relationship between expression in
primary and metastatic tumour specimens and treatment response. Expression of
MGMT appeared to be more closely related to chemotherapy response in
metastatic specimens compared to primary tumours. This would be expected as
DTIC is used to target metastatic disease which is likely to have undergone
profound genetic alterations compared to the primary tumour in the path to
metastasis and expression patterns in primary tumours are less likely to directly
influence chemotherapy response in metastatic disease. In survival analysis from
start of chemotherapy, the association between MGMT expression and shorter
survival in the larger dataset appears to be driven more by expression in primary
tumours. However, greater expression in metastatic tumours is associated with
shorter survival and HRs for survival in the larger dataset, primary and metastatic
tumours remain similar in multivariate analysis adjusting for sub-stage and
chemotherapy response.
This study has used sensitive qRT-PCR gene expression analysis. Activity of
MGMT can be measured to determine the number of active molecules and this
level correlates with protein and mRNA levels [785]. However, MGMT activity
assays have been reported by others to be inaccurate due to contamination by
MGMT positive leucocytes or endothelial cells and immunohistochemistry can be
highly subjective [786, 787]. Use of qRT-PCR to assess gene expression is more
accurate, however it has been shown that there is variation in MGMT expression
within melanoma tumours due to heterogeneity, with some areas expressing high
levels and others none [788]. Therefore, using a tissue microarray needle, as in this
study, to sample a specific area of tumour may not accurately reflect the overall
expression.
MGMT expression is determined by activity of transcription factors, but also the
methylation status of the MGMT promoter, with methylation decreasing expression,
and methylation within the gene, leading to greater expression [756, 785, 789]. The
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positive association between MGMT expression and TMZ treatment response has
been previously noted in melanoma cell lines and the authors of this study found
that this relationship is stronger than a gene expression signature generated using
microarray analysis [265]. A study of frozen metastatic tumour specimens from 75
patients showed that lower expression of MGMT was associated with better
response to DTIC and longer survival [756]. The authors also noted a association
between metastatic tumour MGMT expression and the Breslow thickness of the
primary tumour [756]. Similar results have been found with regards to protein
expression, with lower expression of MGMT in metastatic specimens correlating
with response to DTIC [270].
As reviewed in the introduction, there have been many studies showing no
association between MGMT activity [268, 269], protein expression [270], gene
silencing by promoter methylation [271, 758] and MGMT polymorphisms [267] and
response to TMZ or DTIC in melanoma. It has been suggested that this lack of
association is due to silenced apoptotic pathways, so despite formation of O6-
methylguanine, which lead to double-stranded breaks in DNA, apoptosis does not
occur [785, 790, 791]. The current study confirms that there is a significant
association between MGMT expression levels and chemotherapy response in
melanoma tumours.
In the current analysis, examples of other genes associated with chemotherapy
response in primary tumours were MLH1 and ERCC4. PCNA and XPA were
differentially expressed in association with chemotherapy response in metastatic
specimens, the larger dataset and those who received monotherapy with DTIC or
TMZ only. What is notable is that over-expression of all of these genes are
associated with poorer response to chemotherapy and that these genes are
involved in many DNA repair pathways and processes, namely mismatch repair
(MLH1), nucleotide excision repair (ERCC4 and XPA) and PCNA is a DNA
polymerase related gene [482, 497, 499, 767, 768]. This suggests that resistance to
DTIC or TMZ reflects a general over-expression of DNA repair genes, which would
be consistent with the data from the CGEA-1 array and the hypothesis that over-
expression of DNA repair genes related to maintaining genomic integrity also
causes resistance to chemotherapy [177, 264]. The situation is similar for genes
with expression associated with survival. Examples of genes other than MGMT in
the larger dataset are ATM, a gene defective in ataxia telangiectasia where DNA is
sensitive to DNA damaging agents, PRKDC which is involved in non-homologous
end joining and PARP1 which is active in base excision repair [482, 497, 499, 767,
768]. ATM is particularly interesting as single nucleotide polymorphisms in this
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gene have been associated with susceptibility to melanoma in genome-wide
association studies [792]. Again, over-expression is associated with shorter survival
and many pathways are involved, suggesting a generalised response of DNA repair
mechanisms associated with resistance.
The differences between the genes identified as involved in chemotherapy
response and those associated with survival suggests that survival is modified by
other factors, not associated with chemotherapy response. The survival analysis
presented adjusts for prognostic factors in stage IV disease (stage subset),
however there are clearly other factors which will modify survival in this very poor
prognosis group, including chemotherapy toxicity, co-morbidities, but also the
prognostic influence of gene expression. The survival analysis presented includes
all patients treated with chemotherapy, however the response analysis did not
include 17% of patients for whom response data was not available. For the majority
of patients this was because they deteriorated clinically or died before a formal
assessment of response could be made, therefore survival analysis is reflecting
expression of genes associated with early deaths which will not be associated with
chemotherapy response. Twenty-three percent of patients involved in this analysis
received DTIC or TMZ along with another chemotherapy, these being platinum-
containing chemotherapies. In response analysis, the two genes associated with
response in the larger dataset and the smaller set of patients treated with DTIC or
TMZ monotherapy only were MGMT and XPA. This suggests that results in the
larger dataset reflect genes associated with DTIC or TMZ response. Different genes
were associated with survival compared to response data in the monotherapy
group, again reflecting the different patients and end-points used in these analyses
as discussed above.
This study represents the most comprehensive assessment of DNA repair gene
expression in association with chemotherapy response for melanoma, the
preliminary results of which are described in this chapter. Currently, there are a
number of limitations to this study. I have assessed genes associated with
response and also those associated with survival after starting chemotherapy. The
different results from these analyses reflect that survival is also assessing the role
of DNA repair genes as prognostic biomarkers, for which there is large amounts of
evidence as described in Chapter 4 [177, 264, 335, 505]. Further analysis is
required to unravel the prognostic and predictive nature of DNA repair gene
expression and this will be explored. Other limitations are the use of both primary
and metastatic specimens and patients who have received other chemotherapies in
addition to DTIC or TMZ to identify chemotherapy response genes. This reduces
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the power of the study to identify genes associated with chemotherapy response in
these subgroups. Recruitment to the study continues and analysis will be repeated
when further samples are available. A further significant limitation is the quality of
response data available for this study. A small proportion of patients recruited were
involved in clinical trials and trial data will be accessed to obtain response data
according to RECIST criteria and analysis repeated for this subset of patients.
However, for other patients, response data have come from a number of sources,
across the UK and Europe. Where possible, response from imaging has been
recorded to RECIST standards, however there is likely to be much variability in
reporting across centres. Central radiological review of imaging would ensure
consistency and this will be explored. Finally, there are likely to be biological
determinants of DNA repair gene expression that have not been explored in
melanoma. It will be important to fully characterise the tumours used in this study,
for example by assessing BRAF and NRAS mutation status, to allow further
assessment of DNA repair genes associated with chemotherapy response in
different biological subgroups. The ability to perform these subgroup analyses is
dependent on number of tumour samples available, therefore recruitment
continues.
The results presented in this chapter are preliminary, however this chapter
demonstrates the potential of this study to identify determinants of chemotherapy
response. The collection of matched primary and metastatic tumour samples will
allow further assessment of how gene expression changes as a tumour progresses.
Despite these study limitations, it is clear that MGMT expression is important in
chemotherapy response and survival. Clinical trials aiming to deplete or inactivate
MGMT have not shown positive results [271-273, 759], however further
investigation into use of MGMT expression levels as a biomarker are warranted
based on my data. In particular further investigation into the different effects in
primary and metastatic tumours would be of interest.
In summary, in this large scale assessment of gene expression profiles in FFPE
primary melanomas I have identified over-expression of DNA repair genes in a
variety of pathways as being associated with poorer responses to chemotherapy. In
particular, over-expression of MGMT is associated with poorer responses to DTIC
and TMZ and shorter survival after starting chemotherapy treatment. Although new
therapeutic agents are effective for the treatment of melanoma, it is very likely that
a role for DTIC will remain and the identification of predictive biomarkers will remain
of crucial importance.
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9 Final discussion
Current prognostic markers in the form of the American Joint Committee on Cancer
(AJCC) staging criteria [58] are inadequate for a subset of patients with malignant
melanoma [121, 134]. The work summarised in this thesis was designed to identify new
prognostic markers in nucleic acids extracted from formalin-fixed paraffin-embedded
(FFPE) melanoma tissue. An important aim of the work was to show that stored
samples from mature studies might be used in a similar way in other cancer studies in
the future.
The presence of BRAF mutations is predictive of response to the newer targeted
therapies, inhibitors of mutant BRAF (BRAFi) but these need to be improved to predict
resistance. There is also a need for predictive biomarkers in melanoma for older
treatments such as chemotherapy with dacarbazine (DTIC) and identification of
biomarkers and genes involved in treatment responses to these drugs has also been
assessed in this thesis. To identify biomarkers and gain insight into tumour biology, I
have used novel technologies to assess genetic alterations in FFPE tissues. This
thesis presents an overview of my experience with these assays and detailed
methodological assessments.
9.1 Prognostic biomarkers
Previous studies using microarray technology to assess gene expression have been
limited by the small number of samples assessed [161]. This thesis reports the
successful use of the cDNA-mediated annealing, selection, extension and ligation
(DASL) assay to identify prognostic markers in a large number of primary FFPE
melanoma tumours. This assay was developed especially for use on degraded RNA
from FFPE tumours. Chapter 3 describes the identification and validation of SPP1
using this technology as a gene whose expression was shown to be independently
associated with relapse-free survival. SPP1 codes for osteopontin. In multivariate
analysis adjusting for current prognostic factors, doubling of SPP1 gene expression
was associated with a 2.5 times increased risk of relapse. Identification of this
candidate has been previously reported to be associated with melanoma prognosis
using immunohistochemistry [163, 176, 793], which increased confidence that the
DASL assay was generating biologically relevant results and these data have been
published [187].
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I combined the test and validation datasets used this in work to produce more power
and this lead to the identification of over-expression of DNA repair genes, specifically
those involved in repairing double-stranded DNA breaks, as being associated with
shorter relapse-free survival time (Chapter 4). Expression of RAD52 and TOP2A were
independently prognostic in multivariate analysis. These data were consistent with
those produced previously by others using frozen samples [177, 178], providing further
support to the assay. Following publication of this work [505], a large study of primary
tumours using the whole-genome DASL assay was reported which confirmed the
prognostic importance of DNA repair gene expression [335]. I also assessed DNA
repair gene expression associated with poor histological features, namely tumour
thickness and mitotic rate in this chapter. This was further expanded in Chapter 7,
where differentially expressed genes were identified in ulcerated tumours and
discussed in reference to the prognostic and predictive influence of this tumour feature.
Factors shown to be associated with ulceration included down-regulation of genes
associated with cell adhesion, hypothesised to allow melanoma cells to dissociate from
keratinocyte mediated growth control. Deranged expression of fibroblast growth factors
and receptors, presence of lymphatic invasion, greater microvessel density and
macrophages were also associated with ulceration, all factors which may contribute to
the prognostic influence of this tumour feature.
I hypothesised that greater insight into the biological processes which determine nodal
metastases would be achieved by analysis of gene expression profiles in matched
primary and nodal specimens from the same patient. I report a pilot study designed to
assess the utility of the DASL assay to perform such an experiment using small FFPE
sentinel node biopsy samples was described in Chapter 5. In this limited analysis,
again deranged expression of fibroblast growth factors was identified in nodal
specimens compared to primary tumours, a finding that requires confirmation in a
larger sample set.
A final prognostic marker was identified in Chapter 6, as the presence of a V600K
BRAF mutation was shown to be associated with shorter relapse-free survival
compared with the V600E BRAF mutated tumours, NRAS mutated tumours and wild-
type specimens. This association in primary tumours remained independently
associated with relapse-free survival in multivariate analysis adjusted for current
prognostic factors, increasing risk of relapse 2.6 times. The importance of this finding
has been highlighted by a recent publication of similar results in a cohort of metastatic
tumour specimens [593].
To summarise, this thesis describes identification of statistically independent prognostic
tumour markers which add additional prognostic information to current staging criteria.
- 295 -
Validation of these findings is at different stages, but previous reports associating
SPP1 and DNA repair gene expression to prognosis suggest that these are true
findings. Osteopontin protein expression has already been reported to be associated
with survival [163], and similarly investigation of protein expression of DNA repair
genes would be useful to support my gene expression findings. Validation of factors
association with ulceration and the prognostic effect of V600K BRAF mutations in
independent sample sets is required. This will be achieved by collaborations with other
groups and increasing the number of samples screened for mutations with
transcriptomic analysis from patients recruited to studies running in Leeds.
9.2 Predictive biomarkers
The topic of predictive markers has been addressed in Chapter 8, in which I described
studies in which over-expression of DNA repair genes, most significantly MGMT, was
associated with response to DTIC or TMZ therapy and survival after starting
chemotherapy. MGMT was confirmed to be associated with response and survival
when adjusted for current prognostic markers in stage IV disease. This analysis is
limited by the heterogeneous nature of the sample set and requires further
investigation when more samples are available.
In Chapter 7, I report work done to understand the biological associations with
ulceration status of the primary tumour as a predictive marker of response to interferon-
 (IFN) therapy. A number of factors were identified as being associated with ulceration
which may modify the response of a tumour to IFN therapy. Suppression of adaptive
immune responses by infiltration of macrophages, likely from the M2 phenotype, over-
expression of the pro-inflammatory gene, IL6, and deranged expression of genes
involved in the type 1 IFN Jak-STAT signalling pathway were demonstrated which may
all contribute to improved responses of ulcerated tumours to IFN.
Chapter 6 reports identified gene expression profiles associated with BRAF and NRAS
mutations in primary tumours. Results from this analysis provide some further insight
into the biological processes within mutated tumours, for example over-expression of
ETV1 was seen in BRAF mutated tumours. With regards to treatment with BRAFi,
these results may offer insight into mechanisms of resistance and further targets for
therapeutic intervention.
As discussed previously, validation of gene expression results associated with
ulceration and mutation status is being sought in collaboration with other groups and
samples in Leeds, which I hope will confirm the significance of these findings.
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9.3 Methodological assessments
This thesis includes extensive methodological assessments of technologies for gene
expression profiling and mutation detection in FFPE melanoma tumour samples
(Chapters 2-6 and 8). Results from gene expression profiling using the DASL assay
and the 502-gene Human Cancer panel have been used repeatedly in this thesis.
Results are reproducible and appear to be biologically relevant and use of this
technology has significantly enhanced progress in identification of prognostic gene
expression markers in melanoma in our group and another at the University of Lund
[187, 335, 445, 505]. Preliminary experiments with the whole-genome DASL HT assay
when that became available suggested that this assay was not sufficiently robust. I
identified a lack of reproducibility, highlighted the problem with the company and more
recently have studied a revised product and these studies now suggest that the assay
is reproducible (Chapter 2). The new product will be used for further gene expression
studies in the near future. Use of Taqman® gene expression assays and the Fluidigm
quantitative Real-time PCR (qRT-PCR) system have been assessed in detail using
FFPE melanoma tissue (Chapters 4 and 8). Both systems generate reliable results,
however I have shown that correct normalisation procedures are required to ensure the
accuracy of qRT-PCR data (Chapter 4) and when using a DNA binding dye, such a
EvaGreen, thorough assessment of melt curves and no template control samples will
allow accurate interpretation of data.
9.4 Limitations and future study
The greatest limitation of the work presented in this thesis is that gene expression
studies used a 502-gene Human Cancer panel for gene expression profiling rather than
a whole genome array. The genes on this panel were derived from 10 publically
available cancer gene lists. The limited number of genes assessed is biased which
limits use of further bioinformatics analysis as discussed in Chapter 4. Whole-genome
expression profiling allows a more agnostic approach, however it is likely that RNA-seq
technology will supersede microarray gene expression profiling in the near future as it
has many advantages, including detection of alternative splice variants and detection of
transcripts from gene fusion events [197, 198]. Further limitations are the current lack
of validation for many of my findings in independent sample sets. Other groups, for
example, Goran Jonsson at Lund University, Sweden, have now generated gene
expression data from large cohorts of well-annotated metastatic and primary melanoma
tumour specimens [180, 335] allowing validation of our findings and have agreed to test
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my findings in their data sets, this analysis is currently underway. In addition, a number
of publically available gene expression datasets with accompanying clinico-pathological
data are available, for example from Winnepenninckx and colleagues [178], which will
allow further validation of gene expression profiles, for example those associated with
ulceration. The samples assessed in this thesis are from a small proportion of patients
recruited to the Leeds Melanoma Cohort study described in Chapter 2. Gene
expression profiling and mutation screening will continue in samples from patients in
this study, allowing assessment of gene expression profiles identified in this thesis in
larger sample sets and validation in a further sample set.
The “Predicting Response to Chemotherapy in Malignant Melanoma” study continues
to recruit patients, which will increase numbers of samples available for further
evaluation of the use of expression changes in DNA repair genes as predictive
biomarkers, These samples will also allow analysis of subgroups within this
heterogeneous sample set. More extensive genomic characterisation, for example
BRAF and NRAS mutation screening, will define biological subgroups further.
Standardisation of reporting for imaging to assess chemotherapy response will also
improve the data quality for this study and this will be addressed.
The focus of this thesis has very much been on gene expression, however to further
explore biological function of alterations in gene expression, protein expression will
also need to be assessed. This is also relevant to the clinical use of biomarkers, as
currently use of qRT-PCR in a routine clinical setting with tissue samples is limited, with
immunohistochemistry (IHC) techniques being more frequently available. Tissue
sections are available from the samples in the Chemotherapy study and will be used
for IHC studies once candidate genes have been confirmed. For other studies, further
collaboration will be required to access tissue for IHC analyses.
This thesis has been successful in identifying prognostic tumour markers, which add
more to current staging algorithms in melanoma. I have also identified potential
predictive markers of response to DTIC or TMZ chemotherapy, with further data
helping to define biological processes in melanoma tumours. Use of these prognostic
and predictive markers could potentially assist clinicians and patients in making
informed choices about their melanoma treatment.
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10 Appendix I: Genes on the Human Cancer panel
Alphabetical Gene List
ABCB1 BTK CTSD ERCC1 FOSL2 IL13
ABCC2 CASP10 CTSL ERCC2 FRAP1 IL1A
ABCG2 CASP2 CUL2 ERCC3 FRZB IL1B
ABL1 CASP3 CXCL9 ERCC4 FVT1 IL1RN
ADPRT CASP8 CYP1A1 ERCC5 FYN IL2
AHR CAV1 CYP1B1 ERCC6 FZD7 IL3
AIM2 CBFA2T1 DAB2 ERG G22P1 IL4
AKT1 CBL DAP3 ESR1 GADD45A IL6
AKT2 CBLB DAPK1 ETS1 GAS1 IL8
ALK CCNA2 DCC ETS2 GAS7 ILK
ALOX12 CCNC DCN ETV1 GFI1 ING1
APAF1 CCND1 DDB2 ETV6 GLI INHA
APC CCND2 DDIT3 EVI1 GLI2 IRF1
AR CCND3 DDX6 EVI2A GLI3 ITGB1
ARAF1 CCNE1 DEK EXT1 GML ITGB4
AREG CCNH DKC1 EXT2 GRB2 JAK2
ARHA CD34 DLC1 FANCA GRB7 JUN
ARHGDIB CD44 DLEU1 FANCG GRPR JUNB
ARHH CD59 DLG3 FAT GSTP1 JUND
ARHI CD9 DMBT1 FER HCK KAI1
ARNT CDC2 DSP FES HDAC1 KDR
ATF1 CDC25A DTR FGF1 HDGF KIT
ATM CDC25B DVL3 FGF12 HIF1A KRAS2
AXL CDC25C E2F1 FGF2 HLF L1CAM
BAD CEBPA E2F2 FGF3 HMMR LAF4
BAG1 CHEK1 E2F3 FGF5 HOXA9 LAMB1
BAK1 COL18A1 E2F5 FGF6 HRAS LCK
BARD1 COL1A1 EGF FGF7 ICAM1 LCN2
BCL2 COL4A3 EGFR FGF8 IFNG LIF
BCL2A1 COMT EGR1 FGF9 IFNGR1 LIG1
BCL2L1 COPEB ELK1 FGFR1 IFNGR2 LIG3
BCL3 CREBBP ELK3 FGFR2 IGF1 LIG4
BCL6 CRK ELL FGFR3 IGF1R LMO1
BCR CRKL EMS1 FGFR4 IGF2 LMO2
BIRC2 CSF1R ENC1 FGR IGF2R LTA
BIRC3 CSF2 EPHA1 FHIT IGFBP1 LYN
BIRC5 CSF3 EPHB4 FLI1 IGFBP2 MAD
BLM CSF3R EPO FLT1 IGFBP3 MADH2
BMI1 CSK EPS15 FLT3 IGFBP5 MADH4
BMP4 CSPG2 EPS8 FLT4 IGFBP6 MAF
BRAF CTGF ERBB2 FOLR1 IL11 MALT1
BRCA1 CTNNA1 ERBB3 FOS IL12A MAP3K8
BRCA2 CTNNB1 ERBB4 FOSB IL12B MAPK10
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Alphabetical Gene List continued
MAPK14 MXI1 PLA2G2A RAP1GDS1 SYK TOP1
MAS1 MYB PLAG1 RAP2A TAL1 TOP2A
MATK MYBL2 PLAT RARA TCF7L2 TP53
MBD2 MYC PLAUR RARB TDGF1 TP73
MCAM MYCL1 PLG RASA1 TEK TPR
MCC MYCL2 PML RB1 TERT TRAF3
MCF2 MYCN PMS1 RBBP1 TFAP2C TRAF4
MCL1 NAT2 PNUTL1 RBBP2 TFDP1 TSC1
MDM4 NBS1 PPARD RBBP5 TFE3 TSC2
MDS1 NEO1 PPARG RBBP6 TFF1 TSG101
MEL NF1 PPP2R1B RBL2 TFG TYMS
MEN1 NFKB1 PRCC RECQL TFRC TYRO3
MET NFKB2 PRKAR1A REL TGFA VAV1
MLF1 NFKBIA PRKR RELA TGFB1 VAV2
MLF2 NGFR PTCH RET TGFB2 VBP1
MLH1 NOS3 PTCH2 RIPK1 TGFB3 VEGF
MLL NOTCH1 PTEN RLF TGFBI VEGFB
MLLT3 NOTCH2 PTGS1 ROS1 TGFBR1 VHL
MLLT4 NOTCH4 PTGS2 RRAS TGFBR2 VIL2
MLLT6 NQO1 PTHLH S100A4 TGFBR3 WEE1
MMP1 NRAS PTK2 SEMA3F THBS2 WNT1
MMP10 NTRK1 PTK7 SERPINE1 THPO WNT10B
MMP14 NTRK2 PTPRF SH3BP2 TIAM1 WNT2
MMP2 NTRK3 PTPRG SHH TIMP1 WNT2B
MMP3 NUMA1 PTPRH SIAH1 TIMP2 WNT5A
MMP7 OGG1 PURA SKI TIMP3 WNT8B
MMP9 OSM PXN SKIL TK1 WRN
MOS PBX1 QARS SMARCA4 TNF WT1
MPL PCNA RAD23A SMARCB1 TNFAIP1 XPA
MRE11A PCTK1 RAD50 SOD1 TNFRSF10A XPC
MSF PDGFA RAD51 SPARC TNFRSF10B XRCC1
MSH2 PDGFB RAD52 SPI1 TNFRSF1A XRCC2
MSH3 PDGFRA RAD54B SPP1 TNFRSF1B XRCC4
MSH6 PDGFRB RAD54L SRC TNFRSF5 XRCC5
MST1R PGF RAF1 STAT1 TNFRSF6 YES1
MTA1 PGR RALB STAT3 TNFSF10 YY1
MTHFR PIK3CA RAN STAT5B TNFSF6 ZNF146
MUC1 PIM1 RAP1A STK11 TNFSF8 ZNFN1A1
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